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ABSTRACT 
The discovery, in 1989, of the gene responsible for Cystic Fibrosis (CF), the 
cystic fibrosis transmembrane conductance regulator (CFTR), led to the 
development of mouse models of this disease. Such models were designed to 
facilitate the dissection of disease pathogenesis, to study the correlation 
between genotype and phenotype and to establish an invaluable resource for 
the development and evaluation of novel therapeutic agents. Fundamental to 
the success of such studies was the requirement that the mutant animals 
should develop the key phenotypic features of CF in humans. Initial 
characterisation of the first mouse models of CF demonstrated that they 
could be unequivocally distinguished from their wild type littermates and 
displayed many important disease features. However, the most important 
clinical consequence of CF, the development of chronic pulmonary infection 
with fibrotic lung damage, was not initially evident. In studies that preceded 
this thesis, we demonstrated an abnormal pulmonary phenotype in the 
Edinburgh CF mouse (Cftr`"''"gu /Cftr`"''Hgu), on an outbred MF1 background, in 
response to repeated exposure to CF related respiratory pathogens. These 
observations established this mouse as an important model system for 
studies aimed at elucidating the mechanisms involved in the development of 
CF lung disease. The aims of this thesis were 1) to further characterise lung 
disease in mouse models of cystic fibrosis, and 2) to study the mechanisms 
underlying the development of this disease. 
Firstly, this thesis describes 1) the development and quantification of 
methods for the delivery of bacteria to the murine lung and 2) the analysis of 
the histopathological phenotype of mouse models of CF congenic on a 
C57B1 /6N background, in response to such techniques. These studies were 
performed using a clinical strain of Staphylococcus aureus, a pathogen that is 
characteristic of the early stages of lung infection in CF. The experiments 
addressed the null hypothesis that there was no difference between the 
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histopathological responses of 1) Cftrti°"g" /CftrtrulHgu mice or 2) CftrtmlHgu 
/Cftrt"'"'"` compound heterozygote mice, and non -CF littermates. The results 
led to the following conclusions; a) mouse models of CF (Cftrt"''Hg" /Cftrt"t1H u 
and Cftrt"' s "/ Cftrt "' "` "` ) congenic on a C57B1 /6N background developed lung 
pathology in response to repeated exposure to nebulised S. aureus, b) 
significantly more severe pathology was observed in CF mice compared to 
non -CF littermate controls, c) the spectrum of disease observed in CF mice 
and non -CF littermates congenic on a C57B1 /6N background was narrowed 
in comparison to those on an outbred MF1 background, with wild type mice 
more severely affected, d) No difference was observed between the severity 
of disease in the Cftrt",1H g " /C f t uL mice in comparison to the C f t tut g u /C f t tm1H 
mice, implying that the reduction in background levels of wild type CFTR 
did not have a major influence upon the observed response to pathogen 
exposure, and e) assessment of the histopathology suggested an exaggerated 
response rather than abnormality in any one aspect of this response. 
Until recently the mechanisms by which dysfunction of CF lR could lead 
to the development of characteristic CF lung pathology remained unclear. 
However, several compelling, and competing, hypotheses have been 
proposed, based largely on in vitro studies. This thesis also describes studies 
designed to complement the published research by utilising mouse models of 
CF and address the relevance of several of these theories in this model 
system. 
It has been proposed that CFTR interacts directly with P. aeruginosa to 
internalise these bacteria into airway epithelial cells. It is postulated that this 
process plays a role in lung defence and is compromised in CF. This thesis 
describes preliminary in vivo studies addressing this mechanism in mouse 
models of CF. Although internalisation of P. aeruginosa was observed, no 
difference was demonstrated between CftrtinlHg" /Cftrtrr,lHgu mice and non -CF 
littermates 
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Airway surface liquid (ASL) from primary cultures of human airway 
epithelial cells has been shown to display salt sensitive antibacterial activity, 
the dysfunction of which has been implicated in the pathogenesis of CF lung 
disease. Airway Beta Defensins have been demonstrated to constitute an 
important component of this defence system. This thesis describes studies to 
characterise mouse Beta Defensin -1 (mBD1) and contrast it with human Beta 
Defensin -1 (hBD1) and concludes that a) synthetic hBD1 and mBD1 both 
display salt- sensitive antibacterial activity, b) hBD1 may play a role in 
determining the spectrum of lung pathogens that characterise CF and the 
predilection of P. aeruginosa for the human CF lung, c) dysfunction of mBD1 
in Cftr helHgu mice may contribute to the lung phenotype observed in 
response to S. aureus, and d) the differences demonstrated between mBD1 
and hBD1 may result in species specific profiles of bacterial susceptibility 
secondary to CFTR dysfunction. In order to complement these studies by 
performing analysis of native murine ASL this thesis describes the 
development and characterisation of a primary culture model of 
differentiated mouse tracheal epithelium, grown at air/ liquid interface. This 
model demonstrates confluent, polarised epithelium, with differentiation to 
produce ciliated and secretory cells, expression of Cftr and murine Beta 
Defensin genes and a characteristic electrophysiological profile. 
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Chapter 1: Introduction 
1.1 Preface 
In 1989 the gene responsible for Cystic Fibrosis (CF) was cloned and 
the predicted protein designated the cystic fibrosis transmembrane 
conductance regulator (CFTR). The ten years since that discovery have 
witnessed rapid progress in our understanding of this common genetic 
disorder. Progressively more detailed knowledge of the disease causing 
mutations, the gene expression patterns, the protein structure, its functions 
as an ion channel and as a conductance regulator, has allowed the 
development of reliable screening programmes, the creation of animal 
models and the design of novel therapeutic approaches. The biological basis 
of many aspects of the disease phenotype are becoming clearer, including 
recent significant advances in understanding the pathogenesis of the 
characteristic and ultimately fatal lung disease. While this great expansion of 
knowledge has started to bridge the gap between our understanding of the 
genetic defect and the well documented clinical sequelae, it has also served 
to demonstrate the mechanistic complexity of this "simple" single gene 
defect. 
1.2 Cystic fibrosis -A clinical overview 
1.2.1 Epidemiology 
Cystic Fibrosis is the most common lethal autosomal recessive genetic 
disorder in Caucasian populations with a carrier frequency estimated at 1 in 
29 and an incidence of about 1 in 3300 (National Institutes of Health 
2 
Developmental conference Statement on Genetic Testing for Cystic Fibrosis 
1999). The disease also has a fairly high incidence amongst Hispanics but it 




Number / Total 
Whites 1 / 3300 1 / 29 
Hispanics 1 / 8000 - 9500 1 / 46 
Ashkenazi Jews 1 / 3300 1 / 29 
American Indians 1 / 1500 - 4000 1 / 19 - 1 / 32 
African Americans 1 / 15300 1 / 60 
Asian Americans 1 / 32100 1 / 90 
TABLE 1.1 Incidence and carrier frequency of CF 
The incidence and carrier frequency of CF in different ethnic populations in 
the USA, adapted from National Institutes of Health Developmental 
conference Statement on Genetic Testing for Cystic Fibrosis 1999. 
1.2.2 Diagnosis 
The diagnosis of CF was, for many years, made using the sweat test 
(Le Grys et al 1994, Quinton 1999). This protocol, designed to detect elevated 
sweat chloride levels in individuals with CF, was the gold standard for CF 
diagnosis, although false positives have been described in severe 
malnutrition, adrenal insufficiency and nephrogenic diabetes insipidus. 
However patients were identified with atypical presentations and 
intermediate sweat electrolyte levels in whom diagnosis of CF remained 
uncertain. An alternative diagnostic test is measurement of the nasal 
potential difference (Knowles et al 1981, Alton et al 1990). Alterations in 
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active ion transport across CF epithelia contribute to characteristic bioelectric 
profiles in CF individuals, which can be measured in the inferior nasal 
turbinates. This test has a high sensitivity, but may be influenced by the 
presence of nasal polyps, upper respiratory tract infections and previous 
nasal surgery. Since the cloning of the CFTR gene, a definitive diagnosis can 
now be offered to most patients by testing for the presence of mutations in 
CFI R. By combining detection of the most common mutations as 
appropriate for specific ethnic groups a mutation detection sensitivity of 
approaching 90% can be achieved in US whites and higher in some 
populations (National Institutes of Health Developmental conference 
Statement on Genetic Testing for Cystic Fibrosis 1999). 
Criteria suggested for the clinical diagnosis of CF are shown in Table 
1.2, requiring at least one criterion from class A and one from class B, with 
nasal potential difference measurements suggested as an additional tool 
where required (Kerem and Kerem 1995). 
Class A 
Typical pulmonary manifestations 
Typical gastrointestinal manifestations 
History of CF in the immediate family 
Class B 
Sweat chloride concentration > 60 mEq /L 
Identification of two CFTR mutations 
TABLE 1.2 Criteria for the diagnosis of CF 
Adapted from Kerem and Kerem 1995. 
The median age at diagnosis is 6 to 8 months. Almost two thirds of 
CF individuals are diagnosed before 1 year of age (National Institutes of 
4 
Health Developmental conference Statement on Genetic Testing for Cystic 
Fibrosis, 1999). 
Screening for CF is performed using an assay of immunoreactive 
trypsinogen from a dried blood spot. At the present time, about 16% of 
neonates are screened for CF in the United Kingdom (Dodge 1999). Evidence 
of the value of such screening programmes remains controversial. One 
prospective controlled study in Wisconsin found that early diagnosis and 
treatment could prevent the decline in nutritional status that commonly 
affects CF children (Farrell et al 1997), while various health benefits have 
been reported using comparison with historical data (Dankert -Roelse and Te 
Meerman 1997). However, another prospective trial, carried out in Wales 
and the West Midlands, has found no evidence that screening per se has any 
major clinical benefit (Dodge 1999). Further studies are required to establish 
reliable data. However, many clinicians feel that the ability to institute 
specialised care and treatment early must be considered advantageous. This 
may prove particularly important in the future, given that the emphasis in 
much novel therapy development is on the prevention of disease progression 
rather than alleviation of symptoms. 
1.2.3 Clinical manifestations and aetiology 
CF is a multi- system disease with variable presentation. The classical 
phenotype is of salty sweat, pancreatic insufficiency, intestinal obstruction, 
male infertility and severe pulmonary disease. 
These clinical manifestations reflect the tissue and cell specific 
expression pattern of CFTR (see section 1.3.7), being highly expressed in the 
sweat ducts, the pancreatic ducts, the digestive tract, the biliary ducts, the 
salivary glands, the reproductive organs and the airway submucosal glands. 
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Historically, this characteristic pathology has been ascribed primarily 
to the dysfunction of exocrine glands; producing viscid mucus, consequent 
mucus plugs and eventual organ destruction. However, since the cloning of 
CFTR it has become widely accepted that the fundamental defect in CF is not 
mucus production, but abnormalities of electrolyte transport in all affected 
epithelial tissues (reviewed in Quinton 1999). This defect results from the 
primary function of CFTR as a chloride ion channel and its secondary 
influences on other ion channels (see section 1.3.6). 
In 1983, an abnormally high baseline transepithelial potential 
difference and anion impermeability was demonstrated in microperfused CF 
sweat ducts, when compared to those from non -CF subjects (Quinton 1983). 
This provided an explanation for the high salt content of CF sweat, in the 
form of a defect in ductal electrolyte absorption from the iso- osmotic fluid 
secreted in the acinar portion of the duct. It also demonstrated the presence 
of an electrolyte transport abnormality in the absence of morphological 
changes and independent of infection, inflammation or the effects of mucus. 
These studies thus provided the first description of the basic cellular defect 
that has now become recognised as the hallmark of the CF cell and underlies 
the abnormal electrophysiological profiles of affected tissues in CF. These 
bioelectrical abnormalities, reflecting alterations in the transport of chloride 
and sodium ions across the apical membrane of CF cells, have since been 
used extensively to characterise the electrolyte transport defects in affected 
organs in CF (reviewed in Anderson et al 1992). 
Pancreatic lesions were amongst the first abnormalities to be 
documented in CF patients and prompted Andersen to use the term "cystic 
fibrosis of the pancreas" (Andersen 1938). Pancreatic insufficiency (PI) 
occurs in approximately 90% of patients with CF and shows a clear 
genotype /phenotype relationship (see section 1.3.4). Dysfunction is 
detectable at birth but the onset of signs of insufficiency is variable. Indeed, 
only 10% of residual pancreatic function is required to prevent 
malabsorption, with consequent malnutrition, steatorrhoea and failure to 
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thrive (Figarella and Carrere 1994). The typical pathogical features include 
mucus accumulation, ductal dilatation and obstruction with inspissated 
secretions, fibrosis and cyst formation. Progressive atrophy occurs with loss 
of acinar and ductal structures and the formation of scar tissue, separated 
only by isolated islets of Langerhans (Robbins and Kumar 1987). The 
explanation for this deterioration also lies in the dysfunction of fluid and 
electrolyte transport. The inhibition of fluid secretion in the pancreas results 
in abnormally concentrated macromolecules and a low volume output, with 
decreased HCO3 concentration. Consequently stagnation of proenzymes 
occurs with premature activation in the pancreatic ducts, causing progressive 
destruction (reviewed in Quinton 1999). 
In addition to exocrine pancreatic insufficiency, approximately 50% of 
CF patients have impaired glucose tolerance, with overt diabetes occurring 
in roughly 10% (reviewed in Figarella and Carrere 1994). The incidence and 
prevalence of these conditions increases with age. Despite the fact that the 
pancreatic islands are relatively spared from the progressive fibrotic damage, 
this destructive process was considered to be responsible for the endocrine 
dysfunction. However, unlike the exocrine insufficiency, the endocrine 
dysfunction is unrelated to the CF genotype (Lanng et al 1991). It has, 
therefore, been suggested that it may not be a primary manifestation of CF. 
The gastro -intestinal tract is also affected in CF (reviewed in Boat et al 
1989). Meconium ileus, an obstruction of the small intestine with thick, 
dehydrated, mucoid material, occurs in 10 -20% of CF individuals in the first 
few days of life and is virtually diagnostic. Its pathogenesis has been 
attributed to failure of enzyme secretion and the accumulation of undigested 
proteins in utero. However, an autopsy study of CF infants found no 
difference in the exocrine pancreas from those with or without meconium 
ileus, suggesting no relationship between pancreatic pathology and intestinal 
obstruction (Sturgess and Imrie 1981). This observation is supported by 
studies in mouse models of cystic fibrosis, in which intestinal obstruction 
occurs in the absence of pancreatic disease (see section 1.7.3). 
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Beyond the newborn period, the most common gastointestinal 
problem is distal intestinal obstruction syndrome (DIOS), occurring in 20% of 
patients. Similar to meconium ileus this is an obstruction of the terminal 
ileus with sticky, incompletely digested intestinal contents. With the 
exception of these intestinal obstructions, pathological changes in the 
intestinal tract are not prominent. Brunner's glands of the duodenum are 
hypertrophied, with ductal dilatation, mucus filled acini and an increased 
proportion of goblet cells. However there is little histopathological 
abnormality in the small intestinal mucosa, nor in the colon. Studies of the 
electrolyte abnormalities in the gut have demonstrated the increased sodium 
dependent glucose uptake and decreased secretory responses characteristic 
of the loss of CF'11{ chloride conductance (reviewed in Quinton 1999). It is 
these abnormalities that are considered to be fundamental to the intestinal 
manifestations in CF. 
Hepatobiliary involvement may also occur in CF (reviewed in Boat et 
al 1989). Symptomatic biliary cirrhosis occurs in 2 -5% of patients, but 
microscopic evidence of focal biliary cirrhosis is found in 25% of autopsies, 
with inspissation of secretions within the bile ducts, ductal dilatation, 
inflammation and fibrosis. Cholelithiasis is also observed, occurring in as 
many as 20% of CF patients. 
Abnormalities of the genitourinary tract occur, presenting as 
azoospermia in over 95% of men with CF as a result of congenital bilateral 
absence of the vas deferens (CBAVD) (reviewed in Boat et al 1989). This 
tissue seems to be the most sensitive to CF' I R dysfunction, with fibrotic, 
atrophic or absent vas deferens, epididymis and seminal vesicles. Only 2 -3% 
of CF males are fertile, despite active spermatogenesis. Fertility in women 
with CF is higher at approximately 10 %, but complicated by anovulation, 
secondary to poor nutrition or chronic lung infections. This low fertility rate 
may be attributable to the impediment to sperm caused by tenacious, cervical 
mucus, shown to be dehydrated and have abnormal electrolyte 
concentrations (reviewed in Boat et al 1989). 
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The most serious clinical manifestation is lung disease, which causes 
90% of the morbidity in CF individuals and can severely compromised 
quality of life (National Institutes of Health Developmental conference 
Statement on Genetic Testing for Cystic Fibrosis 1999). Lung disease in CF is 
characterised by chronic microbial colonisation and repeated acute 
exacerbations of pulmonary infection, with distinctive bacterial flora, 
precipitating progressive, irreversible, inflammatory lung damage. Until 
recently the mechanism by which CFTR dysfunction could result in this 
pulmonary phenotype was not clear. However, recent studies have begun to 
bridge the gap between the development of airway disease and the genetic 
abnormality. Lung disease in CF will be considered in detail in section 1.4. 
Since the cloning of the CFTR gene our understanding of the aetiology 
and cellular basis for the development of CF disease has progressed rapidly, 
incorporating the fundamental role of electrolyte transport abnormalities. 
However, this may not represent the whole picture. CI-TX has been 
demonstrated to have functions other than its activity as a chloride channel, 
as discussed in section 1.3.6. In particular, a recent study has revived interest 
in the metabolism of essential fatty acids in CF (Freedman et al 1999). It 
suggests that a defect in lipid balance may occur as a direct consequence of 
CFTR dysfunction and play an important role in the expression of the 
disease. 
1.2.4 Disease course and outcome 
CF disease today has a very variable presentation and course. In some 
individuals serious gastro- intestinal problems and severe, early -onset 
pulmonary disease result in considerable morbidity, whereas others have 
relatively mild disease with presentation during adolescence and young 
adulthood. This variation appears to have both genetic and environmental 
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components and is discussed in later sections. As a result, outcomes vary 
from death due to complications of meconium ileus in the first few days of 
life or early death due to severe respiratory tract problems, through to mild, 
atypical symptoms in early adulthood and, rarely, a normal lifespan. 
When first described in the 1930's (Anderson et al 1938), few CF 
children survived beyond 5 years. A combination of improved knowledge of 
the pathophysiology and recent advances in treatment has produced a 
dramatic improvement in prognosis. Median survival had increased to 18 
years by 1976 and to 30 years by 1995 (National Institutes of Health 
Developmental conference Statement on Genetic Testing for Cystic Fibrosis 
1999). However, there was little change in life expectancy between 1990 and 
1995 and despite advances in therapy there remains no cure for CF. 
1.2.5 Treatment 
As our understanding of the molecular and biological basis of CF 
becomes more comprehensive, the goal of successful treatments becomes 
more accessible. New insights into the disease pathogenesis create 
opportunities for novel therapeutic interventions while also revealing the 
limitations of current treatments. Table 1.3 details the array of therapies now 
in use, or in development. 
The major goals of traditional therapies have been to alleviate the 
pulmonary, gastrointestinal and pancreatic manifestations of the disease 
(reveiwed in Ramsay 1996). 
Treatment of the airways has focused upon: 1) clearance of airway 
secretions, using chest physiotherapy with postural drainage, 2) antibiotic 
therapy; a) for the treatment of exacerbations of pulmonary infection, and b) 
as maintenance therapy designed to decrease bacterial colonisation, reduce 
the frequency of exacerbations and slow the disease progress, and 3) anti- 
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inflammatory drugs to minimise the inflammatory cascade and consequent 
lung damage. The value of bronchodilator therapy as an additional 
approach is more controversial, but is also considered. A more recent 
addition to therapy protocols is the use of inhaled purified, recombinant 
human deoxyribonuclease I (rhDNase I). This can be used to break down 
break down extracellular neutrophil DNA, reducing the viscoelasticity of 
sputum from CF patients and increasing mucus "clearability ". 
Treatment of the gastrointestinal and pancreatic systems has revolved 
around the use of pancreatic enzyme supplementation, to improve digestion, 
and high protein -energy diets with fat -soluble vitamins to maintain good 
nutrition. 
Problems Solutions Treatments 





Abnormal processing of 
CFTR 
Relocalisation Molecular chaperones 




Abnormal ion transport Increase chloride 
transport 
Block sodium uptake 
UTP 
Amiloride 
Abnormal fatty acid 
balance 
Correct imbalance Fatty acid therapy 
Thick obstructive mucus Decrease viscosity Mucolytics 
DNase 
Impaired clearance Augment clearance Chest physiotherapy 
Pulmonary infection Decrease bacterial load Antibiotics 
Salt- insensitive 
antimicrobial peptides 
Pulmonary inflammation Diminish host reaction Anti -protease 
Bronchiectasis Replace when 
irreversible damage 
Lung transplant 
TABLE 1.3 Therapeutic approaches for CF lung disease 
Adapted from Davidson and Porteous 1999. 
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The use of aggressive regimen incorporating these treatment 
mainstays has been responsible for the improvements in survival achieved 
thus far. However, novel approaches are required to make further increases 
in the life expectancy, while also aiming to improve quality of life rather than 
simply to alleviate symptoms. Thus, while there is a continuing need for the 
development of new antimicrobial agents, mucolytics and antiproteases, 
novel solutions are being sought in the new genetic knowledge (reviewed in 
Zeitlin 1999). These approaches include 1) the use of aminoglycosides to 
overcome stop mutations at the protein translational level, by suppressing 
termination, resulting in a full length CFTR, 2) relocating mutant CN I1( to the 
apical surface by the modulation of chaperone protein associations, using 
butyrate compounds, or correcting the trafficking defect using chemical 
chaperones such as glycerol, 3) upregulating the function of correctly 
localised mutant CFTR, using compounds such as Genistein or CPX (8- 
cyclopently-1,3- dipropylxanthine), 4) compensatory regulation of alternative 
ion channels, by inhibiting sodium absorption using amiloride or stimulating 
chloride secretion through pathways that are not dependent upon cAMP, 
such as using UTP ( Uridine triphosphate) to activate a P2 purinergic receptor, 
5) fatty acid replacement therapy with Docosahexaenoic acid (DHA) based 
product to address the apparent fatty acid imbalance, and 6) gene therapy, to 
directly replace the faulty gene. This final approach is possibly the most 
exciting novel therapy to have been borne from the new genetic knowledge, 
with the potential to correct all the downstream consequences that arise from 
CFTR dysfunction at once. However, initial enthusiasm has been tempered 
by a more realistic assessment of the many barriers to successful gene 
therapy, using both viral and non -viral based approaches, that have been 
revealed in the course of phase 1 trials (reviewed in Porteous and Innes 1999, 
Boucher 1999, and Welsh 1999). The problems faced in delivering gene 
therapy as a treatment for CF and some of the possible solutions are 
summarised in Table 1.4. 
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Further development of animal models and continuing basic research 
into the cellular and molecular biology of CF is essential for the analysis and 
optimisation of these novel therapies and to establish improved surrogate 
markers of clinical relevance. 
Problems Solutions 
Inefficient gene delivery Improved vectors and delivery devices 
Inflammatory response to vector Engineering and formulation of viral 
vectors and liposomes 
Lack of cell specific targeting Viral subtypes 
Receptor mediated cell targeting 
Transient expression Episomal maintenance 
Safe site integration 
Transfect stem cells 
Non physiological expression Genomic context vectors 
Cell specific expression 
TABLE 1.4 Challenges in gene therapy for CF 
Adapted from Davidson and Porteous 1999. 
1.3 The cystic fibrosis transmembrane 
conductance regulator 
1.3.1 The cloning of the gene 
The gene responsible for CF; the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene, was cloned in 1989 (Rommens et al 1989, 
Riordan et al 1989, Kerem et al 1989). Located on the long arm of human 
chromosome 7, it was originally estimated to span over 250 kb, however, 
recent genomic sequencing indicates that it spans -489kb (Ellsworth 2000). It 
contains 27 exons and encodes a 1480 residue transmembrane glycoprotein. 
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1.3.2 CFTR protein structure and function 
The protein structure, proposed in 1989, was based upon comparison 
with members of the ATP -binding cassette (ABC) transporter family to 
which CFTR belongs (Riordan et al 1989). This model has proven to be 
remarkably accurate (Figure 1.1). CFTR consists of two repeated motifs, 
made up of six membrane spanning domains (MSD) and a nucleotide 














FIGURE 1 A model of the proposed structure of CFTR 
Adapted from Sheppard and Welsh 1999. 
Site directed mutagenesis studies targeting the membrane spanning 
domains (MSD) have been shown to alter the conduction and permeation 
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properties of CFTR, suggesting that these domains form a pore in the cell 
membrane. This pore is proposed to have a diameter of -5.3 -6 A at its 
narrowest point, with larger vestibules on either side (reviewed in Sheppard 
and Welsh 1999). Studies suggest that this pore is kept "closed" by the R 
domain in its unphosphorylated state (reviewed in Gadsby and Nairn 1999). 
The R domain has 10 dibasic consensus phosphorylation sites, at least 5 of 
which are used in vivo. Phosphorylation at these sites, by cAMP dependent 
protein kinases (PKA and PKC), appears to have two effects; firstly 
permissive, perhaps releasing steric inhibition, and secondly stimulatory, 
facilitating interaction between the nucleotide binding domains (NBD) and 
ATP. This phosphorylation is a requirement for pore opening and can be 
reversed by intracellular phosphatases. The "opening" of the pore requires 
the hydrolysis of nucleoside triphosphates by the NBDs after the 
phosphorylation of the R domain (Anderson et al 1991b). Several models 
have been proposed for this process (reviewed in Sheppard and Welsh 1999). 
The minimal model predicts one open state and two closed states with 
binding and hydrolysis of ATP by NBD, opening the channel. It has been 
suggested that the release of energy by ATP hydrolysis may be required for a 
conformational change in pore opening. The closure of the pore then 
requires ATP hydrolysis at NBD,. A recent study also proposes a role for the 
NH,-terminal tail in the stabilisation of pore opening through interaction 
with the R domain (Naren et al 1999). While this model currently provides a 
useful framework it is likely to prove simplistic and will, no doubt, be 
revised further in the light of future discoveries. One area of current 
controversy affecting such models debates whether or not CI- -1 R functions as 
a monomer. Biochemical data supports the view that CHI( functions as a 
monomer in the cell membrane, sedimented as a monomer using sucrose 
density gradients (Ostedgaard and Welsh 1992). However a recent study 
suggests that two CFTR molecules interact together to from a single pore 
(Zerhusen et al 1999). This could have important consequences for our 
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understanding and modelling of CF, particularly with regard to compound 
heterozygote and heterozygote status. 
To confirm the function of CFTR as an apical membrane chloride 
channel, studies using recombinant CFTR were performed. The expression 
of CFTR was shown to generate cAMP- regulated chloride channels in cells 
that did not normally contain such channels or express endogenous CF'1'R 
(Anderson et al 1991a). Furthermore, the properties and regulation of these 
channels was shown to be similar to that of native CH R in epithelial cells, 
with the following features; 1) a small single channel conductance (6 -10 pS), 
2) a linear current -voltage relationship, 3) selectivity for anions over cations, 
4) an anion permeability sequence of Br >_ Cr > I-, 5) activity regulated by 
cAMP- dependent phosphorylation and the hydrolysis of nucleoside 
triphosphates (reviewed in Welsh 1996). Mutation of specific residues in 
CFTR was shown to alter the ion selectivity of CF1'R (Anderson et al 1991a). 
Finally, analysis of purified CFTR reconstituted in planar lipid bilayers 
demonstrated its function as a cAMP -regulated chloride ion channel protein 
with properties identical to those in native epithelium (Bear et al 1992). 
Thus CFTR functions as a PKA- and ATP- regulated chloride channel, 
the gating processes of which involve the interaction of its cytosolic domains. 
In the absence of functional CI- IX there is a failure of chloride ion transport 
at the sites of CFI R localisation. 
1.3.3 Mutations in CFTR 
Since the isolation of the CFTR gene there have been over 800 different 
mutations identified (National Institutes of Health Developmental 
conference Statement on Genetic Testing for Cystic Fibrosis 1999). Analysis 
of these reveal that about 50% are missense mutations, 20% are frame shift 
mutations caused by small insertions or deletions and 15% are nonsense 
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mutations. The remainder are splice site mutations and other variations 
(Kerem and Kerem 1996). There are several mutation hotspots with a high 
concentration of the more common mutations occurring in NBF, (reviewed in 
Tsui et al 1992). The most common of these is the ÁF508 mutation. This is a 3 
base pair deletion, between 1652 and 1655 in exon 10, which removes 
phenylalanine 508 from NBD,. It accounts for 70% of the mutant alleles in 
the caucasian population and for large portions of the alleles in other racial/ 
ethnic groups (Table 1.5). Only a handful of others are common ( >1% of the 
total) but some of these are significantly enriched or depleted in specific 
ethnic populations. The vast majority of mutations are very rare. While 
these constitute a challenge to the clinical geneticist with respect to molecular 
diagnosis, they are also of considerable valuable in studies that seek to link 
protein structure to function and genotype to phenotype. 




Whites 70 13 - 
Hispanics 46 11 - 
Ashkenazi Jews 30 67 - 
American Indians 0 25 69 
African Americans 48 4 23 
TABLE 1.5 CF mutations in specific ethnic groups 
Adapted from National Institutes of Health Developmental conference 
Statement on Genetic Testing for Cystic Fibrosis 1999 
Different mutations can cause different defects in the production and 
function of CF1 R (see Figure 1.2). 
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FIGURE 1.2 CFTR mutations classes 1 to 4 
These mechanisms have been classified into five groups as described below 
(Welsh 1996): 
Class 1 mutations:- Defective protein production. 
The mutations in this group result in premature termination signals 
and protein truncation. Some cases, such as R553X, result in unstable mRNA 
and no detectable protein, in others unstable truncated proteins may be 
produced. 
Class 2 mutations:- Defective protein processing. 
These mutations have been shown to result in a failure to traffic CFTR 
to the correct cellular location. This group includes the most common 
mutation ÁF508 and the G480C mutation. 
Studies have shown that CF'l'R progresses through several stages of 
glycosylation (Cheng et al 1990). This maturation can be observed by 
analysis of purified CF1'R on an SDS- polyacrylamide gel. Nascent, non- 
glycosylated CF 1R is observed as a 130 kDa band (band A), this is processed 
in the endoplasmic reticulum, to its core glycosylated form, detected as a 135 
kDa band (band B). Wild type CF1'R is then transported to the Golgi 
apparatus where it will undergo complex glycosylation resulting in mature 
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CFTR, observed as a 170 kDa band (band C), before transportation to the cell 
membrane and other sites. However, studies have shown that the majority 
of wild type CFTR becomes degraded before reaching the band C form 
(Cheng et al 1990). 
In cells expressing CN1R with the AF508 mutation, band B protein fails 
to mature to produce any band C CFTR protein (Cheng et al 1990). 
Mechanisms are proposed to exist in the endoplasmic reticulum, whereby 
prolonged association with chaperone proteins may prevent the transport of 
mutant /misfolded /incorrectly complexed protein for further processing. 
The mutant protein is instead degraded in the endoplasmic reticulum by the 
ubiquitin -proteasome system (reviewed in Kopito 1999). 
However, under permissive conditions in vitro, such as reduced 
temperature (Denning et al 1992), correct processing and localisation of 
mature protein can occur. Correction of the trafficking defect for class 2 
mutations can allow the mutant CFTR to reach the apical membrane where it 
can demonstrate chloride channel function. This function can be comparable 
to wild type CFTR, in the case of G480C (Smit et al 1995), or, in the case of 
AF508, sub -optimally with between 30% (Denning et al 1992) and 100% (Li et 
al 1993) of normal wild type activity reported. 
A considerable body of research supports this model for the 
dysfunction of CN'1'R containing class 2 mutations. However, the studies 
have been performed almost entirely in heterologous model systems and 
doubts exist about extrapolation to the in vivo situation. In a recent study 
immunohistohemical analysis was used to examine the localisation of both 
wild type CFTR and protein containing the AF508 mutation in tissue samples 
(Kälin et al 1999). The results suggested a tissue specific variability in the 
impact of this mutation on the expression and localisation of CH R. Further 
studies are required to confirm and explain these findings 
Class 3 mutations:- Defective Regulation 
The mutations in this category, such as G551D, have less impact on the 
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processing and localisation of CFI R. Some of the mutant protein becomes 
correctly localised but defective regulation of chloride channel activity 
results in very little residual function. These proteins show little response to 
agonists under physiological conditions. 
Class 4 mutations:- Defective Conduction 
Mutations occurring in the putative membrane spanning domains, 
such as R117H and R334W, result in substantially reduced levels of ion 
transport, These mutant proteins are correctly processed, localised and 
regulated, but show reduced single channel conductance and a lower open 
state probability. 
Class 5 mutations:- Reduced levels of normal RNA or protein 
This category encompasses mutations that alter the quantity of normal 
mRNA and protein, such as the 5- thymidine (5T) variant of the intron 8 
polypyrimidine tract (IVS8 -T). This mutation results in alternative splicing 
of CFTR mRNA and gives rise to two transcripts; one normal and one with 
an in frame deletion of exon 9 (Chu et al 1992). The protein product of the 
latter is devoid of cAMP activated chloride conductance activity. The level 
of normal transcript has been shown to be tissue specific (Rave -Harel et al 
1997) and to be dependent upon the associated IVS8 -T. The 5T variant is 
associated with the lowest levels, these are increased with the 7T variant and 
highest with the 9T variant (Mak et al 1997). 
In each class of mutation when the level of functional CF 1 R at the 
apical membrane of epithelial cells in CF patients falls below a critical level 
this results in the characteristic clinical abnormalities in the organs in which 
CFTR is expressed. 
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1.3.4 The genotype - phenotype relationship 
Understanding the relationship between genotype and phenotype has 
obvious diagnostic and therapeutic implications. It can prove informative in 
determining the pathophysiology of the disease and the prospects for novel 
interventions. It is also critical in the design and interpretation of model 
systems 
Mutations in CFTR are usually classified as either "mild" or "severe" 
dependent upon whether they confer pancreatic sufficiency (PS) or 
pancreatic insufficiency (PI). 
Assessing the severity of mutations with reference to the classification 
described in section 1.3.3, those in classes 1 to 3 are generally "severe ", while 
those in classes 4 and 5 tend to result in "mild" mutations (Durie et al 1999). 
The common ÁF508 mutation is classified as "severe ", conferring pancreatic 
insufficiency. It is also associated with meconium ileus in approximately 
10% of affected neonates. Although the G551D mutation is also "severe" and 
confers pancreatic insufficiency, it is observed to be associated with a much 
lower incidence of meconium ileus. R117H is a "mild" mutation, and is 
generally associated with pancreatic sufficiency. Despite these differences all 
three mutations are associated with infertility and lung disease. In contrast, 
the 5T mutation shows partial penetrance and a wide variability in disease 
expression. Individuals homozygous for the 5T allele have been documented 
to be asymptomatic despite expressing as little as 8% of normal CFI R in 
some tissues (Chu et al 1992). In other instances these individuals present 
with congenital bilateral absence of the vas deferens (CBAVD), but no other 
symptoms associated with CF. 
This relatively clear relationship between genotype and phenotype 
demonstrated in the pancreas does not apply to all the affected systems (The 
Cystic Fibrosis Genotype- Phenotype Consortium 1993). In particular the 
severity of lung disease does not show a clear genotype correlation. 
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However, one study reported that ÁF508 heterozygotes with the second CF 
allele in the NBD- encoding exons has an increased risk of acquiring P. 
aeruginosa infection early in life (Kubesh et al 1993). 
The relationship between genotype and phenotype is of course further 
complicated by compound heterozygosity and /or the presence of more than 
one mutation on the same allele. The presence of one "mild" allele will result 
in pancreatic sufficiency. Thus the "mild" allele appears to confer a 
dominant effect over the "severe" allele (Durie et al 1999). Individuals 
carrying the R117H allele are typically more severely affected if the R117H 
mutation is in cis with the 5T polymorphism as opposed to the 7T variant. 
This is probably because the associated IVS8 -T will affect the quantity of 
already functionally impaired CFI R that is correctly spliced (Estivill et al 
1996). 





5T / 5T 
5T / 5T 
R117H I CFsevere 
R117H +5T I CFsevere 
CFsevere / CFsevere 
FIGURE 1.3 The effect of alterations in the quantity and quality of CFTR 
Adapted from Estivill et al 1996. 
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Thus it is clear that the disease phenotype can be affected by 
alterations in both the quantity and the quality of CN l'R (see Figure 1.3). 
Furthermore, the clinical characteristics of the disease may relate to the 
sensitivity of specific organs to CN°lR dysfunction and tissue specific effects 
may impact upon the manifestation of identical mutations in different 
tissues. 
The effects of alterations in the quantity of CFTR also help to address 
the important question of how much functional CH R is required for 
therapeutic benefit. In studies using mixed epithelial cell monolayers of CF 
and non -CF cells, the results have suggested that functional CF'l'R is only 
required in approximately 10% of cells to restore chloride ion transport to 
normal (Johnson et al 1992). In contrast, the relationship between the 
proportion of CF cells and the level of sodium absorption is linear. Further 
work with transgenic CF mice (see section 1.7.3.1) broadly supports the non- 
linear relationship between CFTR levels and chloride transport in vivo (Dorin 
et al 1996). However, while the former studies examined variation in the 
proportion of cells with normal CFTR levels, the latter studies described the 
effects of variation in the levels of CFTR, expressed in a constant number of 
cells. Together with clinical observations of diminished disease severity in 
the presence of residual function alleles, these studies demonstrate a non- 
linear relationship between genotype and phenotype. This hypothesis serves 
to model an important component of disease pathogenesis and severity and 
also underpins the hopes for successful treatment by gene therapy. 
1.3.5 Phenotype modification 
While studies examining specific mutations and levels of functional 
CN'l'R can begin to explain some aspects of phenotype, this only provides a 
23 
partial explanation. The clinical phenotypes of individuals carrying identical 
mutations in CFTR can still demonstrate substantial variation. 
CF is a single gene disorder in which all individuals inheriting two 
mutated alleles of the CFTR gene will manifest classical disease symptoms 
and pathology. This statement is broadly correct, although individuals with 
only class 5 mutations in both alleles (see section 1.3.3) may be diagnosed as 
having CBAVD rather than CF. Nevertheless, any disease process may be 
affected by environmental factors and by mutations in other genes that can 
impact upon related systems or processes. The latter influence is that of 
independently segregating phenotype modifier genes. 
Mouse models of CF are a valuable resource in which to study these 
factors because of the ability to control both the environment and the genetic 
cross. In this manner it has been possible to compare the effect of specific 
CFTR mutations on different inbred strains and search for genetic modifiers 
of disease (see section 1.7.4). The first such modifier locus was identified in 
1996, on the proximal region of mouse chromosome 7. This locus was shown 
to modify the onset and severity of intestinal pathology and survival 
(Rozmahel et al 1996). The region shows conserved synteny with human 
chromosome 19q13, and led to the detection of a modifier locus (CFM1), at 
19813.2, for meconium ileus but not pulmonary function (Zielenski et al 
1999). It had been suggested that this modifier could take the form of a 
calcium dependent chloride channel that may be able to partially compensate 
for the absence of CFI R and alleviate the symptoms. However, no such 
candidate gene has yet been discovered at this locus. Further studies to 
establish genetic modifiers for pulmonary pathology in mouse models of CF 
are ongoing (see section 1.7.4) (Haston et al 1999, Trines and Dorin 1999). 
A recent study investigating pulmonary phenotype modifiers in 
humans reported an association between mannose- binding lectin gene 
(MBL2) heterogeneity and the severity of lung disease and survival in CF 
(Garred et al 1999). Mutations in MBL2, and /or its promoter, result in 
decreased serum levels of MBL, a serum protein that forms part of the innate 
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immune defence (see section 1.6.2.5). These mutations are shown to correlate 
with life expectancy, the rate of pulmonary deterioration in CF individuals, 
(particularly in response to infection with P. aeruginosa) and perhaps 
susceptibility to B. cepacia. 
Further insights may come from phenotype comparison of individuals 
with the same genotype and ethnic background in very different 
environments and from studies of CF twins with age matched siblings in 
similar environments and with the same CFTR genotype. A European study 
of this kind is currently underway (Bronsveld et al 1998). 
Thus, independently segregating genes modify the effects of CN'lR 
dysfunction in different tissues and are responsible for some of the 
phenotype variability observed. However, it is likely that environmental 
influences also play an important role in disease pathogenesis, particularly in 
the development of lung disease. A more thorough understanding of 
phenotype determinants will no doubt require the resolution of a complex 
series of interactions between specific mutation effects, genetic modifiers and 
environmental stimuli. Animal models of disease have great potential in the 
pursuit of this knowledge. However, in order to realise this potential, it is 
critical that the role of all of these phenotype determinants is appreciated and 
that consideration in given to the limitations of every model system. 
1.3.6 Other roles for CFTR 
Although the primary defect in CF is the failure of chloride transport, 
there is evidence that CF I also acts as a conductance regulator, influencing 
the activity of other ion channels. It has been proposed that CFTR is 
involved in the regulation of ENaC activity, the function of outwardly 
rectifying Cl- channels (ORCC) and the transport of ATP. In addition 
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intracellular CFTR has been proposed to influence exocytosis, endocytosis 
and the acidification of intracellular organelles. 
In normal airway epithelium the dominant ion transport activity is the 
absorption of sodium ions by ENaC. The addition of amiloride will block 
this activity, with the remaining current being Cl- secretion, induced by the 
resultant hyperpolarisation of the apical membrane and voltage clamping. It 
is worth noting, however, that in vivo (and in the absence of amiloride, under 
open- circuit conditions) the transepithelial gradient for Cl- movement is 
absorptive. In CF epithelia there is an increase in the basal Na+ absorption 
and a decrease in amiloride resistant current (Boucher 1994). 
In vitro studies, using transfected Madin -Darby canine kidney 
(MDCK) cells (Stutts et al 1995) and lipid bilayers (Ismailov et al 1996), have 
demonstrated that CFIR can regulate the activity of ENaC in these systems. 
These studies have shown that in the absence of CN'l'R the basal rate of Na+ 
transport by ENaC is enhanced and can be further stimulated by cAMP. 
However in the presence of wild type Cr" l'K there is a decrease in the single 
channel open probability (Po) of ENaC and an inhibitory effect with the 
addition of cAMP. A study utilising the yeast two hybrid system has 
suggested a direct protein interaction between the C- terminal end of the a- 
subunit of ENaC and a domain of wild type CF I R incorporating NBDI and 
the R domain may be critical for this interaction (Kunzelmann et al 1997). 
However, the underlying mechanism is unresolved. 
In contrast to these studies, recent research using isolated sweat ducts 
demonstrated that ENaC activity was dependent upon, and increased with, 
the activity of CFTR (Reddy et al 1999). It has been suggested that the 
absorptive cells in the airway epithelium may behave in the same way as the 
sweat duct. However, because the airway epithelium contains both 
absorptive and secretory cells, the net effect of diminished absorptive 
transport and loss of secretory transport may appear as a net increase in 
sodium absorption in CF airways. 
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The role of ENaC and the transport of Na+ ions may be of considerable 
significance in the pathogenesis of CF lung disease and will be seen to be 
fundamental to the hypotheses concerning the composition and function of 
the airway surface liquid (ASL) (see section 1.5.1). 
CFTR has also been demonstrated to have a regulatory role in the 
activity of ORCC (reviewed in Schweibert et al 1999). The stimulation of 
ORCC requires the PKA- and ATP -dependent activation of CFTR and the 
transport of ATP across the cell membrane. This extracellular ATP then acts 
as an agonist, via purinergic receptors to stimulate ORCC activity. The 
release of extracellular ATP in the absence of active CF "1 R is not adequate for 
the activation of ORCC. Thus an additional role for CF l'R involving direct 
interaction with ORCC is proposed. Whether the role of CF i'R in the 
transport of ATP is direct, as an ATP channel, or indirect, as a regulator of 
ATP transport, is yet to be resolved. However, the results of various studies, 
including the demonstration that CFI R in lipid bilayers does not possess 
intrinsic ATP channel activity (Li et al 1996), suggest that CFTR plays an 
indirect role in this process. It has been suggested that C1-."1R may also 
influence the activity of Ci channels from the C1C family and Ca+- dependent 
chloride channels. In this manner CFTR may promote the transport of CF 
ions not only through its intrinsic Cl channel activity, but also through 
regulatory interactions with other apically localised ion channels. 
The intracellular localisation of CH'R has been studied using 
immunological and functional approaches. While care must be taken over 
the interpretation of results where overexpression of CF'l'R and heterologous 
systems have been used, these suggest the presence of CHR in the Golgi, ER 
and in sub -apical clathrin- coated vesicles (reviewed in Bradbury 1999). This 
is perhaps not surprising, given the requirement to traffic CN°l'R to the apical 
membrane. However, various studies suggest that CFTR is not simply in 
transit, but has functional significance at these sites. 
In studies performed using CF and non -CF salivary glands, from both 
humans (McPherson et al 1986) and mouse models of CF (Mills et al 1995), a 
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failure of exocytosis was demonstrated in the CF tissues. This defect was 
manifest in the CF tissues as a decrease in mucin and amylase release in 
response to cAMP agonists, in comparison to non -CF samples. Further 
studies using cell lines have demonstrated that endocytosis and exocytosis 
are co- ordinately regulated by cAMP in the presence of functional CFTR, but 
not CI-TR carrying clinical mutations. This effect on membrane recycling 
results in increased exocytosis and decreased endocytosis in response to 
raised levels of cAMP (Bradbury et al 1992). 
These results have led to the hypothesis that CF I R may modulate the 
traffic of membrane vesicles. Furthermore, CFTR may regulate exocytic 
insertion of itself into the plasma membrane upon appropriate cellular 
stimulation, with recycling and endocytic retrieval after the removal of such 
stimuli. This hypothesis may be of significance to the pathogenesis of lung 
disease, with particular relevance to the possible internalisation of P. 
aeruginosa (see section 1.5.2.2) and the secretion of components of the innate 
lung defence (see section 1.6) by epithelial cells. 
It has also been suggested that CFTR may be responsible for chloride 
transport across the membranes of intracellular organelles. Dysfunction of 
CFTR has been shown to result in defective acidification of these organelles 
(Barasch et al 1991). This has the potential to produce a myriad of secondary 
effects by altering the processing other glycoproteins in the Golgi apparatus, 
including the pattern of sulphation, sialylation and fucosylation. These 
changes could be of significance in the pathogenesis of CF lung disease, 
having the potential to create increased sites of adherence for respiratory 
pathogens (see section 1.5.2.1). However, more recent studies have produced 
conflicting results, finding no evidence of changes in organelle pH in CF cells 
(Seksek et al 1996, Chandy et al 1999). 
These secondary defects serve to remind us of the complexities of the 
physiological processes in which CF'l'R is involved and the gaps in our 
knowledge. The role that these defects may play in disease pathogenesis 
remains unclear, but Na+ hyperabsorption and the altered pattern of 
28 
glycoprotein sialylation have been proposed as fundamental to the 
development of lung disease in CF (see section 1.5). 
1.3.7 Tissue specific localisation of CFTR 
The expression pattern and localisation of CI-11( in wild type tissues 
has been demonstrated to be both tissue and cell specific, using 
immunohistochemistry and in situ studies (reviewed in Cohn 1994). 
The predominant site of CF ER in the eccrine sweat ducts has been 
shown to be the luminal reabsorptive duct cell. In these cells CFTR is 
localised primarily in the apical domain (Kartner et al 1992). 
In the pancreas CFTR is observed at the highest levels in the apical 
region of the intralobular duct cells. It is also present at much lower levels in 
the cells lining the larger pancreatic ducts (Marino et al 1991). 
Studies of the gastrointestinal tract have revealed that CFTR 
expression gradually decreases across both the proximal -to- distal axis and 
the crypt -villus axis. The highest levels have been shown to occur apically in 
the crypt enterocytes and submucosal glands (Brunner's glands) of the 
proximal small intestine (Strong et al 1994 ). High levels of CFI R have also 
been detected, with a punctate pattern throughout the cytoplasm, in a small 
subpopulation of enterocytes scattered throughout the villi, and in the 
secretory compartments of the goblet cells of the small intestine (Kälin et al 
1999). 
Expression of CFTR in the liver has been shown to occur primarily in 
the intrahepatic bile duct cells (Cohn 1999) and to be localised to the apical 
compartment. 
Studies in the rat have demonstrated that the highest levels of CI- °I'R in 
the reproductive system occur in the epithelial lining of the endometrium 
and in the seminiferous tubules. In the latter, this expression was shown to 
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be stage specific with respect to spermatogenesis (Trezise and Buchwald 
1991). 
Finally, the predominant site of CFTR expression in the lungs has been 
shown to be in the submucosal glands, with only low levels in the bronchial 
epithelium (Engelhardt et al 1992). Expression in the submucosal glands is at 
or near the apical membrane, uniform in the epithelia of the serous tubules, 
but observed in only a small subpopulation of non -ciliated epithelial cells in 
the collecting and ciliated ducts. 
It is clear that the clinical manifestations reflect many of these 
observations, however the pattern of CFTR distribution also raises various 
questions, not least about the role of the submucosal glands in the 
development of CF lung disease. 
1.4 Lung disease in cystic fibrosis 
While the phenotypic analysis described in the previous section has 
provided a considerable amount of information about disease of the 
pancreas, vas deferens and digestive tract, the severity and course of 
pulmonary disease are not clearly predicted by the CFTR genotype. 
Lung disease in CF is characterised by chronic microbial colonisation 
and repeated acute exacerbations of pulmonary infection, with a distinctive 
spectrum of pathogens. These episodes precipitate progressive, irreversible, 
inflammatory lung damage. Despite the recent advancement of various 
hypotheses the precise aetiology of CF lung disease is still relatively poorly 
understood. 
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1.4.1 Pathology of the CF lung 
Clinical and pathological studies have clearly characterised end stage 
lung disease in cystic fibrosis and the most common sequence of events in its 
pathogenesis (reviewed in Pilewski and Frizzell 1999). The most prominent 
features being; excessive production of viscous mucopurulent secretions, 
airway obstruction and atelectasis, cytokine imbalance and a neutrophil 
dominated cellular response, resulting in severe bronchiectasis and 
respiratory failure. 
The CF lung is macroscopically normal at birth, but studies have 
reported subtle histological abnormalities evident in the tracheal submucosal 
glands of CF foetuses (Ornoy et al 1987) and newborns (Esterly and 
Oppenheimer 1968). These studies describe hypertrophy and hyperplasia of 
the submucosal glands with inspissation of mucus secretions. However, 
another report suggested that similar pathology was evident in the 
submucosal glands of newborns that had died from other airways diseases, 
introducing questions about the relevance of these observations in CF 
(Oppenheimer 1981). Despite this report it does appear that mucus secretion 
is defective at an early stage in the pathogenesis of CF lung disease. More 
critical to our understanding of this process is whether or not this 
abnormality precedes infection. 
The development of lung disease in young CF individuals is 
characterised by the onset of repeated bacterial infection. Studies of the 
clinical course suggest that this leads to airway inflammation and lung 
damage. However, studies in CF infants have raised the question of whether 
inflammation may, in fact, precede airway infection. In one study the 
analysis of bronchoalveolar lavage (BAL) samples from CF infants 
demonstrated pulmonary inflammation present very early in life and in the 
absence of bacterial colonisation (Khan et al 1995). In contrast, a subsequent, 
larger and more rigorous study failed to support the latter conclusion. In 
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this case the inflammatory profile of CF infants, that had no history of 
respiratory symptoms, no exposure to antibiotics and no BAL pathogens 
detected, was analysed. This was found to be significantly different from 
that of CF infants with evidence of pulmonary infection, but not to be 
significantly different from disease control subjects (Armstrong et al 1997). 
Furthermore, a longitudinal component to this study demonstrated 
resolution of inflammation following antibiotic treatment. This supports the 
hypothesis that infection plays a role in initiating and maintaining the airway 
inflammation that characterises CF lung disease. 
The clinical course of CF lung disease is then characterised by a 
vicious cycle of infection, inflammation and airway damage, with complex 
interaction between pathogens, airway epithelial cells, cytokines and the 
immune system. Pulmonary secretions from CF patients contain an 
excessive neutrophil load and high levels of proinflammatory cytokines, 
including IL -8. These secretions also contain proteolytic enzymes produced 
by the neutrophils, such as elastase and cathepsin G, at sufficient levels to 
overwhelm the lungs anti -protease defence mechanisms (see section 1.6.2.3). 
Consequently these enzymes are capable of direct tissue injury, impeding 
bacterial clearance mechanisms and interfering with host immune 
mechanisms. In addition, the DNA from autolysing neutrophils aggregates 
into large fibrils with a consequent increase in the viscosity of the sputum. 
Mucus secretion may be stimulated both by the products of inflammatory 
cells and by bacterial endotoxins (reviewed in Shelhammer 1997). 
Furthermore, P. aeruginosa LPS has been demonstrated to profoundly 
upregulate transcription of the mucin gene MUC2 in epithelial cells (Li et al 
1997). The consequent hypersecretion of mucus from hypertrophied 
submucosal glands and hyperplastic goblet cells contributes to the viscous, 
mucopurulent pulmonary secretions that are so characteristic of CF. 
Studies suggest that, aside from changes to the submucosal glands, 
the earliest lesions occur in the distal airways, with mucus obstruction of the 
bronchioles and inflammation of the bronchiolar walls (Esterly and 
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Oppenheimer 1968). Progression of the disease results in even more 
pronounced bronchiolitis and bronchitis, with goblet cell hyperplasia and 
metaplasia extending distally into the bronchioles and luminal obstruction 
with plugs of mucus and inflammatory infiltrate. Chronic colonisation with 
P. aeruginosa appears to accelerate this decline (see section 1.4.2.4) eventually 
leading to end stage lung disease, characterised by severe 
bronchopneumonia and bronchiectasis (Oppenheimer and Esterly 1975). 
Post mortem examinations have made a considerable contribution to 
the characterisation of lung disease in CF, but are obviously restricted in a 
variety of ways. The main studies report either on predominantly end stage 
lung disease or observations from CF newborns that have died of meconium 
ileus. As a result of improved diagnosis and treatment the latter reports are 
rather older. It is obviously difficult to establish the relative roles of the 
many possible contributing factors, and the interplay between them, from 
these kinds of data. Nor is it possible to draw too many conclusions about 
the likely sequence of events. Theoretically, mouse models of CF provide a 
system with which to target these gaps in our knowledge. Such model 
systems may be manipulated to control all the factors contributing to 
phenotype development and allow characterisation, by histopathological or 
other means, at any timepoint required. In this manner these observations 
made in humans may provide the framework around which to construct a 
detailed explanation for the development of CF lung disease. 
1.4.2 Microbiology of the CF lung 
Lung disease is the major cause of morbidity and mortality in CF and 
is characterised by chronic microbial infection. The environment of the CF 
lung is unique, resulting in infection with a rather narrow spectrum of 
pathogens. This most commonly includes respiratory syncytial virus (RSV), 
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Staphylococcus aureus, Haemophilus influenzae, Pseudomonas aeruginosa and 
Burkholderia cepacia. In general, these occur in a similar sequence, with RSV 
infections and colonisation with S. aureus in infancy, followed by H. 
influenzae in early childhood, P. aeruginosa in later childhood to early 
adolescence and the highest incidence of B. cepacia in late teenage years 
(reviewed in Govan and Nelson 1992). 
1.4.2.1 Viral infections 
Infants with CF are typically subject to viral respiratory infections, 
most commonly with RSV, although disagreement exists as to whether such 
infections are more common in CF than in the general population. A 
longitudinal, observational study of an unselected cohort of CF infants 
identified in a screening programme examined the incidence of such 
infections in hospital admissions (Armstrong et al 1998). Almost 40% of the 
cohort were admitted to hospital for respiratory illness within the first year 
of life. Greater than 50% of these admissions were associated with viral 
infections, predominantly RSV. In those infants, the infections were self - 
limited, but the airway inflammatory responses were observed to be similar 
to the infants with bacterial infections. Furthermore, infants admitted with 
severe, or persistent, respiratory symptoms were found to be at increased 
risk of acquiring P. aeruginosa infection within the first five years of life. 
Thus, it seems possible that early viral respiratory infections could be 
involved in establishing the vicious cycle of infection and inflammation that 
characterises the development of CF lung disease. 
1.4.2.2 Staphylococcus aureus 
The organism first recognised to cause chronic lung infection in the 
lungs of young CF individuals was S. aureus (Di Sant'Agnese and Anderson 
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1946). Colonisation with this bacteria once killed the majority of CF patients 
in infancy, but aggressive antibiotic therapy has enabled increased control 
over this infection in recent years. 
S. aureus is a Gram -positive, non -motile, non -spore -forming, 
unencapsulated coccus. It is human commensal, commonly isolated from the 
anterior nares and the skin, but is also an important pyogenic organism. 
Approximately 30% of healthy people carry S. aureus in the nasopharynx, 
however, lower respiratory tract infection with S. aureus does not occur in 
the general population. It is characteristically the first bacteria to colonise the 
respiratory tract of CF individuals and is the predominant infection in the 
first two years of life (reviewed in Govan and Nelson 1992). No specifically 
CF- associated strains of S. aureus exist. The strain that is isolated from the 
lower airways of a CF individual is generally also carried in the nasopharynx 
and by non -CF family members (Tümmler and Kiewitz 1999). 
S. aureus produces a variety of virulence factors including coagulase, 
leucocidin, protein A, catalase, hyaluronidase, haemolysins and exotoxins. 
However, the precise role of these factors in CF lung disease remains unclear. 
The S. aureus strains isolated from CF sputum can be classified as 
three morphologically separate types; mucoid, non -motile and small colony 
variant (SCV). These vary with respect to the production of virulence factors 
and degree of antibiotic resistance (reviewed in Hutchison and Govan 1999). 
Mucin- binding capacity has also been shown to vary between strains, 
however all three colonial morphotypes have an affinity for human mucin 
(Tivier et al 1997). 
A recent study examined the localisation of S. aureus in sections of 
infected bronchi and bronchioles of CF patients after lobectomy (Ulrich et al 
1999). The bacteria detected were predominantly mucus bound, embedded, 
and uniformly distributed in the obstructing mucus plugs. Furthermore, 
utilising a cell ball model of respiratory epithelium, S. aureus was shown to 
adhere predominantly to the secreted mucus and not to the airway epithelial 
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cells. This mucus binding was not observed to be any greater in cell balls 
from CF patients than those from non -CF individuals. It was suggested that 
the binding of S. aureus to the mucus layer may in fact prevent contact with 
the epithelial cells, damage from bacterial toxins, invasion and systemic 
infection. It is possible that this mucin- binding capacity may enhance the 
ability of S. aureus to infect the CF airways as a result of impaired 
mucociliary clearance mechanisms (see section 1.5.1.1). 
Despite the results of the cell ball studies described above, there is 
considerable in vitro evidence that S. aureus can bind strongly to specific 
bacterial receptors on the surface of airway epithelial cells (see section 
1.5.2.1). These receptors are present at greater density on CF and 
regenerating airway epithelium, may be upregulated by bacterial products 
and can also act as receptors for P. aeruginosa. This hypothesis and studies 
detailing the affinity for mucus -binding need not be viewed as mutually 
exclusive. It is possible that epithelial cell adherence is a rare event, with 
serious consequences, which occurs with increased likelihood in CF. The 
role of epithelial damage and regeneration may also be critical, potentially 
increasing cell contact with bacteria and the number of receptors present on 
those epithelial cells. 
Although the threat posed by S. aureus has diminished in the 
antibiotic era it may still play an important role in the initiation of CF lung 
disease and the creation of a unique environment that provides the 
opportunities for subsequent colonisation by other bacteria. Furthermore, it 
is unclear to what extent the extensive use of anti- staphylococcal 
chemotherapy has affected the spectrum of atypical pathogens that now 
characterise later stage lung disease in CF. Finally, as a consequence of the 
use and overuse of antibiotics in society, multi -drug resistance is becoming 
much more widespread. The emergence of methicillin resistant S. aureus 
(MRSA) is of considerable concern and has the potential to produce further 
re- evaluation of the threat posed by this organism in the future. 
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1.4.2.3 Haemophilus influenzae 
Pulmonary infection with Haemophilus influenzae is common in young 
CF individuals, but the significance of this observation and the role of the 
organism in the development of CF lung pathology is controversial and its 
effect may be underrated. Many clinics do not routinely treat patients 
colonised with this organism, judging it to be almost commensal at low 
numbers (Hutchison and Govan 1999). 
H. influenzae is a Gram -negative coccobacillus. The capsulated strains 
can cause diseases such as meningitis and osteomyelitis, while the non- 
capsulated strains are mainly responsible for exacerbations of chronic 
bronchitis and bronchiectasis in individuals with and without CF. The 
majority of isolates from CF patients are non -capsulated. CF individuals are 
often colonised with multiple strains of H. influenzae, with one predominant 
strain (Hutchison and Govan 1999). 
H. influenzae infection can generally be well controlled with antibiotic 
therapy. However, as is the case for S. aureus, antibiotic resistance is also 
appearing in certain strains of this bacteria isolated from CF lungs. 
1.4.2.4 Pseudomonas aeruginosa 
After the first two years of life infection with the opportunistic 
pathogen Pseudomonas aeruginosa predominates. Evidence of infection in the 
lower airways occurs in a third of CF infants by the age of 5 years, 
(Grimwood et al 1997), rising to 90% of CF adults (Hutchison and Govan 
1999). It remains unclear to what extent this organism is reliant upon 
previous infections and /or antibiotic therapies to alter the milieu of the CF 
lung and create an environment suited to its requirements. 
P. aeruginosa is a Gram -negative, motile, non -sporing, non -capsulate 
bacillus that is widely distributed in water and soil. It is naturally resistant 
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to many antibacterial agents as a result of the relative impermeability of the 
OprF porin in the outer membrane, an active efflux system and the activity of 
ß- lactamase (reviewed in Hancock 1998). P. aeruginosa is an opportunistic 
pathogen for plants and animals. Isolates produce numerous virulence 
factors including exotoxin A, exoenzyme S, elastase, alkaline protease, 
pyoverdin, haemolysins, lipopolysaccharide (LPS), pili and an unusual 
exopolysaccharide resembling the algae alginate (Gilligan 1991). In humans 
it can affect a variety of organs, such as infections of the eye, ear and burn 
wounds. It can also be the aetiological agent responsible for nosocomial 
pneumonia, causing disease primarily in immunocompromised individuals. 
Infection with P. aeruginosa in CF is atypical in several key ways 
(Govan and Harris 1986); firstly, the host is immunocompetent in terms of 
cellular and humoral responses, secondly, the infection remains localised to 
the respiratory tract and finally, interaction between the host and pathogen 
results in a characteristic transformation of the bacteria. This transformation 
is from a classic non -mucoid to a mucoid colonial phenotype. 
It has been suggested that initial asymptomatic, and often 
intermittent, colonisation of the upper respiratory tract occurs, preceding 
aspiration to the lower airways. Indeed, following lung transplantation in 
CF, colonisation of the new lungs occurs with the same strain of P. aeruginosa 
responsible for pre -transplant colonisation, suggesting a reservoir exists in 
the upper respiratory tract (Walter et al 1997). 
Initial colonisation typically occurs with motile, planktonic P. 
aeruginosa. These bacteria have a non -mucoid colonial phenotype, smooth 
LPS and can be seen widely dispersed throughout the sputum. The 
distribution and frequency of strains seen in CF individuals matches that 
observed in other diseases and in the environment (Tümmler and Kiewitz 
1999). Thus, colonisation may be possible with practically any strain. 
However, it seems likely that some strains have a greater propensity for the 
CF lung than others. In one study, two unrelated CF individuals were 
demonstrated to have become colonised with the same non -mucoid strain 
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after sharing a hydrotherapy pool, despite at least 5 other strains being 
present in the water (Nelson et al 1990). Interestingly, this strain was found 
to be highly mucinophilic, demonstrating chemotaxis and adhesion to CF 
mucin. 
Early colonisation with non -mucoid strains may be eradicated, 
however, most individuals soon become colonised with a single strain of P. 
aeruginosa that remains throughout the patients lifetime (Römling et al 1994), 
despite the presence of anti- pseudomonal antibodies. Subsequent isolation 
of other strains is rare. Unrelated CF individuals are usually colonised with 
different strains, but siblings with CF tend to show colonisation with the 
same strain of P. aeruginosa, suggesting that cross -infection may occur if there 
is prolonged, close contact. 
The transformation of P. aeruginosa in the CF lung is practically unique 
and almost diagnostic for the disease. This process results in colonisation 
with a non -motile, mucoid phenotype with rough LPS existing within a 
complex biofilm (reviewed in Govan and Deretic 1996). These strains lose 
their flagella and become LPS deficient (non -typable or polyagglutinating 
rough) with the loss of O side chains and increased susceptibility to human 
serum. Mutations in mucA gene, leading to inactivation, result in the 
constitutive expression of alginate biosynthesis genes (Martin et al 1993). It is 
the selection for these mutants in the CF lung that creates the mucoid 
phenotype. This process results in mucoid and non -mucoid organisms co- 
existing in the CF lung and in many cases a heterogeneous population of 
mucoid strains with different mutations in mucA (Boucher et al 1997). The 
environmental stimuli that provoke the conversion to mucoidy are as yet 
unclear. However, recent studies have suggested key roles for neutrophils 
and their oxygen radicals (Mathee et al 1999) and the dysfunction of naturally 
occurring antibacterial peptides (Singh et al 1999) (see section 1.6.1) in the 
creation of mucoid phenotypes. While all wild -type, non -mucoid strains of 
P. aeruginosa have the potential to undergo the transformation to mucoidy, 
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the only other natural niches known for the overtly mucoid form, outside of 
the CF lung, are in bronchiectasis and the rare occurrence in urinary tract 
infections (Boucher et al 1997). 
The alginate produced by mucoid P. aeruginosa is an 
exopolysaccharide polymer made up of guluronic acid and mannuronic acid 
(reviewed in Govan and Deretic 1996). It confers further antibiotic resistance 
to the organism and an electrolyte -rich physical barrier to the host immune 
system, interfering with opsonic and non -opsonic mechanisms and 
quenching reactive oxygen intermediates. Alginate is the primary 
constituent of the biofilm, which supports the growth of these bacteria as 
microcolonies, adherent to the airway epithelium. These biofilms are 
complex "pillar" and "mushroom" -like structures with water channels 
between them, within which subgroups of bacteria may behave in quite 
diverse manners (Molin et al 1999). Bacteria within these biofilms may utilise 
a system known as quorum sensing to provide an index of population 
density, to regulate biofilm differentiation and integrity and the production 
of virulence factors. This is achieved with at least two cell -to -cell signalling 
systems communicating via the production of acylhomoserine lactone 
molecules (Davies et al 1998). Understanding these systems may establish 
novel approaches for therapeutic intervention. 
While there is considerable variability in the time scale for the 
emergence of mucoid variants of P. aeruginosa, this process can occur in as 
little as three months after the initial colonisation (Govan and Deretic 1996). 
Subsequently, the forced expiratory volume in the first second (FEV1), which 
is the single best predictor of mortality, will decline more quickly in these 
individuals. A recent study suggested that infection of CF individuals with 
mucoid P. aeruginosa was associated with both genotype and the level of 
opsonic antibodies specific for P. aeruginosa mucoid exopolysaccharide. 
However the only factor associated with the degree of functional impairment 
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of the lungs was the presence or absence of infection with mucoid strains 
(Parad et al 1999). 
Thus lung colonisation with P. aeruginosa in CF involves a complex 
series of modifications from infection with a relatively innocuous strain 
through to the establishment of chronic infection with a mucoid organism 
and subsequent more rapid clinical deterioration. Despite considerable 
advances in the development of anti- pseudomonal therapy, it remains 
palliative and seldom, if ever, results in eradication of mucoid strains. 
1.4.2.5 Burkholderia cepacia 
Since the 1980s, infection with Burkholderia cepacia has become an 
increasing concern in CF and has led to policies within the CF community in 
an attempt to minimise cross infection. 
B. cepacia was originally described as a plant pathogen, capable of 
causing the soft rot of onions (Burkholder 1950), and not considered to be 
pathogenic to humans. It is a Gram -negative, non -spore forming, aerobic, 
motile baccilus, found in soil, water and vegetation. It has an unusually 
large genome, with three replicons, a total DNA content of over 7 Mb and 
demonstrates considerable plasticity. Recent taxonomic studies have defined 
five distinct species within what is now referred to as the B. cepacia complex; 
genomovars I -V (Vandamme et al 1997). The majority of clinical strains are 
from genomovars II and III and show the greatest association with acute 
clinical decline. B. cepacia has been reported to produce a number of 
virulence determinants including haemolysin, protease, lipase, catalase and 
endotoxin, but the clinical significance of these observations is not yet clear 
(reviewed in Hutchison and Govan 1999). B. cepacia is notoriously resistant 
to antibiotics and disinfectants and no effective antimicrobial therapy is 
available. Indeed one study demonstrated the ability of this microbe to 
utilise Penicillin G as the sole source of carbon and energy (Beckman and 
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Lessie 1979). Furthermore, B. cepacia is resistant to killing by antimicrobial 
peptides (see section 1.6.1). 
Strains of this multi- resistant organism constitute a threat both to CF 
individuals and also to those with Chronic Granulomatous disease (CGD). 
In individuals with CGD there is failure of oxidative killing by the 
phagocytic cells as a result of an inability to produce a respiratory burst 
(Sanders and Crystal 1997). This disease is characterised by recurrent 
infections, suppurative granulomas and infiltration of the viscera with 
pigmented, lipid -laden macrophages. It remains to be seen whether 
dysfunctional CFI1( can also cause a defect in oxidative killing, although it 
has been suggested that inducible nitric oxide synthase (iNOS) associated 
antibacterial activity may be compromised in CF (see section 1.5.3.3). 
The prevalence of B. cepacia infection in CF has risen from -10% in 
1971 (Isles et al 1984) to around current levels of -20% (Hutchison and Govan 
1999). However, localised rates can vary between 5% and 70 %. The 
consequences of infection vary from asymptomatic colonisation through to B. 
cepacia "syndrome" in approximately 20% of cases. This "syndrome" is 
characterised by acute necrotising pneumonia with fever, septicaemia, 
leukocytosis and a raised erythrocyte sedementation rate (ESR) and is 
rapidly fatal. B. cepacia colonisation in CF reduces the average life 
expectancy by 50% (Hutchison and Govan 1999). 
Studies have demonstrated that B. cepacia infection can occur by direct 
cross infection between patients (Govan et al 1993). This has led to 
segregation within CF clinics and communities in an attempt to prevent 
spread. This cross infection may occur via skin contact, aerosols and shared 
food or equipment, but probably occurs most easily by close and frequent 
social contact and by kissing. The transmissability of B. cepacia is strain 
dependent and outbreaks of infection have resulted from "epidemic strains ", 
such as the notorious intercontinental ET /12 or Edinburgh- Toronto lineage 
(Govan and Deretic 1996). This isolate, and others responsible for epidemic 
spread, demonstrate considerable adhesion to respiratory mucin, associated 
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with giant cable pili (Sajjan et al 1995). The gene responsible for the cable pili 
has been identified as cbl. However, this is not present on all epidemic 
clones, suggesting the presence of other important virulence factors 
(Mahenthiralingham et al 2000). 
As aggressive antimicrobial chemotherapy has dramatically reduced 
the impact of bacteria such as S. aureus, so unusual opportunistic pathogens 
not previously associated with human disease, such as B. cepacia, have arisen. 
It has been suggested that reducing the load of antibiotic sensitive bacteria 
creates a niche for highly resistant organisms to fill. Indeed the recent 
increase in the isolation of organisms such as Alcaligenes xylosoxidans, 
Ralstonia pickettii and Stenotrophomonas maltophilia may support this 
hypothesis (Hutchison et al 2000). 
In this manner, the solution to one threat appears to be the catalyst for 
the onset of even greater problems. However, the basic underlying defect in 
CF remains the same. This reinforces the critical requirement for an 
improved understanding of disease pathogenesis. Why is the CF lung is so 
susceptible to infection, and why does it become colonised with these 
particular organisms? 
1.5 The aetiology of CF lung disease 
The lungs of CF neonates are macroscopically normal (see section 
1.4.1), although the observation of submucosal gland abnormalities may be 
important. However, pulmonary infection and inflammation are evident 
from a very early age, with the isolation of RSV and S. aureus and raised 
levels of pro -inflammatory cytokines demonstrated (Armstrong et al 1998). 
Although some studies suggest that markers of inflammation are raised in 
advance of airway infection (Khan et al 1995), it is difficult to distinguish 
between cause and effect in CF humans. Regardless of this issue, this marks 
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the beginning of a series of insults that will eventually lead to bronchiectasis 
and death in the great majority if CF individuals. Despite considerable 
progress in the last few years, the precise mechanisms by which defective 
transepithelial C1 transport results in development of the characteristic 
pulmonary pathology remain poorly understood and the topic of 
considerable debate. 
It has been proposed that CFTR mutations may cause a primary defect 
in lung function, which alters the lung environment. This alteration may be a 
point of no return, after which a self -perpetuating process begins and 
subsequent pathology need not result from a direct interaction with CF'IR. 
This theory attempts to distinguish between CF disease, caused and perhaps 
maintained by CFTR dysfunction, and CF lung disease, a disease phase 
triggered by the former (Drittanti et al 1997). The alternative implies a direct 
role for mutant CFTR, or the absence of functional MR, throughout the 
disease process. In the former scenario, therapies designed to replace, or 
restore function to mutant CF'1'R may not be of significant value once CF lung 
disease was established. Thus, such models have significant bearing on the 
direction of future research and the emphasis in the design of novel 
therapies. 
Whether CF°l'R dysfunction results in; 1) the creation of an abnormal 
lung environment which harbours, or fails to clear, infectious particles, or 2) 
an abnormal response to CF associated pathogens or impacted, dehydrated 
mucus, are questions that have been difficult to address. The dissection of 
the complex pathogenesis of this disease has suffered from the limitations 
imposed by restricted access to clinical material, a reliance on autopsy 
specimens with "end stage" lung disease and in vitro techniques. The 
development of improved primary culture models has facilitated novel 
approaches and a variety of interesting and at times conflicting hypotheses 
have arisen. Mouse models of CF provide an in vivo system in which to test 
out these hypotheses. 
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Two of the most prominent theories dealing with the fundamental 
defect in the CF lung have concentrated on the role and ionic composition of 
the airway surface liquid (ASL). These have become known as the "isotonic 
absorption /mucus dehydration" theory and the "hypotonic /defensin" 
theory. Other well established hypotheses examine the role of interactions 
between the epithelial cells and specific CF associated bacteria (see Figure 
1.4). Further areas of research emphasise the importance of the submucosal 
glands, cytokines, nitric oxide (NO), antiproteases and the role of the cellular 
inflammatory response. These theories are not all mutually exclusive and it 
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FIGURE 1.4 The pathogenesis of CF lung disease 
Adapted from Davidson and Porteous 1998. 
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1.5.1 The airway surface liquid 
The ASL is a thin layer of liquid, approximately 10 - 20 pm in depth, 
that covers the airway epithelium (reviewed in Pilewski and Frizzell 1999) 
and acts as the first line of lung defence. It is comprised of the periciliary 
liquid (or sol) layer, the minimum depth of which is proposed to be about 6 
µm (the average cilia length), and mucus gel layer. The ASL contains 
mucins, proteins, lipids, peptides, ions and DNA. The upward movement of 
this liquid through the trachea is estimated to be 10 -100 ml /day. The origin 
of the ASL is uncertain, as is the extent of the contribution made by the 
submucosal glands. It is proposed that the volume and /or ionic composition 
of the ASL is regulated by ion transport across the airway epithelium and 
that its composition plays a crucial role in airway host defence. The major 
active ion transport process across human airway epithelia is amiloride 
sensitive absorption of Na +, with Cl- acting as the major counter -anion 
(Knowles et al 1981). 
Two major hypotheses linking the dysfunction of CFTR to the 
pathogenesis of CF lung disease have focused investigation upon salt and 
fluid absorption mechanisms across the airway epithelium (reviewed in Wine 
1999). The studies upon which these theories are based have been performed 
predominantly using air /liquid interface primary cultures of human airway 
epithelium. The apparently contradictory nature of their results may relate 
to important differences in the nature of these culture models (reviewed in 
Guggino 1999). 
1.5.1.1 The isotonic absorption/ mucus dehydration theory 
In the traditional model for the development of CF lung disease, 
mucus hypersecretion and dehydration results in dysfunction of the normal 
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mucociliary clearance mechanisms. Bacterial infection and hyperviscous 
secretions result in the accumulation of mucus in the airways and airflow 
obstruction. Colonisation with CF associated pathogens occurs and 
persistent neutrophil influx contributes to an excessive and damaging 
inflammatory response and cytokine imbalance. Suppuration leads to 
ulcerative bronchitis and ultimately bronchiectasis. Recent studies have 
altered and clarified aspects of this model, proposing the "isotonic volume 
transport /mucus clearance" theory. 
Na CI Hp CI 
I pica! 
IF CFTR 0 ENaC 0 Tight Junction 111 Na /K ATPase 
FIGURE 1.5 The Isotonic absorption / mucus dehydration theory 
Adapted from Wine 1999. 
This hypothesis proposes that the volume of ASL, in particular the 
periciliary liquid layer, is of critical importance and the result of a balance 
between secretion and absorption by the epithelium (see Figure 1.5). It 
proposes that the ASL is produced in the distal airways and removed 
proximally. The surface area of the distal airways is greater than that of the 
proximal airways, resulting in the need for volume absorption (Boucher 
1994). Air /liquid interface primary cultures of airway epithelium were 
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utilised to demonstrate that the driving force for water absorption in the 
normal airways is the active, transcellular absorption of Na+ (Matsui et al 
1998). This is accompanied by the diffusion of Cr ions through tight 
junctions between the cells, followed by water, thus maintaining osmolarity. 
Consequently, this hypothesis predicts that the NaCl concentration of the 
ASL should be isotonic. This was demonstrated in the primary culture 
model, with the concentrations of Na+ and Cl- exceeding 100mM (Matsui et al 
1998). According to this hypothesis, abnormally high Na+ absorption, 
secondary to CF' l'R dysfunction (Stutts et al 1995), would result in an 
increased rate of water absorption. Primary cultures of CF airway epithelial 
cells demonstrated a decreased rate of reduction of ASL height under "thick 
film" and "thin film" conditions, when compared to non -CF cultures (Matsui 
et al 1998). Furthermore, the height of the periciliary liquid layer was 
observed to decrease below that of the cilia and induce rotational mucus 
transport defects in these cultures. Hence, this theory proposes that the 
pathogenesis of lung disease in cystic fibrosis is related primarily to a 
reduction in the volume of ASL. The consequences of this defect are 
suggested to be failure of ciliary transport of the ASL, with mucus retention 
creating a nidus for infection. Infection and inflammation may then 
upregulate mucus production and further exacerbate the defect (Li et al 
1997). 
One premise for this theory, requiring further examination is the need 
to absorb large volumes of fluid produced in the distal airways (reviewed in 
Pilewski and Frizzell 1999). Firstly, most distal airway cells are reported to 
be absorptive in nature, not secretory. Secondly, it may be that the mucus 
gel is moved proximally over the sol, with the latter acting as a stationary 
environment within which the cilia can beat. Furthermore, although studies 
on mucus from CF individuals suggest a spectrum of rheological 
abnormalities (Puchelle et al 1985), in vivo mucociliary clearance studies have 
been inconclusive (Yeates et al 1976, Regnis et al 1994). Finally, it is also 
worth noting that classical CF lung disease is not observed in individuals 
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with Primary Ciliary Dyskinesia Syndrome. This is a disorder of mucociliary 
clearance, which results in rhinitis and bronchitis and can lead to 
bronchiectasis, but generally causes a much less severe lung disease than CF 
(Afzelius 1997). However, in these individuals, mucus hydration, the 
volume of the periciliary layer and the cough reflex are all intact and may be 
able to compensate for the ciliary dysfunction to some extent. 
1.5.1.2 The hypotonic / defensin theory 
The second hypothesis proposes that the normal airway epithelium is 
capable of selectively absorbing salt, without water, to generate a hypotonic 
ASL (Zabner et al 1998) (see Figure 1.6). The theory describes the 
predominant mode of CY transport as occurring transcellularly via chloride 
channels in the apical membrane and non -CFI'R cAMP- activated C1 channels 
in the basolateral membrane (Uyekubo et al 1998), with concomitant Na+ 
absorption through ENaC. This hypothesis predicts that the NaC1 
concentration in the ASL should be hypotonic, with the volume maintained 
constant by osmotic pressure from non -diffusable osmolytes capillary 
pressure from the cilia, or impermeability of the epithelium to water. CF'1'R 
has been demonstrated to be the major chloride channel regulating these ion 
effluxes. Hence this theory predicts that CFTR dysfunction would 
compromise the ability of the cells to absorb C1 ions from the ASL. This 
failure and the consequent impairment of Na+ absorption would result in a 
raised salt concentration in the ASL of CF individuals. Studies utilising 
air /liquid interface primary cultures of airway epithelium have 
demonstrated that transcellular pathways for both Na+ and C1 are required 
for normal fluid absorption. In non -CF epithelia, initial isotonic absorption, 
under "thick film" conditions, is followed by selective absorption of NaC1 
under "thin film" conditions. In the absence of CN I R this process cannot 
occur. A degree of CY absorption occurs through the paracellular route, 
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however this is seen to plateau, having a Na+ to Cr selectivity greater then 1. 
These studies estimate ASL Na+ and Cr concentrations of 50 mM and 37 mM, 
respectively, in non -CF cultures and 100 mM and 90 mM, respectively, in CF 
(Zabner et al 1998). In both cases the same final depth of liquid was 
observed. 
Studies have demonstrated that a hypotonic environment is required 
for the function of antibacterial agents within the ASL (Smith et al 1996). This 
antibacterial property of the ASL was demonstrated in studies utilising 
air /liquid interface primary cultures of normal airway epithelial cells, but 
found to be markedly reduced in the ASL from cultures of CF cells. 
Increasing the salt content of ASL isolated from non -CF cultures was shown 
to dramatically impair its antibacterial activity. Furthermore, this activity 
could be restored to ASL from CF cultures by decreasing the salt 
concentration. These results suggested that the components of the defence 
system are intact, but unable to function correctly in an environment of high 
levels of NaCl (Smith et al 1996). This led to speculation that CF1'K 
dysfunction would alter the ionic environment of the CF lung, leading to 
impairment of the first line of lung defence against bacteria and viruses. This 
would predispose these individuals to infection and possibly precipitate a 
more pronounced compensatory response from other components of the 
defence system, affecting neutrophils, macrophages and cytokine 
production. 
These studies have prompted further research to establish the key 
components of the innate lung defence system. These efforts have centred 
upon naturally occurring antimicrobial peptides; human ß- defensins 1 and 2 
(hBD1, (Goldman et al 1997), and hBD2, (Harder et al 1997), lysozyme and 
lactoferrin, (Travis et al 1999b) (see section 1.6). 
Although this presents an attractive hypothesis, it is worth noting that 
individuals suffering from Pseudohypoaldosteronism (PHA) do not develop 
classical CF lung disease. In these individuals mutations in subunits of 
ENaC result in a salt- wasting disorder. Following the "hypotonic / 
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defensin" theory, a failure to produce hypotonic ASL might be anticipated in 
this condition. The systemic form results in elevated sweat sodium and 
chloride levels and chronic excessive secretion from the respiratory tract. 
However, despite predisposition to pulmonary infections and asthma like 
symptoms, they seldom develop bronchiectasis (Kerem et al 1997), nor the 
display the characteristic bacteriological profile of CF lung disease. 
Furthermore, this hypothesis offers no explanation for the susceptibility to 
pulmonary colonisation with B. cepacia, which has been demonstrated to be 
inherently resistant to cationic peptides (Hancock 1997). 
® CFTR 0 ENaC Tight Junction Nail( ATPase 
FIGURE 1.6 The Hypotonic/ defensin theory 
Adapted from Wine 1999. 
1.5.1.3 In vivo measurements of the ASL NaCI concentration 
In view of these apparently contradictory hypotheses to explain CF 
pathogenesis, it is critical that the precise ASL composition is determined. 
However, the depth of this layer is so small in normal airways that ASL is 
difficult to sample in vivo without disturbing the underlying epithelium. In 
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addition, ASL is likely to be a complex mixture produced by the secretory 
cells of the surface epithelium, by the glands in the trachea and bronchi, and 
contributions from the bronchiolar and alveolar liquid. Thus, studies on 
isolated or cultured epithelium are not the ideal tools for analysing ASL 
composition. 
The techniques used for ASL collection in humans have largely 
focused on the use of small pieces of filter paper to harvest the fluid (Joris 
and Quinton 1992, Knowles et al 1997). However the filter paper technique 
yields relatively large volumes of fluid compared to the amount of ASL 
present at the epithelial surface, raising the possibility that the collected 
samples do not reflect the physiological characteristics of the ASL. 
Alternative techniques have recently been applied to animal models (see 
Chapter 6, section 6.3). 
Thus, perhaps not surprisingly, attempts to determine the 
concentration of Na+ and Cl- in the ASL of CF and non -CF individuals in vivo 
have provided conflicting results (see Table 1.6). One study using the filter 
paper technique demonstrated hypotonic ASL, perhaps reflecting collection 
induced gland secretion, with no difference observed between CF and non- 
CF individuals (Knowles et al 1997). It may be significant that this study was 
performed on newly diagnosed CF infants with no evidence of lower airway 
infection. Other studies have reported raised levels of NaC1 in CF samples, 
using the filter paper technique (Joris et al 1993) or aspiration by a dry 
catheter (Gilljam et al 1989). The later was performed in older individuals 
with evidence of colonisation. Another study, using a nitrocellulose 
membrane to collect ASL, found no significant difference in Na+ levels 
between CF and non -CF infants (Hull et al 1998). However, a significantly 
lower Cl" concentration was recorded in CF infants with no evidence of 
inflammation than non -CF controls. This difference was not significant when 
studying CF infants with obvious signs of inflammation. No significant 
difference was observed when CF infants with and without inflammation 
were compared. A study utilising the bronchial xenograft model found a 
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small increase in the NaCl concentration in the ASL from CF cells, but a more 
significant hyperabsorption of NaC1 and volume by the same xenografts 
(Zhang and Engelhardt 1999). The therapeutic consequences of the two 
theories discussed above are significantly different. Thus, the future 
development of techniques to provide accurate measurements and resolve 




















Site N* N B B B B B - 
CF 
Status U I I U I U 
n 9 9 3 10 5 7 27 
Mean age 27 y 14 m ** 24 y 3 m 2 y - 
Na (mM) 95 110 80 121 NR 78 84 NR 
CI (mM) 110 130 75 111 170 77 95 125 
K (mM) 20 30 25 22 5 NR NR NR 
non 
CF 
Status U U I U U 
n 8 15 19 10 7 48 
Mean age 32 y 26 y 54 y 59 y 7 m - 
Na (mM) 95 110 90 82 NR 85 NR 
CI (mM) 110 125 90 84 85 108 114 
K (mM) 20 30 20 29 4 NR NR 
TABLE 1.6 Estimates of the ionic concentration of the ASL 
Site: N = Nasal, B = Bronchial, Status: U = Uninfected, I = Infected, Mean 
age: y = years, m = months, * stimulated with chilli extract, ** 3 patients; 
aged 6 months, 16 years and 31 years. 
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1.5.2 Bacteria and epithelial cell interaction 
The hypotheses describing abnormalities of the ASL both provide 
convincing theories to explain a generalised increase in susceptibility to 
infection. However, neither provides much explanation for the rather 
narrow spectrum of unusual pathogens that characterises CF lung disease. 
In contrast, the hypotheses concerned primarily with interaction between 
bacteria and epithelial cells specifically address the relevant bacteria. This 
area of research encompasses two main hypotheses; 1) the adherence of P. 
aeruginosa to asialylated glycoproteins (aGM1) on the cell membrane and 2) 
the internalisation of P. aeruginosa by epithelial cells. 
1.5.2.1 Bacterial adherence 
The ability to rapidly remove, or kill, bacteria from the airways is 
crucial to lung defence. An increase in the number of epithelial receptors for 
the bacteria that characterise CF lung disease has been proposed. This has 
been suggested as a mechanism by which these pathogens may gain 
purchase within the airways and perhaps stimulate a destructive, pro - 
inflammatory response. 
Studies utilising primary culture models of airway epithelium, have 
reported that P. aeruginosa adheres to CF cells significantly better than to 
controls. 
Pilin have been demonstrated to be responsible for -50% of P. 
aeruginosa binding. Pilin recognise and bind to the GalNAcß1 -4Gal sequence 
which is exposed in cell surface asialoganglioside 1 (aGM,), but not in the 
sialylated forms of the glycolipid (GM,) (Saiman and Prince 1993). Flow 
cytometric studies have demonstrated that a greater proportion of these 
glycolipids are asialylated in CF cells ( Saiman and Prince 1993) than non -CF 
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cells. Thus receptors for P. aeruginosa are represented at higher levels in CF 
airway epithelia than controls, at the expense of the sialylated GM1. The 
level of aGM1 on CF cells has been found to be increased further in response 
to P. aeruginosa neuraminidase (Saiman and Prince 1993). Thus, this 
pathogen may be able to upregulate the expression of receptors for 
subsequent use and promote its adherence to the epithelial cells. The 
adherence of P. aeruginosa to CF cells can be blocked using both anti-aGM1 
antibodies and a broad spectrum neuraminidase inhibitor (Davies et al 1999). 
In addition, this increased affinity for P. aeruginosa has also been 
observed in damaged and regenerating epithelial cells. During epithelial 
repair, particularly in CF, regenerating cells have been shown to display a 
further increase in the levels of aGM1 (de Bentzmann et al 1996). 
It has been proposed that the alteration in aGM1 levels observed in CF 
cells may be a consequence of defective acidification of intracellular 
organelles, secondary to CFTR dysfunction (Barasch et al 1991). However, 
this mechanism has been questioned by more recent studies (see section 
1.3.6). Regardless of the exact mechanism, further evidence for the role of 
CFTR in modulating the level of bacterial adherence comes from experiments 
utilising primary culture of respiratory epithelium from CF patients, before 
and after transfection with human CFTR gene therapy constructs (Davies et al 
1997). The adherence of P. aeruginosa was found to be reduced in these 
studies following transfection of these cells. 
It is worth noting that these observations are based largely upon 
studies using cells from OF508 homozygotes. One study, despite replicating 
these observations, reported no significant difference in P. aeruginosa 
adherence when using cells from patients with other CF mutations (Zar et al 
1995). The adherence characteristics of immortalised CF cells were also 
reported to be different, demonstrating no significant difference from non -CF 
lines (Saiman et al 1992). 
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Interestingly, aGMI receptors are not specific for P. aeruginosa. 
Although bound P. aeruginosa could not be displaced by E. coli, it has been 
shown to be effectively displaced by S. aureus and H. influenzae. These two 
pathogens also reported to bind to aGMI receptors (Imundo et al 1995, Prince 
1999). 
Thus, this hypothesis suggests putative binding sites for CF related 
pathogens on airway epithelial cells, present in greater quantity on CF cells, 
particularly after injury, and further upregulated by bacterial exoproducts. 
Recent reports suggest that bacterial binding to aGMI is capable of triggering 
epithelial IL -8 expression, perhaps due to activation of Cat + -dependent 
kinases (Prince 1999). However, the full consequences of bacterial binding 
and their in vivo relevance are not yet clear. 
It appears likely that these mechanisms may play an important role in 
the development of CF lung disease in the presence of increasing quantities 
of bacteria and lung damage. However, this theory fails to address the role 
of the mucus layer and ASL, which lie between the epithelial cells and 
pathogens entering the lung environment. As such, it may not represent the 
earliest defect manifest in CF lung disease. Furthermore, post mortem 
evidence reveals conflicting observations, with P. aeruginosa observed as 
microcolonies in an extracellular mucus layer, and rarely adherent to cells. 
1.5.2.2 Bacterial internalisation 
The interaction between epithelial cells and bacteria is also 
fundamental to another hypothesis, which suggests that airway epithelial 
cells may internalise P. aeruginosa as part of the host defence mechanism. 
The key studies contributing to this hypothesis utilised a gentamicin- 
exclusion assay (see Chapter 2, section 2.8.1) to study the internalisation of P. 
aeruginosa into airway epithelial cells. In studies performed with cultured 
human airway epithelial cells, cells over -expressing normal Cr I R were 
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demonstrated to internalise significantly more P. aeruginosa than non- 
expressing cells, or cells over -expressing ÁF508. The level of this bacterial 
internalisation was dependent upon the nature of the LPS of the bacterial 
strain selected, with those expressing a "rough" LPS phenotype less well 
ingested (Pier et al 1996). This LPS specificity was also demonstrated using a 
neonatal mouse model. In further studies, this internalisation was reported 
to be specifically blocked, both in cell lines and infected wild -type BALB /c 
mice, by pre- incubation with either a monoclonal antibody, directed against 
the first extracellular domain of CFTR, or with the peptide used to raise this 
antibody (Pier et al 1997). These results suggested that the first predicted 
extracellular loop (amino acids 108 -117) of CF'l'R may act as a specific cellular 
receptor for the lipopolysaccharide core oligosaccharide of P. aeruginosa, 
resulting in bacterial ingestion. It is interesting to note that a deletion from 
the N- terminal to the fourth membrane spanning domain has been reported 
to have no effect on the ion channel properties of CF'1'K (Carroll et al 1995). 
Immuno- localisation and electron microscopy studies were used to 
demonstrate a specific contact point between CF' I R and P. aeruginosa at the 
cell surface and in the intracellular vesicles after internalisation. 
Furthermore, immuno- fluorescent detection of apical CF°l'R appeared to 
show enhanced apical expression after incubation with P. aeruginosa (Pier et 
al 1997). This suggests that the low level of CFTR expression on the apical 
surface of airway epithelial cells may be significantly upregulated, by 
unknown mechanisms, upon contact with P. aeruginosa. This CFTR may then 
form a point of adherence with the bacteria and consequently ingest the 
organism. 
It is postulated that when exposed to low environmental levels of 
bacteria, focal internalisation and cell shedding might clear pathogens in this 
manner. This may be achieved by a minority of cells approaching 
desquamation. Indeed a similar mechanism has been reported, in which P. 
aeruginosa is internalised specifically by superficial exfoliating corneal cells 
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(Fleiszig et al 1995). Recent reports implicate a CH R- regulated apoptotic 
mechanism as part of this clearance process (Pier et al 1999). 
Thus, this hypothesis suggests that CF1'R acts directly as a receptor for 
the internalisation of P. aeruginosa and that this constitutes a crucial lung 
defence mechanism that would be inoperative in the absence of functional 
CH R. Such a mechanism may be impaired in the absence of apical C1-4 R or 
in the presence of correctly localised, but dysfunctional, protein. 
However, the in vivo relevance of these observations is uncertain and 
this theory has been the subject of considerable scepticism. The definitive in 
vitro experiments were carried out using cell lines that over -expressed 
human CF'l'R and appear to require further induction of CFIR. Whether this 
induction is at the transcriptional, translational, post -translational or 
recycling level is not clear. In the small airways of the lung where infection 
is believed to initiate, CF"l'R expression is low. In addition, the monoclonal 
antibodies used in these studies have previously been reported to detect a 
cross -reacting protein (Walker et al 1995). In an earlier report, which 
observed the internalisation of P. aeruginosa in vivo, internalisation was seen 
mainly in those animals that developed severe pneumonia and was 
postulated as a route to more widespread infection (Tang et al 1995). This 
does not lend support to internalisation as a defence mechanism in vivo. 
Furthermore, the internalisation hypothesis would appear to conflict with 
the bacterial adherence theory, in which increased adherence is expected in 
CF cells, and does not explain why CF individuals are susceptible to infection 
with variety of other respiratory pathogens, not just P. aeruginosa. Finally, 
this theory also fails to address the issue of the mucus barrier, which protects 
the cells from the luminal contents. 
The availability of mouse models of CF provides an ideal opportunity 
to test this hypothesis in vivo and establish the potential role of such a 
mechanism in the pathogenesis of CF lung disease. 
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1.5.3 Inflammatory mechanisms 
The extensive study of airway inflammation in the CF lung has 
revealed a characteristic profile of cytokine and protease /anti - protease 
imbalance with an excessive infiltration of neutrophils. However, it remains 
unclear to what extent these are secondary to infection or the direct effects of 
C1-11( dysfunction. The phagocytic function of neutrophils is normal and 
the humoral antibody responses are intact (reviewed in Konstan and Berger 
1993), however opsonophagocytosis in vivo may be impaired by excess 
neutrophil elastase. 
1.5.3.1 Cytokine imbalance 
The inflammatory response is regulated by a complex balance 
between pro- and anti -inflammatory cytokines. The production of these 
proteins by epithelial and inflammatory cells in the CF lung has been the 
subject of considerable research. Excessive production of pro -inflammatory 
cytokines has been clearly demonstrated in the infected CF lung, however 
their role in the development of the disease is less clearly defined. 
A study of BAL from CF patients, with mild, stable lung disease, and 
non -CF controls, reported increased levels of the pro -inflammatory cytokines 
IL -8, IL -6, tumour necrosis factor -a (TNF -a) and inhibitors of TNF -a activity 
(TNF soluble receptor fragments) in CF lavage fluid, in comparison to 
controls. A concomitant decrease in the level of IL -10 in CF individuals was 
also observed (Bonfield et al 1995), indeed this anti -inflammatory cytokine 
was undetectable in half of the CF samples. These observations were 
supported by immunohistochemical studies of macrophages extracted from 
the BAL samples. Further analysis, with fresh bronchial epithelial cells, 
demonstrated the same pattern of cytokine imbalance using 
59 
immunofluorescence and enzyme -linked immunoadsorbant assays (ELISA) 
(Bonfield et al 1999). Another study, examining sputum samples from CF 
individuals and controls, broadly supports these observations (Osika et al 
1999). However, these reports differ significantly with regard to IL -6 levels, 
with the latter study reporting significantly less IL -6 in CF samples and re- 
evaluating the role of this cytokine to emphasise its anti -inflammatory 
functions. 
In support of these observation, significantly increased levels of pro - 
inflammatory cytokines (TNF -a, IL -113, IL -6, MIP -2 and KC) have been 
reported in BALF from CftrtiilLnc /Cftrtmlunc mice after inoculation with P. 
aeruginosa laden agar beads, in comparison to wild type controls (van 
Heeckeren et al 1999). In addition, in contrast to wild type mice, the anti- 
inflammatory cytokine IL -10 was reported not to be measurable in 
trtnil Unc/ ftrtrnl Unc mice. 
These observations indicate that a characteristic profile of cytokine 
imbalance occurs in CF lung disease. Pro -inflammatory cytokines can cause 
cachexia, hyperglobulinaemia and airway infiltration with neutrophils 
(Bonfield et al 1995). TNF -a is capable of direct tissue injury and can increase 
the expression of IL -1, IL -6 and IL -8, while IL -8 is a potent chemoattractant 
and can stimulate neutrophils to release harmful lysosomal enzymes. IL -6 
can stimulate B -cells and may lead to increased antibody production and 
local immune complex deposition. However, it may also induce the 
production of anti- inflammatory acute phase protein, C- reactive protein and 
al- antitrypsin (Osika et al 1999). IL -10 has been called the "cytokine synthesis 
inhibitory factor" (Bonfield et al 1995). This anti- inflammatory cytokine has 
been reported to decrease macrophage production of TNF -a, IL -1, IL -6 and 
IL -8. 
Studies in IL- 10- deficient transgenic mice have also provided 
interesting results. IL- 10- deficient mice on a C57B1/6J strain background 
have been found to have a significantly better bacterial clearance rate and 
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decreased levels of TNFa after exposure to aerosolised P. aeruginosa strain 
PAO1, but a significantly greater mortality in comparison to wild -type 
controls (Yu et al 1998). Those that survived demonstrated no difference in 
lung pathology in comparison to the wild -type controls. However, in 
response to repeated exposure, the IL- 10- deficient mice developed 
significantly more severe, but qualitatively similar, lung pathology. This 
suggests that IL -10 may be important in suppressing lung inflammation in 
the continued presence of P. aeruginosa. Another study demonstrated 
significantly more severe pathology, weight loss and BAL neutrophil counts 
in IL- 10- deficient mice, following the intratracheal instillation of agar beads 
laden with a clinical isolate of P. aeruginosa, than in wild -type controls 
(Chmiel et al 1999). However, no difference in overall survival rates of the 
animals, or the bacterial numbers in lung homogenates was observed. This 
was interpreted as evidence that in the absence of IL -10, increased 
inflammation led to excessive, injurious local responses to "chronic 
infection" with no more efficient bacterial killing. 
Thus, the cytokine imbalance observed in CF would clearly be capable 
of conferring a profoundly pro -inflammatory phenotype and contributing to 
escalating inflammation. However, it is unclear whether this imbalance is 
secondary to infection in a compromised host or a direct effect of CF 1 R 
dysfunction, which precedes airway infection. 
Studies in CF infants have suggested that inflammation and cytokine 
imbalance may constitute the primary event in the establishment of CF lung 
disease. BAL analysis demonstrated pulmonary inflammation to be present 
in a cohort of CF infants, in the absence of bacterial colonisation (Khan et al 
1995). Furthermore, in two case studies, CF infants with recent onset 
respiratory infections were treated with antibiotic chemotherapy to clear the 
infection. In both cases typical cytokine imbalance, with raised levels of IL -6 
and IL -8 and no detectable IL -10, was reported two months later, in the 
absence of infection (Bonfield et al 1999). However, another study 
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examining the inflammatory profile of CF infants, with no signs or history of 
pulmonary infection, reported no difference in comparison to non -CF control 
subjects (Armstrong et al 1997). 
Thus a harmful cytokine imbalance is clearly evident in CF lung 
disease. This has been postulated to result primarily from a down regulation 
of the anti- inflammatory cytokine IL -10, leading to the persistent production 
of pro- inflammatory cytokines. However, it remains unclear whether this is 
a direct effect of CF1K dysfunction or whether infection plays a key role in 
initiating and maintaining the airway inflammation in CF. It seems unlikely 
that this issue can be easily resolved with human studies, in which there are 
obviously serious restrictions on the degree of manipulation and analysis 
acceptable. It may be that the continued use of mouse models can provide 
insights from which to extrapolate. 
1.5.3.2 Protease - antiproteases 
CF lung disease is characterised by an excessive influx of neutrophils, 
the products of which result in an imbalance between the levels of proteases 
and antiproteases in the airways (reviewed in Döring 1999). 
Sputum samples from CF individuals with chronic lung inflammation 
may contain up to 109 neutrophils per ml. These neutrophils release 
powerful enzymes, stored in azurophilic granules, either in a fully active 
state (serine proteinases) or as pro- enzymes (metalloproteinases (IVIMP)). 
The serine proteinases include neutrophil elastase (NE), cathepsin G and 
proteinase 3. These display broad substrate specificity. NE is capable of 
direct injury to epithelial cells and cleaving antiproteases, immunoglobulins, 
complement and fibronectin. By cleaving the opsonic receptors on 
neutrophils and components of complement that act as ligands for these 
receptors, NE may interfere with opsonophagocytosis (Berger et al 1989). In 
addition NE may alter ciliary activity and mucociliary clearance, and 
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stimulate airway gland secretion. MMPs may be activated by NE and are 
specifically involved in the degradation of extracellular matrix. In CF further 
damage may result from bacterial MMPs, P. aeruginosa produces 3 known 
proteinases; elastase, alkaline proteinase and LasA. 
In the non -CF lung damage from neutrophil proteases is prevented by 
protease inhibitors. The most abundant plasma protease inhibitor is a,- 
antitrypsin (a,AT), an acute phase protein produced by the liver in response 
to inflammation and IL -6. a,AT may also be produced by the alveolar 
macrophages and epithelial cells and is upregulated by pro -inflammatory 
cytokines TNF -a, IL -1 and bacterial LPS. It inactivates NE quickly and 
irreversibly and is the major protective component of the alveoli. The major 
antiprotease in the upper airways is secretory leukoprotease inhibitor (SLPI), 
secreted by the epithelial cells and upregulated by defensins and a1AT (van 
Wetering et al 2000). This protein has both antiprotease and antibacterial 
activity. In addition to SLPI, elafin, elastase- specific antiprotease, is also 
active in the airways (Simpson 1999). 
Studies of the ASL from CF individuals have demonstrated an excess 
of NE elastase that overwhelms the antiprotease defences, even in young 
children (Birrer et al 1994). In almost all cases the NE- antiprotease balance 
was found to be in favour of NE, with free active NE present, despite normal 
local concentrations of SLPI and aIAT. 
Neutrophils also produce reactive oxygen species, which can produce 
direct tissue damage and inactivate antiproteases. In addition, reduced 
levels of glutathione (GSH) in the CF ASL have been reported. GSH may 
play an important role as an antioxidant in the lung, directly scavenging free 
radicals and acting as a co- substrate in the reduction of hydrogen peroxide 
(reviewed in Kelly 1999). Indeed, it has been suggested that CN°1'K may be 
permeable to GSH and involved in regulating its level in the ASL (Lindell 
and Hanrahan 1998). 
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It is clear how this vicious cycle may contribute to the steady 
deterioration of lung function in CF. However, it is not yet evident whether 
this constitutes an abnormal reaction to infection or a disastrous 
compensatory response occurring as a consequence of failure of another 
component of the lung defence system. If a comparable phenotype were 
demonstrated in mouse models of CF, it would greatly assist in dissecting 
out the key components of this process. 
1.5.3.3 The role of Nitric Oxide 
Nitric oxide (NO) has also been implicated in the establishment of CF 
lung disease, as the result of a variety of studies (reviewed in Grasemann 
and Ratjen 1999). 
NO appears to be involved in a wide range of processes; as a signal 
molecule inducing vasodilation and bronchodilation, as a powerful 
antimicrobial agent and suggested to have a role in the activity of ENaC 
channels. However, in excess NO causes inflammation and oxidative tissue 
damage through reactive intermediates. It is synthesised from L- arginine by 
constitutive and inducible isoforms of nitric oxide synthase. Expression of 
the latter form is initiated by inflammatory cytokines and bacterial products. 
Increased levels of NO in exhaled breath have been reported in 
asthma and in patients with lung infections. However, despite chronic 
infection and inflammation, studies in CF individuals have demonstrated 
NO levels to be normal or low (Ho et al 1998). Although the source of NO 
in the lungs is not clear, inducible nitric oxide synthase (iNOS) has been 
reported to play a key role. iNOS expression has been demonstrated in the 
epithelial cells of the nose, trachea and bronchi (Kelley and Drumm 1998). 
However, although expression was found to be normal in the airway 
inflammatory cells, it was significantly decreased in the bronchial epithelial 
cells of CF lung specimens and CF cell lines (Meng, Q. -H. 1998). The 
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expression of iNOS has also been reported to be significantly reduced in 
mixed strain . CftrtrrrlKth /¡+Ljtr,rlKth mice, homozygous for the OF508 mutation 
(Kelley and Drumm 1998). In addition, mice deficient in iNOS are more 
susceptible to infection with Listeria monocytogenes (MacMiking et al 1995), 
while wild type BALB /c mice treated with the iNOS inhibitor 
aminoguanidine are less able to clear a pulmonary dose of P. aeruginosa 
(Kelley and Drumm 1998). Thus, it has been suggested that iNOS related 
antimicrobial activity may be compromised in CF, resulting an in increased 
susceptibility to lung infection. 
1.5.4 The role of the submucosal glands 
The submucosal glands are found in the cartilaginous airways of the 
human respiratory tract, located in the submucosa, between the cartilage and 
the epithelium (reviewed in Pilewski and Frizzell 1999). It has been 
estimated that there are approximately 5000 glands in the adult human 
bronchial tree. The glands are tubuloacinar, with a duct opening onto and 
continuous with the airway epithelium. The glandular acini are composed of 
both mucous and serous cells, the secretions of which contribute to the ASL. 
The serous cells demonstrate the highest level of expression of CFI'K in the 
airways (Engelhardt et al 1992) and secrete fluid containing a variety of 
antimicrobial agents, such as lysozyme, lactoferrin and 13- defensins. The 
mucous cells are the major source of mucin in the airways. The most distal 
end of the gland is composed of serous acini (Meyrick et al 1969). Their 
secretions must pass through the mucus tubules, where the mucin, secreted 
by the mucous acini, may be hydrated and moved on. This mixture moves 
through the collecting ducts, to the ciliated ducts and finally onto the tracheal 
surface epithelium. 
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The role of CFTR in fluid secretion and /or ion reabsorption in the 
submucosal glands is not clear. Nor are the relative contributions of the 
surface epithelium and submucosal glands to the ASL. However, a recent 
study using porcine bronchi reported that fluid secretion was driven by 
CFTR and predominantly produced by the submucosal glands (Ballard et al 
1999). 
The earliest pathological findings in CF infants have been reported to 
be mucus inspissation, obstruction and dilatation of the submucosal glands 
newborns (Esterly and Oppenheimer 1968). It is it is clear that submucosal 
glands have the capacity to play a critical role in the development of CF lung 
disease. Inadequate hydration of the submucosal gland secretions could lead 
to the development of this pathology and contribute to a failure of 
mucociliary clearance mechanisms. Furthermore, failure of fluid and ion 
transport regulation in the production of ASL by the submucosal glands 
could contribute to dysfunction of salt sensitive antimicrobial components of 
the ASL. As a result the submucosal glands are now the focus of 
considerable attention, as studies aim to elucidate their role in the 
pathogenesis of CF lung disease. 
The potentially critical role of the submucosal glands in the 
development of CF lung disease is important to consider in the interpretation 
and extrapolation of results from model systems. Despite frequent 
references to the contrary, submucosal glands are present in murine airways. 
However, unlike the human, these glands are predominantly localised in the 
most proximal part of the trachea and do not extend into the bronchi 
(Borthwick et al 1999). In the case of primary culture models of airway 
epithelium, no submucosal glands are present. This may affect the ability of 
these cultures to accurately reflect the in vivo situation in the airways. 
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1.6 The innate lung defence system 
The adaptive immune system is relatively new in evolutionary terms 
and co- exists in higher animals with a more basic innate immune system 
(Ganz and Lehrer 1995). Recent studies have focused considerable attention 
upon the latter and in particular the role of antimicrobial peptides. 
Professional phagocytic cells ingest microbes into vacuoles and kill them 
using both oxidative mechanisms and antimicrobial peptides, stored within 
microbicidal organelles. Such antimicrobial peptides are also secreted by 
epithelial cells and constitute an initial barrier to infection. This innate 
immune system is not only the first line of defence, but may also determine 
the antigens to which the acquired immune system will respond and the 
nature of that response. The ASL contains a host of antimicrobial 
compounds, including defensins, cathelicidin, lysosyme, lactoferrin, SLPI 
and collectins (Ganz 1998). 
The discovery that the ASL from primary cultures of airway 
epithelium displayed a salt- sensitive antibacterial activity (Smith et al 1996) 
prompted additional interest in the components of the innate lung defence 
system. The "hypotonic /defensin" theory proposes that Cr I R dysfunction 
directly affects the ionic composition of the ASL, thus compromising the 
antimicrobial activity of the salt sensitive first line of lung defence. This 
protection breached, the organisms would have a better chance of colonising 
the lung. In addition it is possible that a compensatory response from other 
elements of the defence mechanism may occur, resulting in an increased 
neutrophil influx, the release of damaging elastase, cytokine imbalance and 
the triggering of inflammatory cascades, while cell - bacteria interactions 
may select for specific organisms. 
The initial studies demonstrated that the antibacterial activity of the 
ASL was compromised by raised NaC1 levels, that the antibacterial agent had 
a low molecular weight and that it was heat stable. However, the key 
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components of the innate lung defence involved were not identified. A 
subsequent report, utilising the bronchial xenograft model, confirmed the 
results of the earlier study and demonstrated restoration of antibacterial 
activity after adenoviral delivery of CFTR to the CF cells (Goldman et al 
1997). This study implicated human f3- defensin -1 (HBD -1), demonstrating 
expression throughout the airways and salt- sensitive antibacterial activity. 
Furthermore, the antibacterial properties of the ASL were reported to be 
largely abolished following the ablation of HBD -1 expression using antisense 
DNA. As a result of this report, considerable attention has been placed on 
the role of ß defensins in CF. However, more recent results have suggested 
that while HBD -1 may play an important role it is unlikely to be wholly 
responsible for the CF lung phenotype and that there are many antibacterial 
components of the ASL worthy of investigation. 
1.6.1 Defensins 
Naturally occurring cationic peptides with broad spectrum 
antimicrobial activities have recently been discovered to contribute to the 
host defences of animals, insects and plants (reviewed in Lehrer and Ganz 
1999, Huttner and Bevins 1999, Hancock 1997). These peptides are less than 
100 amino acids (and generally < 35) and include defensins and cathelicidins. 
1.6.1.1 Defensin structure 
Defensins are small, 3-4 kDa peptides characterised by the presence of 
6 cysteines, stabilised by disulphide bonds (reviewed in Ganz and Lehrer 
1995). These peptides are cationic, due to the presence of the amino acids 
arginine and lysine. They are classified on the basis of the spacing and the 
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connectivity of their cysteines. In animals the two main types are a- 
defensins, in which the cysteines are linked 1 -6, 2 -4, 3 -5, and 13-defensins in 
which the cysteines are linked 1 -5, 2 -4, 3 -6 (see Figure 1.7). Despite these 
differences defensins share a similar cationic 13-sheet-rich amphipathic 
secondary structure, stabilised by the disulphide bridges. A hydrophobic 
region is spatially separated from the cationic region of the peptide (Ganz 
1999). This structure is thought to be critical to the mechanism of action of 
these peptides and is conserved despite many naturally occurring amino acid 
substitutions within different defensins. A recent report suggested that the 
potency of antimicrobial peptides might correlate with the hydrophobicity 
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FIGURE 1.7 Defensin structure 
The spacing and connectivity of cysteines in a- and 13- defensins 
1.6.1.2 Defensins - mode of action 
The mode of activity of antibacterial peptides remains the subject of 
investigation. However, the current model suggests a 2 stage process in 
which peptides disrupt the membrane of the target cell then enter the cell 
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and interfere with its metabolic function in an as yet unspecificed manner 



















FIGURE 1.8 The proposed mechanism of action of defensins 
Adapted from Hancock and Chapple 1999. 
In the case of gram negative bacteria the peptides must breach both 
the outer and the cytoplasmic membranes. Only the latter is required for 
gram positive organisms. In the first stage, the positively charged peptides 
interact with the negatively charged divalent cation binding sites on the 
surface LPS, competitively displacing these ions. This disrupts the normal 
barrier of the outer membrane leading to self -promoted uptake (Hancock 
1997). The peptides then insert into the cytoplasmic phospholipid membrane 
with the hydrophobic region in the membrane interior, while the cationic 
region interacts with the anionic phospholipid head groups. These peptides 
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are thought to assemble into multimeric pores, disrupting the membranes. 
However, at this stage the process is still reversible. Peptides subsequently 
enter the cell and produce irreversible damage. The mode of action of this 
second stage is less clear. It has been suggested that DNA damage, 
interference with protein synthesis or both may be responsible. 
The cell membranes of animals are rich in neutral phospholipids and 
cholesterol. Both of these inhibit the incorporation of peptides into these 
membranes and afford a degree of protection to these cells (Ganz and Lehrer 
1999). Eukaryotic cells may still be damaged by antimicrobial peptides, but 
much higher concentrations are required than are necessary for antibacterial 
activity. 
Interestingly B. cepacia has been demonstrated to be inherently 
resistant to killing by antibacterial peptides (Hancock 1997, Morrison et al 
1998). This may be the result of a non -interactive bacterial cell membrane. 
1.6.1.3 a-defensins 
The genes that encode for the a- defensins and the (3- defensin families 
are clustered on chromosome 8p23 in humans (and the Defcr locus on 
proximal chromosome 8 in the mouse (Huttner et al 1997, Bals et al 1998a, 
Morrison et al 1998, Morrison et al 1999, Bals et al 1999)) and are thought to 
share common ancestry (Linzmeier et al 1999). However the two groups 
have evolved some major differences. 
The a- defensins are initially synthesized as prepropeptides (Ganz 
and Lehrer 1995). These have a characteristic amino -terminal signal 
sequence for insertion into the endoplasmic reticulum, a propiece and the 
mature peptide at the carboxy -terminal. The propiece is anionic in nature 
and neutralises the cationic end of the peptide. This has been proposed as a 
mechanism to prevent spurious interactions with other proteins or the lipid 
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membrane and to facilitate folding. The a- defensins do not display 
antibacterial activity until cleavage has occurred to create the mature peptide 
(Valore et al 1994). 
Once the mature peptide is formed, a- defensins have been reported 
to display broad spectrum antibacterial activity over the range of 1 -100 
µg /ml. This activity has been demonstrated against gram positive and gram 
negative bacteria, fungi and enveloped viruses, and to be inhibited by cations 
(reviewed in Ganz and Lehrer 1995). In addition, a host of other putative 
functions have been attributed to these peptides, including the induction of 
IL -8 and SLPI from epithelial cells, a role in the reduction of glutathione 
levels and the inhibition of cortisol secretion by the adrenal gland (reviewed 
in van Wetering et al 1999). 
There are currently six a- defensins identified in humans (reviewed in 
van Wetering et al 1999). Human neutrophil peptides (HNP) 1-4 are found 
in the azurophilic granules of neutrophils. HNP1 -3 make up 5 -7% of total 
neutrophil protein and 30 -50% of the protein content of the azurophilic 
granules, making them the most abundant neutrophil proteins. Neutrophils 
engulf microbes into vacuoles and kill them using either; oxygen dependent 
mechanisms, in which the respiratory burst produces superoxide anions, 
hydrogen peroxide and other oxidative metabolites, or antibacterial 
peptides. Thus HNPs are thought to act primarily at high concentrations in 
phagolysosomes. Human defensins (HD) 1 and 2 are found in the secretory 
granules of Paneth cells, where they are proposed to protect intestinal stem 
cells in the crypts from infection. 
Although mice have been demonstrated to have an extended family 
of a defensins produced by Paneth cells in the intestine, called cryptidins, 
studies suggest that no a- defensins are present in murine neutrophils 
(Eisenhauer and Lehrer 1992). A recent study demonstrated that activation 
of cryptidins, by cleavage of the pro -region, was dependent upon matrilysin, 
a matrix metalloproteinase localised in the Paneth cells (Wilson et al 1999). 
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Matrilysin- deficient transgenic mice were found to have significantly 
impaired antimicrobial activity in studies of small intestinal extracts, isolated 
crypts stimulated with cholinergic agonists to produce Paneth cell 
degranulation and the gastrointestinal tract in vivo, using an oral infection 
model. In addition, the 50% lethal dose of Salmonella typhimurium for 
matrilysin- deficient transgenic mice was found to be a tenth of that for wild - 
type littermates. These studies demonstrate the important role of mature 
defensins in the murine gastrointestinal system. 
1.6.1.4 ß-defensins 
The E3-defensins were first described in cattle, with thirteen ß- 
defensins expressed in bovine granulocytes and two in the bovine trachea 
(tracheal antimicrobial peptide (TAP) and lingual antimicrobial peptide 
(LAP)). Similar peptides have now been reported in a variety of other 
animals including humans and mice. The genes that encode for the [3- 
defensin families are on chromosome 8p23 in humans and in the Defer locus 
on proximal chromosome 8 in the mouse. 
The (3- defensins are also initially synthesised as prepropeptides. 
However, unlike the a- defensins, the cleavage of the propiece does not 
appear to be necessary for antimicrobial activity. Indeed, multiple isoforms 
of HBD -1 have been reported in kidney tissue and urine, with different 
amino terminal trunctations (Valore et al 1998). While the most common 
form (the 36 as peptide) was the most potent and the least salt sensitive, all 
forms were reported to show differing profiles of antibacterial activity and 
salt sensitivity. These results imply that the proregion of [3-defensins does 
not have an inhibitory role. In addition, this study synthesised defensins 
using a baculovirus system and demonstrated variation between cell lines in 
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the processing of HBD -1. This raisies the possibility that the post - 
translational modifications of defensins may occur in a cell specific manner. 
In addition to their salt sensitive antibacterial activity, a recent report 
raised the possibility that, like a- defensins, the 3- defensins may play a role as 
signalling molecules (Yang et al 1999). This study reported that human [3- 
defensins, in submicromolar concentrations, can attract memory T -cells and 
immature dendritic cells to the sites of infection, promoting adaptive 
immunity. 
There are two 3- defensins known in humans; HBD -1 and HBD -2. The 
dysfunction of the former has been suggested to play a critical role in the 
development of CF lung disease (Goldman et al 1997). HBD -1 was originally 
isolated from human blood filtrate as a 36 aa, 3.9 kDa peptide (Bensch et al 
1995). The gene encoding HBD -1 (HBD -1) was cloned, located roughly 100- 
150 kb from HNP -1 and shown to be over 7 kb. It has a large intron of 6962 
bp and two exons (Liu et al 1997, McCray and Bentley 1997). The first exon is 
128 bp and encodes the signal sequence and propiece, while the second exon 
is 234 bp and encodes the mature peptide. HBD -1 expression has been 
demonstrated to be maximal in the urogenital tract and the kidney, but is 
also present in the trachea, submucosal glands, bronchus, nasal epithelium, 
salivary gland, pancreas, prostate, testes and small intestine (Zhao et al 1996, 
Goldman et al 1997, McCray and Bentley 1997) (see Table 1.7). No difference 
in the levels of expression have been observed in tissue from CF individuals 
when compared to non -CFs. It is not expressed prenatally, nor upregulated 
in response to inflammatory stimuli. hBD -1 synthetic peptides have been 
shown to display salt sensitive antimicrobial activity against P. aeruginosa 
(Goldman et al 1997, Morrison et al 1998, Singh et al 1998) in isolation, in vitro. 
The second human 13- defensin, HBD -2, was isolated from psoriatic 
human skin as a 41 aa peptide with 39% identity to HBD -1 at the amino acid 
level. It has been shown to have antibacterial activity against gram negative 
bacteria and candida albicans (Harder et al 1997) and to be approximately ten 
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times more potent than HBD -1 (Singh et al 1998). These studies have 
demonstrated that the salt sensitivity of this activity can be overcome by 
increasing the concentration of the peptide. The gene encoding HBD -2 
(HBD -2) is smaller, at 1610 bp, with two exons (Bals et al 1998b, Liu et al 
1998). The first exon is 81 bp and encodes the signal sequence. The second 
exon is 238 bp and encodes the mature peptide and a short segment of the 
propeptide. HBD -2 is located approximately 100 -600 kb centromeric of HBD - 
1 on chromosome 8. The DNA sequence of HBD -2 revealed four NFiB 
binding sites in the UTR. Such elements are not found in HBD -1 but are 
observed in the TAP and LAP genes, which are upregulated in response to 
inflammatory stimuli (Russell et al 1996). This upregulation has also been 
demonstrated for HBD -2 (Harder et al 1997, Bals et al 1998b, Liu et al 1998, 
Singh et al 1998). It is expressed in inflamed skin, but not in uninflamed skin. 
High levels have also been demonstrated in the respiratory tract, particularly 
in the epithelium of the proximal conducting airways and the serous tubules 
of the submucosal glands. HBD -2 has also been reported in the urogenital 
tract, salivary gland and uterus (see Table 1.7). Expression has been observed 
in tissue from both CF and non -CFs individuals, but the concentration of 
HBD -2 in BAL collected from colonised CF individuals was found to be 
raised (Singh et al 1998). 
Despite the reported absence of a- defensins in murine neutrophils, 
four murine ß- defensin genes have been reported; Defb1 (or mBD -1), Defb2, 
mBD -3 and mBD -4. These genes are all localised to the Defcr locus on 
proximal chromosome 8 in the mouse, the conserved syntenic region of 
which is at chromosome 8p23 in humans. Aspects of the characterisation of 
mBD -1 peptide will be detailed in Chapter 6. 
The first murine 13- defensin gene (Def b1 or mBD -1) was found by 
homology to HBD -1 (Huttner et al 1997, Bals et al 1998a, Morrison et al 1998). 
Def b1 has two exons and a 15 kb intron. The first exon encodes the signal 
sequence and part of the propiece, while the second encodes the rest of the 
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propiece and the mature peptide. The 204 bp open reading frame encodes a 
69 aa prepropeptide, with 51% identity to HBD -1 and 36% identity to HBD -2. 
Constitutive Def b1 expression has been shown in the epithelia of the 
proximal conducting airways, the kidney, tongue, heart and reproductive 
tract (see Table 1.7). It has also been shown to display salt- sensitive 
antibacterial activity against a range of microbes. 
The gene for murine 3- defensin -2 (Defb2) was recently identified, with 
exon /intron boundaries at the same site as Defb1 (Morrison et al 1999). It 
encodes a 71 aa prepropeptide, with a 41% identity to mBD -1, a 34 % identity 
to HBD -1 and 30% identity to HBD -2. The DNA sequence did not reveal any 
relevant regulatory control elements in the UTR, however expression was 
shown to be upregulated in response to LPS. Defb2 expression was 
demonstrated in the kidney and uterus and found to be induced in the 
trachea after exposure to pro -inflammatory stimuli (see Table 1.7). 
The murine 3- defensin -3 gene (mBD -3) demonstrates a similar 
intron /exon structure with a 1.7 kb intron and has an NFKB binding site in 
the 5' UTR (Bals et al 1999). It encodes a 64 aa prepropeptide with 40% 
homology to HBD -2. Unlike all the other murine and human (3- defensins, 
mBD -3 does not display identical spacing of the cysteine residues, with one 
less residue between cysteines 2 and 3. It is expressed at low levels in the 
lung, gastrointestinal tract, salivary gland and reproductive tract with 
induction observed in the airway epithelium and liver after lung instillation 
of P. aeruginosa (see Table 1.7). Baculovirus expressed mBD -3 has been 
demonstrated to have antibacterial activity against E. coli and P. aeruginosa, 
although salt sensitivity has not been described. 
A further member of this gene family, mBD -4, was recently reported, 
encoding the mBD -4 (3- defensin (Jia et al 1999). This peptide shares 45% 
identity with HBD -2. It is likely that further members of the family are still 
to be discovered within this gene cluster. 
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Tissue HBD-1 HBD-2 Defbl Defb2 mBD-3 
Skin + ++++ NR NR NR 
Lung + ++++ ++ NR ++ * 
Trachea + ++++ * ++++ + ++ * 
Gut ++ _ NR NR + 
Salivary + _ NR NR + 
Urogenital ++++ + + + NR 
Kidney ++++ - ++++ ++ NR 
Liver + - ++ NR ++ * 
Heart NR NR + + NR 
TABLE 1.7 Expression pattern of ß- defensins in humans and mice. 
+ expression, - no expression, NR - not reported, * in response to 
proinflammatory stimuli 
The role of ß- defensins in the development of CF lung disease remains 
uncertain. While one study implicates the dysfunction of HBD -1 as critical to 
the innate immune system, this is difficult to reconcile with the low 
concentrations estimated in the ASL (see Table 1.8). However, HBD -2 is 
upregulated in response to inflammatory stimuli, demonstrates ten times the 
potency of HBD -1, in vitro, and may be present at antibacterial concentrations 
in the ASL (Singh 1998). The defensin concentrations estimated in ASL may 
of course be inaccurate. The collection of the ASL in vivo has proved 
extremely challenging (see section 1.5.1.3) and the process of collection may 
significantly alter the composition of the collected fluid. In addition, it is 
possible that the charged nature of antimicrobial peptides may cause them to 
accumulate locally at epithelial surfaces or at the mucus interface and 
consequently distort attempts to quantify their concentration. These 
peptides may therefore be present at much greater concentrations localised 
within a particular phase of the ASL. 
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Establishing the roles of individual components of the ASL is 
complicated by synergistic interactions (Singh and Welsh 1997, Bals et al 
1998b) as well as technical difficulties in the estimation of in vivo 
concentrations. This impact of synergy between all the antibacterial agents 
within the ASL has yet to be fully established, as have the signalling 
properties of defensins. The discovery of a homologous family of 13- 
defensins in the mouse provides the opportunity to study the roles of these 
peptides in a murine model and the characterisation of defensin knockout 
mice may provide further illumination. 
Travis 
et al 1999b 
Schnapp 
et al 1998 
Singh 
et al 1998 
Ganz 1998 
non-CF non -CF 
non - 
CF CF non -CF 
Lysozyme 0.7 µg /ml - 0.75 -101.1g /m1 2 -16µg /ml 
Lactoferrin 0.9 µg /ml - - - - 
SLPI 0.1 -21.tg /ml - - - - 
HBD -1 - - <_ 2 ng /ml 
0.2 -2 ng /ml 





LL37 /hCAP -18 
- - - - - 
HD1 -3 - 86 - 143 ng /ml - - - 
TABLE 1.8 Estimated concentrations of antibacterial components of 
ASL in BAL (estimated - 100 fold dilution of ASL) 
78 
1.6.2 Other antibacterial components of the ASL 
The primary focus of research into the antibacterial properties of the 
ASL has concerned the role of defensins. However, these peptides are 
actually a fairly minor component of the ASL (see Table 1.8), which also 
contains, lysozyme, lactoferrin, SLPI, elafin, cathelicidin and collectins. All of 
these components have been proposed to have antibacterial activity and have 
the potential to be involved in the development of CF lung disease. 
1.6.2.1 Lysozyme 
Lysozyme is a component of both the phagocytic and secretory 
granules of neutrophils and is produced by macrophages and airway 
epithelial cells, particularly the serous cells of the submucosal glands. It is 
the most abundant antimicrobial protein found in BAL (Travis et al 1999b), at 
0.7 -10 µg /ml. It is a 14 kDa enzyme directed against peptidoglycan, a 
structurally important component of the bacterial cell wall. Lysozyme 
displays potent, salt sensitive antibacterial activity against many gram 
positive and gram negative organisms (Travis et al 1999b). However, reports 
suggest that lysozyme may only be bacteriostatic against P. aeruginosa, with 
these bacteria able to recover from this insult with time (Ganz 1998). It has 
been proposed that a "second hit" in the form of ß- defensins may be required 
or that removal by mucociliary clearance might be expected prior to this 
recovery in vivo. Thus, while the role of lysozyme in CF airways may be 
directly compromised by a high salt environment, it may also be affected by 
defensin dysfunction and /or a mucociliary clearance defect. 
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1.6.2.2 Lactoferrin 
Lactoferrin is another abundant antibacterial component of the ASL. 
It is an 80 kDa iron -binding protein, closely related to transferrin, present 
both in neutrophils and airway epithelial secretions. It inhibits bacterial 
growth by sequestering iron, but also has a direct, salt- sensitive, 
antimicrobial activity due to its amino terminal cationic fragment. It is less 
potent than lysozyme but is present in antibacterial concentrations in BAL 
(Travis et al 1999(b)). The direct antibacterial role of lactoferrin may be 
compromised in CF airways by a high salt environment. 
1.6.2.3 Protease inhibitors 
SLPI and elafin are antiproteases secreted by the airway epithelial 
cells (see section 1.5.3.2), both of which have been demonstrated to have 
antibacterial activity in vitro. In the case of SLPI, the carboxy -terminal 
domain acts as an inhibitor of NE and the amino terminal has modest 
antibacterial activity (Hiemstra et al 1996). This activity has been shown to 
display salt -sensitivity (Travis et al 1999b). The majority of the antibacterial 
activity of elafin also resides in the amino terminal domain, but it displays 
more potent activity than SLPI at all doses tested in vitro (Simpson et al 1999). 
In both cases, the full length molecule demonstrated greater antibacterial 
activity than either terminal fragment. 
1.6.2.4 Cathelicidin 
The cathelicidins are a large family of antimicrobial peptides with a 
conserved amino -terminal domain of roughly 100 aa and highly 
heterogeneous carboxy -terminal peptide sequences of 10 -40 aa. In some 
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cathelicidins the full molecule displays antibacterial activity, whereas in 
other cases proteolytic cleavage of the active carboxy -terminal peptide is 
required. The only known human cathelicidin is hCAP -18, a 140 aa 
precursor to LL -37, the mature 37 aa peptide. LL -37 /hCAP -18 has been 
demonstrated in neutrophil granules and is expressed in a wide range of 
tissues, highest in the bone marrow. In the lungs it is expressed by the 
airway epithelial cells, the serous and mucus cells of the submucosal glands 
and has been identified in BAL. Synthetic LL -37 has been shown to have 
broad spectrum, salt- sensitive antibacterial activity in vitro and to display 
synergy with lactoferrin (Bals et al 1998c). Thus, LL- 37/CAP -18 may be 
compromised in a high salt ASL and also has the potential to play a role in 
the development of CF lung disease. 
1.6.2.5 Collectins 
The collectins are a family of polypeptides involved in mammalian 
host defences that includes surfactant proteins SP -A and SP -D and mannose 
binding lectin. They are the most abundant proteins found in lavages of the 
distal lung and constitute an important part of the innate lung defence 
system (Whitsett 1999). 
SP -A and SP -D are produced by alveolar type II cells, the non -ciliated 
epithelial cells of the airways and by the submucosal glands. SP -A has been 
demonstrated to form multimeric structures and bind to bacteria and 
receptors on alveolar macrophages in vitro. It is also proposed to stimulate 
macrophage chemotaxis. SP -A knockout mice have been shown to display 
increased susceptibility to pulmonary infections with various pathogens, 
including P. aeruginosa, leading to airway inflammation, neutrophilic 
infiltrates and cytokine induction (LeVine et al 1998). In addition, alveolar 
macrophages from SP -A knockout mice displayed impaired phagocytosis of 
these pathogens. SP -D knockout mice have been reported to develop 
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progressive severe pulmonary emphysema and fibrosis from the age of three 
weeks with marked lung restructuring and accumulation of lymphocytes. 
These mice also display a failure of the respiratory burst in alveolar 
macrophages (Whitsett 1999). 
The antibacterial activity of the collectins has not been proposed as 
salt sensitive in nature. However they may play an important role in the 
innate lung defence and as such dysfunction of these lectins would be 
expected to impact upon CF lung disease. Indeed, mutations in the MBL 
gene have recently been proposed as genetic modifiers of the CF lung disease 
phenotype (see section 1.3.5). 
1.7 Mouse models of Cystic Fibrosis 
1.7.1 The murine Cftr gene 
The murine homologue of the human CFTR gene (Cftr) was isolated, 
on mouse chromosome 6, in 1991 (Tata et al 1991). The genomic region has 
recently been sequenced and comparative analysis performed with human 
CFTR (Ellsworth et al 2000). The Cftr gene spans -152 kb, with all 27 exons 
highly similar to the human homologue at the sequence level. The intron 
and exon structure of the two homologues is mostly the same, with splice 
sites occurring at identical positions in both. The genomic sequence is 
reported to be highly conserved throughout, including large intronic 
segments, raising the possibility that they serve functionally important roles. 
The putative regulatory elements -10 kb upstream of CFTR exon 1 are well 
conserved in Cftr. Interestingly, the polymorphic polyT tract located 
upstream of CFTR exon 9, implicated in Class 5 splicing defects (see section 
1.3.3), is absent in murine Cftr. 
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The murine CFTR protein is very similar to the human (78% overall 
sequence identity at the amino acid level), particularly in the two nucleotide 
binding folds. The majority of known CF mutations occur in well conserved 
regions, suggesting conservation of function across species. The predicted 
mouse protein has a phenylalanine residue corresponding to that deleted in 
the common ÁF508 mutation, flanked by a 28 amino acid region identical to 
man. The putative first extracellular domain, implicated in the 
internalisation of P. aeruginosa (see section 1.5.2.2), is also well conserved 
with 13 of the 15 amino acids identical. 
The degree of homology between human CFTR and mouse Cftr and 
the existence of the necessary molecular techniques made the development of 
mouse models of CF a viable proposition and established an array of novel 
investigative approaches in the study of CF. 
1.7.2 Creation of mouse models of CF 
The first mouse models of CF were created within three years of the 
isolation of the CFTR gene, using gene targeting in embryonic stem cells to 
disrupt the Cftr gene (Snouwaert et al 1992, Dorin et al 1992). A further 
twelve mouse models of CF have been reported since, with varying degrees 
of characterisation (Ratcliff et al 1993, O'Neal et al 1993, Colledge et al 1995, 
Hasty et al 1995, van Doorninck et al 1995, Zeiher et al 1995, Delaney et al 
1996, Rozmahel et al 1996, Dickinson et al 1998, Merrill et al 1998). These 
models fall, broadly, into two categories; those designed to grossly disrupt 
Cftr and those that aim to model clinical mutations, such as ¿F508, G551D 
and G480C. 
83 
Mouse Mutation Cftr mRNA Original Strain 
m1Unc Cft 





No wild type 
mRNA detectable 
C57B1 /6 /129P2 /OIaHsd 
BALB /c /129P2 /OlaHsd 
B6D2 /129P2 /OlaHsd 
CRt m1Hgu 
et al 1992 
Exon 10 
Insertional 
10% of normal 
levels of wild type 
mRNA 
MF1 /129P2 /OlaHsd 
Cftrtmlc;am 




No wild type 
mRNA detectable 
MF1 /129P2 /OlaHsd 





No wild type 
mRNA detectable 








<2% of normal 
levels of wild type 
mRNA 
C57BI /6/12957 /SvEvBrd 
Cfttim38ay 
Hasty et al 1995 
Exon 2 
Replacement 
No wild type 
mRNA detectable 
C57BI /6/12957 /SvEvBrd 
CftrtmlCam 






30% of normal 
expression levels 
C57B1 /6 /129P2 /OlaHsd 
CemlKth 



















FVB /129P2 /OlaHsd 
Cftrrm16551u 






53% of normal 
expression levels 
CD1 /(129X1 /SvJ x 
129S1/Sv -) 
TABLE 1.9 Mouse models of CF 
The first mouse models were designed to be "knockouts ", disrupting 
the Cftr gene to create absolute nulls, with no normal CFTR production. 
Different gene targeting strategies were used to create the various mouse 
models. The first strategy was a replacement gene targeting, designed to 
replace an exon of Cftr with disrupted homologous sequence. This method 
produced absolute nulls by replacing exon 10 (Cftrt e""` ( Snouwaert et al 1992), 
Cftrt "'" "' (Ratcliff et al 1993)), exon 2 (Cftrt"'38ny (Hasty et al 1995)) or exon 1 
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(cftrtm1Hsc (Rozmahel et al 1996)). In these mutants there is no mechanism for 
the production of wild type CFTR. The second strategy was replacement 
gene targeting, to generate duplication of exon sequences in either exon 10 
(Cftrtmmgu 
(Dorin et al 1992)) or exon 3 (Cftrt "'1Bay (O'Neal et al 1993)). The use of 
this strategy produced insertion into the target gene without loss of genomic 
sequence. Thus, in theory, these mutants retain the potential for reversion to 
wild type and the production of normal Cftr mRNA by various mechanisms. 
In the Cftrt"'1Bay mouse, duplication of the intact exon produced a 
frameshift and premature stop codon. In this mutant less than 1 -2% of 
normal levels of wild type mRNA were reported and the phenotype was as 
severe as the other "null" mice. However, in the C rtmlHgu tmlHgn ft /Cftr mouse, in 
which there is introduction of an incomplete exon 10 running into plasmid 
sequence containing stop codons, exon skipping and aberrant splicing result 
in -10% of normal levels of wild type mRNA expression (Dorin et al 1994). 
This has resulted in the description of this mutation as "residual function ". 
The low level of normal CFI'R may be responsible for significant phenotype 
differences observed between the Cftr tii1 /Cftrt "''" mouse and the absolute 
nulls (see section 1.7.3). However, human compound heterozygotes, such as 
R347P/AF508 or R117H /zF508, are predicted to retain approximately 15% 
and 7.5% of normal CFTR function respectively (Sheppard et al 1993). These 
individuals are still diagnosed as having CF and although pancreatic 
sufficient, can develop severe lung disease. 
The second wave of mouse models of CF focused on accurately 
reproducing known clinical mutations. The replacement gene targeting 
strategy was used to created two models of the ÁF508 mutation (Cftr "" ZGam 
(Colledge et al 1995)) and Cftrt "i11th (Zeiher et al 1995)) the G551D model 
(Cftri lG551D (Delaney et al 1996)) and mouse models of the R117H and Y122X 
mutations (Merrill et al 1998). The other ¿ F508 model (CftrtiilEur (van 
Doorninck et al 1995)) and the G480C model (Cftrt mm" (Dickinson et al 1998) 
were created using a double homologous recombination ( "Hit and Run ") 
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procedure (Hasty et al 1991). This elegant technique produces a mutated 
exon without selection marker genes or plasmid sequences in the intronic 
structure of the gene. The presence of such intronic "debris" may be 
responsible for unwanted effects of transcriptional interference in the other 
models. In one study a mouse model containing only a neomycin resistance 
gene in intron 4 was established as a control line (Merrill et al 1998). 
Preliminary data suggested that this was sufficient to reduce the expression 
of wild -type Cftr mRNA to 10% of normal levels and produce an abnormal 
phenotype similar to other mouse models of CF (Merrill, personal 
communication). 
1.7.3 Phenotype 
The phenotypes of the different mouse models of CF bear most of the 
same hallmarks, however important differences have been observed. These 
phenotype variations have been shown to relate to the specific mutation, to 
environmental influences and to independently segregating modifier genes. 
The level of significance now attached to such phenotype modifiers was not 
evident during the initial characterisation of the many mouse models of CF. 
As a result, direct comparisons between the different models must be made 
with considerable care and with attention to the environmental conditions 
and background strain (see Table 1.9). The models in which the majority of 
significant studies have been performed are the Cftr`'°1Hgu, Cftrhn1Lnc and Cftr 
thus special attention will be paid to their characterisation. 
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1.7.3.1 Survival 
Mutation Perinatal death Adulthood Body weight 
Human ÁF508 10% MI 20% DIOS Impaired 
Mouse Cft /mlUnc 50% by day 7 
40% death at weaning 
<5% survival 
to adulthood 
10 - 50% 
reduction 
CftrrmlHgu 
5% by day 7 





Cftrr ivam 80% by day 7 





Cftrtm1Hsc 55% by day 7 




Cftr"ml5ay 40% by day 7 
10% death at weaning 
NR 70% 
reduction 
Cftr 313ay NR 40% survival 
at 1 month 
reduced 
Cftim2c;am 35% by day 16 <5% survival 
to adulthood 
NR 




/mltut- None normal 20% 
reduction 
Cft/ m1G551U NR 67% survival at day 35 
in SPF conditions 
27% survival at day 35 
in normal conditions 
30 - 50% 
reduction 
TABLE 1.10 Survival and body weight in mouse models of CF 
Intestinal pathology and the resultant mortality appear to be the 
predominant hallmark of Cftr mutation in the mouse. The survival rates 
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reported in the initial characterisation of the different mouse models of CF 
vary from <5% in the Cftrt"'"'"` /Cftrt''' nulls, and similar rates in the majority 
of models, to -90% in the Cftrtm1Hgu /Cftrt'"'Hgu mice (see Table 1.10). The 
remaining 10% of Cftr t "''ttgu /Cftrtell'igu animals die around weaning as a result of 
intestinal obstruction, resembling meconium ileus. Interestingly, this is a 
similar proportion to the rate of meconium ileus in CF humans. The low 
level production of normal CFTR has been proposed to be the explanation 
for the significantly greater survival rate in the Cftrt"'' "g" /CftrtnilHgu mice. The 
results of a study addressing the relationship between the levels of intestinal 
Cftr mRNA, the electrophysiological profile and the survival rate, indicate 
that quite small corrections in gene activity can have marked 
electrophysiological and dramatic pathological consequences (Dori" et al 
1996). The improved survival of the Cftrt l'igu /Cftrtn''Hgu mice provides obvious 
advantages for the study of large cohorts over longer time periods. 
The mortality associated with intestinal disease has been reported to 
be manifest at two distinct periods; firstly within a few days of birth and 
secondly around the time of weaning to solid food (approximately 21 days). 
Study of the survival at these time points in the Cftr " "1Hsc/ Ctr"n1Hsc mice, 
congenic on different inbred backgrounds revealed a modifier locus for 
intestinal phenotype in mouse models of CF (see section 1.7.4) (Rozmahel et 
al 1996). The high mortality at the time around weaning appears to result 
from the consumption of solid food, and the use of a liquid diet has been 
found to prolong the lifespan of Cftr "'1 /Cftrt"' "'nc mice (Kent et al 1996). An 
alternative approach utilised the expression of human CFTR cDNA in the 
intestinal tract of these mice, under the control of the rat intestinal fatty acid - 
binding protein gene promoter. This has been demonstrated to correct the 
lethality of the intestinal defect in Cftr " " ' /Cftrt "' mutant mice and lead to 
longer term survival, despite inappropriate cell- specific expression (Zhou et 
al 1994). However, concern persists about the confounding effects of 0- 1R 
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expression outwith the gastrointestinal system and follow -up studies have 
not been published. 
These approaches prolong the survival of the Cftrt ?1 nc /Cftrt:nlUnc mice, 
providing increased cohort size and the potential for longer term study. 
However, it is important to appreciate that the minority of these null 
mutants survive, raising the possibility that some form of selection for less 
severely affected animals may occur. This is of particular importance where 
the mutation has not been bred to be congenic on an inbred strain. In 
addition, mice weaned on a liquid diet have been suggested to suffer the 
effects of malnutrition (Ip et al 1996) which may impact upon further 
phenotypic observations. 
1.7.3.2 Intestinal disease 
The most pronounced pathology in mouse models of CF has been 
reported in the gastrointestinal system. Variation between models has been 
reported in the specific pathology observed and the degree of severity. 
However, in most cases, characterisation of the mutant mice has revealed 
pathology similar to that initially reported for the CftrtrnlUnc /¡ihnlUnc null mice 
(Snouwaert et al 1992). These observations include runting and failure to 
thrive, goblet cell hyperplasia, mucin accumulation, crypt dilation and 
intestinal obstruction (bearing similarity to meconium ileus), with resultant 
perforation, peritonitis and death. The Cftrtml' /Cftrt "'" mice display a 
rather less severe phenotype, without runting or failure to thrive, however 
characteristic intestinal pathology is observed (Dorin et al 1992). Although 
characteristic pathology has been observed in the Cftrhn1G551D mice, 
this model has been reported to display less mortality resulting from 
intestinal complications (Delaney et al 1996). It is interesting to note that 
compound heterozygote humans with G551D and ÁF508 mutations have a 
89 
lower incidence of meconium ileus than AF508 homozygotes (Hamosh et al 
1992). The intestinal phenotype reported for the Cftrtm7Eur trfm1Eur 
mouse is the least severe, with only a degree of runting and mild goblet cell 
hyperplasia observed (van Doorninck et al 1995). This is surprising in light of 
the phenotypes of other AF508 mouse models and CF individuals 
homozygous for AF508. The observations highlight the caution that must be 
used when interpreting the phenotype of mouse models of CF and the 
importance of clearly distinguishing between the different models and 
background strains utilised. 
Studies characterising the electrophysiological profile of the intestines 
in mouse models of CF have found broadly similar phenotypes in the 
different models (Clarke et al 1992a, Dorin et al 1992, Ratcliff et al 1993, Clarke 
et al 1994, Colledge et al 1995, Hasty et al 1995, Smith et al 1995, van Doornick 
et al 1995, Zeiher et al 1995, Delaney et al 1996, Rozmahel et al 1996, 
Wilchanski et al 1996) (see Table 1.11). On the basis of this form of analysis 
mutant mice could be unequivocally distinguished from wild type 
littermates. Furthermore, these profiles closely model the 
electrophysiological phenotype in CF humans (reviewed in Grubb and 
Boucher 1999). 
All of the mouse models of CF have been reported to display a 
significant decrease in the baseline potential difference (PD) and short -circuit 
current (Ix) in the intestine. This is likely to be the result of a decreased rate 
of unstimulated chloride secretion. In addition, a complete absence, or a 
significant decrease, of cAMP- stimulated CY secretion has also been reported 
in all of the models. 
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Cat + - related 
CI- response 
CF Human GI tract 44 or T 9 9 Cft /m1Unc jejunum 
caecum 
colon 
9 9100% 9 
Cfttimmigu jejunum 9 965% 
caecum 9 965% 9 
cfen1Cam caecum 9 9100% NR 
Cf/m1Hsc rectum NR 9100% T 
* ileum NR 9100% T 
Cft /mltiay ileum E-4 980% NR 
Cft /m3aay colon NR 9100% 9 
Cftlrmlc;am colon 9 9100% 9 
Cftrtmn`th jejunum F4 9100% NR 
Cftlimbur ileum 9 966% 4 
Cftrtm1G.551U jejunum 9 999% NR 
caecum 9 995% NR 
TABLE 1.11 Intestinal electrophysiology in mouse models of CF 
Comparison of the electrophysiological profiles of the intestinal epithelium in 
CF humans and mouse models of CF, on the original background strain. 
Increased (T), decreased (9) or preserved ((-4) in comparison to non -CF 
controls. NR - Not reported. * Patch clamped isolated ileal crypt cells. See 
text for references. 
While the "residual function" nature of the Cftrt "m" mutation may 
provide the explanation for the mild intestinal phenotype of the 
Cftrt"° "4 " /Cftrt"'1H4" mice (Dorin et al 1994), the improved survival rates of 
Cftrtii1G551D /Cftrtt "' mice and the mild nature of the intestinal disease in the 
Cftrt'" 
1E 
"r /Cftrtm]Eur ÁF508 mice is less clear. Electrophysiological analysis of the 
intestines of Cftrt "'1G551 ° /Cftrtii1G551D mice demonstrated a small Cl- current, 
suggesting a low level of activity from the mutant CFTR (Delaney et al 1996), 
compatible with observations in G551D humans. It has been proposed that 
this may alleviate the severity of the phenotype. The Cftrt "i1 E "r /CftrttrtlEur mice 
have also been shown to display a residual chloride permeability (van 
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Doorninck et al 1995), not observed in the intestinal tract of the other AF508 
models. This may relate to the level of transcription from the targeted allele. 
Unlike the other AF508 models, the Cftrthh1 r mutation does not retain a 
selection cassette in the intron, with the capacity to impair transcription. In 
the presence of a greater amount of AF508 CF1'R it is conceivable that a 
proportion may be correctly localised and display reduced function. 
Alternatively, or additionally, these phenotype observations may relate to 
the background strain used (see Table 1.9) or environmental conditions in 
different animal facilities. Indeed the survival rate of Cftrh" " °m /Cftrt "tlCant mice 
has been reported to be much greater in Rotterdam than that reported in the 
literature for the same mice housed in Cambridge (van Doorninck et al 1995). 
This may relate to pathogen status of the facility, food, bedding or the 
founder mice sent to Rotterdam. The survival of Cftrt' "1G551 ° /Cftrtm1G551D mice 
was also observed to be quite different when housed in a conventional non - 
SPF unit in comparison to an SPF facility (Delaney 1996). 
1.7.3.3 Pancreatic disease 
In CF disease in humans pancreatic insufficiency is a prominent 
manifestation of CFTR dysfunction. In contrast, pancreatic disease has not 
been convincingly demonstrated in most of the mouse models of CF. The 
only models in which any pancreatic disease has been observed are the 
absolute nulls. The initial characterisation of the Cftrtm"` "`/Cftrtmfl mice 
reported that 2 out of 5 mutant animals displayed a degree of acinar 
distention and the presence of eosinophilic material (Snouwaert et al 1992). 
While 5 out of 10 of the Cftrh"'G °m /Cftrh "'Gm" mutants were reported to display 
dilatation and blockage of the small pancreatic ducts (Ratcliff et al 1993). 
Subsequent studies have reached differing conclusions on the extent 
of pancreatic disease in these models. In one study, in which Cftrt"'"`"` /Cftrtm' 
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mice were weaned on a liquid diet, significant differences in pancreatic 
growth and specific enzyme activities were observed (Ip et al 1996). 
However, wild type controls showed similar, although less severe, 
abnormalities on this diet when compared to those on a solid diet. In 
conclusion, the abnormalities were suggested to be predominantly secondary 
to malnutrition. A further study, using a liquid elemental diet (Peptamen), 
reported luminal dilatation and the accumulation of zymogen granules at the 
apical pole of the ductal epithelial cells, in CftrtntlUnc/Cftrt"''Unc mice (DeLisle 
1995). This phenotype has since been used, and corrected, in a study of the 
role of dietary fatty acids in CF. The role of the original diet in this 
phenotype may yet prove to be significant. 
These observations suggest that there may be important differences 
between the human and murine pancreas with regard to the role of CH'l'R. 
Whereas high level expression of CFTR has been demonstrated in the human 
pancreas (Marino et al 1991), the level of expression of Cftr in the murine 
pancreas has been shown to be low (Snouwaert et al 1992). Furthermore, an 
alternative fluid secretory pathway which is activated by increases in 
intracellular calcium has been demonstrated in murine pancreatic cells (Gray 
et al 1995). These Ca'-activated Cl- currents (CACC) can be observed in 
murine pancreatic duct cells which have no detectable CH R. These CACC 
are a similar magnitude in mouse models of CF and wild type littermates, 
and are about 15 fold larger than CH R currents. It appears likely that 
mouse models of CF do not develop significant pancreatic pathology, of the 
severity that occurs in the human disease, as a result of these physiological 
differences. 
1.7.3.4 Reproductive Tissue 
Most male patients with CF are infertile and a significant proportion 
of those with CVABD have class 5 mutations in CFTR, such as 5T (see section 
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1.3.3). These observations suggest that the male reproductive tract is 
particularly sensitive to CFTR dysfunction. High levels of expression of Cftr 
mRNA is reported in the murine testes and epididymis (Snouweart et al 
1992). Female mice homozygous for the Cftr`'' or Cftr1G551D 
mutations are infertile, while homozygote males have a reduced fertility. 
Both male and female mice homozygous for the Cftr` "'' "g" mutation are fertile, 
but have a reduced fertility, which is more pronounced in the females (Doria, 
personal communication). 
1.7.3.5 Lung disease 
Lung disease is the primary concern for CF individuals, physicians 
and research scientists alike. Consequently, the value of mouse models of CF 
in dissecting the disease pathogenesis and developing novel therapies is 
largely dependent upon on the extent to which they mimic the lung disease 
seen in human CF patients. 
Initial characterisation of the mouse models provided little indication 
of gross pulmonary abnormalities. These observations were greeted with 
some surprise. However, upon reflection, an expectation of mucus plugging, 
neutrophil accumulation and bronchiectasis in these mutant animals may be 
considered to be unrealistic. This is particularly true if bacterial interaction is 
required to initiate a cycle of infection and inflammation, given that most of 
these mutant animals were maintained in semi- sterile barrier facilities. 
Furthermore, the development of characteristic lung histopathology in CF 
individuals is a gradual process that occurs over years. The initial 
assessment of mouse models of CF was made after only a few weeks to 
months. Indeed, in the case of null mice, the vast majority died of 
gastrointestinal complications before a systematic assessment could be made. 
In this respect the prolonged survival of the Cftr""' "g" /Cftr`"'' "g" mice proved to 
be particularly valuable. 
94 
Despite this apparent absence of pulmonary pathology, 
electrophysiological analysis of the mouse models of CF have been shown to 
clearly differentiate between mutants and wild type littermates (reviewed in 
Grubb and Boucher 1999). Studies have addressed both the bioelectric 
profile of the nasal epithelium (see Table 1.12) and that of the lower airways 
(see Table 1.13). 






CF Human T T 4 F4 
Cfttimlunc T T 4100% T 
CfelHgu T T 470% F4 
Cftlimluam T NR NR NR 
CftrrmlHsc T T 4100% T 
Cfttfrmltur T T Response to CI- gradient 
CftltmlKtn ,r ,r 4100% NR 
Cftrtm16551U T T 9100% f-4 
TABLE 1.11 Nasal electrophysiology in mouse models of CF 
Comparison of the electrophysiological profiles of the nasal epithelium in CF 
humans and mouse models of CF, on the original mixed genetic background 
strain. Increased (T), decreased (4) or preserved (E- -3) in comparison to 
non -CF controls. NR - Not reported. See text for references. 
The analysis of the nasal epithelium has . demonstrated 
hyperabsorption of Na+ in all of the mouse models of CF for which the 
electrophysiological profile has been reported (Dorin et al 1992, Hyde et al 
1993, Grubb et al 1994a, Smith et al 1995, van Doorninck et al 1995, Zeiher et al 
1995, Delaney et al 1996, Rozmahel et al 1996, Wilschanski et al 1996) (see 
Table 1.12). This is manifest in a raised baseline PD and a significantly 
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greater decrease in PD in response to the ENaC inhibitor amiloride, than 
observed in wild type littermates. In addition a decrease, or absence, of 
cAMP- stimulated Cr conductance was observed in all the models tested, 
except for the C trt "'lE "r /C tr`m1Eur mice. In the C ft rtmlEur  f f /Cftr tmlEur mice the response 
to a large chloride gradient was studied by substitution of chloride with 
gluconate in the apical solution and found to be quantitatively similar to 
non -CF controls (van Doorninck et al 1995). In these respects, the nasal 
epithelium in most of the murine models of CF accurately replicates the 
defects observed in the human airways. However, in contrast to human 
bioelectric profiles, the nasal mucosa of Cftrtiil "" /Cftrt "i1 ""` mice has been 
reported to display upregulation of the Caz +- mediated Cr secretory pathway, 
responsive to ionomycin and, to a lesser extent, forskolin (Grubb et al 1994a). 
Similar observations have not been observed in studies of the Cftrtmmgu mice 
(Smith et al 1995). 
The analysis of the distal airways has proved to be more complex (see 
Table 1.13). In contrast to the human airways, studies in the mouse models 
of CF report no difference, or a reduction, in the amiloride- sensitive ISc (Hyde 
et al 1993, O'Neal et al 1993, Grubb et al 1994b, Colledge et al 1995, Smith et al 
1995, Delaney et al 1996). This suggests that the loss of Cr°I R does not result 
in the upregulation of ENaC in this tissue. The cAMP- stimulated Cl- 
responses were mixed, while some showed no difference, others 
demonstrated a significant decrease. However, cAMP- stimulated CY 
currents were still demonstrated in this tissue in all the mouse models of CF. 
It has been proposed that an alternative Caz +- mediated CF secretory 
pathway is dominant in the murine trachea and that this may be stimulated 
by forskolin (Grubb et al 1994b). It has been suggested that this pathway 
may be particularly dominant in the Cftrt l " "` /Cftrt l " "` mice, but may be 
eliminated using pre -treatment with calcium agonists tert- 
Butylhydroquinone (TBHQ) and ionomycin (MacVinish et al 1997). 
Although this pathway was not found to be altered in the majority of the 
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mouse models of CF, it has been reported to upregulated in the 
Cftrtm2c.,' /Cftrt"'2c (J "' AF508 mice and Cftr`"°GS57D /Cftrti°c55'D mice, when compared 
to wild -type littermate controls (Colledge et al 1996, Delaney et al 1996). 
More recent studies have demonstrated that the ion transport properties of 
the murine trachea are regulated by independently segregating modifier 
genes and show considerable variation between mouse strains (Farley et al 
1998, Zapp and Drumm 1998) (see section 1.7.4). 






CF Human T or 44 T 40 44 
Cftrlmlunc E4 E4 E4 4-4 
CelHgu 40 40 40 60% F4 
Cftllmlcam 40 y 40 75% 44 
Cftrtmlt3ay 4-4 NR ** 9 70% NR 
Cftlimlcam 44 44 *44t0960% T 
Cft.im1U551U 44 4-4 40 60% T 
TABLE 1.13 Tracheal electrophysiology in mouse models of CF 
Comparison of the electrophysiological profiles of the tracheal epithelium in 
CF humans and mouse models of CF, on the original mixed genetic 
background strains. Increased (T), decreased (9) or preserved (44) in 
comparison to non -CF controls. NR - Not reported. * Greatest decrease 
observed in the youngest mice. ** Studied in cultured foetal tracheal cells. 
See text for references. 
As a consequence of these electrophysiological profiles it has been 
suggested that the murine trachea may not be the ideal model for the human 
airways. Nevertheless, the mouse models of CF do display 
electrophysiological abnormalities as a result of Cftr mutation. Thus, any 
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resultant pathology is of interest, interpreted in the context of knowledge of 
both the similarities and the differences between humans and mice. 
Additional concerns have been raised about the cellular composition of 
the murine airways and the distribution of submucosal glands. The human 
airways are composed primarily of ciliated cells, whereas the murine airways 
are predominantly composed of Clara cells (Pack et al 1980). It has been 
suggested that for this reason the murine airways may be a better model of 
the human bronchioles than the large airways. Despite reports to the 
contrary, mice do have submucosal glands in the airways. However, unlike 
the human, these glands are predominantly localised in the most proximal 
part of the trachea and do not extend into the bronchi (Borthwick et al 1999). 
Furthermore, the distribution pattern of these glands is affected both by 
strain background (see section 1.7.4) and Cftr mutation (Imes and Dorin 
1999). 
The first observations relating to abnormal phenotype in a mouse 
model of CF were made in the Cftr ̀ "`'Hg ° /CftrtnlHgu mice. In initial studies of 
outbred MF1/129 Cftr` "''Hg " /CftrtntlHgu mice no gross lung disease was observed 
at birth, or in animals born and raised in isolator conditions (Davidson et al 
1995). However, histopathological evidence of pulmonary pathology was 
noted in mice reared in normal (non- specified pathogen free (SPF)) animal 
house conditions. Although no significant difference existed between the 
genotypes, there was a trend towards worse pathology in the CF mutant 
mice. Subsequent studies on CftrtnhlHgu /Cftrt "' mice provided additional 
indications of an abnormal lung phenotype in untreated mice. 
An evaluation of the cytokine levels in BAL from untreated MF1 /129 
Cftrt "'11 " /CftrtrnlHgu mice revealed significantly increased levels of the pro - 
inflammatory cytokine TNF -a in the mutant mice in comparison to non -CF 
littermates (Morrison 1999b). Interestingly this was only demonstrated in 
studies of animals maintained in standard, non -SPF conditions. In the 
animals maintained in a full barrier, SPF facility the levels of TNF -a were 
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significantly lower in both mutant and non -CF mice, with no significant 
difference between the genotypes observed. This suggests that an abnormal 
lung phenotype may not be manifest without exposure to pathogens. 
Further histological analysis of untreated MF1 /129 u/cftrtmitigii 
mice revealed a significant increase in the number of inflammatory cells 
(predominantly lymphocytes) present in the lamina propria, in comparison 
to non -CF littermates (Zahm et al 1997). In addition, the mucociliary 
transport of inert particles in vivo was demonstrated to be significantly 
impaired in the Cftr 6"1Hgu trn7Hgu /Cftr mice in comparison to non -CF littermates. 
Although a significant decrease in particle transport rate was observed, no 
difference in the ciliary beat frequency was noted (Zahm et al 1997). A 
subsequent study, using embedded, cultured lung slices from mice with the 
Cftrt "' "` "` mutation, partially backcrossed onto the C57B1/6 background, 
repeated these observations (Cowley et al 1997a). In addition this study 
reported that ciliary beat frequency could be increased by infection with P. 
aeruginosa, whereas particle transport rate was dependent upon both 
infection and CF status. 
Studies performed by myself and colleagues at the Human Genetics 
Unit prior to this thesis, demonstrated that the MF1 /129 Cftrtttt7Nsu /Cf trtm7Hgu 
mice displayed an abnormal lung phenotype in response to aerosolised, CF 
associated bacteria (Davidson et al 1995). Utilising nebulisation techniques 
(see Chapter 3) aerosolised bacteria were delivered to the lungs of cohorts of 
mutant and non -CF mice. Bacteriological and histological analysis was 
performed to establish the clearance of these pathogens and the 
histopathological response to repeated exposure. These studies 
demonstrated significantly impaired airway clearance of aerosolised S. 
aureus and B. cepacia in the mutant mice, in comparison to non -CF littermates. 
Furthermore, the MF1 /129 Cftrtii7Hgu /Cftrtm7Hgu mice developed significantly 
more severe, pathogen specific, lung pathology after repeated exposure to 
these bacteria, in comparison to non -CF littermate controls. The spectrum of 
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abnormal pathology included lymphocytic aggregates, goblet cell 
hyperplasia (GCH) and metaplasia, mucus retention, bronchiolitis, 
pneumonia and oedema. 
These initial studies provided the first demonstration of an abnormal 
pulmonary phenotype, other than electrophysiological profiles, in a mouse 
secondary to Cftr mutation. Consequently this provided the opportunity to 
investigate disease pathogenesis in a model system for CF, to interrupt the 
process at defined stages, with appropriate controls, in defined and 
manipulated genotypic and environmental conditions. The aims of this 
thesis were to further characterise the pulmonary phenotype and to examine 
the factors contributing to its development. These studies and the relevant 
contemporary studies in other mouse models of CF will be discussed in the 
following chapters. 
1.7.4 Phenotype modification 
Mouse models of CF provide a valuable resource in which to assess 
the role of CFTR and dissect the initiating and potentiating factors in disease 
pathogenesis. In addition, they provide an ideal resource in which to 
establish the contribution of independently segregating modifier genes to CF 
phenotype. 
The greatest advantage of mouse models for such studies is the ability 
to control both the environment and the genetic background. Strains of 
laboratory mice have been specifically inbred over generations to establish 
inbred strains. Within such strains all the mice are practically 100% 
genetically identical. Repeated backcrossing of mouse models of CF with 
chosen inbred strains has been performed. The resultant offspring are 
considered to be certified congenic after 10 backcross generations and 99.9% 
inbred. The study of congenic inbred mouse mutants of CF should result in a 
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more homogeneous phenotype than that observed in an outbred strain, in 
which many genetic differences exist between littermates. In addition it 
decreases the potential pitfall of phenotype influencing genes co- segregating 
with the Cftr mutation in a proportion of the outbred mice. Different 
mutations of Cftr have been established on the same genetic background. In 
these animals the only genetic difference should be the nature of the 
mutation in Cftr. This allows the direct comparison of mutations and the 
elucidation of mutation specific effects upon phenotype. In addition, the 
same Cftr mutations have been established on different inbred lines. This has 
introduced the possibility of comparing the effects of genetic differences 
between various inbred strains and facilitated the search for independently 
segregating genetic modifiers of disease. 
The first modifier locus was identified on the proximal region of 
mouse chromosome 7 (Rozmahel et al 1996). The Cftrtm7Hsc/ Cftr"'" mouse was 
originally studied on a mixed outbred CD1 /129 background and classified 
into three categories dependent upon survival. The original founder mouse 
was then bred with a selection of different inbred strains to produce F, 
heterozygotes. These were then bred together to produce F2 animals, 
homozygous for the mutation with different genetic backgrounds. Analysis 
of these mice demonstrated long term survival, beyond weaning, in a 
proportion of the mutant mice on some backgrounds, but not others. A 
genome scan was then performed with polymorphic DNA markers to 
identify potential modifier loci. It has been suggested that a gene encoding a 
Ca +- activated Cl- channel may be responsible, however, to date the gene 
responsible has not been reported. As a direct consequence of this study a 
genetic modifier locus for meconium ileus in humans has been identified on 
the syntenic region on human chromosome 19. 
The Cftrt"''Hg" and Cftrt """ mutations have been inbred to congenic on 
the C57B1/6 strain (Dorin et al 1997, Kent et al 1997). The inbred C57B1/6 
Cftr,tml 
Unc / Cftr,tml Unc mice demonstrate only 6% survival at day 20, despite 
weaning onto a liquid diet, while mice with the CftrtmlUnc /Cftrtml Unc continue to 
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show high rates of survival. Initial analysis of the phenotype of the inbred 
C57B1/6 Cftrtril "" /Cftrtiil""` mice, reported a host of pulmonary abnormalities. 
However, aspects of the methodology relating to the evaluation by light 
microscopy and pulmonary function tests, were inappropriate and many of 
these original observations have not been substantiated by future analysis 
(Haston, personal communication). Nevertheless quantitative trait loci 
(QTL) analysis based on alveolar thickening and collagen deposition in the 
inbred C57B1/6 CftrtnilUnc /CftrtiilUnc, relative to inbred BALB /c Cftrtmlu" CL.rtml Unc 
mice has identified one locus meeting the criteria for suggestive linkage 
(Haston et al 1999). In addition, increased lung neutrophil counts and 
myeloperoxidase levels in inbred CftrtiilUnt /Cftrtril ""` mice are being assessed 
on different strain backgrounds. 
Studies of the CftrtmlHgu /Cftrt'nlHgu mice have demonstrated that the 
distribution of submucosal glands in the murine trachea is determined both 
by the Cftr genotype and the genetic background (Imes and Dorin 1999). In 
Cftrt"'IHg " /Cftrtm1Hgu mice, both inbred and outbred, the submucosal glands have 
been observed to extend more distally than in wild -type littermate controls. 
Utilising recombinant inbred strains two putative loci associated with this 
phenotype have been identified, on mouse chromosomes 9 and 10. The 
region on chromosome 9 includes several genes, of which one candidate may 
be the gene encoding Glutathione S- transferase (GST). 
Analysis of inbred mouse strains has also revealed strain specific 
variation in the electrophysiological properties of the murine airway 
epithelium (Farley et al 1998, Zapp and Drumm 1998). These studies 
demonstrate the existence of genetic modifiers that determine the ion 
transport profile of both the nasal and tracheal epithelium. Furthermore, 
these studies raise the possibility of independent genetic factors determining 
the expression and /or function of CFTR in these tissues. The tracheal 
forskolin response is reported to consist of two main components. Pre- 
treatment with calcium agonists has been used to reveal the cAMP- mediated 
C1 secretion (MacVinish et al 1997). This approach abolished the forskolin 
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stimulated response in C57B1/6 mice but not in BALB /c mice. This suggests 
that only the latter strain of mouse had an appreciable level of CF 1 R activity 
in the trachea and that the major mode of chloride transport in the former 
was via Caz +- activated channels. This demonstrates that other genetic 
influences may modify phenotype and may be important in the 
interpretation of the electrophysiological profiles of different mouse models 
of CF, on different background strains (see section 1.7.3.5). Furthermore, it 
suggests that tracheae of BALB /c mice are more likely to display an 
abnormal phenotype as a result of Cftr mutation than are C57B1/6 mice. 
These studies intend to map the genetic modifier responsible for these 
phenotype variations. 
While it is possible that genetic modifiers for lung disease in mouse 
models of CF may have no relevance in the human disease process, the first 
example shows that in some cases they may reveal biologically relevant 
mechanisms in both mouse and man. It is hoped that these discoveries may 
provide insight into the pathogenesis of CF and even reveal possible targets 
for novel therapies. 
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1.8 Aims of this thesis 
The initial demonstration of abnormal pulmonary phenotypes in 
CftrtmlHgu /Cftrt "'' "gu mice established these animal as an important model for the 
development of lung disease in CF. However, the original studies were 
performed using outbred mice and displayed a broad spectrum of pathology 
in response to pathogens. This thesis aimed to- 
a) establish reliable bacterial exposure techniques by evaluating and 
quantifying methods of bacterial delivery to the murine lung. 
b) assess the relative roles of genetic strain background, residual 
CFTR function and environmental influences upon the variability 
of pulmonary phenotype observed in outbred CftrtmlHgu /Cft.rtm1Hgu 
mice in response to repeated bacterial exposure. This was 
addressed by assessment of the pulmonary phenotype of mouse 
models of CF in response to repeated exposure to Staphylococcus 
aureus, using: 
1) Cftrt"'' "g /Cftrt"'' "gu mice inbred onto the C57B1/6 background 
to assess the phenotype of this mutation on an inbred strain 
2) Cftrt "11-47 Cftrt "'' compound heterozygote mice, inbred onto 
the C57B1/6 background, to assess the effect of decreasing 
the level of normal CF'1R 
c) address the factors contributing to the development of an 
abnormal pulmonary phenotype in the Cftrtm' "gu /CftrtmlHgu mice 
assessing both the similarities and the differences between the 
104 
human and murine lungs. The relevance of current theories for the 
pathogenesis of CF lung disease in humans was examined by: 
1) studying the role of internalisation of bacteria by murine 
epithelial cells 
2) studying and comparing the antibacterial profile of human 
and murine 3- defensins 
d) establish and characterise an air /liquid interface primary culture 
model of murine tracheal epithelial cells 
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Chapter 2 
Materials and Methods 
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Chapter 2: Materials and Methods 
2.1 Animals 
All wild type mice used were supplied by Charles Rivers UK Ltd., 
Margate, UK. All mouse models of CF were bred in house with 
assistance from Dr Julia Dorin and Dr Sheila Webb, MRC Human 
Genetics Unit, Edinburgh. Mice were used at various ages for different 
studies as specified in the details for individual experiments. Where 
non -CF littermate controls were used, cohorts were age and weight 
matched. With the exception of mice used for primary culture studies, 
animals were housed in the Biomedical Research Facility, Western 
General Hospital, Edinburgh and maintained under standard conditions. 
These conditions were not specified pathogen free (SPF). For primary 
culture studies C57B1 /6N mice of both sexes were used, aged 5 -7 weeks 
and maintained in the Transgenic Unit, Evans Building, Western General 
Hospital, Edinburgh, under SPF conditions. Routine health screening 
was performed by Harlan UK Ltd., Blackthorn, Bicester, Oxon., UK. All 
experimental work complied with the UK Animal (Scientific Procedures) 
Act 1986. 
2.2 Genotype analysis of mouse models of CF 
A breeding colony of mouse models of CF was maintained in the 
Biomedical Research Facility, Western General Hospital, Edinburgh. 
Anaesthetised mice were ear clipped for identification and tail tipped for 
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genotyping with the assistance of Vincent Ranaldi, Biomedical Research 
Facility, Western General Hospital, Edinburgh. Genotyping was 
performed as described below. Mice were also supplied from an 
alternative breeding colony maintained by Dr Julia Dorin and Dr Sheila 
Webb, MRC Human Genetics Unit, Edinburgh. These mice were 
genotyped by Dr Sheila Webb, MRC Human Genetics Unit, Edinburgh. 
2.2.1 Preparation of total genomic DNA from tail tips 
Tail tips were incubated overnight at 50 °C in 500 ml of Quick Lysis 
Buffer (100 mM Tris HC1 pH 8.5, 5 mM EDTA, 200 mM NaC1, 0.2% SDS) 
containing 50 µg of Proteinase K (Boehringer Mannheim UK, Lewes, East 
Sussex, UK). The samples were then vortexed vigorously and centrifuged for 
10 minutes at 15 000 rpm. The resultant supernatants were added to 0.5 ml 
of 100 % ethanol and the precipitated DNA spooled onto glass rods. The 
DNA was washed with 70 % ethanol and then air -dried for 5 minutes, after 
which it was resuspended in 50 µl of TE (10 mM Tris HC1, 0.1 mM EDTA, pH 
4.0). 
2.2.2 Restriction enzyme digestion of DNA 
Genomic DNA was digested overnight at 37 °C with 0.67 u /µl Xba I 
and 0.67 u /µl Sal I restriction enzymes (both supplied, with buffer by 
Boehringer Mannheim UK, Lewes, East Sussex, UK) in lx Buffer H with 3.34 
mM spermidine. Digestions were analysed for completeness by gel 
electrophoresis. 
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2.2.3 Agarose gel electrophoresis 
DNA molecules were separated according to their size on horizontal 
agarose gels. The percentage of agarose used to make the gel depended on 
the size range of the DNA molecules to be resolved. Digested genomic or 
plasmid DNA was commonly run at 0.7 -1% w/v agarose gels, whereas 
smaller fragments, such as most PCR products, were run on 1 -2% agarose 
gels. The agarose was dissolved and cast in TAE buffer (0.04 M Tris -base; 
0.001 M EDTA, 0.02 M Na Acetate, pH to 8.2 with glacial acetic acid) which 
was also used as the running buffer. Ethidium bromide (5 µg /100m1) was 
added directly to the molten agarose. lx loading buffer (10x DNA loading 
buffer: 20% Ficoll (Pharmacia Biotech, St. Albans, UK), 100 mM EDTA, 
Orange G (Sigma- Aldrich Co. Ltd, Poole, Dorset, UK)) was added to the 
DNA prior to loading the sample on the gel. Gels were run in 
electrophoresis apparatus (Biosciences Services) at 20 -100 V depending upon 
the resolution and run -time required. 
200 -500 ng of the appropriate size marker was used per gel; 
a) X DNA digested with HindIIl (Boehringer Mannheim UK, Lewes, East 
Sussex, UK) 
b) (DX 174 digested with HaeIII ( Boehringer Mannheim UK, Lewes, East 
Sussex, UK) 
The sizes of the bands given by these markers is listed below: 






















2.2.4 Southern blot transfer of DNA 
DNA fragments were separated by agarose gel electrophoresis, 
visualised under a mid -range UV transilluminator and photographed, next 
to a ruler to allow for future sizing of DNA fragments, using a video copy 
processor. The gel was soaked in Denaturing Buffer (0.5 M NaOH, 1.5 M 
NaC1) for 30 minutes and then in Neutralisation Buffer (0.5 M Tris, 1.5 M 
NaCl, pH 5.5) for 10 minutes. The gel was then placed in water until ready 
to blot. A large strip of chromatography paper (17 Chr; Whatman 
International Ltd., Maidstone, UK) was soaked in 20 x SSC (3 M NaCl, 0.3 M 
Na citrate) and placed on a glass plate, so that the ends of the paper were in a 
reservoir of 20 x SSC, forming a wick. A piece of chromatography paper (3 
MM Chr; Whatman International Ltd., Maidstone, UK) was then cut, slightly 
larger than the size of the gel, soaked in 20 x SSC and placed on top of the 
wick. The gel was placed upside down on top of the wet chromatography 
paper and a piece of Hybond -N nylon transfer membrane (Amersham 
Pharmacia Biotech UK Ltd, Little Chalfont, Buckinghamshire, UK), soaked in 
2 x SSC (0.3 M NaC1, 0.03 M Na citrate) placed directly onto the surface of the 
gel to cover the entire surface of the gel, excluding any trapped air bubbles. 
Two pieces of 3MM chromatography paper, pre- soaked in 2 x SSC, were 
placed on top of the membrane. Areas of exposed wick were covered in 
Saran wrap (Dow Chemical Company). A weighted stack of paper towels 
was placed on top to draw the fluid through the gel and transfer the DNA to 
the membrane by capillary transfer. Gels were blotted overnight. The 
membrane was rinsed in 2 x SSC, fixed by baking at 80 °C for 20 minutes and 
then stratalinked by exposure to 1200 µJoules of UV irradiation (Stratalinker 
1800, Stratagene). Membranes were stored between two sheets of 3MM 
chromatography paper at room temperature. 
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2.2.5 Radioactive hybridisation 
2.2.5.1 Preparation of radioactively labelled DNA probes 
Labelled probes from double stranded DNA were made by the 
random priming method (Feinberg and Vogelstein 1983). The labelling 
reaction involves random priming from hexanucleotides and then 
polymerisation along the DNA strand catalysed by the Klenow fragment of 
E. coli polymerase I. The reaction mix includes dATP, d111, dGTP and 
radiolabelled [a -32P] -dCTP so that radioactivity is incorporated into the 
newly synthesised strand. Approximately 50 ng of purified DNA in a total 
volume of 12 µl was boiled for 10 min to ensure denaturation, cooled rapidly 
to prevent reannealing of the strands, and spun down. The denatured DNA 
was then labelled using 4 µl of High Prime (Boehringer Mannheim UK, 
Lewes, East Sussex, UK) and 30 laCi [a -32P] dCTP (Amersham International 
P.L.C., Amersham, Bucks.). The reaction was incubated at 37 °C for 30 
minutes. Incorporation was estimated by washing a small amount of the 
probe on a GF /B circular filter (Whatman International Ltd., Maidstone, UK) 
with trichloroacetic acid (TCA) to remove unincorporated material, and the 
probe used if the incorporation was 50% or above. The probe was stripped 
by boiling for 10 min with 1 mg sonicated salmon sperm and 1 mg mouse 
genomic DNA followed by incubation at 68 °C for 45 minutes. The probe 
was then added to the prehybridised filters. 
2.2.5.2 Hybridisation of radioactive DNA probes 
Under a solution of 2 x SSC, the filters were placed between two 
slightly larger sheets of gauze, with up to 3 layers of filters. Air bubbles 
trapped between the filters and gauze were expelled, the layers were rolled 
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up together, transferred to hybridisation bottles (Hybaid Ltd., Ashford, 
Middlesex, UK) and unrolled onto the surface of the bottle. Filters were pre - 
hybridised at 68 °C for a minimum of 1 hour in rotating hybridisation bottles 
with 20 ml Hybridisation Solution (6 x SSC, 10% Dextran sulphate, 0.5% SDS, 
0.1% BSA, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 0.1% disodium 
pyrophosphate). After pre -hybridisation, radiolabelled probe (see section 
2.2.5.1) was added directly to the solution and the blots hybridised overnight 
at 68 °C. Filters were washed with 2 x SSC /0.1% SDS at 68 °C for 15 minutes 
and then 0.2 x 55(70.1% SDS at 68 °C for 15 minutes monitoring the 
background radiation with a Geiger counter. 
The filters were exposed to Kodak X -OMAT AR film at -70 °C in light - 
tight cassettes containing intensifying screens, for a length of time dependent 
upon the intensity of the radiolabelled probe (several minutes to days). The 
film was developed in a RGII (Fugi) automatic x -ray film processor. 
Wild type mice were identified by a hybridising fragment of - 6 kb 
between Xba I restriction sites in introns 9 and 10, whereas a smaller 
hybridising fragment of -5 kb, between the Xba I restriction site in intron 10 
and a Sal I restriction site introduce by the insertional mutation, was 
diagnostic for the Cftr` °'' "g° mutation. 
To remove the radioactive probes from the filters, they were placed in 
a metal tray containing water at 100 °C. The heat was immediately removed 
from the tray and the contents allowed to cool. 
2.3 Preparation of bacteria 
Bacteria were provided by Professor John Govan and prepared by 
Wendy Hannant, Dr Cathy Doherty or Dr Jayne Hughes, Department of 
Medical Microbiology, University of Edinburgh. The bacterial strains used 
were; Staphylococcus aureus CF clinical isolate C1705, Pseudomonas aeruginosa 
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CF clinical isolate J1385 and strain PAO1, Escherichia coli clinical isolate J2408 
and Burkholderia cepacia CF clinical isolate J2315. Pseudomonas aeruginosa CF 
clinical isolate J1385 has been documented to have preferentially infected 
several CF individuals, despite exposure to other strains simultaneously in a 
jacuzzi, and be particularly mucinophilic (Nelson et al 1990). Burkholderia 
cepacia CF clinical isolate J2315, is the virulent Edinburgh- Toronto epidemic 
strain ET /12 (Govan and Deretic 1996). 
An aliquot of the appropriate strain was recovered from storage, in 
10% w/v skimmed milk at -70 °C, thawed and streaked on the appropriate 
media. This was incubated at 37 °C overnight (or for 48 hours for B. cepacia). 
Nutrient broth (25 g /L, 0.5% w/v Yeast extract; Oxoid Ltd., Basingstoke, 
Hampshire, UK) was inoculated with a few colonies and incubated at 37 °C 
overnight in an orbital incubator. The bacterial suspension was centrifuged 
at 3000x g for 10 minutes and the supernatant removed. The bacterial pellet 
was resuspended in 0.85% saline and standardised using a 
spectrophotometer (CamLab) at OD590, to a density previously determined to 
correspond to - 109 cfu /ml. 
The following media were used: S. aureus was grown on Blood agar 
(39 g/L Columbia base agar (Oxoid Ltd., Basingstoke, Hampshire, UK), 5% 
defibrinated horse blood (E & O Laboratories Ltd., Burnhouse, Bonnybridge, 
Scotland) added after autoclaving and cooling), P. aeruginosa was grown on 
Pseudomonas isolation agar (45 g /L, 2% glycerol; Difco Laboratories Ltd., 
West Molesey, Surrey, UK), E. coli was grown on MacConkey agar (44.5 g /L; 
Mast Diagnostics, Mast Group Ltd., Bootle, Merseyside, UK), B. cepacia was 
grown on Cepacia medium (32.5 g /L, Ticarcillin 100mg /L, Polymixin B 
300,000 u /L; Mast Diagnostics, Mast Group Ltd., Bootle, Merseyside, UK). 
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2.4 Construction of bacterial delivery apparatus 
Murine nebuliser apparatus designs were adapted from an original 
design by Professor David Porteous, Medical Genetics Section, Department 
of Medical Sciences, University of Edinburgh (formerly MRC Human 
Genetics Unit, Edinburgh) (see Figure 3.1). The apparatus was constructed 
with the assistance of Duncan Fletcher and Leonard Hay, MRC Human 
Genetics Unit, Edinburgh. The apparatus was constructed in house from 
perspex (see Figure 3.2). The individual tubes within which each mouse was 
positioned were adapted from 50 ml catheter tip syringes (Terumo, Surgicon 
Ltd., Brighouse, W. Yorks., UK). 
Tracheal intubation catheters were constructed in house by Duncan 
Fletcher and Leonard Hay, MRC Human Genetics Unit, Edinburgh. These 
were adapted spinal needles (25G x 3.5 "; Terumo, Surgicon Ltd., Brighouse, 
W. Yorks., UK), shortened to 6 cm, blunted and with a 30° bend positioned 1 
cm from the end. Intubation frames were also constructed in house by 
Duncan Fletcher and Leonard Hay, MRC Human Genetics Unit, Edinburgh, 
based on a previously published design (Ho and Furst 1973). 
2.5 Bacterial delivery methods 
2.5.1 Nebulisation 
Mice were maintained in HEPA air filtered isolator cabinets for the 
duration of the experiment and caged in groups of mixed genotype. 
Exposed and unexposed control mice were housed in separate cages within 
the same isolator unit. Where mouse models of CF were analysed, groups of 
mutant mice and non -CF littermates, of comparable age and weight, were 
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exposed to bacteria in parallel. A maximum of six mice, of < 30g body 
weight, were restrained in radially arranged tubes in nebulisation apparatus 
(see section 2.4). Each animal was placed in a separate tube, with a cone 
shape for the mouse's nose open into the main chamber at one end and the 
other end obstructed with a rubber bung, greased with Vaseline. A carrier 
gas mixture of 95% OZ and 5% CO, (BOC gases, Guildford, Surrey, UK), 
regulated via an XR600 oxygen regulator (Oxylitre Ltd., Manchester, UK) 
was passed through a sidestream nebuliser (System -22 Optimist ®, Medic - 
Aid, Pagham, Sussex, UK), containing the bacterial suspension or PBS, at a 
rate of 12 L /minute. The addition of a baffle (a kind gift from Dr Peter 
Middleton, Ion Transport Laboratory, National Heart and Lung Institute, 
London) was used to reduce the air particle size. The aerosolised solution 
was circulated in the main chamber from which the mice were breathing and 
vented from the delivery chamber to be purged twice through Virkon 
disinfectant (Antec International Ltd., Sudbury, Suffolk, UK). 
The standard exposure protocol for the assessment of the bacterial 
delivery profile of the apparatus was the nebulisation of -4 ml of bacterial 
suspension over 5 minutes, either with or without the baffle. Mice were 
removed from the apparatus and immediately sacrificed by lethal 
intraperitoneal injection of 20 mg of sodium phenobarbitone (Euthatal, 
Rhone Merieux) and processed as described in section 2.6. 
The standard exposure protocol for the repeated exposure studies 
comprised the nebulisation of -4 ml of bacterial suspension over 5 minutes, 
with the baffle followed by the nebulisation of -4 ml of bacterial suspension 
over 5 minutes without the baffle. Treated animals were then returned to 
standard cages within the isolator. This protocol was repeated on a daily 
basis, 5 days a week, for 4 weeks. On the final day of exposures, 4 previously 
unexposed mice were also exposed, after which all the animals were given 24 
hours clearance time. Mice were sacrificed by lethal intraperitoneal injection 
of 20 mg of sodium phenobarbitone (Euthatal, Rhone Merieux) and 
processed as described in section 2.7. In some cases, unexposed mice, 
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maintained in the same isolator as the exposed mice but not actively exposed 
to bacteria, were also sacrificed and studied. 
A glass impinger was used to assess the viability of nebulised bacteria. 
The nebuliser outlet was connected directly to the inlet of the impinger via 
plastic tubing and the nebulised solution was bubbled through PBS to collect 
the bacteria. The resultant suspension was analysed using standard 
bacteriological methods. 
2.5.2 Direct intratracheal instillation 
Adult mice were anaesthetised with an intraperitoneal injection of 
Avertin (4.4 mM 2- 2- 2- tribromoethanol, 2.5% 2- methyl- 2- butanol, in distilled 
water), using 200 µl per 10 g body weight. Anaesthesia was induced within 1 
minute and lasted for approximately 45 minutes. The instillation was 
performed using a non -surgical, intratracheal instillation method adapted 
from a published technique (Ho and Furst 1973). The anaesthetised mouse 
was placed with its upper teeth hooked over a wire at the top of the support 
frame (see Figure 3.4) with a spring pushing the thorax forward to position 
the pharynx, larynx and trachea in a vertical straight line. The lower jaw was 
held open with a loop of thread around the lower teeth and weighted. The 
airway was illuminated externally using a swan neck fibre optic lamp placed 
against the mid sternum. The tongue was moved to one side and an 
intubation catheter (see section 2.4) was inserted between the vocal folds at 
the base of the larynx and passed into the clearly illuminated tracheal lumen. 
With the catheter held steady, 20 gl of bacterial suspension or 5% methylene 
blue dye in PBS was placed in a well at the proximal end of the catheter. A 
1m1 syringe was then attached to the end of the catheter and the solution 
gently instilled into the trachea with 200 µl of air. The animal was 
maintained in an upright position for 2 minutes after instillation to allow the 
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fluid to drain into the respiratory tree. Mice were sacrificed by lethal 
intraperitoneal injection of 20 mg of sodium phenobarbitone (Euthatal, 
Rhone Merieux) and processed as described in section 2.6 or 2.8. 
2.6 Microbiological assessment of murine tissue 
2.6.1 Bacteriological assessment of murine lungs 
Animals were sacrificed by lethal intraperitoneal injection of 20 mg of 
sodium phenobarbitone (Euthatal, Rhone Merieux). The lungs and trachea 
were removed together into 1 ml PBS at room temperature. In some 
instances the trachea and proximal primary bronchi were separated from the 
lung lobes and processed in a separate 1 ml aliquot of PBS. The tissue was 
homogenised (Omni International homogeniser, Camlab Ltd., Cambridge, 
UK) in the PBS, using a separate, sterile homogeniser head for each sample. 
Homogenisation was performed in a Class II laminar flow hood. Serial ten- 
fold dilutions of the homogenates were performed in PBS and 100 µ1 aliquots 
were plated out on appropriate agar (see section 2.3). Plates were incubated 
at 37 °C overnight (or for 48 hours for B. cepacia), the resultant colony 
forming units were counted and extrapolated to provide the cfu count for the 
neat sample. 
2.6.2 Bacteriological assessment of murine stomach 
Animals were sacrificed by lethal intraperitoneal injection of 20 mg of 
sodium phenobarbitone (Euthatal, Rhone Merieux). The stomach and 
oesophagus were removed together to 1 ml PBS at room temperature. Tissue 
was processed in an identical manner to murine lungs (see section 2.6.1). 
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2.6.3 Virological assessment 
Animals were anaesthetised with Hypnorm /Hypnovel (4:2:1 mix of 
distilled water: Hypnorm (Roche, Welwyn Garden City, UK): Hypnovel 
(Janssen Pharmaceutical Ltd., Gove, Oxford, UK); 10 p.l /g of body weight). 
Tail tip venesection was performed for the collection of a -1.5 ml blood 
sample. Animals were sacrificed by lethal intraperitoneal injection of 20 mg 
of sodium phenobarbitone (Euthatal, Rhone Merieux). Blood samples were 
centrifuged at 7000x g and the serum was tested using a Murine 
ImmunoCombTM kit (Orgenics Ltd., Charles River UK Ltd., Margate, UK) in 
accordance with the manufacturers instructions. 
2.7 Histological assessment of murine lungs 
2.7.1 Preparation of murine lungs for wax sectioning 
The thorax was opened to clearly reveal the lung fields and an 
intravenous catheter (24G x 3/4 "; Terumo, Surgicon Ltd., Brighouse, W. 
Yorks., UK) was passed into the proximal trachea, just below the thyroid 
cartilage. The needle was removed from the catheter and a length of surgical 
suture was tied around the trachea to secure the plastic catheter sheath in 
position. The lungs were then gently inflated in situ by passing - 1 ml 
fixative through the catheter. The catheter was removed and the surgical 
suture simultaneously tightened to occlude the proximal trachea. The lungs 
were then removed and placed in fixative. 
Tissues were fixed in either: a) 10% Neutral Buffered Formalin (10% 
formaldehyde, 0.15 M NaH2PO4, 0.1 M sodium hydroxide) at room 
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temperature for at least 4 hours, or b) 50% Acetone, 50% Methanol mix, at 
room temperature for 20 minutes to 1 hour. 
The fixed tissues were then placed in a Tissue -Tek Vacuum Infiltration 
Processor 4621 (Bayer Diagnostics, Newbury, Berkshire, UK) and processed 
through a programme that consisted of the following steps: 
1. PBS 
2. 30% ethanol 
3. 50% ethanol 
4. 70% ethanol 
5. 85% ethanol 
6. 95% ethanol 
7. 100% ethanol 
8. 100% ethanol 
9. xylene 
10. xylene 
11. paraffin wax 
12. paraffin wax 
13. paraffin wax 
14. paraffin wax 
-1 hour at 40 °C 
- 1 hour at 40 °C 
-1 hour at 40 °C 
- >_ 1 hour at 40 °C 
- 1 hour at 40 °C 
-1 hour at 40 °C 
-1 hour at 40 °C 
- 1 hour at 40 °C 
- 1 hour at 40 °C 
- 1 hour at 40 °C 
- 1 hour at 60 °C 
- 1 hour at 60 °C 
- 1 hour at 60 °C 
- 1 hour at 60 °C 
The lungs were then divided into three portions to separately process 
the trachea, the large single left lobe and the smaller right lobes. The tissues 
were then placed in metal moulds, covered with molten paraffin wax and a 
plastic Tissue -Tek cassette (Bayer Diagnostics, Newbury, Berkshire, UK). 
The wax was allowed to cool and solidify on ice and the paraffin wax block 
containing the tissue was removed from the mould ready for sectioning. 
Paraffin wax blocks were sectioned on a Reichert -Jung 2030 
microtome using disposable blades. The large left lobe was orientated and 
sectioned in such a manner as to section through the length of the major 
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bronchus as shown in Figure 2.1. Representative sections were cut anterior 
to, posterior to and through the major bronchus. Sections were cut at 3 -5 µm 
and floated out on water at 40 °C. The sections were then mounted onto 
glass slides and left to dry at room temperature. Glass slides had been 
previously coated with VectabondTM (Vector Laboratories Ltd., Orton 
Southgate, Peterborough, UK) according to the manufacturer's instructions. 
Sections were stored at room temperature. 
Bronchus 
Left lung lobe C 
c 
C 
FIGURE 2.1 LUNG SECTIONING 
The large left lung lobe was orientated and sectioned through the 
length of the major bronchus. 
2.7.2 Preparation of murine lungs for cryostat sectioning 
The thorax was opened to clearly reveal the lung fields and an 
intravenous catheter (24G x 3/ "; Terumo, Surgicon Ltd., Brighouse, W. 
Yorks., UK) was passed into the proximal trachea, just below the thyroid 
cartilage. The needle was removed from the catheter and a length of surgical 
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suture was tied around the trachea to secure the plastic catheter sheath in 
position. A 25% Tissue Tek O.C.T. embedding solution (Agar Scientific, 
Stansted, Essex, UK) in PBS solution was gently passed into the lungs via a 
cannula. Tissues were placed in a plastic tube and then placed directly into 
liquid nitrogen. Samples were stored at -70 °C. 
Samples were sectioned on a Cryostat CM3000 (Leica, Milton Keynes, 
UK). The temperature controls on the cryostat were set as follows: chamber 
-40 °C, cutting head -25 °C. The tissue was removed from the liquid nitrogen 
and placed in the cryostat chamber for at least an hour allowing the tissue 
temperature to equilibrate. To mount the tissue for sectioning a drop of 
Tissue Tek O.C.T. embedding solution was placed on a metal chuck and just 
before solidification the tissue was placed on top. Tissue Tek O.C.T. 
embedding solution was used to completely cover the tissue on the chuck 
which was then mounted onto the cutting head and fixed in position. 10 pm 
sections were cut from mouse lung which were adhered to VectabondTM 
(Vector Laboratories Ltd., Orton Southgate, Peterborough, UK) coated glass 
slides and stored at -70 °C until required. After the delvery of methylene 
blue dye the partially sectioned block was also examined. 
2.7.3 Rehydration of paraffin wax embedded sections 
Paraffin wax embedded tissue section slides were incubated at 60 °C 
for 30 minutes to melt the wax and then processed manually through the 
following steps at room temperature : 
1) xylene -10 minutes 
2) xylene -10 minutes 
3) 100% ethanol -5 minutes 
4) 100% ethanol -5 minutes 
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5) 90% ethanol -5 minutes 
6) 70% ethanol -5 minutes 
7) 50% ethanol -5 minutes 
8) 30% ethanol - 5 minutes 
9) distilled water - 5 minutes 
2.7.4 Periodic Acid Schiff staining of tissue sections 
This staining technique was used to visualise mucin containing cells 
which stain a bright magenta colour. Tissue section slides were rehydrated, 
through xylene and an ethanol series, to distilled water (see section 2.7.3) and 
then stained by immersion in the following solutions at room temperature, 
unless otherwise specified: 
1) 1% a- Amylase solution in distilled water -1 hour at 37 °C 
2) wash well in running water -2 minutes 
3) 1% Periodic Acid -5 minutes 
4) wash well in running water - 2 minutes 
5) Schiff reagent -10 minutes 
6) wash well in running water -10 minutes 
The following counter stain was then performed: 
1) Haematoxylin -5 minutes 
2) wash well in running water -2 minutes 
3) acid alcohol (1% HCl in 70% ethanol) -10 seconds 
4) wash well in running water - 2 minutes 
5) saturated lithium carbonate -10 seconds 
6) wash well in running water -2 minutes 
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The slides were then dehydrated and mounted as described in section 2.7.6. 
a- Amylase, Periodic Acid, Schiff reagent and Haematoxylin were all 
supplied by Sigma -Aldrich Company Ltd., Poole, Dorset, UK. 
2.7.5 Haematoxylin and Eosin staining of tissue sections 
This staining technique was used to examine basic tissue morphology. 
Tissue section slides were rehydrated through xylene and an ethanol series 
to distilled water (see section 2.7.3) and then stained by immersion in the 
following solutions: 
1) Haematoxylin -5 minutes 
2) wash well in running water -2 minutes 
3) acid alcohol (1% HC1 in 70% ethanol) -10 seconds 
4) wash well in running water - 2 minutes 
5) saturated lithium carbonate -10 seconds 
6) wash well in running water -2 minutes 
7) Eosin solution -2 minutes 
8) wash in water - 30 seconds 
9) 100% ethanol -15 seconds 
10) 100% ethanol -1 minute 
The slides were then dehydrated and mounted as described in section 
2.7.6. Haematoxylin and Eosin were supplied by Sigma -Aldrich Company 
Ltd., Poole, Dorset, UK. Eosin solution consisted of 3 parts of 1 % aqueous 
eosin to 1 part of 1% ethanol /0.05% acetic acid. 
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2.7.6 Dehydration and mounting of tissue sections 
Following staining, tissue section slides were dehydrated as follows: 
1) 30% ethanol -2 minutes 
2) 50% ethanol - 2 minutes 
3) 70% ethanol - 2 minutes 
4) 90% ethanol - 2 minutes 
5) 100% ethanol - 5 minutes 
6) 100% ethanol -5 minutes 
7) xylene -5 minutes 
8) xylene - 5 minutes 
Once the xylene had evaporated a small amount of DPX mountant 
(BDH Laboratory Supplies, Poole, Dorset, UK) was added to the slide and a 
coverslip gently placed over the tissue section ensuring no air bubbles were 
trapped. The slides were left to air dry overnight. 
2.7.7 Bright field microscopy and image capture 
Brightfield imaging of tissue sections was performed on an Ortholux 
microscope (Leitz Wetzlar, Germany). Images were captured on slide film 
using a Wild Photoautomat MPS45 and Wild MP55 camera (Wild, 
Heerbrugg, Switzerland). Slide images were developed and transferred to 
digital format by Norman Davidson, Sandy Bruce and Douglas Stuart, MRC 
Human Genetics Unit, Edinburgh. Adobe photoshop software (Adobe 
Systems Incorporated, Mountain View, CA, USA) was used for the 
annotation of images. 
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2.7.8 Assessment of lung pathology 
Sections of wax embedded murine lungs were stained using a Periodic 
acid Schiff stain and analysed by bright field light microscopy. Three 
representative sections of the large left lobe, cut anterior to, posterior to and 
through the major bronchus, and 3 sections through the right lobes from each 
animal were examined and scored blinded to genotype and treatment 
protocols. Samples were assessed on the basis of 5 features, graded on a 
scale of 1 to 5 on the basis of specified criteria (see Chapter 4 Table 4.1 and 
Figures 4.1a and 4.1b). Assessment of lung histopathology was performed 
twice, using these criteria, and the scores ranked before the study was 
unblinded. Duplicate blinded analyses of the total score were compared 
using a weighted Kappa measure of agreement (see section 2.12). Two - 
sample T -tests and Kruskal- Wallis tests were used to test for significance, 
with assistance from Peter Teague, MRC Human Genetics Unit. 
2.7.9 Peroxidase Immunohistochemistry 
Paraffin wax embedded tissue section slides were rehydrated to 
distilled water as described in section 2.7.3, but without prior heat treatment 
to melt the wax. The first two xylene immersions were performed for 30 
minutes. Cryostat sections were prepared by fixing tissue sections in acetone 
for 10 min at -20 °C and then air dried. The region of interest was delineated 
by marking a ring around the tissue section with a wax PAP pen (Agar 
Scientific Ltd., Stansted, Essex, UK). Slides were then immersed sequentially 
in the following solutions, at room temperature unless otherwise stated: 
1) Peroxo -block (Zymed Laboratories Inc., San Francisco, CA, USA) was 
used to block endogenous peroxidase activity: 
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paraffin wax sections -2 minutes 
cryostat sections - 45 seconds 
2) wash 3 times with PBS -10 minutes 
3) Blocking solution and Avidin block - 20 minutes 
(Blocking solution : 2% normal animal serum from the species that the 
secondary antibody was raised in, 0.2% Tween (Polyoxyethylenesorbitan), 
2% w/v BSA, 7% Glycerol) 
4 drops per ml of Avidin solution from a Biotin /Avidin Blocking kit 
(Vector Laboratories Ltd., Orton Southgate, Peterborough, UK) was added 
to the Blocking solution to block non specific binding of Biotin /Avidin 
system components, according to the manufacturer's instructions. 
4) gently remove blocking solution 
5) Primary antibody and Biotin block - 60 minutes 
Primary antibody was diluted to the appropriate concentration in 
Blocking solution (see step 3). 
4 drops per ml of Biotin solution from a Biotin /Avidin Blocking kit 
(Vector Laboratories Ltd., Orton Southgate, Peterborough, UK) was added 
to the diluted primary antibody to block non specific binding of Biotin/ 
Avidin system components, according to the manufacturer's instructions. 
6) wash 3 times with PBS 
7) Secondary antibody 
-10 minutes 
- 30 minutes 
The biotinylated secondary antibody was diluted to the appropriate 
concentration in Blocking solution (see step 3). 
8) wash 3 times with PBS -10 minutes 
9) Avidin : Biotinylated peroxidase Complex - 30 minutes 
Avidin : Biotinylated peroxidase Complex (Vector Elite ABC Kit, Vector 
Laboratories Ltd., Orton Southgate, Peterborough, UK) was prepared 30 
minutes before use, according to the manufacturer's instructions. 
10) wash 3 times with PBS -10 minutes 
11) Peroxidase substrate 
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- 5 minutes 
VIP Peroxidase substrate (Vector Laboratories Ltd., Orton Southgate, 
Peterborough, UK), was prepared following the manufacturers 
instructions. 
12) wash with running water -5 minutes 
13) dehydrate and mount as described in section 2.7.5 
When a primary antibody raised in mouse was used on mouse tissue 
an additional 20 minute blocking stage was performed before step 3, using 
Blocking solution (see step 3) with 1% unlabelled anti-mouse IgG, raised in 
sheep (SO20 -220) and 1% unlabelled anti-mouse immunoglobulins, raised in 
sheep (SO21 -220), both supplied by the Scottish Antibody Production Unit, 
Law Hospital, Carluke, Scotland. 
Monoclonal anti -Protein A antibody (P2921) was supplied by Sigma - 
Aldrich Company Ltd., Poole, Dorset, biotinylated anti-mouse IgG (H & L) 
antibody (BA -9200) and goat serum (S -1000) were supplied by Vector 
Laboratories Ltd., Orton Southgate, Peterborough, UK. 
2.8 Assessment of bacterial internalisation 
2.8.1 Gentamicin exclusion assay 
Adult mice (3 -6 months old) were anaesthetised with an 
intraperitoneal injection of Avertin (4.4 mM 2- 2- 2- tribromoethanol, 2.5% 2- 
methyl-2- butanol, in distilled water), using 200 µl per 10 g body weight. 
Tracheal intubation and direct intratracheal instillation of bacteria were 
performed as described in section 2.5.2. Mice were inoculated with 
suspensions of fresh, overnight cultures of P. aeruginosa CF clinical isolate 
J1385. After an incubation period of two hours, the mice were sacrificed by 
lethal intraperitoneal injection of 20 mg of sodium phenobarbitone (Euthatal, 
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Rhone Merieux). The lungs and tracheae were removed and finely chopped 
in a petri dish, using a scalpel blade. The chopped lung tissue was 
transferred to 5 ml Dissociation solution (100 gg /m1 Dispase I (neutral 
protease) (Boehringer Mannheim UK, Lewes, East Sussex, UK), 300 u /ml 
Collagenase Type XI (Sigma- Aldrich Company Ltd., Poole, Dorset, UK) in 
PBS), prewarmed to 37 °C. The petri dish was rinsed with the same solution. 
The suspension was incubated at 37 °C for 20 minutes in an incubator shaker, 
before being vigorously agitated by repeated aspiration and expulsion with a 
sterile fine tip pastette (Alpha Laboratories Ltd., Eastleigh, Hampshire, UK) 
for 30 seconds. The suspension was incubated at 37 °C for a further 20 
minutes, followed by vigorous agitation as before, after which it was 
centrifuged at 1000x g for 15 minutes at room temperature. The supernatant 
was removed and the pellet was resuspended in 5 ml of 2.5 µg /ml Trypsin 
solution (Sigma- Aldrich Company Ltd., Poole, Dorset, UK) in PBS at room 
temperature. This suspension was vigorously agitated as before, incubated 
at room temperature for 30 minutes and then vigorously agitated again. The 
suspension was centrifuged at 1000x g for 15 minutes at room temperature. 
The supernatant was removed and the pellet was resuspended in 10 ml 
Hank's Balanced Salt Solution (HBSS) without calcium, magnesium or 
Phenol red (GIBCO BRL, Life Technologies Ltd., Paisley, Scotland), at room 
temperature. The resultant single cell suspension was then split into a 6 ml 
Aliquot A and a 4 ml Aliquot B as illustrated in Chapter 5, Figure 5.1. 
Aliquot A was homogenised using an Omni homogeniser, with replaceable 
heads, (CamLab Ltd., Cambridge, UK) after which Triton X -100 (t- 
Octylphenoxypolyethoxyethanol; Sigma- Aldrich Company Ltd., Poole, 
Dorset, UK) was added to a final concentration of 0.5% and vortexed to lyse 
all the cells and release any internalised bacteria. Duplicate tenfold serial 
dilutions were performed from Aliquot A, using HBSS, and plated on 
Pseudomonas Isolation agar (45 g /L, 2% glycerol; Difco Laboratories Ltd., 
West Molesey, Surrey, UK). This sample (Sample 1) indicated the total 
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number of bacteria delivered. Gentamicin (Sigma -Aldrich Company Ltd., 
Poole, Dorset, UK) was added to the remains of Aliquot A and the whole of 
Aliquot B to a final concentration of 250 µg /ml and incubated for 1 hour at 
37 °C in an incubator shaker. This killed the extracellular bacteria, but not 
intracellular (Pier et al 1997). The samples were centrifuged at 1000x g for 15 
minutes at room temperature, the supernatant was removed and the pellet 
was resuspended in 10 ml HBSS. This was repeated three times to wash off 
the gentmicin and finally resuspended in the original volume. The samples 
were homogenised, after which Triton X -100 was added to a final 
concentration of 0.5% and vortexed to lyse all the cells and release any 
internalised bacteria. Duplicate tenfold serial dilutions of samples from the 
gentamicin treated Aliquot A (Control 1) and Aliquot B (Sample 2) were 
performed in HBSS and plated on agar. Sample 2 indicates the number of 
bacteria surviving the gentamicin treatment and is proposed to represent the 
internalised bacteria, released by cell lysis. Control 1 confirms the 
bactericidal activity of gentamicin on all the exposed bacteria and should not 
contain any viable organisms. A dilution of the original bacterial suspension 
(1% of the total dose delivered to the mice) was added to the remains of the 
gentamicin treated Aliquot A after washing. Duplicate tenfold serial 
dilutions were performed in HBSS and plated on agar (Control 2). Control 2 
confirms that the washing steps are sufficient to remove the gentamicin and 
thus that any internalised bacteria released by cell lysis will not be subject to 
the effects of this aminoglycoside antibiotic. In addition, the lungs and 
trachea of an untreated mouse were removed, homogenised, treated with 
0.5% Triton X -100 and a dose of bacteria equal to that delivered to the live 
mice added. Duplicate tenfold serial dilutions of samples were performed in 
HBSS and plated on agar (Control 3). Control 3 evaluates any antibacterial 
activity of the homogenised, lysed cellular material. Plates were incubated 
overnight at 37 °C, the resultant colony forming units (cfu) were counted and 
extrapolated to provide the cfu counts for the neat suspensions. 
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2.8.2 Gentamicin sensitivity assay 
P. aeruginosa CF clinical isolate J1385 was recovered from storage at - 
70 °C, thawed and streak on Pseudomonas isolation agar (45 g /L, 2% 
glycerol; Difco Laboratories Ltd., West Molesey, Surrey, UK). This was 
incubated at 37 °C overnight. Nutrient broth (25 g /L, 0.5% w/v Yeast 
extract; Oxoid Ltd., Basingstoke, Hampshire, UK) was inoculated with a few 
colonies and incubated at 37 °C overnight in an orbital incubator. 100 µl 
aliquots of this fresh bacterial suspension were added to 10 ml volumes of 
Nutient broth containing gentamicin (Sigma- Aldrich Company Ltd., Poole, 
Dorset, UK) at final concentrations of 0 mg /ml, 1 mg /ml, 10 mg /ml, 100 
mg /ml, 250 mg /ml and 500 mg /ml and incubated at 37 °C overnight in an 
orbital incubator. Pseudomonas isolation agar plates were inoculated using 
a multiplate inoculator, with each sample. The presence or absence of 
bacterial growth was examined at each concentration of gentamicin to 
establish minimum bactericidal concentration levels. 
2.8.3 Visualisation of single cell suspension 
100 µl samples of enzymatically dissociated murine lung cells, from 
various stages in the protocol described in section 2.8.1, were used to make 
air -dried samples by cytospin (Shandon Scientific). Glass slides were 
precoated with Vectabond (Vector Laboratories Ltd., Orton Southgate, 
Peterborough, UK) according to the manufacturer's instructions. The air - 
dried samples were fixed and stained with Diff -Quik ® (Dade, Garridor Ltd., 
Abingdon, Oxfordshire, UK) according to the manufacturer's instructions. 
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2.9 Assessment of synthetic defensin peptides 
2.9.1 Synthesis of synthetic defensin peptides 
Synthetic defensin peptides (hBD -1 and mBD -1) were designed to 
represent the mature portion of the prepropeptides of HBD -1 and Defb -1 
respectively. The peptides were purchased from and synthesised by 
Albachem Ltd., King's Buildings, Edinburgh, UK, as described below. 
hBD -1 was synthesised from Fmoc -Lys(Boc) loaded Wang resin (0.25 
mM), and mBD -1 was synthesised from Fmoc -Ser loaded Wang resin (0.48 
mM). 1 mM of the amino acids was single coupled via HOCt /DIC, with the 
exception of His, which was coupled with 3 mM HOCt. The hBD -1 peptide 
was cleaved from the resin by stirring in EDT (0.25 ml), thioanisole (0.5 ml), 
water (0.5 ml) and phenol (0.75 g) for 2 minutes, then adding TFA (9.5 ml) 
and stirring for 4 hours at room temperature. The resin was removed by 
filtration into ether from which the peptide was precipitated, washed with 
ether and applied to a Vydac C18 column (flow rate 5 ml /minute, 5 ml loop, 
10 -50% B over 28 minutes). mBD -1 peptide was cleaved from the resin by 
stirring in EDT (0.25 ml) and water (0.5 ml) for 2 minutes before adding TFA 
(9.5 ml). The mixture was stirred at room temperature under nitrogen for 2 
hours before being filtered into ether from which the cleaved peptide was 
precipitated, washed with ether, taken into aqueous acetonitrile and 
lyophilised. The peptide was then applied to a Vydac C18 column (flow rate 
8 ml /minute, 5 ml loop, 10 -90% B, 40 minutes). The purified peptides were 
analysed by RP HPLC (Vydac C18, 5 min loop), Rt = 17 minutes, which, in 
both cases resulted in a single peak, and MALDI TOF MS analysis showed 
the correct molecular weight for hBD -1 and mBD -1. 
The peptides were lyophilised, weighed and then applied to a Vydac 
C18 analytical HPLC column with the absorbance set at 214 nm and 280 nm 
to confirm the weight of the peptide. Equal quantities of each peptide were 
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analysed and their W absorbance measured. Both had similar profiles on 
HPLC and the peak heights were almost identical, confirming the accurate 
balance measurements. On this basis the peptides were divided into 100 µg 
aliquots by dissolving in a known volume of water and dividing 
appropriately. The peptide aliquots were then lyophilised and stored at -20 
°C. 
2.9.2 Functional analysis of synthetic defensin peptides 
Fresh, overnight cultures of bacteria were prepared as described in 
section 2.3 and supplied in 0.85% saline at - 1 x 109 colony forming units per 
ml. Immediately prior to use, 1 ml aliquots of bacterial suspension were 
centrifuged at 1000x g for 10 minutes at room temperature and resuspended 
in 10 ml of 10 mM Phosphate buffer (8 mM K2HPO4, 2 mM KH2PO4, 5.6 mM 
D- Glucose) containing either 0 mM, 30 mM, 60 mM, 90 mM, 120 mM or 150 
mM NaCI (buffer pH 7.60 at OmM NaCI, pH 7.40 at 30 mM NaCl, pH 7.33 at 
60 mM NaCI, pH 7.27 at 90 mM NaCI, pH 7.23 at 120 mM NaCI and pH 7.20 
at 150 mM NaCI). A 1 in 50 dilution of the bacterial suspension was 
performed in the same buffer providing a suspension of -2 x 106 cfu per ml. 
Two sets of duplicate 500 µl reactions were prepared containing 50 µl of 
either 10 mM Phosphate buffer alone or 10x stock of synthetic peptide (0.5 
mg /ml to give a final concentration of 0.05 mg /ml unless otherwise stated) 
rehydrated in 10 mM Phosphate buffer, 47.5 µ1 of 10 x stock of NaCI in 10mM 
Phosphate buffer (0 mM, 300 mM, 600 mM, 900 mM, 1.2 M or 1.5 M NaCI) 
and 377.5 µl of 10mM Phosphate buffer, to which 25 µl of bacterial 
suspension (-j 5 x 104 cfu) in the appropriate salt concentration was added. 
These reactions were incubated for 30 minutes at 37 °C, after which duplicate 
sets of serial tenfold dilutions were prepared from each sample, in 10 mM 
Phosphate buffer with the appropriate concentration of NaCl. 100 µl samples 
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were plated out on the appropriate agar (see section 2.3), incubated at 37 °C 
for 24 hours (48 hours for B. cepacia), colony counts were performed and 
extrapolated to provide the cfu count for the neat sample. The anti- microbial 
activity of the peptide was compared against buffer alone, to control for the 
effects on the bacteria of varying the NaCI environment. These studies were 
repeated to ensure the validity of results, reproducing the salt- sensitive 
antibacterial profile on a minimum of two separate occasions for each set of 
conditions. 
The optimisation of this method was performed with the assistance of 
Dr Duncan Borthwick, MRC Human Genetics Unit, Edinburgh, UK. The 
analysis of the antibacterial activity of synthetic peptides against B. cepacia 
was performed with assistance from Dr Alison Maxwell, Department of 
Medical Microbiology, University of Edinburgh, UK. Repeated confirmatory 
studies were performed with the assistance of Susannah MacLean, MRC 
Human Genetics Unit, Edinburgh, UK. 
2.9.3 Statistical analysis of synthetic defensin peptides 
Assessment of the appropriate statistical methodologies and analysis 
of the initial studies was performed by Peter Teague, MRC Human Genetics 
Unit, Edinburgh. 
The bacteriological studies of the synthetic defensin peptides 
produced results in the form of colony forming unit counts, with duplicate 
reactions and duplicate dilutions providing four values for each point. These 
data were observed to have a Poisson distribution (with a number of rare 
events within a fixed area), thus a square root transformation was performed 
to allow valid statistical analysis. Applying this transformation stabilised the 
group variances within but not between each study, thus each experiment's 
data set was analysed by analysis of variance separately. Analysis of 
133 
variance was performed and standard errors for the group means were 
derived from the mean square error in the analysis of variance. The 
minimum standard distance could now be calculated for 5 %, 1% and 0.1% 
significance levels. In repeated experiments it was observed that significance 
at the 0.1% level was reliably repeatable, whereas significance at the 5% level 
was frequently unrepeatable. Analysis of the significance of differences 
between peptide and control samples was performed using the minimum 
standard distance and illustrated graphically, plotting the NaC1 
concentrations against cfu means under square root transformation, with 
group standard errors. 
The standard means of the colony forming unit counts were used to 
calculate the quantity of bacteria surviving in the peptide treated samples as 
a percentage of the counts from the buffer only samples, to control for the 
effects of changes in NaC1 concentration alone. These percentages were 
expressed as "percentage killing ", an variance for this ratio was calculated 
as:- 
Var (meanP /meanB) = (meanB)2 x var (meanP) + ( meanP) 2 x var ( meanB) 
(meanB)4 
Where P is the peptide sample, B is the buffer only control and Var is the 
variance. This was used to calculate standard errors and the data was 
displayed graphically. 
2.10 Primary culture of murine tracheal epithelium 
2.10.1 Animals 
All mice used for primary culture experiments were specified 
pathogen free. C57B1/6N mice of both sexes were used, aged 5 -7 weeks 
(Charles Rivers UK Ltd., Margate, UK). All experimental work complied 
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with the UK Animal (Scientific Procedures) Act 1986. Animals were 
killed by asphyxiation with CO2. 
2.10.2 Isolation and culture of tracheal epithelial cells 
On day 1 the mice were killed by asphyxiation with CO2, doused with 
70% ethanol and tracheae excised, severed at the proximal surface of the 
thyroid cartilage and at the bifurcation of the bronchi. The thyroid glands 
and other adherent tissues were removed from the superolateral surfaces 
(while retaining the underlying proximal tracheae). Tracheae were cut open 
lengthways, washed in PBS and transferred to Collection Media (see section 
2.10.3), pre- warmed to 37 °C. Batches of eight tracheae were transferred to 20 
ml of pre- warmed Dissociation Media, containing Pronase and DNase (see 
section 2.10.3) and incubated at 37 °C for 60 minutes. To stop digestion, 5 ml 
of sterile foetal calf serum was added before tracheae were gently agitated to 
dissociate epithelial cells. This was achieved by lightly inverting the 
suspension 12 times. The suspension was not shaken vigorously. The 
tracheal "husks" were removed from the suspension and gently washed in 
10 ml of Culture Media (see section 2.10.3) by lightly inverting the 
suspension 12 times, as before. The resultant cell suspensions were pooled 
and centrifuged at 120x g for 5 minutes at room temperature. After 
removing supernatants, the pellets were resuspended and washed in 10 ml of 
Culture Media, centrifuged at 120x g for 5 minutes and resuspended in 5 ml 
of Culture Media. This suspension was incubated at 37 °C for 2 hours on a 
100 mm culture dish (Premaria Tm (Falcon 3803); Becton Dickinson UK Ltd, 
Oxford, UK) to remove contaminating non -epithelial cells. After this 
incubation, the media was collected with a fine pastette to collect the 
unattached cells, centrifuged at 120x g for 5 minutes and resuspended in 
Culture Media (200 µ1 of for every two tracheae used). Viable cell counts 
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were performed using a 50:50 dilution of cell suspension and 1% Trypan 
Blue (Sigma- Aldrich Company Ltd., Poole, Dorset, UK), utilising a 
haemocytometer. The number of stained and unstained (viable) cells was 
counted in two grids, under an inverted light microscope, with the total 
number of viable cells estimated as 2 x mean viable cell count x 104 /ml. The 
dissociated cells from two tracheae (-- 4 x 105 cells) were seeded onto one 
tissue culture insert semi- permeable support membrane (Costar Transwell- 
clear Th" (3470), tissue culture treated polyester membrane 24 well plate 
inserts, 0.4 pm pore; Corning Costar, High Wycombe, UK) in 200 µl of 
Culture Media, with 600 pl outside the insert. To pre -coat these inserts with 
Type VI, Acid Soluble, Human Placental Collagen (HPC) (C -7521; Sigma - 
Aldrich Company Ltd., Poole, Dorset, UK), 100 pl of collagen solution (0.5 
mg m11 HPC in distilled water with 0.2% glacial acetic acid) was added to the 
semi- permeable membrane, air dried overnight and then washed twice with 
PBS before use. The cells were incubated at 37 °C, in 6% CO2 in a humidified 
WTC Binder incubator (Philip Harris, Ashby de la Zouch, Leicestershire, UK) 
for 3 days. On day 4 the media on the apical surface of the cultured cells was 
removed, along with any non -adherent cells and debris, and the media on 
the outside of the insert (bathing the basolateral surface) was replaced with 
600111 USG Media (see section 2.10.3). Once the cells had reached confluency 
the apical surface of the insert appeared dry, this normally occurred from 
day 4 onwards. The media bathing the basolateral surface was replaced 
twice weekly. The primary cultures were maintained in this manner and 
retained an air interface for as long as the culture remained viable (up to 80 
days). 
The preparation of primary cultures of murine tracheal epithelia was 
performed with the assistance of Fiona Kilanowski, MRC Human Genetics 
Unit, Edinburgh, UK. 
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2.10.3 Media formulations 
COLLECTION MEDIA 
1:1 mix of Dulbecco's Modified Eagle Medium (DMEM) (1966 -029; 
GIBCO BRL, Life Technologies Ltd, Paisley, UK) and HAM'S F -12 (21765- 
029, GIBCO BRL Life Technologies Ltd, Paisley, UK) media containing 
100 iu /ml Penicillin / 100 µg /ml Streptomycin (Sigma- Aldrich Company 
Ltd., Poole, Dorset, UK). 
DISSOCIATION MEDIA 
Calcium- and Magnesium -free Minimum Essential Media (MEM) (44 mM 
NaHCO3, 54 mM KC1, 110 mM NaC1, 0.9 mM NaH2PO4, 0.25 µM FeN3O9, 1 
pM Na Pyruvate, 42 µM Phenol Red, pH 7.5), 60 iu /ml Penicillin / 60 µg /ml 
Streptomycin, 1.4 mg /ml Pronase (165121; Boehringer Mannheim UK, 
Lewes, East Sussex, UK), 0.1 mg /m1 DNAse (DN -25; Sigma -Aldrich 
Company Ltd., Poole, Dorset, UK). 
CULTURE MEDIA 
1:1 mixture of DMEM and HAM'S F -12 media containing 100 iu /ml 
Penicillin / 100 pg /ml Streptomycin, 5% FCS and 120 iu /L Insulin (Nova 
Human Actrapid NOV100M; AAH Pharmaceuticals, Glasgow, UK). 
USG MEDIA 
1:1 mixture of DMEM and HAM'S F -12 media containing 100 iu /ml 
Penicillin / 100 pg /ml Streptomycin and 2% Ultroser -G serum substitute 
(15950 -017; GIBCO BRL, Life Technologies Ltd, Paisley, UK). 
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2.10.4 Electron Microscopy 
Scanning (SEM) and transmission (TEM) electron microscopy were 
performed on primary cultures of murine tracheal epithelia and tracheal 
specimens. 
2.10.4.1 Scanning electron microscopy 
For SEM, specimens were prepared in the following manner: 
1) wash with PBS x 5 - 20 minutes 
2) fix in 2.5% Glutaraldehyde in PBS - 30 minutes 
3) wash with PBS x 3 -10 minutes 
4) fix with 1% Osmium Tetroxide in PBS 
cultured cells - 45 minutes 
tissue samples - 90 minutes 
5) wash with PBS x 3 - 5 minutes 
6) wash with distilled water -5 minutes 
7) 50% ethanol -15 minutes 
8) 70% ethanol -15 minutes 
9) 95% ethanol - 30 minutes 
10) 100% ethanol - 30 minutes 
10) dry 100% ethanol - 30 minutes 
11) hexamethyldisilazane - 20 minutes 
12) hexamethyldisilazane - 20 minutes 
13) air dry overnight 
Primary culture specimens were then cut from the plastic insert and 
both these and tracheal specimens were mounted on stubs using carbon 
adhesive discs and silver dag (Agar Scientific Ltd., Stansted, UK) and sputter 
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coated. This final preparatory step was performed by John Findlay, 
Biological Sciences E.M. Facility, King's Buildings, University of Edinburgh. 
Specimens were viewed using a Cambridge S250 scanning electron 
microscope at the Biological Sciences E.M. Facility, King's Buildings, 
University of Edinburgh. Images were recorded on Kodak Tmax 100 film. 
To assess quantitatively the different cell populations present, 
morphometric analyses were performed on SEM images, using primary 
cultures of murine tracheal epithelium at day 4, 8, 14 and 28 after seeding 
and tracheal specimens from 5 week old mice. This was accomplished by 
counting the number of ciliated and non -ciliated cells in >_ 4 fields of 100 cells 
and >_ 2 specimens for each time point. 
2.10.4.2 Transmission electron microscopy 
Preparation of TEM specimens was performed by John Findlay, 
Biological Sciences E.M. Facility, King's Buildings, University of Edinburgh. 
For TEM, specimens were fixed as for SEM (see section 2.10.4.1). After 
dehydration specimens were infiltrated with Spurrs resin by means of 
Propylene oxide in the following manner: 
1) Ethanol : Propylene oxide: Spurrs resin 3 : 1 : 0 - 30 minutes 
2) Ethanol : Propylene oxide: Spurrs resin 2 : 1 : 0 - 30 minutes 
3) Ethanol : Propylene oxide: Spurrs resin 1 :1 : 0 - 30 minutes 
4) Ethanol : Propylene oxide: Spurrs resin 1 : 2 : 0 - 30 minutes 
5) Ethanol : Propylene oxide: Spurrs resin 0 : 3 : 1 -1 hour 
6) Ethanol : Propylene oxide: Spurrs resin 0 : 1 :1 -2 hours 
7) Ethanol : Propylene oxide: Spurrs resin 0 :1 : 2 -2 hours 
8) Ethanol : Propylene oxide: Spurrs resin 0 : 0 :1 -4 hours 
9) Ethanol : Propylene oxide: Spurrs resin 0 : 0 : 1 - overnight 
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Serial sections were cut on a Lecia UCT Ultramicrotome at 80 -110 nm. 
Sections were viewed on a Philips CM120 Biotwin microscope at the 
Biological Sciences E.M. Facility, King's Buildings, University of Edinburgh. 
TEM plates were Kodak SO 163. 
TEM sections were used to provide additional information about the 
ultrastructure of primary cultures of murine tracheal epithelium and the 
morphology of cell types present. Analysis of TEM sections was not 
performed quantitatively. 
2.10.5 Histochemistry 
Primary culture membranes were washed in PBS and fixed with 50% 
acetone : 50% methanol for 5 minutes, while still in intact tissue culture 
inserts. The semi- permeable membrane with attached cells was cut from the 
plastic frame before staining. To indicate the presence of goblet cells a 
standard Periodic Acid Schiff stain was performed (see section 2.7.4), but 
without the use of a- amylase. Cells were viewed without counter staining or 
counter stained with Haematoxylin (see section 2.7.4). Cells were viewed on 
an Olympus CK -2 inverted microscope. Images were captured on slide film 
using a Wild Photoautomat MPS45 and Wild MP55 camera (Wild, 
Heerbrugg, Switzerland). Slide images were developed and transferred to 
digital format by Norman Davidson, Sandy Bruce and Douglas Stuart, MRC 
Human Genetics Unit, Edinburgh. Adobe photoshop software (Adobe 
Systems Incorporated, Mountain View, CA, USA) was used for the 
annotation of images. 
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2.10.6 Fluorescence Immunohistochemistry 
Primary cultures of murine tracheal epithelia and tracheal sections 
were characterised using antibodies to different cytokeratins, vimentin and 
a- smooth muscle actin. This assessment was performed using the following 
antibodies; a mouse monoclonal anti-human pan cytokeratin (C -2562; Sigma - 
Aldrich Company Ltd.) (1:100 dilution), mouse monoclonal anti-human a- 
smooth muscle actin (A -254; Sigma -Aldrich Company Ltd.) (1:400 dilution), 
mouse monoclonal anti-human vimentin (V -6630; Sigma- Aldrich Company 
Ltd.) (1:40 dilution), mouse monoclonal anti -Proliferating Cell Nuclear 
Antigen (PCNA) (P -8825; Sigma -Aldrich Company Ltd.) (1:2000 dilution) 
and rabbit anti -mouse cytokeratin 14 (K14) and rabbit anti-mouse cytokeratin 
18 (K18). K14 and K18 were a kind gift from Dr Scott Randell, University of 
North Carolina Cystic Fibrosis Centre, Chapel Hill, North Carolina, USA. 
K14 and K18 were raised in rabbits immunised with peptide sequences 
present in the mouse homologues of human cytokeratin 14 and 18 (K14 - 
CGKWSTHEQVLRTKN-COOH, K18 - CGRWSETNDTRVLRH- COOH), 
conjugated to maleimide- activated ovalbumin or bovine serum albumin 
(Pierce, Rockford, IL, USA) and affinity purified on peptides linked to 
maleimide- activated Sepharose (Pierce). Negative controls were performed 
omitting the primary antibodies. 
Tissues were fixed in 50% acetone : 50% methanol, processed to 
paraffin wax blocks and cut to 4 µm sections by microtome (see section 2.7.1). 
Paraffin wax embedded tissue section slides were rehydrated to distilled 
water as described in section 2.7.3, but without prior heat treatment to melt 
the wax. The first two xylene immersions were performed for 30 minutes. 
The region of interest was delineated by marking a ring around the tissue 
section with a wax PAP pen (Agar Scientific Ltd., Stansted, Essex, UK). 
Tissue sections were then processed as described below, at room 
temperature, unless otherwise stated. 
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Primary culture specimens were washed 3 times PBS, fixed in 50% 
acetone : 50% methanol for 5 minutes, washed 3 times in PBS again and cut 
from the culture insert. Specimens were processed as described below, at 
room temperature, unless otherwise stated, in wells of a 96 well tissue 
culture plate : 
1) wash with PBS 
2) Blocking solution 
-5 minutes 
- 20 minutes 
(Blocking solution : 2% normal animal serum from the species that the 
secondary antibody was raised in, 0.2% Tween (Polyoxyethylenesobitan), 
2% w/v BSA, 7% Glycerol) 
3) gently remove blocking solution 
4) Primary antibody - 60 minutes 
Primary antibody was diluted to the appropriate concentration in 
Blocking solution (see step 2). 
5) wash 3 times with PBS -10 minutes 
6) Secondary antibody - 30 minutes 
The Fluorescein Isothiocyanate (FITC) secondary antibody was diluted to 
the appropriate concentration in Blocking solution (see step 2). 
7) wash 3 times with PBS -10 minutes 
8) mount in VectashieldTM (H -1000; Vector Laboratories Ltd., Peterborough, 
UK) containing 3.75 µg /ml DAPI (4,6- Diamidino -2- phenlyindole) nuclear 
stain. 
Stained segments of tissue culture insert with attached cells were 
mounted in VectashieldTM (H -1000; Vector Laboratories Ltd., Peterborough, 
UK) on glass slides, taking care that the cells faced upwards. Slides had been 
precoated with Vectabond Reagant (Vector Laboratories Ltd., Peterborough, 
UK) according to the manufacturer's instructions. A glass coverslip was 
overlayed and the edges were sealed with clear nail varnish. 
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When a primary antibody raised in mouse was used on mouse tissue 
an additional 20 minute blocking stage was performed before step 2, using 
Blocking solution with 1% unlabelled anti-mouse IgG, raised in sheep (S020- 
220) and 1% unlabelled anti-mouse immunoglobulins, raised in sheep (S021- 
220) , both supplied by the Scottish Antibody Production Unit, Law Hospital, 
Carluke, Scotland. This additional step was followed by washing with PBS, 
as in step 5 above. 
FITC labelled sheep anti-mouse IgG (5121 -201) and FTTC labelled 
donkey anti -rabbit (S076 -201), sheep serum and donkey serum were supplied 
by the Scottish Antibody Production Unit, Carluke, UK. Secondary 
antibodies were used diluted 1:100 in Blocking solution (see step 2 above). 
Specimens were viewed using an Axioplan 2 microscope (Carl Ziess 
Ltd., Welwyn Garden City, UK). Images were acquired using a Pentamax 
Digital Camera (Princeton Instruments, Marlow, UK). In house capture 
routine scripts and IPLab Scientific Image Processing software, Version 3.1.1c 
(Signal Analytics, Vienna, VA, USA) were used to process images and 
standardise the representation of fluorescence levels between specimens. 
To quantify immunohistochemical data, morphometric analyses were 
performed using primary cultures of murine tracheal epithelia at day 4, 8, 14 
and 28 after seeding. The number of cells staining positive per 100 nuclei 
was counted in 3 fields per sample (n >_ 2 at each time point). Analyses of 
sections of tracheal specimens were also performed (n >_ 3 specimens for each 
antibody). The cell density was assessed by counting the number of nuclei in 
3 fields of view at 630x magnification (n = 4 at each time point). 
2.10.7 Preparation of RNA 
All RNA preparations were performed in a double HEPA filter hood 
(MedicalAir Technology, Manchester) using RNase, DNase free plugged tips. 
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Primary cultures of murine tracheal epithelia were washed once with 
PBS, after which 100 gl RNAzo1 B (Biogenesis Ltd., Poole, UK) was added 
and moved up and down a few times to ensure that all the cells were 
completely lysed. Samples were transferred to a fresh screwcap eppendorf 
tube on ice. 10 gl chloroform was added to each sample and shaken 
vigorously (not vortexed) for 15 seconds, followed by a 5 minute incubation 
on ice. The samples were then centrifuged at 10000x g for 15 minutes at 4 °C 
and the top layer transferred to a fresh screwcap eppendorf tube on ice. The 
RNA was precipitated by the addition of 45 µ1 isopropanol (with or without 
4 µ1 glycogen (10 mg /ml stock)) and incubated for at least 15 minutes on ice. 
The samples were then centrifuged at 10000 x g for 15 minutes at 4 °C and the 
resulting RNA pellet washed, by vortexing with 75 % ethanol (in DEPC 
(diethyl pyrocarbonate) treated water) and dried. The RNA was 
resuspended in 10 gl DEPC treated water and stored at - 70 °C. The quantity 
and quality of the RNA preparation was assessed by spectrophotometry, 
assessing the ratio of values at 260 nm and 280 nm. 
2.10.8 Preparation of cDNA 
All cDNA preparations were performed in a double HEPA filter 
hood (Medical Air Technology, Manchester, UK) using RNase, DNase 
free plugged tips. First strand cDNA synthesis was performed from RNA 
samples using Ready-To-Go® You -Prime First -Strand Beads (Amersham 
Pharmacia Biotech, St. Albans, UK) as described by the manufacturers. A 
2 gg sample of total RNA was diluted to 25 µ1 in DEPC treated water and 
denatured by incubation at 65 °C for 10 minutes, before being placed on 
ice. The sample was transferred to a tube of First -Strand Reaction Mix 
Beads, but not mixed. 0.2 gg of random hexamer (pd(N)6; Pharmacia 
Biotech, St. Albans, UK) was added as the chosen primer with DEPC 
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treated water to make the volume up to 33 µl. This was left at room 
temperature for 1 minute to allow primer annealing. The sample was 
then gentley vortexed and briefly spun down in a microfuge to collect the 
contents at the bottom of the tube, before being incubated at 37 °C for 60 
minutes. 5 µl samples were then used in a standard PCR amplification 
reactions (see section 2.10.9) or stored at - 20 °C. An identical control 
reaction was performed using First -Strand Reaction Mix Beads in DEPC 
water that had been incubated at 95 °C for 5 minutes to heat inactivate the 
Murine Leukaemia virus (M -MuLV) reverse transcriptase to verify for 
RNA amplification. A minus RNA control was also included to assay for 
contamination. 
2.10.9 Amplification of DNA by polymerase chain reaction 
All PCR reactions were performed in a double HEPA filter hood 
(Medical Air Technology, Manchester, UK) using Rnase, DNase free plugged 
tips. 
Specific DNA sequences were amplified using published 
methodology (Saiki et al 1988). The specificity is provided by oligonucleotide 
primers complementary to the 5' ends of the two strands of sequence to be 
amplified. These primers anneal to the template DNA strand and direct 
amplification by a thermostable polymerase. 
A 50 µl reaction containing up to 1 µg of genomic DNA or 1 ng of 
plasmid, 5 µl 10 x PCR buffer (P), 5 µl 25 mM MgCl2, 1µl of 50 x dNTP mix 
(10 mM of each nucleotide; Advanced Biotechnologies Ltd., Epsom, Surrey, 
UK) and 100 ng of each primer was prepared in a 0.5 ml thin- walled PCR 
tube (Advanced Biotechnologies Ltd., Epsom, Surrey, UK). 2.5 units of 
thermostable AmpliTaq DNA polymerase (Perkin Elmer, Roche Molecular 
Systems Inc., New Jersey, USA) were added to the mixture which was then 
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overlayed with 50 µl mineral oil (Sigma- Aldrich Company Ltd., Poole, 
Dorset, UK). 
Thermal cycling was controlled by a programmable heating block 
(OmniGene; Hybaid Ltd., Ashford, Middlesex, UK). Three -step temperature 
cycling conditions varied, depending on the primers used and length of 
amplification. The first step was a high temperature step (92 - 94 °C) to 
denature the template DNA, usually 1 -3 minutes in the first cycle, 10 -30 
seconds thereafter. This was followed by a reduction in temperature to allow 
the primers to anneal to the template. The annealing temperature is critical 
in determining the success of the reaction and is dependent upon the 
structure of the primer. Annealing temperatures were set at -5 °C below the 
primer melting temperatures (Tm). Annealing steps were 30 -90 seconds long. 
Finally the temperature was increased to 72 °C to permit the extension from 
the primers by the polymerase. The extension time is also critical, with 
longer products needing longer extension times (- 2 minute per kb of 
sequence). Multiple cycles of these steps result in exponential amplification 
of the desired sequence. The basic programme was 30 cycles of denaturation, 
annealing and extension steps. 
10 µl of the reaction was visualised by electrophoresis on 1 -2% 
agarose gels (see section 2.2.3). 
The gene expression profile of primary cultures of murine tracheal 
epithelia was investigated using cDNA prepared from the primary culture 
cells as template for intron spanning PCR reactions. A minus DNA negative 
control and a positive control using the appropriate plasmd DNA were 
included in each experiment. 
Oligonucleotide primers were purchased from Genosys 
Biotechnologies Inc. Primers were generally chosen to be between 18 and 24 
nucleotides in length, with a Tm between 50 °C and 70 °C. Only a 2 
nucleotide internal match was allowed if it involved the 3' end and where 
possible the A + T : C +G ratio was near 50 %. 
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Gene Primer name Primer Sequence (5' - 3') Tm 
Cftr 9A1 (exon 9) 5'- AGCAATGGTGACAGAAAACATTCC -3' 68 °C 
11B (exon 11) 5'- CTTGCTAAAGAAATCCTTGCACGC -3' 70 °C 
Hprt 5' H P (exon 3) 5'- CTGTAGATTTTATCAGACTGAAGAG -3' 68 °C 
3'HP (exon 8) 5'- GTCAAGGGCATATCCAACAACAAAG -3' 72 °C 
Defbi defl 5'- CCAGCTGCCCATCTAATACC -3' 72 °C 
def2 5'- AATCCATCGCTCGTCCTTTA -3' 63 °C 
Defb2 DR5'new 5'- GCCATGAGGACTCTCTGCTC -3' 64 °C 
DR3'new 5'- TGTCACTTGACTTCCATGTGC -3' 64 °C 
2.10.10 Radioactively labelled oligonucleotide probes 
DNA oligonucleotides were used as probes following 
radiolabelling using the T4 polynucleotide kinase enzyme, which 
catalyses the transfer of the terminal phosphate of [7-3213] ATP to the 5'- 
hydroxy termini. 
Labelled probes from oligonucleotides 15 -25 bp in length were 
made by end -labelling. Approximately 50 ng of oligonucleotide DNA 
was labelled in a total volume of 20 µl containing 2 of 10 x PNK buffer 
(50 mM Tris HC1 pH 8.5, 10 mM MgCl2, 5 mM DTT), 10 units of 
polynucleotide kinase (Boehringer Mannheim UK, Lewes, East Sussex, 
UK), and 30 mCi [y -32 P] ATP (Boehringer Mannheim UK, Lewes, East 
Sussex, UK). The reaction was incubated at 37 °C for 1 hr and then added 
directly to the prehybridised filters. 
Filters were pre- hybridised at 7 -10 °C below the Tm for the 
oligonucleotide for a minimum of 1 hr in rotating hybridisation bottles with 
20 -50 ml oligo hybridisation buffer (6 x SSC, 0.5% SDS, 0.1% BSA, 0.1% Ficoll, 
0.1% polyvinylpyrrolidone, 0.1% disodium pyrophosphate) and 1 mg 
sonicated salmon sperm. After pre- hybridisation, radiolabelled oligo probe 
was added directly to the solution and the blots hybridised for 4 hours at a 
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temperature of 7 -10 °C lower than the oligo Tm. Filters were then washed 
with 4 x SSC /0.1 % SDS for 15 minutes followed by a second wash of 2 x 
SSC /0.1 % if required. The filters were exposed to Kodak X -OMAT AR film 
at -70 °C in cassettes containing intensifying screens. 
Defb-2 PCR products were not visible on a stained agarose gel after 34 
cycles of PCR but were detectable by hybridisation with a Defb -2 internal 
oligonucleotide probe, with the sequence TGATCAGTCAACGGG. 
2.10.11 Pro -inflammatory stimulation of primary cultures 
Total RNA was prepared from primary cultures of murine tracheal 
epithelium with or without exposure to pro -inflammatory stimuli. A 20 
µl volume of either 80 µg of lipopolysaccharide from E.Coli (serotype 
O26:B6; Sigma -Aldrich Company Ltd., Poole, Dorset, UK) in PBS, or -2 x 
105 cfu of P. aeruginosa CF clinical strain J1385 in PBS was gently added to 
the apical surface of the primary cultures. Untreated controls were 
simultaneously exposed to PBS alone. Primary cultures were incubated 
for 30 minutes at 37 °C in a humidified WTC Binder incubator (Philip 
Harris, Ashby de la Zouch, Leicestershire, UK), after which they were 
washed with PBS and processed as described in section 2.10.7. 
2.10.12 Transepithelial resistance measurement 
To monitor the transepithelial resistance (Re) of cultured murine 
tracheal epithelia, an EVOMTh4 epithelial voltohmmeter (World Precision 
Instruments, Stevenage, UK) was used, after the addition and 
equilibration of 200 jd of USG Media (see section 2.10.3), pre- warmed to 
37 °C, to the apical surface. The longer end of the probe was inserted into 
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the media surrounding the tissue culture insert, while the shorter end 
was inserted into the insert, taking care not to touch the culture cell layer. 
R was monitored at day 4, 8,14 and 28 after seeding. The same technique 
was used to monitored R on HBE cell line cultures (see section 2.11). 
2.10.13 Ussing chamber analysis 
Electrophysiological analysis of primary cultures of murine 
tracheal epithelia was performed using modified Ussing chamber 
apparatus (Jim's Instruments Manufacturing Corp, Iowa City, IA, USA), a 
Physiological Instruments VCCMC2 Dual Channel Voltage -Current 
Clamp (ADlnstuments Ltd., Hastings, UK), a MacLab /4s recorder and 
Chart for Macintosh (version 3) data acquisition and analysis software 
(both supplied by ADlnstruments Ltd., Hastings, UK). 
The circulating waterbath supplying the modified Ussing 
chambers was started and the equipment was given 
at 37 °C. A "dummy" culture insert was mounted in the modified Ussing 
chamber and both the apical and basolateral surfaces bathed with a 
physiological solution containing: 140 mM NaC1, 5 mM KC1, 0.36 mM 
K2HPO4, 0.44 mM KH2PO4, 1.3 mM CaC12, 0.5 mM MgCl 10 mM N -2- 
hydroxyethylpiperazine-N'-2-ethanesulphonic acid (HEPES), 4.2 mM 
NaHCO3 and 5 mM D- glucose, titrated to pH 7.2 with Tris. This solution 
was constantly gassed with 95% CO2, 5% 02. The voltage (ELEC /CV; 
ADlnstuments Ltd., Hastings, UK) and current (Ag /AgC1) electrode pairs 
were connected to the apical and basolateral solutions by polyethylene 
tubing (PE160; Garridor Ltd., Oxfordshire, UK) filled with 3 M KC1 - 3% 
w/v Noble Agar (A5431; Sigma- Aldrich Company Ltd). The Voltage - 
current clamp was switched on and given at least 10 minutes to warm up. 
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The voltage was measured under open circuit conditions and this 
asymmetry voltage between the voltage measuring electrodes was offset 
so that the voltage reads 0.0. The fluid resistance compensation button 
was then used to measure the current and verify that - 60 -68 .tA was 
registered, indicating that the resistance of the current passing bridges or 
electrodes was not excessive. 
Primary cultures of murine tracheal epithelia were then mounted 
in the modified Ussing chambers, being careful not to change the 
positions of the electrode tips, and the transepithelial voltage was 
clamped at 0 mV. Isc was recorded continuously using the MacLab /4s 
recorder, Rt was monitored by 10 mV voltage steps (duration 0.1 second, 
period 10 seconds) and calculated using Ohm's Law. A positive Isc value 
represented a flow of positive charge from luminal (apical) to basolateral 
solution (anions moving in the opposite direction). 
To investigate the electrophysiological characteristics of primary 
cultures of murine tracheal epithelia, the following agents were 
sequentially added: a) amiloride (10 pM) to the apical reservoir to inhibit 
the epithelial Na+ channel (ENaC), b) cAMP agonists (10 µM forskolin, 
100 µM 3- isobutyl- l- methyxanthine (IBMX) and 500 µM 8 -(4- 
chlorophenylthio) adenosine 3':5'- cyclic monophosphate (CPT- cAMP)) to 
the apical reservoir to activate the cystic fibrosis transmembrane 
conductance regulator (CH R) Cl- channel, and c) bumetanide (100 pM) to 
the basolateral reservoir to inhibit the Na +, K 2G co- transporter and 
hence, transepithelial Cl- secretion. Each reservoir contained both the test 
drug and the previously studied drugs within the sequence. The addition 
of each agent was performed only after stablilisation of Isc. This protocol 
was performed on primary cultures of murine airway epithelium at day 
28 after seeding (n = 6). 
Amiloride hydrochloride (A7410), bumetanide (B3023), CPT -cAMP 
(C3912), forskolin (F6886), HEPES (H7523) and IBMX (I7018) were all 
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supplied by Sigma -Aldrich Company Ltd., Poole, Dorset, UK. All other 
chemicals were of reagant grade. 
CPT -CAMP and Amiloride were dissolved in distilled water, 
forskolin and bumetanide in dimethyl sulfoxide (DMSO) and IBMX in 
ethanol. Stock solutions were stored at -20 °C and diluted in the 
physiological solution to achieve final concentrations immediately before 
use. 
2.11 Cell culture 
Human Bronchial Epithelium (HBE) cells lines were seeded at a 
density of 4 x 105 cells per insert, on tissue culture insert semi- permeable 
support membranes (CostarTranswell -clear (3470), tissue culture treated 
polyester membrane 24 well plate inserts, 0.4 pm pore; Corning Costar, 
High Wycombe, UK) in 200 pl of media, with 600 µl outside the insert. 
To pre -coat these inserts with Type VI, Acid Soluble, Human Placental 
Collagen (HPC) (C -7521; Sigma -Aldrich Company Ltd., Poole, Dorset, 
UK), 100 µl of collagen solution (0.5 mg ml-1 HPC in distilled water with 
0.2% glacial acetic acid) was added to the semi- permeable membrane, air 
dried overnight and then washed twice with PBS before use. 
Alternatively inserts were previously incubated overnight at 37 °C with 
Minimal Essential Medium (MEM) containing 0.1 mg /ml (w /v) BSA, 0.1 
mg /ml (w /v) Fibronectin (33016 -023; GIBCO BRL, Life Technologies Ltd, 
Paisley, UK) and 0.05 mg /ml (w /v) mouse collagen IV (33018 -011; 
GIBCO BRL, Life Technologies Ltd, Paisley, UK). Cells were cultured in 
MEM with Earle's salts and L- glutamine (31095 -029; GIBCO BRL, Life 
Technologies Ltd, Paisley, UK) containing 10% FCS, 1% non -essential 
amino acids and 100 iu /ml Penicillin / 100 µg /ml Streptomycin (Sigma - 
Aldrich Company Ltd., Poole, Dorset, UK). The cells were incubated at 
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37 °C, in 6% CO, in a humidified WTC Binder incubator (Philip Harris, 
Ashby de la Zouch, Leicestershire, UK). Cells reached confluency after 
approximately 7 days but were unable to maintain an air -liquid interface. 
Transepithelial resistance measurements were stable from day 7 onwards 
(see section 2.10.12). 
2.12 Statistical analysis 
Calculations of means, standard deviations, Student's T tests and 
Kruskal- Wallis tests were performed using Minitab 12.23 software 
(Minitab Inc.) or Microsoft Excel 97 software (Microsoft Corporation). 
Differences were considered statistically significant when P < 0.05. 
Duplicate blinded analyses of the total score for severity of murine lung 
histopathology (see section 2.7.8) were compared using a weighted 
Kappa measure of agreement. This was performed by distributing the 
scores between 10 categories equally spaced across the range and 
comparing the observed frequencies of exact agreements and levels of 
disagreements with the derived expected numbers. Advice on statistical 
analysis was provided by Peter Teague, MRC Human Genetics Unit, 
Edinburgh. Statistical analysis of the antibacterial activity of synthetic 
defensin peptides is described in section 2.9.3. 
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Chapter 3: Bacterial delivery systems 
3.1 Introduction 
Initial studies using the CftrtnilHgu Cftrtni1Hgu mice demonstrated that no 
gross lung phenotype was evident when the mice were born and maintained 
in sterile conditions (Davidson et al 1995). However, abnormalities were 
observed when these animals were challenged with CF related respiratory 
pathogens (see Chapter 1, section 1.7.3.5). 
These preliminary studies were performed using a relatively crude 
nebulisation chamber. The bacterial delivery profile of this apparatus had 
not been quantitatively determined, examined for reproducibility, or 
analysed in terms of its anatomical distribution pattern. In addition, 
concerns had been raised about the possibility that nebulisation may shear 
bacterial pili. This would have particular significance in the delivery of P. 
aeruginosa. The adherence of pili to aGM, receptors has been suggested to 
play an important part in the predilection of this bacteria for the CF lung (see 
Chapter 1, section 1.5.2.1). Consequently, techniques and apparatus suitable 
for clearly quantified, reproducible bacterial delivery, with and without 
nebulisation, to defined regions of the pulmonary system were assessed and 
developed. 
A variety of modifications of two primary approaches were assessed. 
Firstly, adaptation of the mouse nebuliser apparatus, initially developed by 
Prof. David Porteous in the MRC Human Genetics Unit, Edinburgh. 
Secondly, the development of direct intratracheal instillation techniques. 
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3.2 Mouse nebuliser apparatus 
3.2.1 Design 
The nebuliser apparatus developed for the preliminary studies was a 
relatively crude device. The results of these bacterial exposure experiments 
revealed significant differences between the Cftren' u /CffrtmlHg, mice and their 
non -CF littermates, but with a broad spectrum and considerable overlap 
observed in the phenotypes of the two groups of mice. One possible reason 
for this may have been flaws with the delivery system. Consequently the 
original design was reassessed for further studies. 
FIGURE 3.1 Nebuliser design #1 
The original mouse nebuliser design. Mice are placed in the syringe 
barrels indicated by X. The red arrows indicate the flow of nebulised 
bacterial suspension. 
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The original apparatus (Nebuliser #1) consisted of a Sidestream 
nebuliser feeding directly into a plastic funnel via a plastic tube with a right 
angled bend (see figure 3.1). The wide end of the funnel was attached to six 
50 ml plastic syringe barrels, with the "closed" ends facing into the funnel 
and each punctured with 5 holes. All the surrounding gaps were sealed with 
the exception of one outflow tube. Mice were placed, head first, into each of 
the syringe barrels with the syringe plunger used to prevent them from 
turning around or leaving the tube. A bacterial suspension was then 
nebulised into the funnel area from which the mice would breath. 
This design appeared to have a variety of theoretical and practical 
weaknesses. The bacteria were delivered, by carrier gas, at a flow rate of 12 
litres per minute, directly into a right angled tube, about 7 cm from the 
nebuliser head. It seemed likely that this had the potential to damage the 
bacteria, alter particle size and influence the airflow dynamics of the 
aerosolised bacteria within the funnel area. Both particle weight and the 
position of the outflow tube, placed at the lowest point of the funnel area, 
seemed likely to draw the aerosolised particles towards bottom 
funnel. This may have been sufficient to alter the dose of bacteria delivered 
to the animals, dependent upon the position of the syringe barrel that they 
each occupied. In addition, the shape of the "closed" ends of the syringe 
barrels was a flattened dome. This was not ideally suited to the shape of a 
mouse's head. Although their noses were normally positioned close to a hole 
connecting directly to the funnel, this was not always the case. The other 
holes in the barrel meant that nebulised particles were likely to enter the 
barrel and perhaps coat the fur on other parts of the mouse's body. These 
bacteria would later be removed by grooming and ingested. Furthermore, 
the cluster of syringe barrels made it difficult to monitor the status of all the 
mice during the course of the experiment, particularly the one in the middle, 
in case of signs of distress. Finally, the material from which the syringe 
barrels was constructed was rather too easily chewed. The numerous holes 
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at the end of the barrel gave the mice easy purchase to rapidly destroy the 
apparatus. 
FIGURE 3.2 Nebuliser design #2 and #3 
The radial multi -nebuliser, models #2 and #3. Mice are placed in the 
syringe barrels indicated by X. The red arrows indicate the flow of nebulised 
bacterial suspension. 
The nebulisation apparatus was redesigned (Nebuliser #2) to address 
these concerns and constructed by Duncan Fletcher at the MRC Human 
Genetics Unit, Edinburgh (see figure 3.2). The new design allowed direct 
entry of the nebulised bacterial suspension into a cylinder, at point 
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equidistant from 6 radially arranged 50 ml syringe barrels. Flow was 
directed up toward these barrels with the outflow at the base of the cylinder 
venting the chamber as the particles descended again. To address additional 
safety concerns, the outflow pipe was connected to a dual chamber device, 
containing two volumes of disinfectant, which the outflow gas was bubbled 
through. This design was studied and used in several experiments. 
However, it was still too easily destroyed by the animals and required 
regular repairs. Consequently a further modification was made (Nebuliser 
#3). The "closed" ends of the syringe barrels were removed and replaced 
with a cone, more closely fitted to the shape of a mouse's head. This cone 
was made from hard perspex with a single central hole, which would be 
occluded with a mouse's nose stuck through it, connecting the barrel to the 
chamber. This also had the effect of moving the mouse's protruding nose to 
a more central position, more directly above the upstream of nebulised 
suspension. This design was also studied and used for several experiments. 
A detailed methodology for the use of this apparatus can be found in the 
Materials and Methods section (see Chapter 2, section 2.5.1). 
3.2.2 Quantitative assessment of bacterial delivery 
Quantitative assessment of the mouse nebulisation apparatus was 
conducted using groups of 4-6 non -CF mice on a mixed outbred MF1 /129 
strain background. A standard protocol was followed as described in 
Materials and Methods (see Chapter 2, section 2.5.1 and 2.6.1). Briefly, mice 
were restrained in the nebuliser apparatus while 4 ml of bacterial suspension 
was nebulised into the chamber over a period of 5 minutes. The initial 
quantitative studies were performed using a well characterised B. cepacia CF 
clinical isolate J2315, on the basis that the viability of this organism might be 
less impaired in the lung environment during tissue processing than other 
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bacteria. Subsequent studies were performed using S. aureus CF clinical 
isolate C1705. Bacterial suspensions, prepared from fresh overnight cultures, 
were supplied by Wendy Hannant and Cathy Doherty, Medical 
Microbiology department, University of Edinburgh (see Chapter 2, section 
2.3). Animals were sacrificed immediately after the nebulisation period, the 
lungs were removed and homogenised in PBS, either with or without the 
trachea. In the latter scenario, the trachea and primary bronchi were 
processed separately from the lungs to establish the level of deposition in the 
largest airways (see section 3.2.3). Dilutions of the homogenates were plated 
out on appropriate agar and the resultant colony forming units counted. 
The bacterial deposition established in the murine lungs using these 
nebuliser delivery systems was compared to previously published particle 
inhalability curves for small laboratory animals (Ménache et al 1995). The 
respiratory minute volume for the mice was calculated according to the 
Guyton formula (Raabe et al 1988): respiratory minute volume (ml) = 2.1 x 
(weight (g))075. The mean body weight of the mice used in these studies was 
22 g, providing an estimated respiratory minute volume of - 20 ml. The 
inhaled dose was estimated as the concentration of bacteria per ml x length 
of exposure x respiratory minute volume and corrected for inhalability 
according to the particle size. The inhalability size varies between species. In 
small laboratory animals - 95% inhalability is predicted for particles < 0.7 
gm diameter, with - 45% inhalability predicted for 10 gm diameter particles 
(Ménache et al 1995). At a carrier gas flow of 12 litres per minute the 
sidestream nebuliser has been demonstrated to create particles of 
approximately 1.9 gm (Alton et al 1993). The addition of a "baffle" decreased 
particle size to 1.7 pm. In mice, inhalability of - 85% and - 90% would be 
expected for particles of 1.9 gm and 1.7 pm respectively (Ménache et al 1995). 
These corrections were applied to estimate inhaled dose. 
The lung deposition efficiency is dependent upon particle size and 
increases as a function of particle size when normalised for inhalability 
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(Ménache et al 1995). If all particles are inhalable then as the size increases so 
the percentage of inhaled particles deposited in the lungs approaches 100 %. 
However, above an optimum size, some particles are not inhalable and the 
lung deposition will decrease. Although smaller particles have a higher 
inhalability, the deposition rate of the smallest particles is low. For mice the 
optimum particle size has been estimated to be between 1 gm and 3.5 gm. 
The deposition efficiency calculated is a function of particle size and 
represents the pulmonary deposition as a percentage of the estimated inhale 
dose. For particle sizes of 1.9 pm and 1.7 gm deposition efficiencies of - 50% 
and - 40% would be expected on the basis of previous studies using 
monodispersed aerosols of fused aluminosilicate particles labelled with 169 
Ytterbium (Ménache et al 1995). 
3.2.2.1 Nebuliser #2 
The modified Nebuliser #2 apparatus was used to assess the delivery 
of B. cepacia, as shown in Tables 3.1 and 3.2. The concentration of the 
bacterial suspension was estimated using spectrophotometery and showed 
some variation between experiments, thus study results are not pooled. The 
total lung delivery of viable bacteria using this system is reasonably 
reproducible, with a maximum 6 fold variation observed between mice. This 
variation did not correlate with the position in the apparatus occupied by the 
mouse, or with the weight of the animal. The mean number of viable 
bacteria recovered from the lungs of each mouse was 3.3 x 104 (± 1.9 x 104) in 
the first experiment and 5.6 x 104 (± 1.6 x 104) in the second experiment 
detailed below. This constituted a lung deposition efficiency of 0.77% and 
0.66% respectively. 
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Experiment 1 Total cfu count 
Lung and airways 
Total cfu count 
stomach and oesophagus 
Mouse A 2.2 x 104 4.6 x 103 
Mouse B 3.9 x 104 1.1 x 103 
Mouse C 5.5 x 104 1.6 x 103 
Mouse D 1.3 x 104 1.8 x 103 
Mean 3.3 x 104 2.3 x 103 
SD 1.9x104 1.6x103 
Estimated total nebulised dose 3.0 x 109 in 60 L 
Estimated inhaled dose 4.3 x 106 
Deposition efficiency 0.8 % 
TABLE 3.1 Nebuliser #2 - bacterial delivery profile 1 
Quantification of the bacterial delivery profile of Nebuliser #2, using B. 
cepacia. 
Experiment 2 Total cfu count 





Mouse A 7.7 x 104 7.5 x 104 1.6 x 103 
Mouse B 3.3 x 104 3.3 x 104 - 
Mouse C 5.5 x 104 5.4 x 104 1.1 x 103 
Mouse D 5.1 x 104 5.1 x 104 - 
Mouse E 6.2 x 104 6.2 x 104 - 
Mean 5.6 x 104 - - 
SD 1.6x104 - - 
Estimated total nebulised dose 6.3 x 109 in 60 L 
Estimated inhaled dose 8.5 x 106 
Deposition efficiency 0.7 % 
TABLE 3.2 Nebuliser #2 - bacterial delivery profile 2 
Quantification of the bacterial delivery profile of Nebuliser #2, using B. 
cepacia. 
These studies were repeated using S. aureus. A representative 
experiment is shown in Table 3.3. The total lung delivery of viable bacteria is 
similar to that demonstrated for B. cepacia. The mean number of viable 
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bacteria recovered from the lungs of each mouse was 7.1 x 104 (± 0.8 x 104). 
This constituted a lung deposition efficiency of 1.4% . 
Experiment 3 Total cfu - Lung and airways 
Mouse 7.2x104 
Mouse B 8.1 x 104 
Mouse C 6.1 x 104 
Mouse D 6.9 x 104 
Mean 7.1 x 104 
SD 0.8 x 104 
Estimated total nebulised dose 3.6 x 109 in 60 L 




TABLE 3.3 Nebuliser #2 - bacterial delivery profile 3 
Quantification of the bacterial delivery profile of Nebuliser #2, using S. 
aureus 
These studies demonstrate that Nebuliser #2 provided a reasonably 
reproducible delivery of bacteria to the lungs, with a range of approximately 
1 x 10 4 - 1 x 105 cfu per mouse, and deposition efficiency of 0.7 -1.4 %. This 
apparatus was used for repeated nebulisation studies (see Chapter 4). 
On the basis of previous studies, deposition efficiencies of - 50% 
would be expected for 1.9 µm diameter particles (Ménache et al 1995). Thus, 
the deposition efficiency established for Nebuliser #2 is only - 2% of the 
anticipated level. This is likely to relate to chamber design and the viability 
of the bacteria. The assessment of bacterial delivery will only indicate the 
number of viable organisms in the lung and a considerable proportion of the 
bacteria may be killed by innate lung defences in the tissue processing 
period. In addition, damage to bacteria as a result of the nebulisation process 
cannot be ruled out. To assess the impact of nebulisation upon the viability 
of S. aureus, the nebulised suspension was passed directly into PBS in a glass 
impinger, dilutions were plated and colony counts performed. In repeated 
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studies the number of viable bacteria collected was found to be -10% of the 
total number of bacteria nebulised. This suggests that a large proportion of 
the bacteria nebulised may be killed by this process, although it is possible 
that this technique may have failed to collect all of the nebulised organisms. 
Thus the low deposition efficiency, in comparison to the published studies, is 
likely to be the result of chamber design and bacterial death, both in the 
murine lungs and as a result of the nebulisation process. The effect of the 
"baffle" upon bacterial viability was not quantified. 
The similarity in the proportion of bacteria delivered to the mouse 
lungs whether S. aureus or B. cepacia was used suggests that this delivery 
profile is likely to be independent of the bacteria used. However, 
quantitative assessment should still be repeated before the use of other 
bacteria with this delivery system. 
3.2.2.2 Nebuliser #3 
Nebuliser #3 was constructed to survive the attentions of its 
experimental occupants more effectively, but also altered the position of the 
mouse's nose with respect to the chamber inlet. Consequently, similar 
quantitative studies were performed using this design. It was found to 
increase the dose received per mouse. A representative study is detailed in 
Table 3.4. 
The original repeated exposure studies using mouse models of CF, 
were performed using a standard protocol comprising two periods of 
nebulisation, 5 minutes with and 5 minutes without the addition of a "baffle" 
to alter particle size. At a carrier gas flow of 12 litres per minute the 
sidestream nebuliser created particles of approximately 1.9 µm. The addition 
of the "baffle" to this nebuliser decreased particle size to 1.7 gm (Alton et al 
1993). This was proposed to increase delivery to the smaller airways. The 
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studies described here also examined the impact of the baffle upon bacterial 
delivery. 
Protocol Total cfu count 
Lung and large airways 
Estimated total dose 
nebulised in 5 min 
- 8 x 109 in 60 L 
Mouse A 1.5 x 106 
Mouse B 1.6 x 106 
Mouse C 5 minutes exposure 1.5 x 106 
Mean without the "baffle" 1.5 x 106 
SD 0.1 x106 
Estimated inhaled 
dose 
1.1 x 107 
Deposition efficiency 13.6 % 
Mouse D 
5 minutes exposure 
without the "baffle" 
and 5 minutes 
exposure with the 
"baffle" 
1.0 x 106 
Mouse E 2.3 x 106 
Mouse F 1.9 x 106 
Mean 1.7 x 106 
SD 0.7 x 106 
Estimated inhaled 
dose 
2.3 x 107 
Deposition efficiency 7.4% 
Mouse G 
5 minutes exposure 
with the "baffle" 
5.3 x 105 
Mouse H 6.3 x 105 
Mouse I 5.7 x 105 
mean 5.8 x 105 
SD 0.5 x 105 
Estimated inhaled 
dose 




TABLE 3.4 Nebuliser #3 - bacterial delivery profile 
Quantification of the bacterial delivery profile of Nebuliser #3, using S. 
aureus, with and without the addition of a nebuliser "baffle ". 
The mean number of viable organisms recovered from the lungs of 
each mouse was 1.5 x 106 (± 0.05 x 106) when the protocol detail above for 
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Nebuliser #2 (without the "baffle ") was used. This constituted a lung 
deposition efficiency of 13.6 %. The addition of the "baffle" significantly 
reduced the mean number of viable bacteria recovered from the lungs of 
each mouse to 5.8 x 105 (± 0.5 x 105) (p = 0.004). This constituted a lung 
deposition efficiency of 4.8% of the estimated total number of bacteria 
nebulised into the chamber. Analysis using a protocol of 5 minutes with the 
"baffle" and 5 minutes without, confirmed these data, with the quantity of 
viable bacteria being approximately equal to the sum of the other two 
protocols performed independently (see Table 3.4). This apparatus was also 
used for repeated nebulisation studies (see Chapter 4). 
These studies demonstrate that Nebuliser #3 provided a reproducible 
delivery of bacteria to the lungs, with a range of approximately 1 x 106 - 2 x 
106 cfu per mouse, and a deposition efficiency of 13.6 %. Although this is still 
lower than the 50% deposition efficiency expected for 1.9 gm particles 
(Ménache et al 1995), it is considerably higher than the efficiency achieved 
with Nebuliser #2. This difference demonstrates the importance of chamber 
design. The remaining difference between the deposition efficiency expected 
and that observed is likely to relate to bacterial death, contrasting with the 
use of inert radioactive particles in the published study. 
As anticipated, the smaller particles produced by the addition of the 
"baffle" decreased the deposition efficiency from 13.6% to 4.8 %. Although 
40% deposition efficiency might be expected for 1.7 pm particles (Ménache et 
al 1995), the previously discussed explanations apply. 
3.2.2.3 Nebuliser #1 
Finally, to allow direct comparison to be made between studies 
performed using the original nebulisation apparatus and those with the new 
design, the old apparatus was assessed in the same manner (without the 
"baffle "), using S. aureus (see Table 3.5). 
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Total cfu count 
Lungs and airways 
A 1.8 x 105 
B 1.5 x 105 
- 
_Mouse 
Mouse 'C 1.1 x 105 
Mouse 'D 1.6 x 105 
_Mouse -E 1.0 x 105 
Mouse F 1.2 x 105 
Mean 1.4 x 105 
SD 0.3 x 105 
Estimated Total nebulised dose 2.3 x 109 in 60 L 
Estimated inhaled dose 3.2 x 106 
Deposition efficiency 4.4% 
TABLE 3.5 Nebuliser #1 bacterial delivery profile 
Quantification of the bacterial delivery profile of Nebuliser #1, using S. 
aureus. 
As a result of damage by experimental animals during previous 
studies, the equipment could not be restored to full function and the results 
of this experiment should be viewed only as a general indication of the level 
of bacterial delivery in previous studies. However, the delivery profile 
seems to be broadly comparable with results using the other nebuliser 
designs and indeed, probably better then a dose delivered using Nebuliser 
#2. 
3.2.3 Bacterial distribution profile 
In order to evaluate the distribution of nebulised bacteria, specimens 
from the studies described above (see section 3.2.2.1) were divided before 
processing. The trachea and primary bronchi were detached from the lungs 
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and processed separately. In addition, the stomach and oesophagus were 
dissected from the same animals and also processed in an identical manner. 
These studies demonstrated that approximately 2% of the bacteria 
delivered to the lungs was located in the largest airways immediately after 
nebulisation (n = 2, Table 3.2). The other 98% was in the smaller airways and 
the alveolar spaces. The dose located in the oesophagus and stomach at this 
time point was found to be approximately 10 fold smaller than the lung dose 
(see representative experiment in Table 3.1). 
In addition to these quantitative studies, lungs from mice exposed to 
S. aureus in these experiments were fixed with 10% NBF and processed to 
paraffin wax blocks (n = 6, see Chapter 2, section 2.7.1). Sections cut from 
these specimens were subjected to immunohistochemical analysis, using an 
antibody to S. aureus protein A (see Chapter 2, section 2.7.9). These studies 
demonstrated the presence of S. aureus in the alveolar spaces, following 
delivery by nebulisation (see Figure 3.3). 
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FIGURE 3.3 Delivery of Staphylococcus aureus to the peripheral 
airways 
A light microscopic image of mouse alveoli, demonstrating the 
presence of S. aureus in the alveolar spaces. Clusters of bacteria are 
indicated by white arrows. 
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3.3 Intratracheal Instillation 
An alternative delivery system was also sought that did not involve 
nebulisation of the bacteria and was capable of high dose delivery. To meet 
these requirements methods of direct intratracheal instillation were assessed. 
The most commonly used method involves an incision in the neck of 
the mouse, separation of the submandibular glands and puncture of the 
trachea. This technique was rejected on the basis that it created a wound site, 
which could become infected, unnecessary trauma and could result in severe 
inflammation secondary only to the method of bacterial delivery. In 
addition, this technique was not amenable to repeat dosing, using the same 
mouse over a short time period. 
An alternative technique was employed, optimising a previously 
described non -surgical method (Ho and Furst 1973). This is described in 
detail in Materials and Methods (see Chapter 2, section 2.5.2). Briefly, an 
anaesthetised mouse was placed in a specially constructed frame to 
appropriately configure the position of its head and thorax (see figure 3.4). A 
bright light was placed against the xiphisternum and the tongue extended, 
revealing illumination of the tracheal lumen. An adapted spinal needle was 
passed into the tracheal and 25 µl of bacterial suspension delivered, followed 
through by a small volume of air. This technique required a considerable 
amount of practice, but once mastered proved to be a quick and effective 





Bifurcation of bronchi 
Wire frame 
FIGURE 3.4 Direct Intratracheal instillation 
3.3.1 Quantitative assessment of bacterial delivery 
Quantitative assessment of this non -surgical, direct intratracheal 
instillation technique was performed using groups of 6 non -CF mice on a 
mixed outbred MF1 / 129 strain background. A standard protocol was 
followed, as described in Materials and Methods (see Chapter 2, sections 
2.5.2 and 2.6.1). For the purpose of initial quantification, mice were exposed 
to B. cepacia CF clinical isolate J2315, on the basis that the viability of this 
organism might be less impaired in the lung environment during tissue 
processing than other bacteria. Subsequent studies were performed using 
non -mucoid P. aeruginosa CF clinical isolate J1385. Bacterial suspensions, 
prepared from fresh, overnight cultures, were supplied by Wendy Hannant 
and Cathy Doherty, Medical Microbiology department, University of 
Edinburgh (see Chapter 2, section 2.3). 
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Animals were sacrificed immediately after the instillation, the lungs 
were removed and homogenised, either with or without the trachea. In the 
latter scenario, the trachea and primary bronchi were processed separately 
from the lungs to establish the level of deposition in the largest airways (see 
section 3.3.2). Dilutions of the homogenates were plated out on appropriate 
agar and the resultant colony forming units counted. 
The delivery profile using this technique was initially very variable. 
However, with experience, more reproducible delivery could be achieved. 
The concentration of the bacterial suspension was estimated using 
spectrophotometery and showed some variation between experiments, thus 
study results are not pooled. A typical result is shown in Table 3.6. 
Total cfu count 





MouseA 1.7x107 - 1.7x10' 
Mouse B 1.1 x 107 - 1.1 x 10' 
Mouse C 1.4 x 10' - 1.4 x 10' 
Mouse D 1.4 x 10' - 1.4 x 10' 
Mouse E 9.3 x 106 8.0 x 106 1.3 x 106 
Mouse F 6.8 x 106 6.1 x 106 0.7 x 106 
Mean 1.2x107 - - 
SD 3.4 x 106 - - 
Estimated total dose instilled 3.6 x 107 
recovery of total dose instilled I 33.3% 
TABLE 3.6 Direct intratracheal instillation - bacterial delivery profile 1 
Delivery of B. cepacia to the lungs of a cohort of non -CF MF1 mice by 
direct intratracheal instillation. 
The number of bacteria instilled was assessed by delivery of an 
identical volume of bacterial suspension directly into PBS via the intubating 
cannula. The instillation of 3.6 x 107 cfu of B. cepacia into the airways, resulted 
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in recovery of 1.2 x 10' (± 3.4 x 10') cfu by removal and homogenisation of the 
lungs, with a range of 20 -50% of the delivered dose being recovered. 
The subsequent analysis of this delivery technique using P. aeruginosa 
demonstrated a very similar delivery profile (see Table 3.7). 
Total cfu count 
Lung and airway homogenate Mouse A 1.6 x 10' 
Lung and airway homogenate Mouse A 1.6 x 10' 
Lung and airway homogenate Mouse A 1.3 x 10' 
Lung and airway homogenate Mouse A 1.2 x 10' 
Mean 1.4 x 107 
SD 0.2x107 
Estimated total dose instilled 2.5 x 10' 
% recovery of total dose instilled 
1 
56% 
TABLE 3.7 Direct intratracheal instillation - bacterial delivery profile 2 
Delivery of P.aeruginosa to the lungs of a cohort of non -CF MF1 mice 
by direct intratracheal instillation. 
Delivery of bacteria by direct intratracheal instillation resulted in the 
death of approximately 1 in 20 of the experimental animals. This was 
increased if volumes greater than 25 µl were instilled. 
3.3.2 Bacterial distribution profile 
In order to evaluate the distribution of bacteria delivered by 
intratracheal instillation, some specimens from the studies described above 
(see section 3.3.1) were divided before processing. The trachea and primary 
bronchi were detached from the lungs and processed separately. In addition, 
the stomach and oesophagus were dissected from the same animals and also 
processed in an identical manner. 
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This assessment demonstrated that approximately 10% of the bacteria 
recovered from the lungs were present in the largest airways immediately 
after nebulisation (see Table 3.6). The other 90% were in the smaller airways 
and the alveolar spaces. After a successful delivery, homogenates of the 
stomach and oesophagus were found to contain less than 1% of the dose 
found in the lungs. 
The total number of cfu recovered from the lungs and upper 
gastrointestinal tract was rarely found to exceed 60% of the estimated dose 
instilled. The quantity of bacteria lost in the nasopharynx and mouth 
remains unquantified, but seems unlikely to constitute such a large 
proportion. It is likely that the remaining bacteria are killed or removed by 
the lung defences during the dissection period or perhaps destroyed during 
the processing of the lung homogenate. 
In addition to these quantitative studies, infra tracheal instillation of 
5% methylene blue dye was performed using exactly the same protocol to 
visualise the pattern of distribution of instilled solution in the lung fields (see 
figure 3.5). The lungs were immediately removed, examined and then frozen 
in liquid nitrogen to prepare for cryosection (see Chapter 2, section 2.7.2). 
Both gross specimens and partially sectioned frozen blocks demonstrated 
homogeneous blue staining in the trachea and the large airways of all the 
lung lobes. This staining was observed to extend to the alveolar spaces with 
a more patchy distribution pattern noted. 
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FIGURE 3.5 Distribution pattern of direct intratracheal instillation 
Methylene blue dye was instilled into the mouse lungs by direct 
intratracheal instillation. The distribution pattern was observed in a) 
specimens prepared as frozen blocks for cryosectioning and partially 




The assessment of the pulmonary phenotype of mouse models of CF 
in response to pathogen exposure, requires well- defined and reproducible 
bacterial delivery protocols. These techniques should be judged according to 
the following criteria; a) a well quantified and clearly reproducible delivery 
profile, b) a defined distribution of bacterial delivery within the host systems 
and minimal delivery outwith the lung, c) the option to repeat the delivery to 
the same animals within a short time frame and / or regularly over a longer 
period, d) minimal invasiveness, resulting in as little stress to the 
experimental mice as possible, e) the introduction of the bacteria to the host 
system should reproduce biologically natural phenomenon where ever 
possible, f) minimal mortality as a result of the technique g) minimal 
bacterial damage, and h) technically "user friendly" with high "throughput ". 
The delivery of bacteria to murine lungs using the radial multi- 
nebuliser provides a well quantified, clearly reproducible delivery, low 
dosage to areas outwith the lung and maximal, homogenous distribution 
throughout the airways and lung parenchyma. However, the quantity of 
bacteria delivered is dependent upon the specific nebuliser design used and 
altered by the presence of the "baffle ". It can be easily repeated within a 
short time frame or regularly over a longer period of time. It is minimally 
invasive and appears to cause little stress, mice enter the syringe barrels 
without coercion after just a couple of sessions. The delivery of bacteria by 
inhalation of aerosolised particles is clearly a reasonably natural 
methodology, although the dose delivered may not be. Experimental 
mortality is low, the technique is easy and can be applied to large numbers of 
mice in a short period of time. The major reservation about this technique is 
the consequences of nebulisation for the viability and normal functioning of 
the bacteria. Nevertheless, it clearly satisfies the majority of the criteria 
applied. Although the deposition efficiency was found to be lower than 
175 
previously reported (Ménache et al 1995) this is likely to relate to a) the use of 
particle inhalation curves from pooled data using rabbits, guinea pigs, rats 
and hamsters as well as mice in the published study b) the specific chamber 
design and nebuliser used, and c) the use of inert radioactive particles in the 
published study, as opposed to bacteria, susceptible to killing by the 
nebulisation process and innate lung defences. Ultimately, for the purposes 
of these studies, the critical outcome is reproducible quantification of the 
delivery profiles of the apparatus used. 
The non -surgical direct intratracheal instillation of bacteria is a rather 
more demanding and labour intensive method of delivery that requires some 
training. However, once the technique has been mastered, it can provide 
well quantified, fairly reproducible, high dose delivery to the lung, with 
minimal delivery outwith the lung. A homogenous distribution is observed 
in the large airways, with a more patchy distribution in the lung 
parenchyma. Delivery can be repeated within a short time frame, but is 
probably not suited to regularly dosing over a longer period of time. It is 
relatively non -invasive, however, anaesthetic is required and abrasion to the 
tracheal epithelium and pharynx may occur. The delivery of bacteria in a 
liquid bolus is clearly a less natural technique and the bolus alone may upset 
lung homeostasis. Experimental mortality is more common than by 
nebulisation, but is still relatively low in the hands of an experienced 
technician. This method is more time consuming and consequently cannot 
be applied to such large numbers of mice. However delivery using this 
technique should not affect bacterial viability or result in bacterial damage. 
Although this technique does not fulfil the criteria as fully as nebulisation, 
the ability to deliver high doses of bacteria, without concern about bacterial 
damage, is important for certain experimental protocols. 
An alternative approach to bacterial delivery that was rejected 
without analysis was the use of agar beads. This approach has been adopted 
by several groups (van Heeckeren et al 1997, Gosselin et al 1998) in the study 
of mouse models of CF (see Chapter 4, section 4.7). This method is relatively 
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demanding and labour intensive. It cannot provide particularly well 
quantified, or reproducible bacterial delivery as a result of several key 
problems; a) beads of bacteria encased in agar will become lodged in 
airways, dependent upon their size, b) random breakdown of beads will 
result in the release of large numbers of bacteria capable of rapid 
proliferation, c) attempts to quantify the numbers of bacteria will be 
distorted by agar, preventing unreleased bacteria from growing as individual 
colonies in culture, instead producing one large colony forming unit. This 
technique will result in minimal delivery outwith the lung, but a patchy 
distribution in the airways and lung parenchyma. Repeat delivery could be 
performed, although given that the intention of this technique is to establish 
a chronic colonisation, this is less significant. The method is relatively non- 
invasive, but clearly results in a particularly artificial scenario. The presence 
of the agar is intended to replicate the effect of P. aeruginosa alginate and 
produce microcolonies and chronic infection. However, agar is not the same 
as alginate and chronic infection with mucoid strains does not occur 
instantaneously. This process occurs over time in humans with CF, with 
colonisation by non -mucoid strains occurring, usually after infections with 
other organisms, followed by a series of phenotypic changes within the CF 
lung environment (see Chapter 1, section 1.4.2.4). The agar bead technique 
completely bypasses this process to establish a chronic retention model in an 
environment that has not been subjected to the classical early events in CF 
lung disease pathogenesis. As such, it is very unlikely to reveal any 
significant data about the development of CF lung disease. In addition, it 
remains unclear whether it can be considered a valid model of chronic 
mucoid infection, having simply superimposed retention of bacteria, in an 
artificial medium, on an otherwise unaffected lung. For these reasons, this 
technique was not evaluated. 
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Chapter 4: Repeated bacterial exposure studies 
4.1 Introduction 
Initial studies using the Cftrt"'' "g" /Cftrt"'' "g" mice demonstrated that no 
gross lung pathology was evident when the mice were born and maintained 
in sterile conditions. However, abnormalities were observed when these 
animals were exposed to aerosolised CF related respiratory pathogens 
(Davidson et al 1995). The abnormal pulmonary phenotype observed in 
response to bacteria consisted of a clearance defect and the development of 
more pronounced lung pathology, in comparison to wild type littermates. 
The studies addressing both components of this phenotype demonstrated 
considerable variation between individual mice. Comparisons made on the 
basis of genotype showed broad overlapping spectrums. Thus, while the 
differences between Cftrt"''t-tg" /Cftrt "'' "g" mice and their non -CF littermates were 
statistically significant, the extent of the variation prevented further 
development as a model for therapy testing or the analysis of phenotype 
modifier loci. 
The most likely sources of the variable phenotype observed in these 
studies were considered to be; a) genetic influences: 1) the use of a mouse 
model of CF on an outbred MF1 / 129 background strain, 2) variation in the 
degree of residual function in individual Cftrt "'"" /Cftrt"'' "g" mice, and b) 
environmental influences: differences in the extent of prior, or co- existing, 
lung infection. Experimental strategies were adopted to minimise and 
address the significance of these factors. 
A mouse breeding programme was initiated to repeatedly backcross 
the outbred mice onto three inbred stains (C57B16 /N, BALB /c and FVB). 
This work was performed by Dr Julia Dorin and Dr Sheila Webb, at the MRC 
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Human Genetics Unit, Edinburgh, and established lines of inbred mice 
congenic for the Cftrt "'1 "g" mutation. The degree of genetic similarity of the 
animals within the same inbred line removes the influence of independently 
segregating genetic modifiers and would be expected to result in a more 
homogeneous phenotype. The C57B16 strain has previously been reported to 
be more susceptible to lung disease (Gosselin et al 1995, Stevenson et al 1995) 
and was therefore chosen for further bacterial exposure studies. 
The variation in the degree of residual function in individual 
Cftrtiil 
Hgu 
/Cftrtml Hg" mice has the potential to impact upon the severity of their 
phenotype. The presence of low levels of wild type CI~ "11( in 
CftrtiilHg " /CftrtmlHgu mice appears to afford them protection from the severe 
gastrointestinal disease associated with most of the other mouse models of 
CF (see Chapter 1, sections 1.7.3.1 and 1.7.3.2). This factor would ideally be 
assessed using quantitative RT -PCR to examine the precise levels of normal 
Cftr mRNA produced in the lungs of each mouse studied. However, to date, 
the quantitation of message levels in lung tissues from Cftrt"`1Hgu / Cftrt,nlHgu mice, 
has not been possible. Consequently an alternative approach was adopted. 
CftrhnlHgu 
/C mice have been estimated to express -10% of wild type 
levels of Cftr mRNA (Dorin et al 1994), whereas CftrtmlUnt mice are 
absolute nulls (Snouwaert et al 1992). Thus CftrGn1Hgu /Cftr' compound 
heterozygote mice would be expected to express -5% of wild type levels of 
Cftr mRNA. Analysis of the pulmonary phenotype of Cftrtm1Hgu ftrtmlUnt 
compound heterozygote mice, inbred onto a C57B1 /6N background was 
therefore performed to address the effect of varying the degree of residual 
CF'I'R function. 
Histological analysis was previously performed on lungs from 
C ftrtn,lHgu /Cftrtiil "gu mice, and non -CF littermates, maintained under standard, 
non -SPF animal facility conditions (Davidson et al 1995). In contrast to 
animals born and raised in isolators, this study demonstrated pathological 
changes associated with lung infection and inflammation, with a trend 
towards more frequent and severe pathology in the CftrtrilHg " /CftrtmlHgu mice. 
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These observations included bronchiolitis, pneumonia, goblet cell 
hyperplasia and metaplasia, mucus retention, perivascular and 
peribronchiolar lymphoid aggregates and aspiration pneumonia. The 
differences between genotypes were not statistically significant, but indicated 
the presence of lung pathology in animals maintained under these 
conditions, in the absence of experimental bacterial exposure. Thus in a 
cohort of mice selected for study, differences between individual mice may 
exist in the extent of prior, or co- existing, lung infection. It was not practical 
to breed sufficient numbers of mice for bacterial exposure studies under 
isolator conditions. Hence, the animals used in the subsequent studies were 
all raised under standard, non -SPF animal facility conditions. 
4.2 Bacterial Delivery 
The repeated bacterial exposure studies were performed using the 
radial nebuliser designs described in Chapter 3, section 3.2. (Nebulisers #2 
and #3). The specific protocols used are described in Materials and Methods 
(see Chapter 2, sections 2.5.1 and 2.7) and the key points are highlighted in 
the following sections. Nebuliser #2 was characterised and used to replace, 
and theoretically improve upon, the damaged Nebuliser #1. Damage to 
Nebuliser #2 necessitated its replacement and led to the production of 
Nebuliser #3. This was used for subsequent studies and characterised 
retrospectively, at which stage the considerable difference in delivery profile 
was established. This difference in the dose delivered by the two nebuliser 
designs creates significant difficulties in interexperimental comparisons and 
will be discussed. 
The previous studies using Cftr`' "'Hg " /Cftr` "''"gu mice on a mixed outbred 
MF1 / 129 background strain had demonstrated abnormalities in the response 
to nebulised S. aureus and B. cepacia. On the basis that S. aureus is the bacteria 
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most commonly associated with early stage lung disease in CF children 
(Hutchison et al 1999), this bacteria was used for subsequent studies. S. aureus 
CF clinical isolate C1705 was supplied by Professor John Govan and 
prepared by Wendy Hannant and Cathy Doherty at the Department of 
Medical Microbiology, University of Edinburgh (see Chapter 2, section 2.3). 
4.3 Histopathological analysis 
The previous study served to indicate the predominant 
histopathological features associated with repeated exposure of the murine 
lung to aerosolised S. aureus and the range of severity observed. In order to 
minimise the subjective nature of assessment of the outcomes of subsequent 
experiments and eliminate bias, a scoring system was established based upon 
these original studies. Five main features were selected; a) Bronchiolitis, b) 
Pneumonia, c) Goblet cell hyperplasia and metaplasia, d) Mucus retention 
and e) Perivascular and peribronchiolar lymphoid aggregates. These 
features were graded on a scale of 1 to 5 on the basis of specified criteria (see 
Table 4.1 and Figures 4.1a and 4.1b). Assessment of lung histopathology was 
performed twice, in blinded fashion, using these criteria. The scores thus 
established were assessed using a weighted Kappa measure of agreement to 
assess variability between the duplicate analyses. The preparation of tissue 





1 excess inflammatory cells in some bronchi cross sections 
2 excess inflammatory cells in smaller airways, clusters of cells in many bronchi 
3 numerous cells in many smaller airways 
4 numerous cells in most smaller airways, inflammatory exudate and occasional 
"plugs" obstructing airway 
5 "lu.s" of inflammator cells and exudate obstructin man airwa s 
PNEUMONIA 
Score Interpretation 
1 patchy excess of alveolar and interstitial inflammatory cells, 
2 more widespread, cells in most alveoli, patches with numerous cells per airspace 
3 several cells in most alveoli +/- small areas of consolidation 
4 widespread numerous cells in almost all alveoli in all lobes / several patches 
consolidation 
5 large areas / whole lobes consolidated 
GOBLET CELL HYPERPLASIA & METAPLASIA 
Score Interpretation r 
1 confined to trachea / primary bronchi 
2 extensive in trachea / primary bronchi, extending into small bronchi/ large 
bronchioles 
3 extensive in small bronchi, extending into smaller bronchioles 
4 extending into terminal bronchioles / >50% of epithelial cells in some large 
airways 
5 numerous in terminal and into respiratory bronchioles / majority of epithelial cells 
in majority of larger airways 
MUCUS RETENTION 
Score Interpretation 
1 occasional strands in larger airways 
2 strands in many large airways & into bronchioles, or occasional strands with 
larger masses 
3 numerous strands in smaller airways +/- larger masses 
4 numerous strands and large masses mixed with inflammatory cells 
/ 5 areas of obstruction by large masses of mucus 
LYMPHOID AGGREGATE 
Score Interpretation 
1 minimal presence 
lymphoid aggregation around most vessels and some airways 2 
3 most vessels partially to fully cuffed, most airways partially cuffed 
massive cuffin. man vessels, man airwa s full cuffed 4 
5 most vessels and airways fully cuffed with massive lymphoid aggregates 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.4 Repeated bacterial exposure of inbred mice 
To assess the effect of the Cftrt,IHgu mutation backcrossed onto a 
C57B16 /N background strain, a cohort of age matched CftrtnlHgu /CftrtntlHB" mice 
and non -CF littermates was selected from backcross generation n = 8. This 
cohort consisted of 10 Cftrtu11Hgu /CftrteiHgu mice and 12 non -CF mice (6 wild type 
mice and 6 heterozygotes). The mice were all 2 - 3 months old and were 
raised in standard, non -SPF conditions. All but 4 of the mice (see below) 
were exposed to S. aureus by repeated nebulisation, in a radial multi- 
nebuliser (Nebuliser #2; see Chapter 3, section 3.2.2.1). The daily protocol 
used was 5 minutes with the baffle followed by 5 minutes without the baffle. 
This was repeated 5 days a week, for 4 weeks. No animals died during this 
period. The dose of bacteria delivered was estimated to be approximately 5 x 
104 cfu /mouse /day. On the final day of bacterial exposures the 4 previously 
unexposed members of the cohort (2 Cftrt"° "gu /CftrtnilHgu mice and 2 
heterozygotes) were also exposed, after which all the animals were given 24 
hours clearance time. The lungs and tracheae were removed, inflated, fixed, 
processed, sectioned at defined sites and stained with PAS as described in 
the Materials and Methods (see Chapter 2, section 2.7). 
A total of 6 section profiles were studied per mouse and scored 
blinded as described in section 4.3. This analysis was performed in 
duplicate. A weighted Kappa value of 0.93 was calculated demonstrating 
excellent agreement between the duplicate analyses. The scores generated for 
histopathological features were ranked, individually for each feature and 
using the total score (sum of the scores for all 5 features), before the study 
was unblinded. These scores are displayed graphically in Figures 4.2 and 
4.3. 
Previous assessment of untreated mice (11 CftrtiilHgu /Cftrtiil"' mice, 7 
heterozygotes and 8 wild types) indicated a mean total score of 1.8 ± 3.2. 
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Consequently a total score of 5 is taken to indicate the upper limit expected 












ttest p =0.015 
K -W test p = 0.008 
Cftrtml "9u /Cftrtm1NSu 4 week exposure 
Cftrtm1Hgu /Cftrtm1Hgu 
1 day exposure 
non -CF 4 week exposure 
Enon -CF 1 day exposure 
FIGURE 4.2 Repeated bacterial exposure of inbred mice- Total 
histopathology score. 
The severity of pathology was ranked according to the total score 
(sum of the five features assessed). Each column represents an individual 
mouse. The genotype and level of exposure to bacteria are indicated. The 
white line indicates the upper limit for untreated mice. 
The total scores for each of the 4 week exposed mice were raised 
above 5, regardless of genotype (Figure 4.2). The total scores for each of the 
1 day exposed mice were also raised above 5 (although two were only 
marginally raised). Statistical analysis of the total scores for each mouse, on 
the basis of bacterial exposure, demonstrated significantly more severe 
pathology in the 4 week exposed mice in comparison to the one day exposed 
control mice, regardless of genotype (t -test p < 0.001, Kruskal- Wallis test p < 
0.001). However, although the two least affected animals were both one day 
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exposed controls (1 Cftr ""IHg" /CftrtnilHg" mouse and 1 non -CF mouse), the other 
two controls were as severely affected as most of the non -CF mice. 
The ranked assessment of the total scores for each of the 4 week 
exposed mice demonstrated some overlap, however, the most severely 
affected animals were observed to be Cftr`¡ "IHg" /Cftr` °'IHg" mice, whilst the least 
severely affected were non -CF littermates. Statistical analysis of these 
scores, on the basis of genotype, revealed significantly more severe 
pathology in the Cftr`" °Hg" /Cftr " "' mice in comparison to the non -CF mice (t- 
test p= 0.015, Kruskal- Wallis test p= 0.008; Figure 4.2). 
Assessment of the scores for each of the individual features 
demonstrated considerably more variation (see Figure 4.3). Significant 
differences between the 4 week exposed Cftr'"'IHg" /Cftr' g" mice and non -CF 
littermates were observed for bronchiolitis (t -test p = 0.03, Kruskal- Wallis 
test p = 0.03; Figure 4.3a), goblet cell hyperplasia and metaplasia (t -test p = 
0.04, Kruskal- Wallis test p = 0.03; Figure 4.3c) and mucus retention (t -test p 
= 0.03, Kruskal- Wallis test p = 0.03; Figure 4.3d). However none of these 
features distinguished between genotypes as successfully as the total score. 
In addition, the individual animals having the highest scores for each of 
these features were not always the same animals. Nevertheless, as the total 
score increased, each of the component scores tended to do the same (Figure 
4.3f). No significant difference was observed for pneumonia (t -test p = 0.20, 
Kruskal- Wallis test p = 0.18; Figure 4.3b) or lymphoid aggregates (t -test p = 
0.10, Kruskal- Wallis test p = 0.15; Figure 4.3e). 
Interestingly, although the one day exposed mice were clearly 
observed to have the lowest scores for pneumonia and lymphoid 
aggregates, this was less clear cut for the other features. Indeed, one of most 
severe examples of goblet cell hyperplasia and metaplasia was observed in 
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Cftrtm1Ngu /Cftrtmrxgu 4 week exposure non -CF 4 week exposure 
Cffrtm1xgu /Cftrtmrxgu 1 day exposure non -CF 1 day exposure 
FIGURE 4.3 Repeated bacterial exposure of inbred mice- Component 
histopathology scores 
The severity of pathology for each of the five features assessed was 
ranked; a) bronchiolitis, b) pneumonia, c) goblet cell hyperplasia and 
metaplasia, d) lymphoid aggregate. Each column represents an individual 
mouse. The genotype and level of exposure to bacteria are indicated The 
white line indicates the upper limit for untreated mice. f) represents the total 
score colour coded to demonstrate the value of each of its component parts. 
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4.5 Repeated bacterial exposure of compound 
heterozygote mice 
To assess the effect of an approximately 50% decrease in the level of 
functional CFTR, a cohort of age matched Cftrtnt1Hg " /Cftrtnr7unc compound 
heterozygote mice and non -CF littermates was selected. This cohort 
consisted of 13 Cftrti1"gu /Cftrtrn7unc mice and 14 non -CF mice (4 wild type mice 
and 10 heterozygotes (5 CftrtnrlHgu and 5 Cftrtii11nc / +) backcrossed to 
generation n = 10 onto a C57B16 /N background strain. The mice were all 2 - 
3 months old and were raised in standard, non -SPF conditions. A group of 
18 mice were exposed to S. aureus by repeated nebulisation, in a radial multi- 
nebuliser (Nebuliser #3; see Chapter 3, section 3.2.2.2). The daily protocol 
used was 5 minutes with the baffle followed by 5 minutes without the baffle. 
This was repeated 5 days a week, for 4 weeks. No animals died during this 
period. The dose of bacteria delivered was estimated to be approximately 2 x 
106 cfu /mouse /day. On the final day of exposures, 4 previously unexposed 
members of the cohort (2 CftrtnrlHgu /Cftrt "mg" mice and 2 heterozygotes) were 
also exposed, after which all the animals were given 24 hours clearance time. 
The final 5 members of the cohort (2 CftrtnrlHgu /Cftrt "''Hgu mice, 2 heterozygotes 
and 1 wild type mouse) were maintained in the same isolator as the exposed 
mice, but were not actively exposed to bacteria. As before, the lungs and 
tracheae were removed, inflated, fixed, processed, sectioned at defined sites, 
stained with PAS and scored blinded in duplicate. A weighted Kappa value 
of 0.93 was calculated demonstrating excellent agreement between the 
duplicate analyses. The scores are displayed graphically in Figures 4.4 and 
4.5. 
The total scores for each of the 4 week exposed mice were raised 
above 5, regardless of genotype (Figure 4.4). The total scores for each of the 
1 day exposed mice were also ? 5, whereas all but one of the unexposed 
mice had a total score of less than 5. Statistical analysis of the total scores for 
193 
each mouse, on the basis of bacterial exposure, demonstrated significantly 
more severe pathology in the 4 week exposed mice in comparison to the 
pooled control mice, regardless of genotype (t -test p < 0.001, Kruskal- Wallis 
test p < 0.001). In this study, all the control mice were clearly less severely 
affected than the exposed mice on the basis of total score. 
The ranked assessment of the total scores for each of the 4 week 
exposed mice demonstrated some overlap, as before. However, the most 
severely affected animals were observed to be Cftrtn1Hg" /CftrtnhlUnc mice, whilst 
the least severely affected were non -CF littermates. Statistical analysis of 
these scores, on the basis of genotype, revealed significantly more severe 
pathology in the Cftrtm1Hgu /Cftrt"'lu "c mice in comparison to the non -CF mice (t- 
test p = 0.009, Kruskal- Wallis test p = 0.017; Figure 4.4). 
Assessment of the scores for each of the individual features was 
observed to demonstrate considerably more variation (see Figure 4.5), as 
was observed with C mice. In this study significant 
differences between the 4 week exposed CftrtiilHg" /Cftrtmlunc mice and non -CF 
littermates were observed for pneumonia (t -test p = 0.01, Kruskal- Wallis test 
p = 0.02; Figure 4.5b) and mucus retention (t -test p = 0.02, Kruskal- Wallis 
test p = 0.02; Figure 4.5d). However, the total score more effectively 
distinguished between genotypes than any of its component parts when 
assessed alone. As noted in the previous study, although the highest scores 
for individual features did not occur in the same animals, as the total score 
increased, so each of its component scores tended to do likewise (Figure 
4.5f). No significant difference was observed for bronchiolitis (t -test p = 
0.10, Kruskal- Wallis test p = 0.10; Figure 4.5a), goblet cell hyperplasia and 
metaplasia (t -test p = 0.08, Kruskal- Wallis test p = 0.07; Figure 4.5c) or 
lymphoid aggregates (t -test p = 0.36, Kruskal- Wallis test p = 0.34; Figure 
4.5e). 
Interestingly, although the control mice were clearly observed to 
have the lowest scores for lymphoid aggregates, bronchiolitis and 
pneumonia, this was less clear cut for mucus retention. As in the previous 
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study, one of most severe examples of goblet cell hyperplasia and 
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FIGURE 4.4 Repeated bacterial exposure of compound heterozygote 
mice- Total histopathology score 
The severity of pathology was ranked according to the total score 
(sum of the five features assessed). Each column represents an individual 
mouse. The genotype and level of exposure to bacteria are indicated. The 
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FIGURE 4.5 Repeated bacterial exposure of compound heterozygote 
mice- Component histopathology scores. 
The severity of pathology for each of the five features assessed was 
ranked; a) bronchiolitis, b) pneumonia, c) goblet cell hyperplasia and 
metaplasia, d) lymphoid aggregate. Each column represents an individual 
mouse. The genotype and level of exposure to bacteria are indicated. The 
white line indicates the upper limit previously established for untreated mice. 
f) represents the total score colour coded to demonstrate the value of each 
of its component parts. 
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4.6 Reassessment of previous repeated exposure 
study 
In order to facilitate a more acceptable comparison between the 
original data and these studies, the histology specimens from one of the 
previous studies were reassessed, scored and graded using the criteria 
defined in section 4.3. A cohort of age matched Cftrtii1Hgu/Cftrt'n1Ngu mice and 
non -CF littermates, outbred on a mixed MF1 / 129 background strain, was 
selected. This cohort consisted of 5 Cftrt"''Hgu /Cftrtril""` mice and 7 non -CF mice 
(3 wild type mice and 4 heterozygotes). The mice were slightly older, at 3 -5 
months old, but were raised in the same standard, non -SPF conditions. All 
mice were exposed to S. aureus by repeated nebulisation, in Nebuliser #1 (see 
Chapter 3, section 3.2.2.3). The daily protocol used was 5 minutes with the 
baffle followed by 5 minutes without the baffle. This was repeated 5 days a 
week, for 4 weeks. The dose of bacteria delivered was not estimated, but 
subsequent analysis suggests it was approximately 2 x 105 cfu /mouse /day. 
The processing and scoring was as previously described. A weighted Kappa 
value of 0.86 was calculated demonstrating excellent agreement between the 
duplicate analyses. The total scores are displayed graphically in Figure 4.6. 
As in all the previous studies, some overlap in the total scores was 
observed. However, the most severely affected animals were observed to be 
CftrhnlHgu /Cftrt'gu mice, whilst the least severely affected were non -CF 
littermates. Statistical analysis of these scores, on the basis of genotype, 
revealed significantly more severe pathology in the Cftrtfl u /CftrtmlHgu mice in 
comparison to the non -CF mice (t -test p = 0.01, Kruskal- Wallis test p = 0.02; 
Figure 4.6). The component scores were not analysed separately due to the 
small cohort size in this study. 
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FIGURE 4.6 Repeated bacterial exposure outbred mice- Total 
histopathology score 
The severity of pathology was ranked according to the total score 
(sum of the five features assessed). Each column represents an individual 
mouse. The genotype and level of exposure to bacteria are indicated. 
4.7 Discussion 
Previous studies demonstrated that CftrtmlHgl` /CftrtmlHgu mice on a mixed 
outbred MF1 /129 background strain were impaired in their ability to clear 
aerosolised S. aureus from their lungs (Davidson et al 1995). This is likely to 
be the causative factor in the increased severity of lung pathology 
subsequently seen in these mice in response to a repeated insult. 
The repeated exposure studies described in this chapter were 
performed to examine the sources of variation in the lung phenotype 
observed in CftrtmlHgu ftrtmhHgu mice in response to bacteria. The mutant 
animals were young, unlikely to have experienced repeated previous lung 
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infections and largely normal with regard to lung pathology, prior to 
experimental exposure. For these reasons, it was considered that they were 
most likely to constitute a model for the initiation and early stage features of 
CF lung disease in humans. Hence the bacteria chosen for these studies was 
a CF clinical isolate of S. aureus (see Chapter 1, section 1.4.2.2). 
The studies described in this chapter demonstrate that 
fyjtm1Hgu /CftrtiilHg" mice and Cftrti °Hg " /Cftr`'n11nt mice, backcrossed onto a 
C57B1 /6N background develop lung pathology in response to repeated 
exposure to aerosolised S. aureus. The characteristics of this pathology is 
similar to that observed in the outbred mice. Moreover, as observed in 
studies using the outbred mice, significantly more severe pathology was 
observed in mouse models of CF in comparison to age, weight and sex - 
matched, non -CF littermate controls. 
Unfortunately direct comparisons between the previous studies and 
the experiments described in this chapter are complicated by the significant 
differences in the nebulisation apparatus used, and hence the level of 
bacteria delivered (see Chapter 3, section 3.2). Estimates of the bacterial 
delivery profiles of the three nebulisers used suggested that the doses, in 
cfu /mouse /day, were; -2 x 105 in the original studies, -5 x 104 in the repeat 
bacterial exposure of inbred mice (Expt. 4.4) and -2 x 106 in the repeat 
bacterial exposure of compound heterozygote mice (Expt. 4.5). This 
represents as much as a 40 fold difference and is a significant concern in the 
context of interexperimental comparison. Nevertheless, with this caveat in 
mind, comparisons may still be made. 
The two studies with the most pronounced difference in bacterial dose 
are Expt. 4.4 and Expt. 4.5. In both of these studies the mouse models of CF 
were compared to groups of non -CF littermates, of the same age, 
backcrossed onto a C57B1 /6N background strain. Thus, valid comparison 
can be made between these control groups to assess the impact of the 
bacterial dose. Analysis of these studies resulted in an average total score for 
4 week exposed non -CF mice of 11.5 ± 1.7 (n = 10) in Expt. 4.4 and 11.9 ± 1.8 
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(n = 9) in Expt. 4.5. These scores are not significantly different (p = 0.59), 
demonstrating that the increased dose of bacteria did not affect the severity 
of pulmonary histopathology in non -CF mice. Furthermore, analysis of the 
mouse models of CF in all three studies resulted in average total scores of 
17.0 ± 4.3 (n = 5) in the original study, 15.1 ± 3.2 (n = 8) in Expt. 4.4 and 14.7 ± 
2.2 (n = 9) in Expt. 4.5. Statistical analysis by t -test indicates no significant 
difference between the original study and either Expt. 4.4 or Expt. 4.5 (p = 
0.43 and p = 0.32 respectively) or between Expt. 4.4 and Expt. 4.5 (p = 0.77). 
This indicates that regardless of any of the differences between these studies 
there was no significant difference in the severity of pathology in the mouse 
models. These results suggest that direct comparisons can be made between 
these studies, despite the quantitative differences in the levels of bacterial 
exposure. 
Establishment of the Cftr " "g" mutation congenic on inbred lines will 
have reduced the genetic variation between mutant animals. This was 
intended to decrease the degree of variation in the lung phenotype in 
response to bacterial exposure and the degree of overlap between the 
phenotypes of mouse models of CF and non -CF littermates. 
The spectrum of disease observed in response to bacterial exposure, in 
Cftr " "' "g " /Cftr` "'' "g" and non -CF mice backcrossed onto the C57B1 /6N strain 
does indeed seem to have been reduced (see Figure 4.2) in comparison to 
outbred mice (see Figure 4.6). The range of total scores in the 4 week 
exposed inbred mice of all genotypes is between 8 and 20 (mean 13.1 ± 3.1, n 
= 18) in Expt. 4.4, in comparison to a range of 3 to 22 (mean 11.9 ± 6.6, n = 12) 
in the outbred mice in the original study. Although, the range and SD are 
decreased in the inbred mice, there is no significant difference between the 
mean total scores (p = 0.56). 
When analysis is performed on the basis of genotype, there is a 
significant difference between the Cftr" "'g " /Cftr`"n' and non -CF mice in both 
the original study and Expt.4.4. The level of significance is not increased in 
the inbred animals (p = 0.01 for the original studies, p = 0.015 for Expt. 4.4). 
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In addition, there is no significant difference between the total scores for the 
Cftr` "''yg" /Cftrt"''Hg" in the two studies, 17.0 ± 4.3 (n = 5) in the original study 
and 15.1 ± 3.2 (n = 8) in Expt.4.4 (p = 0.43). The most obvious difference 
between the two experiments is the response of the non -CF mice to repeated 
bacterial exposure. The mean total score for the mixed, outbred MF1 /129 
non -CF mice in the original study was 5.6 ± 2.2 (n = 7), whereas in Expt. 4.4, 
the inbred C57B1 /6N non -CF mice had a mean total score of 11.5 ± 1.7 (n = 
10). This difference is despite a lower estimated dose of bacteria in the latter 
study. However, the difference is not significant (p = 0.18). This non - 
significance is the result of one severely affected non -CF outlier in the 
original study with a score of 19.5 (95% higher than the next most severely 
affected non -CF mouse in this study). It is possible that the lung disease 
observed in this animal was pre -existing and not the result of the 
experimental procedure. Dixon's gap test (Bliss 1967) was applied to assess 
the validity of rejecting this mouse as an outlier. The difference between the 
suspected outlier and the next closest value, as a proportion of the range of 
the sample (for n = 7 non -CF mice), including the suspect variate, was found 
to exceed the normal expectation at p < 0.05. Thus, failure to omit the 
discordant observation would bias the rest of the sample. After removal of 
this outlier, significantly more severe histopathology (p = 0.003) is 
demonstrated in the inbred C57B1/6N non -CF mice in comparison to the 
mixed, outbred MF1 / 129 non -CF mice. 
Thus the spectrum of disease observed in response to bacterial 
exposure is narrowed in the C57B1/6N mice in comparison to the mixed, 
outbred background strain. However, overlap still exists between the 
Cftr` "''Hg ° /Cftr` "''Hgu mice and non -CF littermates. Indeed, the predominant 
effect appears to be an increased severity of disease in the wild type inbred 
mice. This is perhaps not surprising, given that C57B1/6 mice have 
previously been reported to showed increased susceptibility to lung disease 
(Gosselin et al 1995, Stevenson et al 1995). However, this predisposition 
would appear to have no additional effect on the severity of lung disease in 
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CftrtmlHgu 
/CftrtnhlHgu mice. This may indicate that the defect in the defence 
system of the C57B1/6N strain is a component part of the defect arising 
secondary to the Cftrhi1Hgu mutation. Alternatively it may be unrelated, but 
non -additive in its effect. 
Interestingly, a recent study demonstrated that C57B1 /6N wild type 
mice had a low tracheal forskolin response and that this was largely 
abolished by pretreatment with ionomycin and TBHQ, to reduce the calcium 
linked contribution (Farley et al 1998). This suggests that there is little 
functional CFTR present in the tracheae of these mice and that wild type 
C57B1 /6N mice may have a natural "CF- like" defect in the trachea. This is 
compatible with the observation of the repeated bacterial exposure studies. 
However, the basis for this functional defect is unclear. This defect does not 
extend to the nose (Farley et al 1998) and the effect in the smaller airways is 
unquantified. Furthermore, in contrast to these electrophysiological results, 
semi- quantitative RT -PCR indicates normal expression of Cftr in the tracheae 
of C57B1 /6N mice, although the primary source may be the submucosal 
glands rather than the tracheal epithelium (Innes, personal communication). 
Finally, the pulmonary phenotype in response to bacterial exposure is 
significantly different in wild type mice in comparison to CftrtnilHg " /Cftrt+" 1Hgu 
littermates. This indicates that the level of CI- R function must still be 
greater in the wild type mice, at least in the lower airways, or that functions 
of CFTR other than those assessed by electrophysiological techniques must 
vary between the wild type mice and Cftrtf 1Hgu /Cftrtiil "gu littermates. 
The Cftrhi'l un` mutation has also been backcrossed to become congenic 
on a C57B1/6 inbred background. However, in this case C57B1 /6J was used, 
as opposed to C57B1/6N. Cftrtril "n` /Cftrtntl Unc mice on the original mixed strain 
background did not demonstrate any abnormal pulmonary histopathology 
(Grubb and Boucher 1999). In contrast, the inbred Cftrhil"n`/Cftr"i1"n` mice 
demonstrated significantly more severe lung disease in comparison to wild 
type mice and compared to those on a mixed background (Kent et al 1997). 
However, the only two primary characteristics of the reported phenotype 
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that have survived closer scrutiny are an increased deposition of collagen in 
the alveolar interstitium and a moderate increase in the neutrophils present 
in the lungs (Haston, personal communication). The observation of 
abnormal lung pathology in Cftrt"'"' "` /CftrtmiLl" mice congenic on a C57B1 /6J 
strain, but not the original mixed strain, has been attributed to a failure to 
activate an alternative Cat + -dependent Cl- channel in inbred mice. Whereas 
upregulation of this channel is seen in the nasal epithelium of mixed strain 
Cftrhn/Uric 
ftryhnlUnc mice (Grubb et al 1994a), it was not observed in those 
congenic on a C57B1 /6J strain (Kent et al 1997). However, these studies are 
not extended to the lower airways in the inbred mice. The differences in the 
pathology observed in the inbred Cftrt "' "` "` /Cftrt "' "' "` mice and the inbred 
Cftrt"''Hg " /CftrtnrlHgu mice may be attributable to the use of different C57B1/6 
inbred strains. 
The second possible component of phenotype variation addressed 
was the role of residual CFTR function in the mouse models of CF. The 
repeated bacterial exposure of Cftrt"''Hg " /Cftrt "''t"" compound heterozygote mice 
was performed to establish the effect of a - 50% decrease in the background 
level of normal Cftr expression, in comparison to Cftrt"''H /Cftrt"''Hg" mice on the 
same inbred background. No difference was observed between the severity 
of disease observed as a result of this modification, when Expt. 4.5 (see 
Figure 4.4) is compared to Expt. 4.4 (see Figure 4.2). 
There was no significant difference between the mean total scores for 
the 4 week exposed mice of all genotypes (p = 0.81), comparing Expt. 4.5 
(13.3 ± 2.4, n = 18) and Expt. 4.4 (13.1 ± 3.1, n = 18). Analysis on the basis of 
genotype demonstrated no significant difference (p = 0.77) between the mean 
total scores of the Cftr (Expt. 4.5; 14.7 ± 2.2, n = 9) and the 
Cftrtrn1Hgu 
/CftrËii1Ñg" mice (Expt. 4.4; 15.1 ± 3.2, n = 8). It also demonstrated no 
significant difference (p = 0.59) between the mean total scores of the non -CF 
mice in Expt. 4.5 (11.9 ± 1.8, n = 9) and Expt. 4.4 (11.5 ± 1.7, n = 10). As 
described for the previous studies, a significant difference between mouse 
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models of CF (in this case Cftr "" H u /Cftrtnr]Unc mice) and non -CF littermates was 
observed (p = 0.009). 
Thus, Cftrhn7Hgu f tm7Unc /C tr compound heterozygote mice did not 
demonstrate a significantly more severe pulmonary phenotype than 
qtr./pig u /Cftrt'n' "gu mice, backcrossed onto the same inbred background. This 
is despite a higher estimated dose of bacterial exposure and an expected 
reduction in normal levels of wild type Cftr expression from - 10% to -5 %. 
This observation suggests that an abnormal pulmonary phenotype may be 
manifest when the level of functional CFTR falls below a minimum threshold 
level, but will not be exacerbated by further decreases. This is supported by 
observations in human disease patterns. CF individuals with residual 
function mutations and splice mutations are termed "mild" with reference to 
their pancreatic disease, and may have less severe intestinal pathology, 
however, this does not relate to their lung disease (see Chapter 1, sections 
1.3.3 and 1.3.4). The severity of pulmonary disease in such patients may still 
be severe (The Cystic Fibrosis Genotype -Phenotype Consortium 1993). 
However, as discussed above, the function of normal CN'l'lt in the 
tracheae of C57B1 /6N mice may be disrupted and may not correlate with the 
level of expression of Cftr. Thus, it is possible that the use of this strain of 
mouse may undermine the basis of this study. The extent to which this effect 
might be manifest in the lower airways is unclear. 
The experimental design incorporated two types of control animals; 1 
day exposure controls and untreated controls. The severity of lung disease, 
as assessed by mean total scores, in the 4 week exposed mice was 
significantly higher than the control mice in both experiments (Expt. 4.4; p < 
0.001, Expt. 4.5; p < 0.001). The animals with the lowest total scores were 
always controls and the total scores for untreated mice were well below the 
score for the least severely affected 4 week exposed mouse (see Figure 4.4). 
However, some of the 1 day exposed mice had total scores similar to those of 
less severely affected, predominantly non -CF mice (see Figure 4.2). This 
suggests that there was no cumulative effect on the lung pathology in these 
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less severely affected repeatedly exposed mice. However, closer inspection 
of the individual component scores reveals a slightly more complex picture. 
As anticipated, the 1 day exposed mice show little evidence of perivascular 
and peribronchiolar lymphoid aggregates, or of pneumonia, suggesting that 
these develop in response to repeated bacterial exposure. The other 
components are more variable, particularly the level of goblet cell 
hyperplasia and metaplasia observed. Indeed, two of the mice with the 
highest scores for this feature were control animals, one of which was 
untreated. 
These observations indicate that after just one exposure to S. aureus, 
mice can develop features of lung disease comparable to the less severely 
affected repeated exposure mice. In addition, features of lung disease may 
be pre -existing in some of the mice prior to the onset of experimental 
bacterial exposure. The latter consideration however, may complicate the 
assessment of these studies. It is possible that prior abnormal responses to 
lung infections may exacerbate the response of mouse models of CF to 
experimental bacterial exposure and precipitate more pronounced 
differences between these animals and non -CF littermates. 
The cause of this pre- existing pathology is not clear. The lung 
homogenates from 8 randomly selected Cftrt"''"gu /Cftrt'gu mice (n = 4) and 
non -CF mice (n = 4) failed to demonstrate the presence of any significant 
numbers of bacteria in the lower airways. Furthermore, the regular 
microbiological analysis of sentinel mice from the colony, performed 
routinely in the animal facility, did not show evidence of significant bacterial 
infection. However, these screens did occasionally indicate the presence of 
murine viruses. Serological testing for Sendai virus, Coronavirus and 
Murine Pulmonis was performed on randomly selected CftrtmlHgu 
/Cftrtu'1Hgu 
mice (n = 10) and non -CF mice (n = 5) using a Murine ImmunoCom kit. This 
test was strongly positive for Coronavirus in 6/10 Cftrt 'u /CftrtmlHgu mice and 
2/5 non -CF mice, but negative for the two other viruses tested. When this 
test was repeated using Cftrt"''Hgu /Cftrt "''Ftgu mice (n = 5) and non -CF mice (n = 
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5), born and raised in isolator conditions, no positive results were obtained. 
This indicates one possible causative factor for the presence of abnormal lung 
histopathology in animals raised in standard conditions but not in those 
raised in isolators. However, a positive result for the presence of 
Coronavirus was found not to correlate with the presence of abnormal 
histopathology. Although viral infection was not found in the mice born and 
raised in isolator conditions, it was not practical to breed sufficient numbers 
of mice for bacterial exposure studies in this manner. 
In the period following these studies, access to a new SPF barrier 
facility has become available. Gillian Morrison (MRC Human Genetics Unit, 
Edinburgh) has performed studies on the cytokine levels in BAL from mice 
raised in this facility and those from the original standard, non -SPF, animal 
facility. These studies have demonstrated a significantly raised level of BAL 
TNF -a in Cftrt "''Hg " /Cftrt "''Hg" mice in comparison to non -CF littermates, but 
only in animals maintained in the non SPF facility (Morrison 1999). In 
addition, the levels of BAL TNF -a were observed to be higher in animals 
from this facility than those from the SPF facility, regardless of genotype. 
This suggests increased inflammatory stimulus in the mouse models of CF 
from non -SPF conditions, secondary to background levels of microbes 
present in that facility, but not in SPF conditions. This would be compatible 
with a failure to clear or kill inspired microbes as effectively as non -CF 
littermates and supports the previous studies performed on the 
Cftrtell'/Cftrt"''Hg" mice on a mixed, outbred MF1 strain background 
(Davidson et al 1995). 
In conclusion, the variability observed in the original studies using 
outbred mice is likely to be related to independently segregating genes in the 
outbred strain and variation in the degree of pre- existing lung pathology in 
the mice. Differences between individual Cftrt "''Hg " /Cftrtrn 
Hgu mice in the level 
of residual CFTR function are less likely to have had a significant effect. The 
use of inbred strains, from SPF facilities, should enhance the prospects of 
more clearly defined lung phenotypes in Cftrt "''Hgu /Cftrt"''Hg" mice. 
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The occurrence of a histopathological pulmonary phenotype in mice, 
secondary to mutation in Cftr, is important confirmation that mouse models 
of CF may be of value in dissecting the pathogenesis of CF lung disease. 
However, important considerations remain with regard to the mechanisms 
underlying the development of more severe pulmonary pathology in 
response to S. aureus in the mutant mice, the specific nature of this pathology 
and the response to other CF associated pathogens, particularly P. 
aeruginosa. 
In a previous control study, a cohort of 10 mixed, outbred MF1 / 129 
mice (5 Cftrtii1Hg " /Cftr"i1 Hg" mice, 2 heterozygotes and 3 wild type mice), 2 -4 
months old, from non -SPF conditions, were selected. These mice were 
exposed to nebulised PBS (the carrier vehicle for bacteria in the other studies) 
alone, for 4 weeks, using the same protocol as described for the other studies. 
In this experiment, no significant pathology was observed above expected 
background levels (total score 5 5). This indicates that this technique itself 
does not induce pathology. 
It is possible that a large proportion of the bacteria nebulised in these 
studies are killed by this procedure, as suggested in Chapter 3, section 
3.2.2.1. This may result in the delivery of a large number of dead bacteria to 
the mouse lungs, in addition to the dose of viable microbes. It is not clear to 
what extend the pathology observed related to the dead bacteria as well as 
the viable organisms. However, in previous studies using mixed, outbred 
Cftrh"1Hgu 
ftennigu mice, the specific histopathological consequences of 
repeated exposure to B. cepacia were different to those observed in response 
to S. aureus (Davidson et al 1995). Whereas bronchiolitis predominated in the 
CftrtilHg " /CftrtilHg" mice exposed to S. aureus, pneumonia was more frequently 
observed after repeated exposure to B. cepacia. This pathogen specific 
response supports a primary role for the viable bacteria in the establishment 
of the pulmonary pathology observed. 
Histopathological assessment of the lungs of mice repeatedly exposed 
to S. aureus revealed a significant difference between the mouse models of CF 
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and non -CF controls. This was consistently demonstrated when assessment 
was performed using the total score, but not for the scores assigned to the 5 
features from which it was comprised. Thus, the total score assigned for 
severity of pathology was more closely correlated with genotype than any 
individual component part of that score. This suggests an exaggerated 
normal response in these mice, rather than abnormality in any one aspect of 
this response. This is compatible with a general impairment of the 
antimicrobial properties of the murine tracheal ASL, a mucocilary clearance 
defect or any other mechanism that would have resulted in the prolonged 
presence of bacteria in the lungs of mouse models of CF. To further dissect 
the mechanisms underlying the pathogenesis of the lung pathology 
observed, alternative approaches were required. Studies aimed at 
addressing some of these issues are described in the remaining chapters of 
this thesis. 
The specific lung histopathology described in the mouse models of CF 
bear many similarities to CF lung disease, including bronchiolitis, goblet cell 
hyperplasia and metaplasia and mucus retention (see Chapter 1, section 
1.4.1). However, there are equally striking differences. In contrast to CF 
individuals, the mouse models of CF do not display bronchiectasis, or a 
dramatic neutrophil accumulation in the lungs. 
The absence of bronchiectasis in mouse models of CF is likely to be 
attributable to the relatively short life span of mice, in comparison to 
humans. The classical end stage CF lung disease is the end result of repeated 
cycles of infection and inflammation over many years (see Chapter 1 section 
1.4). This difference may also be a consequence of the relatively sterile 
conditions in which most experimental animals are maintained. Even the 
mice described in this chapter are experimentally exposed to bacteria only 
briefly and over just 4 weeks. 
The relative absence of an accumulation of neutrophils in the lungs of 
mouse models of CF repeatedly exposed to pathogens, when compared to CF 
humans, is more perplexing. The Cftrt "'"/Cftr` "'"'"` mice, congenic on a 
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C57B1 /6J strain background, were reported to have a significantly raised 
number of neutrophils in the lung, in comparison to wild type mice, as 
observed by TEM (Kent et al 1997). This increase was only moderate (2-4 
fold), although these mice had not been experimentally exposed to bacteria. 
An increase of similar proportions in the number of interstitial macrophages 
and fibroblasts was also noted. 
The failure of the Cftr`'9" /Cftr`m'ig" mice to respond to bacterial 
exposure with a dramatic neutrophilia may been ascribed to the nature of the 
infectious stimulus. The experiments described in this chapter address only 
the histopathological response to repeated bacterial exposure and provide no 
evidence of chronic infection with S. aureus in these mice. To have provided 
this additional information would have required homogenisation of a 
defined portion of the mouse lung, to be plated on agar and assessed by 
counting the resultant colonies. However, previous studies had 
demonstrated that such infections were frequently lobar in nature. As a 
result, the loss of a portion of the lung for such analysis could have produced 
misleading histopathological assessment and unrepresentative 
bacteriological analysis. Our previous studies have demonstrated that the 
ability of Cftr`"''lig " /Cftr` "'' "g" mice to clear aerosolised S. aureus from their lungs 
is significantly compromised in comparison to non -CF littermates (Davidson 
et al 1995). However, regardless of genotype, all the mice were able to clear, 
or kill, the vast majority of bacteria delivered to their lungs. Thus, it is 
possible that chronic infection is not established as a result of repeated 
exposure protocols and that the phenotype described is a cumulative 
response to delayed clearance, or killing, of bacteria. In the presence of a 
chronic infection, the neutrophil accumulation anticipated might be 
precipitated. In a model purported to simulate chronic lung infection with 
mucoid P. aeruginosa, this bacteria was delivered to the lungs of 
Cftr` mi u "/Cftrt"''' mice encased in agar beads (see below). A severe, 
neutrophil dominated endobronchial inflammation was reported in these 
mice (van Heeckeren et al 1997, Gosselin et al 1998). However, this was a 
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focal response, limited to the parenchyma around the individual beads. 
Furthermore, there was no difference between the lung histopathology or the 
neutrophil counts observed in the Cftr'"` "'"` /Cftr` "` '" mice and those observed 
in the non -CF controls. 
Thus, differences are observed between the lung disease evident in 
mouse models of CF, under the experimental conditions evaluated to date, 
and classical human CF lung disease. This should perhaps not be surprising 
given the numerous differences between them. These include differences in 
the electrophysiological properties of the airways (see Chapter 1, section 
1.7.3.5), lifespan and exposure to environmental risk factors, as discussed 
above. In addition, there are significant differences in lung anatomy and the 
cellular composition of the airway epithelium. Human lungs consist of two 
lobes on one side and three on the other, with submucosal glands present 
throughout the cartilaginous airways. The epithelium of the proximal 
airways is predominantly comprised of ciliated cells, goblet cells and basal 
cells, whereas the most numerous cells lining the distal airways are ciliated 
cells and Clara cells (Ross and Reith 1985). Murine lungs consist of 4 lobes 
on one side and one lobe on the other, with submucosal glands confined 
largely to the proximal trachea (Borthwick et al 1999). The airways are 
predominately comprised of ciliated cells and Clara cells at all levels, with 
few goblet cells present (Pack et al 1980, Pack et al 1981). Thus, murine 
airways are more similar to human bronchioles rather than proximal 
airways. This may prove to be beneficial, with disease of the distal airways 
being characteristic of early stage CF lung disease in humans. 
It has been suggested that the relative absence of goblet cells and the 
lack of submucosal glands beyond the proximal trachea in mouse models of 
CF may prevent the development of classical CF lung disease. However, 
some of the first signs of abnormal pathology in CF individuals occurs in the 
bronchioles, distal to the submucosal glands. In addition, the studies 
described in this chapter clearly demonstrate both goblet cell hyperplasia 
and metaplasia and mucus retention in mice exposed to bacteria. Another 
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/Cft study, using mixed background Cftrtni11ncrtrnlUnc mice, was designed to 
address this concern (Cressman et al 1998). Allergic airways disease was 
induced in these mice, using chicken ovalbumin. This produced an identical 
pattern of goblet cell hyperplasia and metaplasia and lymphocytic 
aggregates in both the Cftrt"`l U "` /Cftrtrr`I U " mice and non -CF controls. These 
mice were then challenged with P. aeruginosa or S. aureus followed by P. 
aeruginosa. No difference was observed in the bacterial clearance profiles of 
the CftrnlUric 
tmlUnc tr /Cftr mice in comparison to the non -CF controls. This 
suggested that increased mucus production was not sufficient to impair 
bacterial clearance in the Cftrt "`l U "` /CftrtrnlUnc mice. However, the effective 
hydration of the excess mucus, as a result of a predominantly Cat + -dependent 
Cl- pathway in the tracheae of mixed background Cftrt"`I U"` /Cftr""IU"` mice may 
be responsible for these observations. 
The intrinsic differences between CF mice and CF humans should not 
be viewed too negatively. While such distinctions may prevent mouse 
models of CF from accurately reproducing all aspects of CF lung disease in 
humans, the differences may prove as illuminating as the similarities. 
Furthermore, many of the features discussed above have also been 
demonstrated to vary between different strains of mice (see Chapter 1, 
section 1.7.4). These contrasting phenotypes are an important strength of 
mouse models. Taken together these approaches may be capable of 
establishing the critical factors in the development of CF lung disease in 
humans. Rather than pursue the development of all aspects of classical 
human CF lung disease in mouse models, it is equally valid and informative 
to study lung disease in mouse models of CF in its own right. In this manner 
the consequence of Cftr mutation in the mouse lung is addressed and the 
underlying mechanisms evaluated. Extrapolation to human disease 
processes can then be performed, recognising both the similarities and the 
differences between mice and humans. 
The final important issue to address is the response of mouse models 
of CF to exposure to bacteria other than S. aureus. It is unclear whether CF 
211 
infants would be abnormally susceptible to organisms such as P. aeruginosa 
and B. cepacia in the absence of previous infections with respiratory viruses 
and organisms such as S. aureus and H. influenzae (see Chapter 1, section 
1.4.2). Nonetheless, studies have been performed to address the response of 
mouse models of CF to these important organisms. 
Previously reported studies demonstrated than Cftrt"'' "gu /Cftrtm7Hgu mice, 
on a mixed, outbred MF1 /129 strain background, demonstrated an impaired 
ability to clear aerosolised B. cepacia from their lungs, in comparison to non - 
CF littermates (Davidson et al 1995). In addition, they developed 
significantly more severe lung pathology in response to repeated exposure to 
this organism. This phenotype was similar to that described after repeated 
exposure to S. aureus. However, in contrast, pneumonia was a predominant 
component of the response to B. cepacia. This demonstrated a pathogen 
specific component to the responses observed in these studies. 
The study of P. aeruginosa in mouse models of CF is complicated by a 
variety of factors. The most important of these is the phenotypic alterations 
that this organism undergoes over the course of chronic infection of the lungs 
of CF individuals (see Chapter 1, section 1.4.2.4). Although the initial 
infections in CF individuals are with planktonic strains, the rapid 
deterioration of the CF lung occurs after transformation of these bacteria and 
colonisation with these mucoid P. aeruginosa (Govan and Deretic 1996). 
Thus, it is unclear whether the most revealing studies will arise from 
challenging mouse models of CF with non -mucoid P. aeruginosa, to evaluate 
predisposition to infection, or modelling colonisation with mucoid strains in 
the absence of previous rounds of infection. The ideal study would of course 
demonstrate increased susceptibility to infection with non -mucoid P. 
aeruginosa, followed by the emergence of mucoid strains within the mouse 
lung and colonisation. In addition, the significance of previous infections 
with other organisms and the consequent antibacterial chemotherapy 
received, in priming the CF lung for P. aeruginosa infection in unclear. Given 
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these complicating factors, it is perhaps not surprising that the chronic P. 
aeruginosa infections observed in CF lung disease have not been successfully 
modelled in CF mice to date. 
A series of studies were performed using Cftrt"''Hg " /CftrtrnlHgu mice inbred 
on a mixed MF1 /129 strain background, and wild type controls. These mice 
were repeatedly exposed to mucoid or non -mucoid clinical isolates of P. 
aeruginosa, both with and without prior exposure to RSV (Larbig et al 1998). 
The delivery of bacteria was performed both by nebulisation and direct 
instillation, using techniques similar to those described in Chapter 3. No 
significant difference was observed between the clearance profiles or the 
pulmonary histopathology of the Cftrt"''Hg" /Cftrt' "'Hg" mice and the non -CF 
controls, under any of these conditions. This is in sharp contrast to the 
results observed using S. aureus and B. cepacia and suggests that 
trtm7Hg 
" /Cftrten" u mice do not show increased susceptibility to infection with 
this organism. However, an alternative explanation must be considered 
relating to the establishment of inbred mixed background mice. Lines of 
inbred mice were established from founder Cftrt "''Hg" /Cftrt '"" mice on a mixed 
outbred MF1 /129 strain background. It is conceivable that this process 
selected for the most fertile mice, potentially those afforded the most 
protection from the Cftrt "'Hg" mutation by independently segregating modifier 
genes. As a result the progeny of these inbred lines may be less severely 
affected than the majority of the original outbred mice. Indeed, a recent 
electrophysiological study of these mice appears to indicate that the CF 
phenotype has been lost (Tümmler, personal communication). 
In a more recent study the clearance of a clinical isolate of P. aeruginosa 
was assessed in Cftrt"' "`t`' /Cftrtml"' mice (carrying the ÁF508 mutation) on a 
mixed C57B16/129 strain background and non -CF littermates (McCray et al 
1999). These animals were exposed to a single dose of - 1 x 106 cfu by 
nebulisation. A marked BAL neutrophilia was reported in all mice, declining 
over 72 hours. The bacteria were shown to be rapidly cleared by 24 hours 
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and no significant differences were observed between the Cftrtni1Kth /Cftrt"'IKth 
mice and non -CF littermates. These studies, in conjunction with the study 
using Cftrt"'lun` with induced allergic airways disease (Cressman et al 
1998), suggest that mouse models of CF do not display increased 
susceptibility to pulmonary infection with P. aeruginosa. 
These studies all attempted to model the process of initial lung 
infection with P. aeruginosa using relevant clinical strains. This approach is 
intended to elucidate the mechanisms underlying increased susceptibility to 
lung infection with this organism in CF individuals, the transition to 
mucoidy (see Chapter 1, section 1.4.2.4) and selection for mucoid variants in 
lung colonisation. Another study, using wild -type C57B1 /6J mice, reported 
significantly less efficient clearance of mucoid strains of P. aeruginosa in 
comparison to the parental non -mucoid strains, following challenge with 
aerosolised bacteria (Yu et al 1998). However, such observations do not 
provide any explanation for the predisposition to colonisation with P. 
aeruginosa and mucoid transformation in the CF lung. 
The use of agar beads has been adopted as an alternative approach in 
two studies (van Heeckeren et al 1997, Gosselin et al 1998). This technique 
involves the direct instillation of P. aeruginosa laden agar beads into the lungs 
of the experimental animals. This is purported to model the colonisation of 
the CF lung by mucoid P. aeruginosa. These studies used CftrtmlUnc ftrtmlUnc 
mice, on either the original mixed C57B1/6J/129 strain (van Heeckeren et al 
1997), or backcrossed onto a inbred C57B1/6 strain using speed congenics 
(Gosselin et al 1998). In both cases the mice were reared on a liquid diet. In 
one study the dose of bacteria delivered was analysed and estimated to be -1 
x 105 cfu. However, such analysis is complicated by the effects of the agar. 
A significantly decreased survival rate of Cftrt "'lU "` /CftrtmlUnc mice in 
response to bronchopulmonary instillation of sub -lethal doses of P. 
aeruginosa laden agar beads, in comparison to non -CF mice, was reported in 
both studies. No deaths were reported after exposure to sterile beads. In 
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addition, one study reported a significantly more severe weight loss in 
Cftrt" °" " /Cftrt " °" "` mice treated with P. aeruginosa agar beads, than in non -CF 
mouse (van Heeckeren et al 1997). However the published data suggest that 
this differential was equally severe after inoculation with sterile beads. This 
would suggest that in terms of weight loss, the major difference between 
genotypes was in fact in response to the technique rather than the bacteria. 
The bacterial load was examined at different time points after 
inoculation. In one study no significant difference was observed between 
genotypes (van Heeckeren et al 1997). The other study presented evidence 
that bacterial proliferation existed regardless of genotype, but also reported 
the recovery of significantly higher numbers of bacteria from the lungs of 
ftrtnaUnc /Cftrt"'i" "` mice, in comparison to non -CF littermates (Gosselin et al 
1998). However, such analysis is notoriously difficult to interpret. The 
breakdown of a single bead within the lung and the consequent release and 
proliferation of bacteria may seriously distort such results (Govan, personal 
communication). 
Analysis of the lung histopathology of these mice revealed severe, 
focal, neutrophil dominated, endobronchial inflammation, obstruction of the 
distal airways with agar beads and inflammatory cells and excessive mucus 
production. However, no significant differences were observed between 
CftrtnflUnc 
/Cftrhh mice and non -CF littermates in either study. 
In one study, significantly higher levels of pro- inflammatory cytokines 
were reported in the Cftrtril t' /Cftrt "'lU ' mice, in comparison to the non -CF 
controls (van Heeckeren et al 1997). This was despite an absence of 
significant differences in the bacterial lung burden or pulmonary 
histopathology. 
Thus, the primary phenotypic difference reported in these studies is 
an increased mortality in Cftrt"'llnc /Cftrt"'i" "` mice in response to the instillation 
of P. aeruginosa laden agar beads. In the absence of other significant findings 
it is unclear what the cause of this increased mortality is. The significantly 
increased bacterial burden in the Cftrtri11nc/ 
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Cftrt' "lU "` mice reported in one study 
was not observed in the other despite replicating the increased mortality 
phenotype. One study reported negative bacteriological analysis of kidney, 
spleen and liver homogenates, ruling out systemic infection (Gosselin et al 
1998). In the other study, despite negative blood cultures, bacteria were 
isolated in splenic homogenates from 1 out of 10 Cftrt"'"'"`/Cftrtmlu" mice and 2 
of 12 non -CF mice. This was only assessed at day 3, before the vast majority 
of the deaths had been observed (van Heeckeren et al 1997). The small 
proportion of Cftrtm'U"` /Cftrtnhlunt mice surviving to adulthood on a liquid diet 
have a lower body weight and demonstrate abnormalities associated with 
malnutrition (Ip et al 1996). As a result they are likely to be systemically 
weaker than their non -CF littermates. In addition, neither study made close 
examination of the intestines, despite gastointestinal disease being the sole 
cause of mortality in the vast majority of the Cftrt"'"'"`/Cftrtm"'"` mice. Thus, 
the cause of death cannot be definitively attributed to pulmonary disease. 
The observation of significantly increased levels of pro -inflammatory 
cytokines has been the subject of a subsequent report (van Heeckeren et al 
1999). The BAL cytokine levels were assessed in Cftrtn'7 CftrtmlUnc mice on 
the original mixed background strain and inbred onto the C57B1 /6J strain. In 
both cases, 3 days after inoculation with P. aeruginosa laden agar beads, 
significantly higher levels of pro -inflammatory cytokines (TNF -a, IL -113, IL -6, 
MIP -2 and KC) were observed in the Cftr in mice, comparison to 
wild type controls. In addition, in contrast to wild type mice, the anti- 
inflammatory cytokine IL -10 was reported not to be measurable in 
Cftrthim" , CftrtmlUnc mice. Furthermore, no significant difference was observed 
between the levels of IL -10 in Cftrt "''U"` /CftrtmlUnc mice and heterozygotes, while 
heterozygotes were also reported to demonstrate significantly raised levels of 
some proinflammatory cytokines in comparison to wild type mice. This is 
the first report to suggest an abnormal phenotype in mice heterozygous for 
mutations in Cftr. These studies support the theory that an inappropriate 
cytokine response to inflammatory stimuli may be important in the 
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development of CF lung disease. However, a recent study examining the 
innate lung defences against P. aeruginosa in a malnourished mouse model 
reported some striking similarities in mice exposed to aerosolised P. 
aeruginosa strain PAO1 after three weeks on a protein energy malnourished 
diet (Yu et al 2000). These mice displayed significantly reduced pulmonary 
clearance (corrected by restoration of a normal diet), TNF -a levels, and iNOS 
levels in comparison to controls and significantly increased levels of MW-2 
and KC. In addition, in contrast to controls, the malnourished infected mice 
had no detectable IL -10. This study suggests that malnutrition in the liquid - 
diet fed Cftrt mlu"/Cftrt"'"'"` mice may contribute to their pulmonary phenotype 
in response to P. aeruginosa laden agar beads, independently of any direct 
effects of CFI R dysfunction in the lung. 
The agar bead model reveals interesting phenotypic differences, 
despite a somewhat artificial microenvironment, and may prove effective in 
the study of the host response to established infection. If the development of 
CF lung disease were simply the consequence of a failure of mucociliary 
clearance, then the ability of this technique to prevent bacterial clearance 
may be important. However, this is not an accurate model of chronic 
infection with mucoid P. aeruginosa in CF, simply superimposing bacterial 
retention, in an artificial medium, on an otherwise unaffected lung. This 
model is unlikely to provide much information about the initiation and 
development of early stage CF lung disease, or the increased susceptibility to 
infection secondary to CFTR dysfunction. While providing an additional 
phenotypic endpoint for analysis of mouse models of CF, the studies 
described above do not provide evidence of an increased susceptibility to P. 
aeruginosa. 
In conclusion, despite the evidence of several significant differences 
between the response of mouse models of CF and non -CF littermates to 
bacteria, important differences exist when compared to CF lung disease in 
humans. Studies such as the repeat bacterial exposure experiments 
described in this chapter are lengthy, labour intensive and unlikely to be 
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sufficient to reveal the mechanisms by which mutations in Cftr result in 
abnormal lung phenotypes. The consequent challenge is to design 
experiments to examine the relevance of existing hypotheses for the 
development of CF lung disease in humans, in the mouse models of CF. In 
addition, these studies should aim to establish the differences between CF 
related lung disease in humans and mice and the underlying mechanisms. 
Such studies will serve to further our understanding of the biology of the 





Chapter 5: Bacterial internalisation 
5.1 Introduction 
The internalisation of P. aeruginosa by epithelial cells has been 
proposed as a CFTR- dependent component of the lung defence system (see 
Chapter 1, section 1.5.2.2). Studies using cell lines and a wild -type neonatal 
mouse model have suggested that the first predicted extracellular domain 
(amino acids 108 -117) of CFTR may act as a specific cellular receptor for the 
lipopolysaccharide core oligosaccharide of P. aeruginosa (Pier et al 1996, Pier 
et al 1997). Bacterial ingestion, followed by epithelial cell shedding, perhaps 
involving a CFTR- dependent apoptotic mechanism, has been proposed as an 
important mechanism in the protection of the lung from P. aeruginosa. 
These studies have demonstrated bacterial internalisation in vivo, in 
neonatal mice, but only wild type mice were examined. The putative first 
extracellular domain of CFTR is well conserved between humans and mice, 
with 13 of the 15 amino acids identical (the two differences are D112E and 
V115E, human to mouse). In addition, the inoculation of a synthetic first 
extracellular domain peptide of human CFTR with the bacterial inoculum 
has been reported to reduce the internalisation of P. aeruginosa by dissociated 
mouse lung cells by > 95% (Pier et al 1997). Thus, mouse models of CF 
represent an ideal system in which to study the role of CFTR in bacterial 
internalisation by airway epithelial cells and the relevance of this process in 
vivo. 
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5.2 Bacterial internalisation in vivo 
The published studies utilised a neonatal mouse model, in which 7 
day old BALB /c mice were inoculated with bacteria intra- nasally and 
performed a gentamicin exclusion assay to assess internalisation. This 
method was extensively adapted and optimised for application using adult 
mice and is described in full in the Materials and Methods (see Chapter 2, 
section 2.8.1 and Figure 5.1). 
INTRATRACHEAL INSTILLATION OF BACTERIA 
4 2 hours Incubation 










Aliquot A Untreated lung 
GENTAMICIN GENTAMICIN 
250 µg/ml 250 µg/ml 
Ilr1 hour 1 hour 
WASH x 3 WASH x 3 
Ilr 47 




Control 1 Control 2 Sample 1 Control 3 
TOTAL 
FIGURE 5.1 Assessment of bacterial internalisation 
Experimental protocol to assess the in vivo internalisation of P. 
aeruginosa by murine lung cells. 
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FIGURE 5.2 Enzymatically dissociated mouse lung single cell 
suspension 
Light micrographs of an enzymatically dissociated mouse lung 
cytospin, stained with Diff -Quik. A single cell suspension is demonstrated at 
a) 100x magnification, and b) 250x magnification. c) Following 
homogenisation and the addition of 0.5% Triton X -100 all the cells are lysed 
(100x magnification). 
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Anaesthetised adult mice (3 -6 months old) were inoculated with 
suspensions of fresh, overnight cultures of P. aeruginosa CF clinical isolate 
J1385 by direct intratracheal instillation (see Chapter 2, section 2.5.2 and 
Chapter 3, section 3.3). Bacteria were prepared by Wendy Hannant, Jayne 
Hughes or Cathy Doherty, Department of Medical Microbiology, University 
of Edinburgh. After an incubation period of two hours, the lungs and 
tracheae were removed and finely chopped. Enzymatic dissociation was 
then performed, optimised for minimal effect upon bacterial viability. The 
resultant single cell suspension (see Figure 5.2a and b) was then split, as 
illustrated in Figure 5.1. Aliquot A was homogenised and treated with 0.5% 
Triton X -100, to lyse all the cells (see Figure 5.2c) and release any internalised 
bacteria. Duplicate serial dilutions of samples were performed and plated on 
agar (Sample 1). This sample indicates the total number of bacteria 
delivered. The remains of Aliquot A and the whole of Aliquot B were treated 
with 250 gg /m1 of gentamicin, which kills extracellular, but not intracellular 
bacteria (Pier et al 1997) and incubated for 1 hour at 37 °C. Gentamicin was 
demonstrated to be bactericidal for P. aeruginosa strain J1385 at 10 µg /m1 (see 
Materials and Methods, Chapter 2, section 2.8.2). Gentamicin was removed 
by washing and the samples were homogenised and treated with 0.5% Triton 
X -100 to lyse the cells. Duplicate serial dilutions of samples from the 
gentamicin treated Aliquot A (Control 1) and Aliquot B (Sample 2) were 
performed and plated on agar. Sample 2 indicates the number of bacteria 
surviving the gentamicin treatment and is proposed to represent the 
internalised bacteria, released by cell lysis. Control 1 confirms the 
bactericidal activity of gentamicin on all the bacteria exposed to it and should 
not contain any viable bacteria. A dilution of the original bacterial 
suspension (1% of the total dose delivered to the mice) was added to the 
remains of the gentamicin treated Aliquot A after washing. Duplicate serial 
dilutions of samples were performed and plated on agar (Control 2). Control 
2 confirms that the washing steps are sufficient to remove the gentamicin 
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and thus that any internalised bacteria released by cell lysis will not be 
subject to the effects of this aminoglycoside antibiotic. In addition, the lungs 
and trachea of an untreated mouse were removed, homogenised, treated 
with 0.5% Triton X -100 and a dose of bacteria equal to that delivered to the 
mice added. Duplicate serial dilutions of samples were performed and 
plated on agar (Control 3). Control 3 evaluates any antibacterial activity of 
the homogenised, lysed cellular material. 
Initial studies were performed on wild type mice. A typical study is 
described below (Table 5.1 and Figure 5.3). An expected dose of 2.5 x 10' cfu 
of P. aeruginosa isolate J1385 was delivered to two anaesthetised, adult, 
outbred CD -1 mice by direct intratracheal instillation. After two hours 
incubation the mice were sacrificed, their lungs were removed and prepared 
as described above. The samples were plated out on agar and cfu counts 
performed after 24 hours incubation. Each control sample was prepared 
from only one mouse. 
Cfu count 
Mouse A 
Sample 1 -TOTAL 7.1 x 107 ±1.5x10' 
Sample 2 - INTERNALISED 1.3 x 105 ± 0.2 x 105 
Mouse B 
Sample 1 - TOTAL 7.2 x 10' ±2.9x107 
Sample 2 - INTERNALISED 1.3 x 105 ± 0.3 x 105 
Control 1 < 1.0 x 102 
Control 2 (expected 2.5 x 105) 4.0 x 105 ± 0.3 x 105 
Mouse C Control 3 2.8 x 107 ± 0.3 x 10' 
Expected dose 
delivered 2.5 x 10 7 
TABLE 5.1 Internalisation of P. aeruginosa by wild type CD -1 mice 
Assessment of the internalisation of P. aeruginosa by wild type CD -1 














FIGURE 5.3 Internalisation of P. aeruginosa by wild type CD -1 mice 
The internalisation of P. aeruginosa by wild type CD -1 mice. The 
points of the graph represent the two individual mice. Colony counts are 
mean ± SD, from duplicate dilutions. 
This study demonstrates the in vivo internalisation of P. aeruginosa by 
mouse lung cells. Using this procedure, the number of bacteria observed to 
be internalised was - 1.3 x 105 cfu per mouse, representing 0.2% of the total 
pulmonary bacterial load of -7 x 10' cfu. The expected total dose delivered, 
calculated on the basis of the quantified bacterial delivery profile for direct 
tracheal instillation (see Chapter 3, section 3.3.1) was - 2.5 x 10' cfu. Control 
3, representing the delivery of this same dose to homogenised and lysed lung 
tissue, suggested no antibacterial effect of lysed cellular material. In both 
mice, sample 1, representing the total dose in the lung, was observed to be 
-2 -3 fold higher than expected, this suggests some bacterial proliferation 
prior to tissue processing. Controls 1 and 2 demonstrated the bactericidal 
activity of gentamicin and its effective removal by washing. 
This experimental protocol was repeated using wild -type C57B1 /6N 
and MF1 mice and Cftr`mlHgu /Cftr`miHgu mice on a mixed, outbred MF1 /129 
225 
strain background (summarised in Table 5.2). In each case, following the 
intratracheal instillation of -2.5 x 10' cfu, the mice were found to have 
internalised - 0.1 -0.2% of the total number of bacteria in the lungs, regardless 
of strain background or genotype. 
Strain Genotype Total cfu 
(sample 1) 
Internalised 
cfu (sample 2) 
% 
internalised 
BCD -1 wild type 7.1 x10' ±1.5x10' 13.0 x 104± 2.0 x 104 0.18 
CD -1 wild type 7.2 x 10' ±2.9 x 10' 13.0 x 104 ±3.0 x loo 0.18 
CD -1 wild type 4.8x10' ±0.4x10' 5.0 x 104± 0.4 x 103 0.11 
C57BI/6N wild type 4.6 x 10' ±0.2 x 10' 10.0 x 104± to x 104 0.22 
C57BI/6N wild type 4.6x10' ±0.3x106 9.0 x 104± 0.2 x 105 0.20 
MF1 wild type 1.7 x 107 ±0.5 x 106 1.8 x 104 ±o.1 x 104 0.11 
MF1 wild type 2.5x107 ±1.4x10' 4.9x104 ±1.1x104 0.20 
MF1 Cftrrm1Hgu 5.4x107 ±1.1x10' 8.2x104 ±0.2x104 0.15 
MF1 CftrrmlHgu 5.0X107 ±1.8x10' 7.4x104 ±0.2x104 0.15 
TABLE 5.2 Internalisation of P. aeruginosa after high dose delivery 
A summary of the in vivo internalisation of P. aeruginosa, following the 
direct intratracheal instillation of -2.5 x 10' cfu. Colony counts are mean ± 
SD, from duplicate dilutions. 
This experimental protocol was repeated using Cftr e''' " /Cftr`" °"g" mice 
and non -CF littermates, backcrossed onto a C57B1 /6N inbred strain 
background. A lower dose of bacteria was instilled, with an expected 
delivery of - 1.3 x 104 cfu. The results are summarised in Table 5.3. In this 
study, both the total number of bacteria in the lungs and the number of 
bacteria internalised decreased as a result of the lower dose of bacteria 
delivered. However, the percentage of the total dose that was internalised 
increased - 10 fold, suggesting that this process may have been saturated 
when the higher dose was used. Nevertheless, the internalisation of bacteria 
was similar in all the mice, regardless of genotype. 
226 
Strain Genotype Total cfu 
(sample 1) 
Internalised 
cfu (sample 2) 
% 
internalised 
C57BI /6N non -CF 1.3 x105± 0.5 x 104 3.3 x 10 ±o.0 2.5 
C57BI/6N non -CF 2.4 x 105± as x 104 3.9 x 103 ±0.1 x io3 
2.0 x 108+0.2 x 103 
1.6 
2.0 C57BI /6N Cft ,JmlHgu 1.0 x 105± 0.2 x 104 
C57BI /6N CftlfmlHgu 1.2 x 105 ±o.o 4.9 x 103 ±0.3 x io3 4.1 
TABLE 5.3 Internalisation of P. aeruginosa after low dose delivery 
A summary of the in vivo internalisation of P. aeruginosa following the 
direct intratracheal instillation of -2.5 x 10' cfu. Colony counts are mean ± 
SD, from duplicate dilutions. 
5.3 Discussion 
The studies described above demonstrate the successful adaptation of 
the gentamicin exclusion assay to assess the internalisation of bacteria by 
adult mouse lung cells. The results achieved using this assay represent 
preliminary studies utilising mouse models of CF to establish the relevance 
of bacterial internalisation in CF lung disease. 
Published studies using transformed cell lines and a neonatal mouse 
model, suggest that CFTR is a cellular receptor for the binding, endocytosis 
and clearance of P. aeruginosa from the normal lung (Pier et al 1996, Pier et al 
1997). In these studies, human and murine epithelial cell lines, over - 
expressing normal human CFTR, have both been reported to internalise 10- 
100 times more P. aeruginosa than control cells, either expressing ÁF508 C1-11{ 
or not expressing CFTR. Nevertheless, even in these control cell lines - 103 
bacteria were reported to be internalised by -105 transformed epithelial cells. 
Significant inhibition of internalisation has been reported using membranes 
from the CFTR expressing cell lines or purified human CFTR. However, 
considerable bacterial internalisation was still observed in these studies. 
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Inhibition has also been demonstrated in a concentration dependent manner, 
using either a) a monoclonal antibody specific to the first extracellular 
domain of CF1 R, but not antibodies specific to the fourth extracellular 
domain or C- terminus, or b) a specific peptide corresponding to the first 
extracellular domain of CFTR, but not a peptide corresponding to the fourth 
extracellular domain, or a scrambled first extracellular domain peptide. 
Interestingly, in some of the inhibition studies, using the monoclonal 
antibody specific to the first extracellular domain of CFTR, complete 
inhibition of internalisation was observed. This is in contrast to all the other 
methods of inhibition reported. In addition to these results, the level of 
internalisation observed in these cell lines was demonstrated to be 10 -100 
fold lower for bacteria with an incomplete LPS core. These rough LPS strains 
of P. aeruginosa represent one of the phenotypic changes observed in chronic 
infection of the CF lung (see Chapter 1, section 1.4.2.4). Taken together, these 
studies have been reported to indicate that the first predicted extracellular 
domain of CFTR acts as a specific cellular receptor for the LPS core 
oligosaccharide of P. aeruginosa. 
The use of a neonatal mouse model to assess the relevance of these 
observations in vivo was also reported. In this model -108 bacteria were 
instilled intranasally using 7 day old BALB /c mice. A very variable number 
of bacteria were isolated from the lungs after 24 hours, with a range of 2 x 104 
- 2 x 107 cfu (mean of 1 x 106 cfu) per gram of lung tissue. The level of 
internalisation reported was equally variable, with a range of 1 x 103 - 1 x 106 
cfu (mean of 1 x 105 cfu) per gram of lung tissue after 24 hours. Interestingly, 
the number of bacteria internalised after 1 hour was reported to be 
unchanged at 24 hours. Inhibition of internalisation was demonstrated using 
the synthetic peptide corresponding to the first extracellular domain of 
human CFTR, but not the control peptides. This antibody inhibited 95% of 
the internalisation and resulted in a significantly raised bacterial load in the 
lungs at 24 hours after instillation. These studies suggest that intact mouse 
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lungs cells ingest P. aeruginosa using murine CN°l'R in a manner analogous to 
cell lines expressing human CFTR. 
On the basis of the published studies, a significant difference in the 
level of internalisation of P. aeruginosa would be predicted between mouse 
models of CF and non -CF mice. An earlier study demonstrated the 
susceptibilty of the neonatal mouse model to infection with intranasally 
instilled P. aeruginosa and contrasted this with the considerable resistance of 
adult mice (Tang et al 1995). This increased susceptibility to infection was 
given as justification for the use of the neonatal mouse model in the studies 
addressing bacterial internalisation. Given that internalisation is proposed to 
be a protective mechanism it seems rather perverse to select a model on the 
basis of increased susceptibility to infection. Thus, for the studies described 
in this chapter, the assays were adapted and optimised for use in adult mice, 
in which resistance to lung infection with P. aeruginosa is reported to be 
greater. If internalisation plays a significant role in lung defence one would 
expect it to be at least as prominent in an adult mouse model. In addition, 
nasal instillation of bacteria, while quick and easy, was found to provide a 
more variable delivery, with less extensive deposition in the smaller airways 
than direct intratracheal instillation. Thus, the latter technique was 
employed. 
The reported studies indicate that the LPS structure of the bacteria has a 
significant bearing on the level of internalisation (Pier et al 1996). A smooth 
LPS, non -mucoid, CF clinical isolate of P. aeruginosa (J1385), known to have 
undergone mucoid transformation in vivo (Nelson et al 1990), was used for 
the studies described in this chapter. 
The level of bacterial internalisation anticipated in an adult mouse, on 
the basis of extrapolation from the published studies, is difficult to ascertain. 
The internalisation of P. aeruginosa by cell lines indicated approximately 1 
bacteria internalised for every 10 cells. However, it seems unlikely that a 
lung defence strategy would involve 10% of cells engulfing bacteria, with 
subsequent desquamation, in response to bacterial challenge. Corneal 
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epithelial cells have been shown to internalise P. aeruginosa following 
physical injury, with desquamating cells engulfing many bacteria (Fleiszig et 
al 1995). The hypothesis that one "primed" cell may upregulate the level of 
bacterial receptors on its apical membrane (see below) and engulf numerous 
bacteria prior to shedding, represents a more viable model. Hence, the value 
of assessing the mean number of internalised bacteria per cell is unclear. In 
addition, the kinetics and saturation of the internalisation process are not 
evident. The published studies reported in vivo internalisation normalised as 
bacteria per gram of lung tissue. The weight of neonatal mouse lungs was 
not reported, although 1 gram of lung tissue was indicated to represent 106 
cells. This would also suggest a level of internalisation of approximately 1 
bacteria per 10 cells, although in this case the cellular population is mixed. In 
addition to these concerns, the studies described in this chapter were 
performed on adult mice with a different strain background, using an 
alternative delivery technique and a different strain of P. aeruginosa. Thus, 
extrapolation from the published data may not be valid. Nevertheless, in 
order to provide a level of comparison between studies, anticipated levels of 
internalisation can be estimated. In the studies detailed in this chapter the 
lungs of an adult mouse were found to weigh - 200 mg and represented 
10' cells. The proportion of these cells representing airway epithelial cells is 
unknown. Previous studies using rats indicate that rat lungs consist of 
approximately 2 x 108 cells, of which 5 x 10' (25 %) are airway epithelial cells 
(Johnson et al 1990, Mercer et al 1994). A similar proportion may be expected 
in murine lungs, suggesting - 2.5 x 106 airway epithelial cells. This would 
lead to an anticipated internalisation of 2.5 x 105 cfu in an adult mouse lung. 
On the basis of the neonatal mouse studies, using the weight of lung tissue 
alone, approximately 2 x 104 internalised bacteria might be anticipated in 200 
mg adult, wild type mouse lungs, after the delivery of 1 x 108 bacteria. On 
the basis of the inhibition studies reported, both in vivo and in vitro, the level 
of internalisation in mouse models of CF might be expected show a reduction 
of between 10% and 99 %. 
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Despite the caveats relating to the differences between the studies 
described in this chapter and those reported in the literature, the level of 
internalisation observed was remarkably close to that anticipated, with - 1 x 
104 -1 x 105 cfu (mean 8.1 x 104± 3.8 x 104) internalised after the delivery of 
2.5 x 107 cfu, and 2 hours incubation (see table 5.2). However, no difference 
was observed between Cftrt"''"xu /Cftrt" °Flgu mice and non -CF mice. On the basis 
of these preliminary results, the sample sizes required to have an 80% power 
to detect a 10% and 90% decrease in internalisation in mouse models of CF 
are n = 394 and n = 6 respectively. Although the strain variations and the 
small number of mice studied prevent firm conclusions being reached, the 
studies described in this chapter do not support the hypothesised role for 
CFTR in the process of bacterial internalisation. Several possible 
explanations for this discrepancy exist. Discrimination between these will 
require a series of further studies utilising this adapted technique. 
The studies performed in adult mice provide supplementary evidence 
for the internalisation of P. aeruginosa by mouse lung cells in vivo. However, 
the conclusion that CFTR is responsible for this process is not supported by 
these experiments. Indeed, even the published studies demonstrate that 
significant internalisation will still occur in cell lines that do not express 
normal CFTR. It is possible that the process of internalisation is not 
primarily reliant on CFTR, but that overexpression of CFTR in cell lines used 
may result in interactions that influence the mechanism responsible in some 
undetermined manner. It is interesting to note that only the monoclonal 
antibody raised against the first extracellular domain of CFTR was capable of 
complete inhibition of internalisation (Pier et al 1997). This antibody has 
been previously demonstrated to cross react with another unknown protein 
(Walker et al 1995). This raises the possibility that this other protein may in 
fact be the relevant receptor for P. aeruginosa. Indeed, it was use of synthetic 
peptides corresponding to this same domain that successfully inhibited 
internalisation in the neonatal mouse model. 
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An alternative explanation might be that significant biological 
differences exist between mice and humans. However, the published results 
using murine epithelial cell lines transfected with human CFTR and the 
inhibition of internalisation in the neonatal mouse model bear sufficient 
similarity to the results using human cell lines to make this an unlikely 
explanation. A more probable explanation may relate to the specific mouse 
model of CF used in these studies reported in this chapter. The 
Cftrtml'u /Cftr'"''Hgu mice have been shown to express a low level of normal wild 
type CHR (Dorin et al 1994). Despite this they clearly demonstrate an 
abnormal phenotype that resembles CF in many respects (see Chapter 1, 
section 1.7.3 and Chapter 4). Nevertheless, it is possible that this low level of 
normal CFTR is sufficient to result in a normal level of internalisation of P. 
aeruginosa. It has been suggested that a considerable amount of CFTR may 
be subapically localised and that CFTR may play a role in the regulation of 
endocytosis and exocytosis (reviewed in Bradbury 1999). In this manner, 
CF1'R may be capable of upregulating the level of its own expression at the 
apical membrane (see Chapter 1, section 1.3.6). Indeed, using the 
monoclonal antibody raised against the first extracellular domain of CFTR, a 
dramatic increase in the positive staining observed in the bronchial epithelial 
cells of mice infected with P. aeruginosa has been reported (Pier et al 1997). 
Thus, it is conceivable that upon stimulation with P. aeruginosa, subapical 
stores of normal CFTR could be relocated to the apical membrane of 
epithelial cells in the residual function Cftr'"''"gu /Cftrt '"gu mice. This could be 
sufficient to confer a wild type level of internalisation despite a low level of 
normal CFTR production. Such a mechanism might also be expected to 
occur in CF individuals with residual function mutations, in whom severe 
lung disease and colonisation with P. aeruginosa are observed (The Cystic 
Fibrosis Genotype- Phenotype Consortium 1993). However, these CF 
individuals have residual function due to reduced activity of abnormal CFTR 
rather than a small amount of normal CFTR, perhaps with different 
consequences. It is unclear how internalisation of bacteria might be affected 
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in CF individuals with class 3 or 4 mutations, in which CFlR is correctly 
localised to the apical membrane but does not operate effectively as a 
chloride ion channel (see Chapter 1, section 1.3.3). These issues could be 
addressed by studying of the level of bacterial internalisation in alternative 
mouse models of CF (see Chapter 1, section 1.7) with less, or no CN'l'R 
(Cftrtr"'"/Cftrt '" compound heterozygote mice or Cftrti°" " /Cftrti°" "` mice) or 
those carrying the G551D mutation (Cftrt " °c55' °/C mice). It is also 
conceivable that the process of P. aeruginosa internalisation by airway 
epithelial cells observed in human cell lines, is only accurately modelled in 
vivo in neonatal mice and /or mice with a BALB /c strain background. 
However, these explanations seem unlikely given the increased susceptibility 
of neonatal mice to infection with P. aeruginosa and the similar levels of 
internalisation observed in three different strains of mice in the preliminary 
studies described in this chapter. 
Thus the degree of internalisation observed in mouse models of CF 
could be related to the specific mutation of the mouse models used and 
even to the age and background strain of the animals. However, 
subsequent reports examining the internalisation of P. aeruginosa, including 
studies utilising various mouse models of CF, have not included any data to 
suggest that differences in the level of internalisation can be observed in vivo, 
secondary to CFTR dysfunction (Pier et al 1999, Cannon et al 1999). Indeed, 
the focus of these follow -up studies has been significantly different, 
concentrating on in vitro and in vivo data suggestive of CFTR dependent 
apoptosis in airway epithelial cells. These recent reports hypothesise that the 
airway clearance of P. aeruginosa involves internalisation by epithelial cells 
with consequent apoptosis of those cells. The apparent inability of CF cells 
to internalise P. aeruginosa is proposed to result in the failure of CF cells to 
undergo apoptosis. The resultant continued presence of P. aeruginosa on the 
epithelial surface would then lead to the continued production of 
inflammatory mediators and inappropriate inflammatory responses. In 
addition, it has been suggested that the normal upregulation of apical CFTR 
233 
in response to P. aeruginosa may be capable of effecting a dramatic local 
decrease in the NaC1 content of the ASL (see Chapter 1, section 1.5.1.2). This 
could consequently enhance the antibacterial activity of defensins and other 
components of the innate lung defence system (see Chapter 1, section 1.6). 
This response would also be impaired in the CF lung. The internalisation 
hypothesis initially appears to contradict the bacterial adherence hypothesis, 
in which increased binding of P. aeruginosa is observed on CF cells (see 
Chapter 1, section 1.5.2.1). However, it has been suggested that the initial 
binding of P. aeruginosa to the epithelial cell may not in fact be an interaction 
with CFTR (Pier et al 1997). The bacteria may initially bind to receptors such 
as aGM, before interacting with upregulated, apically localised CFTR 
precipitating internalisation. In this scenario, more bacteria would bind to 
CF cells than non -CF cells and those that did bind to non -CF cells would be 
internalised. In contrast, those binding to CF cells would remain at the cell 
surface provoking a continued inflammatory response. In this manner the 
role of internalisation would serve to exaggerate the differences in binding 
observed in EM studies of CF and non -CF cells (Davies et al 1997). While 
incorporating several of the major hypotheses proposed for the development 
of CF lung disease, these proposals are highly speculative and the supporting 
evidence for such arguments remains insubstantial at this stage. In addition, 
the internalisation hypothesis still fails to address the role of organisms other 
than P. aeruginosa in the development of CF lung disease and the influence of 
the mucus layer. 
Irrespective of concerns about the role of CFTR in the process of 
internalisation, the adapted gentamicin exclusion assay in adult mice does 
demonstrate the internalisation of P. aeruginosa by mouse lung cells, in vivo. 
However, such studies do not reveal which cell type has internalised the 
bacteria. The implication in the published studies is that the similarity in 
inhibition of internalisation observed in vivo and in epithelial cell cultures 
suggests that epithelial cells are responsible for this process. However, 
phagocytosis of bacteria instilled into the murine lung would be expected 
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both by alveolar macrophages and by neutrophils. Studies to visualise the 
cellular location of P. aeruginosa are required, using immunohistochemical 
techniques or bacteria expressing green fluorescent protein. In addition, 
primary cultures of murine airway epithelial cells could be used to assess 
internalisation by a purely epithelial murine cell culture (see Chapter 7). 
These cultures could be established from different mouse models of CF and 
non -CF controls and unlike cell lines would not have been affected by 
immortalisation, or overexpression of human C1 -, fR. 
In addition to concerns about the cellular compartment responsible for 
the internalisation of P. aeruginosa, the biological consequences of 
internalisation also require careful consideration. To date there is no 
evidence that internalisation of P. aeruginosa by lung epithelial cells has a 
protective role. Such a mechanism has been described in protecting the 
bladder against infection (Orikasa and Hinman 1977, Aronson et al 1988). 
However, a previous study using the neonatal model of lung infection, 
reported that internalisation was seen mainly in those animals that 
developed more severe pneumonia (Tang et al 1995). Indeed, internalisation 
was postulated as a route to more widespread infection in the lung. 
Furthermore, CFTR dependent invasion of intestinal epithelial cells has been 
proposed as a virulence factor for Salmonella typhi (Pier et al 1998). On this 
basis, decreased susceptibility of CF heterozygotes to typhoid fever has been 
suggested as an explanation for the prevalence of CF carrier status in 
caucasian populations. Thus, the role of any airway epithelial cell 
internalisation of P. aeruginosa must be considered uncertain. 
In conclusion, the internalisation of P. aeruginosa as a component of the 
pulmonary defence system remains a speculative and contentious 
hypothesis. As a result of local practical considerations only preliminary 
studies are described in this thesis. These studies, using an adapted 
gentamicin exclusion assay in adult Cftr" "'Hqu /Cftr`"'' "xU mice and non -CF 
controls, do not support a role for CFTR in the process of bacterial 
internalisation. However, further studies are required to consolidate these 
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observations using increased numbers of mice, other mouse models of CF 
and techniques to visualise the cellular compartment responsible for the 
bacterial internalisation observed in vivo. This chapter clearly illustrates the 
potential value of mouse models of CF in evaluating the in vivo significance 






Chapter 6: ß- Defensins 
6.1 Introduction 
The discovery that the airway surface liquid, which lines the epithelial 
surfaces of the lung, demonstrated salt- sensitive antimicrobial activity, 
stimulated considerable interest in the role of the antimicrobial constituents 
of the ASL in the pathogenesis of CF lung disease. 
The ASL produced by primary cultures of human airway epithelia, at 
an air /liquid interface, has been shown to have broad spectrum antibacterial 
activity, impaired by the addition of NaC1 (Smith et al 1996). In contrast, the 
ASL from primary cultures of airway epithelia from CF individuals had 
impaired antibacterial activity. This activity was restored by decreasing the 
ionic concentration, suggesting that the antibacterial agents were present but 
dysfunctional in the environment of CF ASL. Subsequent studies 
demonstrated that the absorption of NaC1 by cultured CF airway epithelia 
was impaired, with consequent failure to produce the hypotonic ASL 
environment required for effective antimicrobial activity (Zabner et al 1998). 
Although other studies provide conflicting evidence (see Chapter 1, section 
1.5.1.1), this established an elegant and simple hypothesis to explain the 
increased susceptibility of CF individuals to lung infection. 
The ASL contains an array of antimicrobial compounds, including 
lysozyme, lactoferrin, SLPI and defensins (see Chapter 1, section 1.6). 
Studies utilising a xenograft model of human airway epithelium assessed the 
role of human 13- defensin -1 in the ASL (Goldman et al 1997). Ablation of 
HBD -1 expression, using antisense DNA specific to the 5' region of HBD -1, 
was shown to largely abolish the antimicrobial activity of the ASL. In 
addition, synthetic hBD -1 peptide was demonstrated to have salt sensitive 
bactericidal properties against P. aeruginosa. These results suggest that HBD- 
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1 may play a pivotal role in the salt sensitive antimicrobial activity of the 
ASL. 
Defb1, a murine homologue of HBD -1, was isolated on mouse 
chromosome 8 (Huttner et al 1997, Bals et al 1998a, Morrison et al 1998). Defb1 
encodes a 69 as prepropeptide, with 51% identity to HBD -1 at the amino acid 
level. It has been shown to be constitutively expressed, with the highest 
levels found in the kidney and trachea, but also expressed in the lung, liver, 
heart, reproductive tract and alveolar macrophages (see Chapter 1, Table 
1.7). To assess the antibacterial profiles, salt -sensitivity and degree of 
functional homology between these human and mouse defensins, synthetic 
peptides were designed, purchased and analysed. 
MRTSYLLLFTLCLLLSEMASGGNFLTGLGHRSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK HBD-1 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 1 1 1 
MKTHYFLLVMICFLFSQMEPGVGILTSLGRRTDQYKCLQHGGFCLRSSCPSNTKLQGTCKPDKPNCCK Defb1 
Exon 1 Exon 2 
Signal piece Pro -piece Mature peptide (synthetic peptides) 
FIGURE 6.1 Comparison of HBD -1 and Defb1 peptide sequences 
Vertical lines show a direct match. The peptide sequences used to produce 
the synthetic peptides are highlighted in bold. 
6.2 The antibacterial activity of synthetic ß- defensin 
peptides 
To assess the antibacterial profiles of HBD -1 and Defb1, synthetic 
peptides were purchased from Albachem Ltd. These peptides were 
synthesised corresponding to the amino acid sequence of the proposed 
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mature peptide of HBD -1 and Defb1 (see Figure 6.1). The success of 
synthesis was analysed by Albachem Ltd., using HPLC; resulting in a single 
peak in both cases, and mass spectroscopy; confirming the correct molecular 
weight for the peptides synthesised. 
The lyophilised peptides were resuspended in phosphate buffer and 
incubated for 30 minutes, at 37 °C, with bacterial suspensions (containing -5 
x 104 cfu) in varying concentrations of NaC1, as described in the Materials 
and Methods (see Chapter 2, section 2.9.2). Duplicate reactions were 
performed, and each was plated in duplicate on the appropriate agar. The 
resultant cfu counts were compared to those for parallel control samples. 
The controls were performed without the addition of peptide to assess any 
contribution of the varying NaCl concentrations to the outcome. A square 
root transformation was applied to homogenise the variance between groups 
to allow statistical analysis, as described in the Materials and Methods 
(Chapter 2, section 2.9.3). The standard means of the cfu counts were used to 
calculate the quantity of bacteria surviving in the peptide treated samples as 
a percentage of the counts from the control samples, to control for the effects 
of changes in NaC1 concentration alone. These percentages were expressed 
as "percentage killing" and the standard errors calculated. Fresh overnight 
cultures of clinical isolates of bacteria were supplied by Professor John 
Govan, prepared by Wendy Hannant, Department of Medical Microbiology, 
University of Edinburgh (see Chapter 2, section 2.3). 
6.2.1 Synthetic hBD -1 
The concentration of HBD -1 in the ASL in vivo is unknown, although 
subsequent estimates have been made (see Chapter 1, Table 1.8). The 
previous study assessing the anti- pseudomonal activity (Goldman et al 1997) 
of synthetic hBD -1, reported similar bacterial killing, in the presence of low 
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NaC1 concentrations, with synthetic hBD -1 concentrations ranging from 0.06 
to 0.5 mg /ml. Hence to conserve peptide stocks, a concentration of 0.05 
mg /ml of synthetic hBD -1 was used. 
The antibacterial activity of synthetic hBD -1 was assessed against P. 
aeruginosa (CF clinical isolate J1385 and laboratory strain PAO1), S. aureus 
(CF clinical isolate C1705), E. coli (clinical isolate J2408) and B. cepacia (CF 
clinical isolate, epidemic strain J2315). Studies were tested for repeatability, 
to reproduce the salt- sensitive antibacterial profile in a minimum of two 
separate studies, and representative experiments are illustrated in Figures 6.2 
and 6.3. 
Synthetic hBD -1 peptide, at 0.05 mg /ml, displayed significant 
antibacterial activity against P. aeruginosa CF clinical isolate J1385 in 
comparison to the control samples (p < 0.001) at all NaC1 concentrations 
tested, over the range of 0 to 150 mM NaC1 (see Figure 6.2a). A significantly 
greater number of bacteria survived despite the presence of synthetic hBD -1 
peptide when the NaC1 concentration was increased from OmM to 30 mM, 
from 30 mM to 60 mM and from 60 mM to 90 mM (p < 0.001 in each case). 
However, the concentration of salt alone was observed to have an effect on 
bacterial viability in the control samples, in the absence of synthetic hBD -1 
peptide. This deleterious effect was greatest at the highest (150 mM NaC1) 
and lowest (0 mM) concentrations of NaC1 studied (see Figure 6.2a). To 
compensate for this effect, the number of bacteria surviving in the presence 
of synthetic hBD -1 peptide was expressed as a percentage of the number of 
bacteria present in the control sample at the relevant NaC1 concentration. 
The inverse of this proportion is referred to as the percentage kill and 
illustrated in Figure 6.2b. This analysis demonstrates 100% killing of P. 
aeruginosa isolate J1385 at 0 mM NaC1, dropping to and stabilising at - 50% 
killing at 90 -150 mM NaCl. At the extremes of NaC1 concentration (0 and 150 
mM) the bacterial viability in the control samples was equally impaired. 
These NaC1 concentrations also represent the conditions under which the 
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FIGURE 6.2 The antibacterial effect of synthetic hBD -1 against P. 
aeruginosa 
Bacteria were incubated with synthetic hBD -1 peptide at 0.05 mg /ml, 
over a range of salt concentrations. Graphs a), b) and c) show hBD -1 versus 
P. aeruginosa CF clinical isolate J1385, graph d) shows hBD -1 versus P. 
aeruginosa strain PAO1. Graph a) demonstrates survival using the mean cfu 
count after square root transformation ± SE, for blank control samples and 
peptide samples, ** p < 0.001, * p < 0.01. Graphs b), c) and d) show the 
mean percentage kill ± SE, assessed by calculating the number of bacteria 
surviving in the peptide treated samples as a percentage of the counts from 
the buffer only control samples, to correct for the effect of NaCI alone. Graph 
c) shows duplicate experiments using P. aeruginosa CF clinical isolate J1385 
and makes comparison with data published by Goldman et al 1997, using an 
alternative P. aeruginosa clinical isolate. 
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greatest and least antibacterial effects were observed using the synthetic 
hBD -1 peptide. This demonstrates that the effect of the peptide is 
independent from any effect of the salt alone in this assay. These studies 
confirm the salt sensitive antibacterial properties of synthetic hBD -1 
previously reported (Goldman et al 1997). 
Studies performed under the same conditions also demonstrated that 
synthetic hBD -1 peptide, at 0.05 mg /ml, displayed significant, salt- sensitive 
antibacterial activity against P. aeruginosa strain PAO1 in comparison to the 
control samples (see Figure 6.3d). However in this case, although significant 
antibacterial activity was observed at 0 mM and 30 mM NaCl (p < 0.001), this 
was lost at 90 mM and 150 mM NaCl. This suggests that the profile of 
antibacterial activity may be specific to individual strains of bacteria. 
Further studies were performed using other bacteria under identical 
conditions to those described above. Synthetic hBD -1 peptide was 
demonstrated to have a significant, salt sensitive antibacterial effect against 
S. aureus CF clinical strain C1705, at 0 mM, 30 mM and 90 mM NaC1 (p < 
0.001 at each salt concentration). This activity was lost at 150 mM NaCl 
(Figure 6.3a and b). Synthetic hBD -1 peptide was also demonstrated to have 
a significant, salt sensitive antibacterial effect against E. coli clinical strain 
J2408, at 0 mM and 30 mM NaC1 (p < 0.001 in each case). This activity was 
not evident in the presence of 90 mM or 150 mM NaC1 (Figure 6.3c and d). 
The antibacterial effect of synthetic hBD -1 was observed to be 
greatest against P. aeruginosa, with 100% killing at 0 mM NaCl and less 
effective against S. aureus and E.coli, with - 75% and - 50% killing 
respectively under optimal conditions in these studies. 
In contrast to the other bacteria studied, synthetic hBD -1 peptide, at 
0.05 mg /ml, was not observed to have any significant antibacterial effect on 
B. cepacia CF clinical isolate J2315 (Figure 6.3e and f). Indeed the opposite 
effect was observed, with a significantly greater number of bacteria present 
after incubation with synthetic hBD -1 peptide at 0 mM NaC1 than in the 
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FIGURE 6.3 The antibacterial effect of synthetic hBD -1 
Bacteria were incubated with synthetic hBD -1 peptide at 0.05 mg /ml, 
over a range of salt concentrations. A selection of bacteria were used; a) 
and b) S. aureus CF clinical isolate C1705, c) and d) E. coli clinical isolate 
J2408, e) and f) B. cepacia CF clinical isolate J2315. Graphs a), c) and e) 
demonstrate survival using the mean cfu count after square root 
transformation ± SE, for blank control samples and peptide samples, ** p < 
0.001, * p < 0.01. Graphs b), d) and f) show the mean percentage kill ± SE, 
assessed by calculating the number of bacteria surviving in the peptide 
treated samples as a percentage of the counts from the buffer only control 
samples, to correct for the effect of NaCI alone. 
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control sample. No significant differences were observed at the other NaC1 
concentrations examined. 
6.2.2 Synthetic mBD -1 
The antibacterial activity of the novel synthetic mBD -1 peptide was 
analysed using the same techniques employed for the analysis of synthetic 
hBD -1, to establish the degree of functional homology between the two 
peptides. Hence, a concentration of 0.05 mg /m1 of synthetic mBD -1 was 
used as standard. 
The antibacterial activity of synthetic mBD -1 was assessed against P. 
aeruginosa (CF clinical isolate J1385), S. aureus (CF clinical isolate C1705), E. 
coli (clinical isolate J2408) and B. cepacia (CF clinical isolate, epidemic strain 
J2315). Studies were tested for repeatability and representative experiments 
are illustrated in Figures 6.4 and 6.5. 
Synthetic mBD -1 peptide, at 0.05 mg /ml, was observed to have 
significant, salt- sensitive antibacterial activity at 0 mM NaC1 (p < 0.001) and 
30 mM NaC1 (p < 0.01) (Figure 6.4a). This activity was maximal in the 
absence of NaC1, killing - 40% of bacteria, and rapidly decreased in the 
presence of increased concentrations of NaC1, completely inhibited at >_ 90 
mM NaC1 (see Figure 6.4b). Thus, synthetic mBD -1 peptide exhibited 
considerably less antibacterial activity against P. aeruginosa CF clinical isolate 
J1385 than synthetic hBD -1 peptide, at the same concentration. An increase 
in the concentration of synthetic mBD -1 peptide used in otherwise identical 
studies resulted in a corresponding increase in the proportion of bacteria 
killed at each salt concentration tested (see Figure 6.4c). At a concentration of 
0.5 mg /ml, synthetic mBD -1 killed - 80% of bacteria in the absence of NaCl. 
This decreased to - 30% in the presence of >_ 120 mM NaCl. Thus, the profile 
of antibacterial activity of synthetic mBD -1 at 0.5 mg /ml was observed to be 
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FIGURE 6.4 The antibacterial effect of synthetic mBD -1 against P. 
aeruginosa 
Synthetic mBD -1 peptide was incubated with P. aeruginosa CF clinical 
isolate J1385 over a range of salt concentrations. The concentration of 
synthetic mBD -1 used was a) and b) 0.05 mg /ml, or c) 0.5 mg /ml, 0.1 mg /ml 
or 0.05 mg /ml. Graph a) demonstrates survival using the mean cfu count 
after square root transformation ± SE, for blank control samples and peptide 
samples, ** p < 0.001, * p < 0.01. Graphs b) and c) show the mean 
percentage kill ± SE, assessed by calculating the number of bacteria 
surviving in the peptide treated samples as a percentage of the counts from 
the buffer only control samples, to correct for the effect of NaCI alone. 
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FIGURE 6.5 The antibacterial effect of synthetic mBD -1 
Bacteria were incubated with synthetic mBD -1 peptide at 0.05 mg /ml, 
over a range of salt concentrations. A selection of bacteria were used; a) 
and b) S. aureus CF clinical isolate C1705, c) and d) E. coli clinical isolate 
J2408, e) and f) B. cepacia CF clinical isolate J2315. Graphs a), c) and e) 
demonstrate survival using the mean cfu count after square root 
transformation ± SE, for blank control samples and peptide samples, ** p < 
0.001, * p < 0.01. Graphs b), d) and f) show the mean percentage kill ± SE, 
assessed by calculating the number of bacteria surviving in the peptide 
treated samples as a percentage of the counts from the buffer only control 
samples, to correct for the effect of NaCI alone. 
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similar to, but still less effective than that of synthetic hBD -1 at 0.05 mg /ml, 
against P. aeruginosa CF clinical isolate J1385 (see Figures 6.4 c and 6.2 b). 
Further studies were performed using other bacteria under identical 
conditions to those described above, with 0.05 mg /ml of synthetic mBD -1 
peptide. Synthetic mBD -1 peptide was demonstrated to have a significant, 
salt sensitive antibacterial effect against S. aureus CF clinical strain C1705, at 0 
mM (p < 0.001), 30 mM (p < 0.001) and 90 mM NaCl (p < 0.01). This activity 
was lost at 150 mM NaC1 (Figure 6.5a and b). Synthetic mBD -1 peptide was 
also demonstrated to have a significant, salt sensitive antibacterial effect 
against E. coli clinical strain J2408, at 0 mM (p < 0.001) and 30 mM NaC1 (p < 
0.01). This activity was not evident in the presence of 90 mM or 150 mM 
NaC1 (Figure 6.5c and d). 
As observed using synthetic hBD -1 peptide, B. cepacia CF clinical 
isolate J2315 was not significantly affected by synthetic mBD -1 peptide at 
0.05 mg /ml (Figure 6.5e and f). Although, significant antibacterial activity is 
demonstrated in Figure 6.5e in the presence of 60mM and 150 mM NaC1 (p < 
0.01), this was not repeatable. 
Thus at 0.05 mg /ml, the antibacterial profile of synthetic mBD -1 
peptide was observed to be almost identical to that of synthetic hBD -1 
peptide against the clinical strains of S. aureus and E. coli tested (see Figure 
6.6). However, although P. aeruginosa CF clinical strain J1385 was observed 
to be extremely sensitive to synthetic hBD -1 peptide, it was relatively 
insensitive to synthetic mBD -1 peptide at the same concentration (see Figure 
6.6). Synthetic hBD -1 peptide demonstrated much greater antibacterial 
activity against P. aeruginosa than any other bacteria tested. In contrast, at 
0.05 mg /ml, synthetic mBD -1 peptide demonstrated greatest antibacterial 
activity against S. aureus CF clinical strain C1705. No repeatable, significant 
antibacterial activity was observed against B. cepacia CF clinical isolate J2315 
using either peptide at 0.05 mg /ml. 
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FIGURE 6.6 The antibacterial effect of synthetic hBD -1 and mBD -1 
Bacteria were incubated with a) synthetic hBD -1 peptide, or b) 
synthetic mBD -1 peptide, at 0.05 mg /ml, over a range of salt concentrations. 
A selection of bacteria were used; S. aureus CF clinical isolate C1705, E. coli 
clinical isolate J2408 and P. aeruginosa CF clinical isolate J1385. Graphs 
show the mean percentage kill ± SE, assessed by calculating the number of 
bacteria surviving in the peptide treated samples as a percentage of the 




The role of the ASL in the pathogenesis of CF lung disease remains the 
subject of considerable controversy (see Chapter 1, section 1.5.1). The 
"isotonic absorption /mucus dehydration" hypothesis proposes that the 
primary defect in the CF airways is excessive isotonic volume absorption 
leading to impaired mucociliary clearance mechanisms (Matsui et al 1998). 
This theory predicts isotonic ASL with no difference in ionic composition 
between CF and non -CF individuals. In contrast, the "hypotonic/ defensin" 
theory predicts that in the absence of functional CFTR channels the 
predominant mode of Cl absorption from the ASL is absent and the ability to 
absorb salt is consequently reduced (Zabner et al 1998). This hypothesis 
predicts a hypotonic ASL in non -CF individuals with a raised NaC1 
concentration in the ASL of CF individuals. An increased level of NaC1 is 
proposed to impair the activity of naturally occurring, salt- sensitive 
antimicrobial components of the ASL (Smith et al 1996), including ß- 
defensins (Goldman et al 1997). If the latter hypothesis is assumed to be 
correct then the antibacterial profiles of the ß- defensins may have a 
significant impact upon the character of CF lung disease. 
The studies described in this chapter, using synthetic ß- defensin 
peptides, confirm the salt sensitive antibacterial properties of HBD -1 peptide 
in vitro. The previously reported study, which examined the antibacterial 
activity of synthetic hBD -1 peptide, did not control for the effect of salt alone 
on bacterial viability, nor was antibacterial activity demonstrated for 
organisms other than a P. aeruginosa clinical isolate (activity against E. coli 
was reported, but these data were not shown) (Goldman et al 1997). 
Nevertheless, illustrating the results from that study in the manner of the 
percentage killing graphs used in this chapter, it is clear that the synthetic 
hBD -1 peptides used in both studies have comparable anti- pseudomonal 
activity (see Figure 6.2c). The salt- sensitive antibacterial nature of HBD -1 
250 
has been further confirmed using purified recombinant HBD -1 peptides 
made using an insect cell /baculovirus system (Singh et al 1998). This study 
demonstrated that the antibacterial effect of HBD -1 is concentration 
dependent and that inhibition by increased levels of NaC1 could be offset by 
greater concentrations of peptide. In this study, salt -sensitivity was assessed 
using a strain of E. coli containing a gene encoding a luminescence protein. 
Interestingly, the antibacterial activity of HBD -1 peptides reported using this 
luminescence assay was much greater than that observed in the studies 
described in this chapter, with 100% of a 10' cfu /ml suspension killed by 1.2 
µg /ml of HBD -1 peptide in the absence of NaCl. This greater antibacterial 
activity against E. coli may relate to the assay, the bacterial strain or the 
method of peptide production employed. 
The studies described in this chapter, using synthetic hBD -1 peptide, 
demonstrate much greater antibacterial activity against P. aeruginosa than 
any other bacteria tested, with 100% killing in the absence of NaC1, 
decreasing to -50% (for CF clinical isolate J1385) in the presence of 90 mM 
NaCl. Nevertheless, significant antibacterial activity was observed against S. 
aureus CF clinical isolate C1705 and, to a lesser extent, against E. coli clinical 
isolate J2408, with - 75% and - 50% killing respectively in the absence of 
NaCl, but no significant effect in the presence of 90 mM NaCl. No significant 
antibacterial activity was observed against B. cepacia CF clinical strain J2315, 
at any concentration of NaCl. Surprisingly, in the absence of NaC1, B. cepacia 
appeared to thrive in the presence of synthetic hBD -1 peptide. It is 
interesting to note that a previous study has shown that this organism can 
actually use penicillin G as its sole source of carbon and energy (Beckman 
and Lessie 1979). 
At a concentration of 0.05 mg /ml, synthetic mBD -1 and hBD -1 
peptides were demonstrated to have very similar antibacterial profiles 
against S. aureus CF clinical isolate C1705 and E. coli clinical isolate J2408. 
However, the antibacterial activity of synthetic mBD -1 peptide against P. 
aeruginosa CF clinical strain J1385 was found to be considerably reduced in 
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comparison to synthetic hBD -1 peptide. This antibacterial activity was 
observed to be concentration dependent, consistent with previous reports 
using human peptides (Singh et al 1998). Synthetic mBD -1 peptide at 0.5 
mg /ml was observed to be similar to, but still less effective than synthetic 
hBD -1 at 0.05 mg /ml, with the murine peptide exhibiting a comparative 
reduction in antibacterial activity in excess of 10 fold against this organism. 
A further study, using the lysates of transfected human adrenal 
adenocarcinoma cells expressing mBD -1, demonstrated that mBD -1 had 
more effective antibacterial activity against a CF clinical isolate of S. aureus 
and a strain of E. coli, than against a clinical isolate of P. aeruginosa (Bals et al 
1998a). In this study, 100% killing of both S. aureus and E. coli was observed. 
However, the concentration of peptides was not quantified, nor was the 
presence of other factors in the lysate that may have been capable of 
antibacterial activity, or displaying a synergistic effect with mBD -1. 
Nevertheless, both these studies suggest that in contrast to HBD -1, mBD -1 
displays less effective antimicrobial activity against P. aeruginosa than against 
other organisms. Synthetic mBD -1 peptide had no repeatable significant 
antibacterial activity against B. cepacia. 
The "hypotonic/ defensin" theory proposes that raised levels of NaCl 
in the ASL result in the dysfunction of (3- defensins and other salt- sensitive 
antimicrobial agents. The consequences of this impairment would probably 
be manifest as increased susceptibility to infection with the organisms 
against which the impaired peptide was most active. Thus, differences in the 
antibacterial profiles of the affected components of the ASL might influence 
the pulmonary phenotype observed. 
Humans are normally resistant to lung infection with P. aeruginosa, 
however CF individuals are exquisitely susceptible to this organism. The 
results discussed above demonstrate that HBD -1 has potent anti- 
pseudomonal activity, in vitro. These results also demonstrate that HBD -1 is 
more active against this organism than against the other human pathogens 
studied. Thus, HBD -1 dysfunction in a high salt environment may result in 
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the affected individual being particularly susceptible to infection with P. 
aeruginosa. 
In contrast, mouse models of CF are clearly not acutely susceptible to 
lung infection with P. aeruginosa. Neither studies using Cftr tm] Hgu / Cf trtru 1 Hgu 
mice (Larbig et al 1998), nor those using Cftr"' °K`" /Cftrt hlKth mice, with the 
OF508 mutation (McCray et al 1999), have been able to see any difference 
between CF mutants and wild -type littermates in response to repeated 
nebulisation with P. aeruginosa. Although CftrtiilLnc/ Cftr "i11nc mice have been 
reported to demonstrate significantly poorer survival rates in response to 
bronchopulmonary instillation of P. aeruginosa laden agar beads (van 
Heeckeren et al 1997, Gosselin et al 1998), in comparison to wild type mice, 
severe bronchopneumonia and evidence of bacterial proliferation existed 
regardless of genotype and the cause of death was not definitively attributed 
to pulmonary disease (see Chapter 4, section 4.7). Thus, in contrast to their 
human counterparts, mouse models of CF display robust resistance to airway 
infection with P. aeruginosa. However, the in vitro results discussed above 
suggest that mBD -1 does not play a significant part in this process, having 
little anti- pseudomonal activity in isolation. Thus, salt- induced dysfunction 
of mBD -1 may have little effect upon the susceptibility of mouse models of 
CF to P. aeruginosa. Alternative antimicrobial agents and /or cellular 
mechanisms may mediate the resistance to P. aeruginosa infection in the 
mouse lung. It is quite possible that these mechanisms are not significantly 
compromised by a high salt environment. In contrast to P. aeruginosa, mBD -1 
does show marked salt -sensitive antibacterial activity against S. aureus, in 
vitro. Dysfunction of mBD -1 in a high salt environment might therefore be 
expected to have a more profound effect upon the susceptibility of the 
murine lung to infection with S. aureus than with P. aeruginosa. This may 
contribute to the impaired airway clearance of S. aureus in the 
CftrtiilNg /Cftrtii"u mice (Davidson et al 1995) and the development of more 
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severe pulmonary pathology in response to repeated nebulisation with this 
organism, which has been observed (see Chapter 4). 
Thus, the existence of species specific differences in the antibacterial 
profiles of these homologous peptides may have the potential to influence 
the profile of bacterial susceptibility secondary to a raised NaC1 
concentration in the ASL. Therefore, it is possible that while the basic 
mechanisms underlying increased susceptibility to lung infection in CF may 
be conserved between mice and humans, this may not be the case for the 
specific profile of bacterial susceptibility. 
This represents an attractive hypothesis. However, a number of 
critical factors must be considered in the interpretation of the results from the 
synthetic defensin peptide studies. These include the use of synthetic 
peptides, resistance of B. cepacia, the role of other antimicrobial agents in vivo, 
the relevant in vivo concentration of I3- defensins and the NaC1 concentration 
of the ASL in human and murine airways in vivo. 
The synthetic hBD -1 peptide used for the studies described in this 
chapter demonstrates a profile of activity against P. aeruginosa identical to 
that previously reported for similar synthetic peptides (Goldman et al 1997). 
In addition, both human and murine synthetic (3- defensin peptides displayed 
antibacterial profiles broadly consistent with other published studies (Bals et 
al 1998a, Singh et al 1998). However, purified HBD -1 produced using an 
insect cell /baculovirus system may have greater antimicrobial activity, at 
lower concentrations, than the synthetic hBD -1 used in the studies reported 
in this chapter (Singh et al 1998). This could be due to the cellular processing 
of the pre -propeptide to the final mature peptide. Indeed, several forms may 
be synthesised in vivo, with varying degrees of antimicrobial activity and salt 
sensitivity (Valore et al 1998). Furthermore, a recent study has described the 
synthesis of a novel theta defensin by the head -to -tail ligation of two 
truncated a- defensins in rhesus macaque leukocytes (Tang et al 1999). These 
studies highlight the potential importance of cellular processing mechanisms. 
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In contrast, the synthetic peptides are chemically synthesised and represent 
only the putative mature form of the 13- defensin peptide. 
The impairment of the antibacterial activity of (3- defensins in a raised 
NaC1 ASL, secondary to CFTR dysfunction, has been proposed as an 
explanation for the increased susceptibility of CF individuals to lung 
infection. However, one of the bacteria characteristic of CF lung disease is B. 
cepacia (see Chapter 1, section 1.4.2.5). The clinical isolate of B. cepacia used in 
the studies described in this chapter, demonstrated resistance to both 
synthetic hBD -1 and synthetic mBD -1. This is consistent with previous 
reports (Hancock 1997) and indicates that this hypothesis can only be, at best, 
a partial explanation. The susceptibility of CF individuals to B. cepacia must 
be mediated by other, as yet undetermined, consequences of Cr 
dysfunction. 
In the studies described in this chapter, the synthetic (3- defensin 
peptides were studied in isolation. This is in contrast to the in vivo situation, 
where ß- defensins are part of a complex mixture of antimicrobial agents 
present in the ASL (see Chapter 1, section 1.6). It seems probable that the 
antimicrobial components of the ASL interact and indeed a synergistic 
interaction has been demonstrated in vitro between ß- defensins and both 
lysozyme and lactoferrin, at non -bacteriostatic concentrations (Bals et al 
1998b). Furthermore, this chapter describes the analysis of synthetic hBD -1 
and mBD -1, but additional (3- defensins, also expressed in the airways, have 
since been isolated (HBD2 in humans (Harder et al 1997), Defb2 (Morrison et 
al 1999), mBD -3 (Bals et al 1999) and mBD -4 (Jia et al 1999) in the mouse). 
These additions to the (3- defensin gene families are inducible by 
proinflammatory stimuli (Harder et al 1997, Bals et al 1998b, Liu et al 1998 
Singh et al 1998, Morrison et al 1999, Bals et al 1999, Jia et al 1999). Purified 
hBD -2, made using an insect cell /baculovirus system, has been 
demonstrated to exhibit salt- sensitive antibacterial activity against P. 
aeruginosa strain PAO1 and a strain of E. coli containing a luminescence 
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plasmid, with the activity exceeding that of HBD -1 peptide by approximately 
10 fold (Singh et al 1998). Purified mBD -3, made using an insect 
cell /baculovirus system has been reported to display antibacterial activity 
against strains of P. aeruginosa and E. coli, although salt -sensitivity has not 
been demonstrated (Bals et al 1999). The degree of functional overlap and 
redundancy between the defensins is unclear although their roles may be 
somewhat different. HBD -1 is constitutively expressed and its product may 
form part of the primary line of lung defence, whereas the inducible 13- 
defensins may be more important once constitutive defences have been 
breached and inflammatory signals are generated. 
In addition to the impact of synergistic interactions with other 
components of the ASL and role of other I3-defensins, the activity of 
defensins as signalling molecules should not be ignored. A recent report 
suggested that 13-defensins in submicromolar concentrations were 
chemotactic for T cells and dendritic cells (Yang et al 1999). It is unclear 
whether a raised NaCl concentration may also impact upon this function. 
Thus, although the studies of synthetic hBD -1 and mBD -1 peptides in vitro, in 
isolation, provide interesting insights, appropriate mammalian cellular 
expression systems, air -interface primary culture model systems and mouse 
models with targeted deletions of specific 13-defensins are required to 
confirm the results. 
The reported studies of (3- defensin activity all suffer from a lack of 
accurate quantitation of the levels of 13- defensins in the ASL. Recent 
investigations of BAL fluid suggest levels of < 2 ng /ml for HBD -1 and 0.1 - 
100 ng /ml for HBD -2 (Singh et al 1998, Ganz 1998). It has been suggested 
that this falls within the range of antimicrobial activity of HBD -2 but not 
HBD -1. These estimated levels are dramatically lower than the 
concentrations of synthetic defensin peptides used in the studies described in 
this chapter and much of the published work. However, the relevant local 
concentrations may not be accurately reflected in BAL measurements and, as 
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before, this is without regard for the effect of synergistic interactions or 
indirect roles for ß- defensins in lung defence. In addition, the concentration 
at which antimicrobial effects have been observed in vitro has been 
demonstrated to be dependent upon the ionic environment (Singh et al 1998). 
Therefore the relevant antimicrobial concentration in vivo is dependent upon 
the NaC1 concentration of the ASL. This critical factor is also unknown and 
the subject of considerable controversy. 
A series of contradictory results have been published reporting 
studies of the ionic composition of the ASL in vivo and no conclusive results 
are yet available (see Chapter 1, section 1.5.1.3 and Table 1.6). Studies using 
human subjects are limited by technical constraints, the requirement to limit 
invasive procedures, the presence of infection in most of the available 
subjects and the lack of appropriate controls. A number of studies have 
circumvented some of these complicating factors by attempting to measure 
the ionic composition of the ASL in murine airways. 
A capillary electrophoresis fluid collection technique has previously 
been used to demonstrate the hypotonic nature of ASL in rats (Cowley et al 
1997b). This technique has also been performed on Cftr' " °" "` /Cftrtr °" "` mice, 
backcrossed onto a C57B1/6 strain background, and non -CF littermates 
(Cowley et al 1998). A hypotonic ASL was also reported in mice, however no 
difference was observed between Cftrtell' /Cftrt """` mice and non -CF 
littermates (Table 6.1). Interestingly, despite this observation, elevated levels 
of Na+ and K+ were observed in these mice following the instillation of P. 
aeruginosa laden agar beads. 
A recent study used a novel cryoprobe collection technique and x -ray 
microanalysis to analyse the elemental composition of the tracheal ASL in 
Cftrt"'"gu /Cftrt"'' mice on a mixed outbred MF1/129 strain, and non -CF 
littermates (Zahm et al 1999). This study also reported that the ASL in mice 
was markedly hypotonic. However, in contrast to the previous study, a 
significantly increased concentration of NaC1 was observed in the ASL 
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collected from Cftrtt 
1"g 
" /Cftrt"'1Hgu mice in comparison to wild type mice (p < 
0.05) (Table 6.1). 
A third study used an E. coli luminescence assay to demonstrate the 
salt- sensitive antibacterial activity of wild type murine BAL fluid and 
confirmed the expression of Deihl in the murine lung (McCray et al 1999). 
An uncharacterised primary culture model of murine tracheal epithelium 
was then utilised and the ionic content of the ASL on these cultured cells was 
assessed using a radiotracer technique. This study also confirmed the 
hypotonic nature of the ASL but found no difference between the Cl- 
concentration of ASL from primary cultures of Cftrtnil"t" /Cftrtri1Kth mice, with 
the AF508 mutation on a mixed C57B1/6/129 strain background, and non -CF 
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TABLE 6.1 The ionic composition of murine ASL 
U = uninfected, I = infected using bronchopulmonary instillation of P. 
aeruginosa laden agar beads, NR = not reported. 
The contrasting results of these studies appear to replicate the 
conflicting results generated by the studies of human ASL. However, the 
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critical factors influencing the data from the mouse model studies may be 
more easily addressed. 
There are several possible explanations to explain the apparent 
contradictions between these studies. Firstly, the genetic background of the 
mice may be critical. The two groups that found no difference between the 
mouse models of CF and non -CF littermates, studied mice on a pure inbred 
or a mixed C57B1/6 background. Inbred C57B1/6 mice do not demonstrate 
significant CFTR function in the trachea in response to forskolin stimulation, 
even in wild type mice (Farley et al 1998). Thus, mutations in Cftr may not 
affect the NaC1 content of the ASL in the tracheas of mutant mice on this 
genetic background. Secondly, the specific Cftr mutation may be important. 
In many of the mouse models of CF studied, upregulation of Ca +- dependent 
Cl- channels has been reported in the airway epithelia of the nose or trachea 
(see Chapter 1, section 1.7.3.5). This upregulation has not been observed in 
the Cftrt"''"gu /CftrtnilHgu mice (Smith et al 1995). Thus, it is possible that despite, 
or even as a result of the residual wild type CFTR present in this model, there 
is a relative absence of alternative chloride channels capable of compensating 
for the loss of CFTR and consequently a more severe lung phenotype. 
Hence, both the background strain and specific Cftr mutation may play a role 
in determining the manifestation of the CF phenotype in the murine trachea 
and determine the most appropriate model for human disease. The 
differences between mouse models of CF are potentially informative with 
regard to establishing the most important factors in determining the ionic 
content of the ASL. 
In addition to the influence of mouse strain and specific Cftr mutation, 
methodological differences are likely to play a significant role in determining 
the values reported by these three studies for the ionic composition of 
murine ASL. The analysis of ASL using capillary electrophoresis requires a 
narrow bore polyethylene tube to be in contact with the tracheal epithelium 
for approximately 30 minutes, through a tracheotomy (Cowley et al 1998). It 
seems likely that this could act as an irritant and a response may be 
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provoked by the procedure. If the "hypotonic /defensin" is correct, there 
may not be sufficient time or epithelial contact to allow the absorption of 
NaC1 from secretions produced in response to such stimulus, resulting in an 
artificially raised NaC1 level. Furthermore it is quite possible that significant 
evaporation may occur over this time, exacerbating this effect. In contrast, 
the cryoprobe technique allows the rapid collection of ASL under conditions 
that do not induce any stimulatory, morphological or functional alterations 
of the airways cells that produce ASL (Bacconias et al 1998). However, as a 
result of the extremely small volume of ASL sampled, this technique is 
heavily dependent upon the accurate assessment of the water content of ASL 
measured. The alternative approach involved the use of an in vitro model 
rather than making direct in vivo measurements of the ASL (McCray et al 
1999). This has the obvious caveat that the system used must be rigorously 
characterised to demonstrate its validity as a model of murine tracheal 
epithelium, but this was not performed, to the extent that the presence of 
CFTR was not demonstrated, either by RT -PCR or electrophsyiological 
analysis. This is obviously critical if Cftr mutation is evoked as a mechanism 
for determining the NaCl content of the ASL. 
In addition to the different conditions of sampling, the exact site of 
sampling within the trachea may be significant, depending upon the role of 
submucosal glands in determining the composition of the ASL. It has been 
suggested that the submucosal glands are the primary source of hypotonic 
ASL (Knowles et al 1997). Thus, failure of salt absorption in the submucosal 
glands could result in abnormal tonicity of the ASL. Whilst the submucosal 
glands in humans extend distally into the bronchi they are restricted to the 
proximal region of the trachea in wild -type mice (Borthwick et al 1999). 
Hence, the exact position of the collection of ASL with respect to the position 
of the submucosal glands may be important in determining the ionic content 
measured. Interestingly, a recent study has demonstrated that 
Cfbimitig" / Cftrtmmgu mice show a significant difference in submucosal gland 
distribution pattern, when compared with wild -type littermates, with glands 
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extending more distally in the trachea (Borthwick et al 1999). This distal 
expansion of the submucosal glands in conjunction with a failure of salt 
absorption, secondary to the CFTR defect, may contribute to the higher ionic 
concentration observed in ASL collected from Cftr`"'' "g" /Cftr` ?"' mice. 
Furthermore, significant variation in the submucosal gland distribution has 
been reported in different strains of mice, with C57B1 /6N mice observed to 
have a relative lack of submucosal glands, concentrated in the proximal 
trachea (Innes and Dorin 1999). This observation may also be relevant when 
comparing the results of the three studies summarised in Table 6.1 and again 
emphasises the importance of the background strain of mice used. In 
addition, it is worth noting that if the submucosal glands do indeed play a 
critical role, studies using primary culture models, which will not contain 
submucosal glands, would not be expected to display a difference in the 
composition of the ASL produced by CF and non -CF cells. 
Despite these considerable differences, all three studies indicate a 
hypotonic ASL, consistent with the predictions made by the "hypotonic/ 
defensin" theory. Although only one study demonstrated a significant 
difference in the NaC1 content of the ASL, differences in the methodology 
and the strain and specific mutations of the mice studied may explain the 
lack of consistency between these three studies. At the increased NaCl 
concentration estimated for ASL collected from Cftr` "I'" /Cftrt"''" mice in vivo, 
in comparison to non -CF littermates, impairment of the antibacterial activity 
of synthetic mBD -1 is observed. However, uncertainty about the relevant in 
vivo concentrations of mBD -1 and the effect of co- existing antimicrobial 
components of the ASL, preclude further extrapolation of the in vivo 
relevance of this observation. 
In conclusion, synthetic hBD -1 and mBD -1 peptides display broad 
spectrum, salt- sensitive, antibacterial activity in isolation, in vitro. The 
antibacterial profiles of these two peptides vary significantly with respect to 
anti- pseudomonal activity, but are otherwise very similar. This may 
contribute to species specific patterns of bacterial susceptibility secondary to 
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Cr lK dysfunction and the resistance of mouse models of CF to lung infection 
with P. aeruginosa. Raised NaC1 levels in the ASL of Cftr'"'' "g"/Cftr""` "R" mice 
may compromise the antibacterial activity of mBD -1 in vivo. On the basis of 
in vitro results, this dysfunction may contribute to the abnormal pulmonary 
responses observed in these mice in response to lung infection with S. 
aureus. Thus, it is possible that while the basic mechanisms underlying 
increased susceptibility to lung infection in CF may be conserved between 
mice and humans, the specific profile of bacterial susceptibility may not be. 
Although Cftr " "' "gu /Cftr " "' "gu mice may not necessarily demonstrate an identical 
bacterial infection profile to humans, the pulmonary response to the classical 
early stage CF- related lung pathogen S. aureus, may provide insights into the 
process of initiation of CF lung disease. 
The results of studies utilising synthetic ß- defensin peptides provide 
interesting results. However, analysis of other members of the ß- defensin 
gene families and other antimicrobial components of the ASL is required to 
provide a more complete understanding. In addition, analysis of the ASL in 
a well characterised air -interface primary culture model system and mouse 
models with targeted deletions of specific ß- defensins are required to 
confirm the results of these in vitro studies. 
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Chapter 7: A primary culture model of 
differentiated mouse tracheal epithelium 
7.1 Introduction 
The development of robust techniques for the primary culture of 
airway epithelial cells from a variety of species, including humans (Yamaya 
et al 1992), rats (Chang et al 1995, Clark et al 1995), dogs (Kondo et al 1991), 
guinea pigs (Adler et al 1990), rabbits (Liedtke et al 1988) and hamsters 
(Whitcutt et al 1988), has provided invaluable in vitro models for the study of 
airway physiology in health and disease. However, the development of 
successful techniques for the culture of mouse airway epithelial cells has 
remained elusive. The most successful published techniques result in the 
establishment of a relatively undifferentiated epithelium, with few, if any, 
ciliated cells (Clarke et al 1992b, Kumar et al 1997). The failure of such 
models to demonstrate appropriate differentiation of murine airway 
epithelium in culture suggests that these will not provide a functionally 
equivalent system for in vitro studies. 
Primary cultures of human airway epithelia, at an air /liquid 
interface, have recently been used to investigate the pathogenesis of lung 
disease in CF (Smith et al 1996, Matsui et al 1998, Zabner et al, 1998). This 
approach has permitted investigation of the characteristics of the ASL and 
suggested that it may play a key role in the development of the chronic 
infection and inflammation that characterise this disease (see Chapter 1, 
section 1.5.1). These models may lack functionally important components of 
the system that regulates the ASL in vivo, such as the submucosal glands (see 
Chapter 1, section 1.5.4). Nevertheless, they do provide a model system in 
which the ASL and airway epithelium are readily accessible for study and 
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manipulation and in which antimicrobial components of the ASL may be 
studied in relative isolation from other complicating influences. 
Despite the prominent role that mouse models of CF have played in 
recent research into this disorder, studies to parallel and further develop 
these critical observations have been hampered by the absence of an 
acceptable primary culture model for murine airway epithelial cells. 
In order to address this situation, a technique was developed for the 
primary culture of differentiated murine tracheal epithelium, grown at an 
air -liquid interface. 
7.2 Establishment of a primary culture model 
A technique for the isolation and primary culture of murine tracheal 
epithelial cells was developed by making a series of adaptations to the 
methods employed in the laboratory of Professor M. J. Welsh, in Iowa, for the 
culture of human airway epithelium. These adaptations included; a) 
optimisation of number of murine tracheae to be processed per tissue culture 
insert and the age of mice used, b) establishment of the portion of the murine 
trachea required to provide subsequent differentiation in culture, c) 
alteration of the conditions for epithelial cell isolation, from overnight at 4 °C 
to one hour at 37 °C, followed by gentle agitation, d) a change in the type of 
tissue culture insert and membrane material used, and e) an increase in the 
period of submerged culture, in Culture Media, from 48 to 72 hours before 
transfer to air /liquid interface and USG Media. This work was carried out 
with technical assistance from Fiona Kilanowski. 
The resultant technique is described in detail in the Material and 
Methods section (see Chapter 2, section 2.10). Briefly, murine tracheae were 
dissected by incision immediately proximal to the thyroid cartilage and at 
the level of the bifurcation of the bronchi. A short enzymatic dissociation of 
265 
pooled tracheae was performed at 37 °C and approximately 2 x 105 cells were 
generated per trachea, with cell viability of - 95% as assessed by trypan blue 
dye exclusion. Isolated cells were seeded at high density on collagen- coated 
semi- permeable membranes, using the dissociated cells from two tracheae (- 
4 x 105 cells) per insert. Following 72 hours of submerged culture, the apical 
media, along with any non -adherent cells and debris, was removed to create 
an air /liquid interface at the apical surface of the cells. Phase contrast light 
microscopy demonstrated that these epithelial cultures had a smooth, 
"cobblestone" appearance. Consistent with this finding, high transepithelial 
resistance (Re) values indicated confluency, with the formation of tight 
junctions, from day 4 onwards. During the second week of culture the 
development of beating cilia was observed with the gradual appearance of 
scattered foci of "cell stacking" noted over the next few weeks. 
Further morphological studies were performed using scanning and 
transmission electron microscopy, histochemistry and 
immunohistochemistry. Additional characterisation was performed using 
RT -PCR to analyse gene expression and Ussing chamber experiments to 
study the electrophysiological profile of the primary cultures. 
7.3 Electron Microscopic analysis 
Scanning electron microscopy (SEM) was performed on primary 
cultures of murine tracheal epithelia on days 4, 8,14 and 28 after seeding (n >_ 
2 at each time point) and tracheal specimens from five week old animals 
(n =2) (Figure 7.1). See Materials and Methods (Chapter 2, section 2.10.4). 
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FIGURE 7.1 Scanning electron microscopy of murine trachea and 
primary cultures 
Scanning electron micrographs of a) a 5 week old mouse trachea, and 
primary cultures of murine tracheal epithelia at day 4 (b), day 8 (c) and day 
28 (d). Cilia are indicated (black arrow). 
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At day 4 a flattened epithelium was observed (Figure 7.1b), with no 
features of differentiated cells. This was characteristic of early stage primary 
culture models using other species and is described for cultured rat tracheal 
epithelial cells. These cells lose their cilia and secretory granules to become 
morphologically indistinct, poorly differentiated cells (PDC) over the first 48 
hours (Chang et al 1995, Clark et al 1995). In these rat models only a small 
proportion of ciliated cells attached to the semi- permeable support 
membrane. These cells lost their cilia but were not observed to proliferate in 
culture (Chang et al 1995). The other cell types were observed to 
dedifferentiate into PDC cells and proliferate prior to the reappearance of 
differentiated cell types (Chang et al 1995, Clark et al 1995). Both basal and 
non -ciliated columnar cells appear to have clonogenic ability and broad 
differentiation potential (Randell et al 1991, Liu et al 1994). It seems likely 
that in our model, the mouse tracheal epithelial cells at day 4 also represent a 
population of undifferentiated cells. 
Basic morphometric analysis was performed after 
immunohistiochemical staining with anti- Proliferating Cell Nuclear Antigen 
(PCNA) antibodies (see Figure 7.2). No positive staining was observed in the 
epithelial cells on sections of murine trachea. However, anti-PCNA 
antibodies detected 78% (± 9) of the cells in primary cultures of murine 
tracheal epithelia at day 4 after seeding. This suggests that the majority of 
cells attaching to the support membrane undergo proliferation in the first 
few days. The proportion of positive staining cells was observed to decrease 
with increasing culture age, reduced to only 25% (± 8) by day 28. These 
results suggest that, as in rat culture models, the majority of cells underwent 
dedifferentiation and proliferation, rather than the proliferation of a small 
subset of stem cells. Furthermore, the level of proliferation decreases as the 
degree of differentiation is observed to increase. 
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FIGURE 7.2 PCNA immunohistochemistry of murine trachea and 
primary cultures 
Fluorescent immunohistochemical characterisation of a mouse 
tracheal section (a) or primary cultures of murine tracheal epithelia at day 4 
(b, c) or day 28 (d, e), with PCNA antibody. Positive FITC signal is 
represented in green, with DAPI nuclear stain in blue. Epithelium (E) and 
submucosal glands (S) are indicated. 
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No ciliated cells were observed by SEM after 4 days of culture (Figure 
7.1b). However, morphometric analyses at day 8 and day 14 revealed 16 (± 
3) and 15 (± 4) ciliated cells respectively, per 100 cells counted (Figure 7.1c). 
By day 28 the proportion of ciliated cells in culture was estimated to be 34% 
(± 9) (Figure 7.1d). This is consistent with a previous quantitative study of 
murine tracheal epithelium, in which the proportion of ciliated cells in the 
epithelium was observed to be about 38% (Pack et al 1980). In addition, a 
similar proportion of ciliated cells (33% ± 5) was estimated by SEM analysis 
of murine tracheal specimens (Figure 7.1a). The non -ciliated cells were 
observed to be flatter and broader in culture in comparison to the domed 
appearance seen in the murine tracheal specimen (Figure 7.1a and d). These 
cells are assumed to be Clara cells, the predominant cell type in murine 
airway epithelium (Pack et al 1980). 
Transmission electron microscopy (TEM) was performed to provide 
additional information about the ultrastructure of the primary cultures and 
the cell types present. Primary cultures of murine tracheal epithelia were 
processed on day 19 (n = 4) (Figures 7.3b and 7.4), by which time 
differentiation was evident on SEM analyses. A tracheal specimen from a 
five week old mouse was also processed (Figure 7.4), for comparison with 
published studies (Pack et al 1980). The preparation of TEM specimens was 
performed by John Findlay at King's Buildings, University of Edinburgh. 
A confluent, polarised epithelium was observed in primary cultures of 
murine tracheal epithelium. The cultured cells were observed to be broader 
and shorter than native murine tracheal epithelial cells, closer to cuboidal 
than columnar in shape. This observation is consistent with studies of the 
primary culture model of guinea pig tracheal epithelium (Adler et al 1990). 
The murine epithelial cultures were comprised predominantly of a single 
layer of ciliated and non -ciliated cells of cuboidal morphology (Figures 7.3b 
and 7.4a) with apical microvilli of varying proportions. Both short, immature 
cilia and long mature cilia were noted, with cytoplasmic basal bodies and 
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FIGURE 7.3 Transmission electron microscopy of murine trachea and 
primary cultures 1 
Transmission electron micrographs of a) a 5 week old mouse trachea and b) 
primary cultures of murine tracheal epithelia at day 19. Sections through 
cilia, identified at the apical surface of the cells by electron dense basal 
bodies, are indicated (black arrow), interspersed with microvilli. 
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FIGURE 7.4 Transmission electron microscopy of murine trachea and 
primary cultures 2 
Transmission electron micrographs of primary cultures of murine 
tracheal epithelia at day 19, demonstrating a) a layer of cuboidal epithelial 
cells, b) an apical junctional complex and basolateral interdigitations and c) a 
flattened "basal -like" cell underlying non -ciliated epithelial cells. Microvilli and 
several cilia (black arrow), a desmosome at the apical junction between two 
epithelial cells (white arrow) and lateral interdigitations between the 
basolateral membranes (large black arrowheads) are indicated. 
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the basolateral cell membrane were observed at the boundaries between the 
cells (Figure 7.4b). These have previously been shown to correlate with 
improved cellular differentiation and ion transport properties in human 
airway cultures (Yamaya et al 1992). Many apical junctional complexes, 
containing tight junctions and desmosomes were noted (Figure 7.4b). Larger, 
flattened cells, with a more squamous morphology, were also observed 
underlying this cuboidal epithelium. These cells had large oval nuclei, a 
high nucleus to cytoplasm ratio and long projections (lamellipodiae) that 
extended over the surface of the insert and provided multiple points of 
attachment beneath the other cells (Figure 7.4c). These cells may represent 
basal cells within this model system. The tall columnar epithelial cells seen 
in native mouse trachea (Figure 7.3a) were not observed in culture. 
However, the morphology described above is similar to that observed in 11 
day old rat tracheal primary cultures (Kaartinen et al 1993), which later 
develop a morphology that more closely resembles native rat tracheal 
epithelium. No goblet cells were observed in the primary cultures by TEM. 
Thus, electron microscopic analysis of primary cultures of murine 
tracheal epithelia demonstrates the presence of ciliated and non -ciliated cells, 
in similar proportions to native epithelia, and putative basal cells. However, 
the ultrastructure of these cultured cells remains significantly altered from 
native murine tracheal epithelial cells. As such, important differences in the 
differentiated state and function of these cells cannot be excluded. 
7.4 Histochemical characterisation 
Analysis of primary cultures of murine tracheal epithelium by TEM did 
not demonstrate the presence of any secretory cells. However, this form 
of analysis was not suited to examining large numbers of cells. 
Thus, histochemical analysis was performed on segments of cultured 
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FIGURE 7.5 Periodic Acid -Schiff's stain of primary cultures of murine 
tracheal epithelia 
Histochemical characterisation of primary cultures of murine tracheal 
epithelia using a Periodic Acid - Schiffs stain. a) Bright field light 
micrograph with haematoxylin counter stain, b) phase contrast micrograph, 
without counterstain. Magenta staining, PAS positive cells are indicated 
(black arrow). 
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epithelia on semi- permeable membranes. A Periodic Acid - Schiff's (PAS) 
stain was performed at day 4, 8, 14 and 28 after seeding (n >_ 4 at each time 
point). This stain revealed occasional PAS positive, magenta stained cells, 
suggesting the presence of mucus producing goblet cells (Figure 7.5). These 
cells were not always present and were variable in number, with no pattern 
observed on the basis of culture age. The reason for this irregularity is not 
clear. Given the scarcity of these cells in the primary cultures it is perhaps 
not surprising that they were not detected by TEM. This minimal presence 
of goblet cells reflects their paucity in the native tracheal epithelium of 
healthy mice (Pack et al 1980). 
7.5 Immunohistochemical characterisation 
To characterise the cell types that constituted the primary cultures of 
murine tracheal epithelia, immunohistochemical analysis was performed at 
days 4, 8,14 and 28 (n >_ 3 for each antibody at each time point), using a panel 
of antibodies, and compared to murine tracheal sections (n >_ 3 specimens for 
each antibody) (Figures 7.6 and 7.7). Morphometric analyses were 
performed as described in Materials and Methods (see Chapter 2, section 
2.10.6). 
The density of cells in primary cultures of murine airway epithelium 
was observed to undergo a 2 -3 fold increase between day 4 and day 28. The 
average number of cells estimated per field of view at day 4, 8, 14 and 28 
were 51 (± 11), 112 (± 17), 123(± 26) and 150 (± 30) respectively. Thus, 
proliferation of the cells within the primary cultures is greatest at the earlier 
stages, in keeping with the observations using anti-PCNA antibodies (see 
section 7.3). 
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Tracheal section Day 4 Day 28 
FIGURE 7.6 Immunohistochemical characterisation of murine trachea 
and primary cultures 1 
Fluorescent immunohistochemical characterisation of mouse tracheal 
sections (a, d, g) or primary cultures of murine tracheal epithelia at day 4 (b, 
e, h) or day 28 (c, f, i), with anti -human pan cytokeratin antibody (a, b, c), no 
primary antibody (negative control) (d, e, f), or anti -mouse cytokeratin 18 
antibody (g, h, i). Positive FITC signal is represented in green with DAPI 
nuclear stain in blue. Epithelium (E) and submucosal glands (S) are 
indicated. 
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Tracheal sections Day 4 Day 28 
FIGURE 7.7 Immunohistochemical characterisation of murine trachea 
and primary cultures 2 
Fluorescent immunohistochemical characterisation of mouse tracheal 
sections (a, d, g) or primary cultures of murine tracheal epithelia at day 4 (b, 
e, h) or day 28 (c, f, i), with anti -mouse cytokeratin 14 antibody (a, b, c), anti- 
human a- smooth muscle actin antibody (d, e, f) or anti -human vimentin 
antibody (g, h, i). Positive FITC signal is represented in green with DAPI 
nuclear stain in blue. Epithelium (E), submucosal glands (S), smooth muscle 
(SM) and lamina propria (LP) are indicated. 
277 
Epithelial cells were characterised using antibodies raised against 
different cytokeratins, a family of intermediate filaments involved in the 
cytoskeleton of epithelial cells. The expression profile of these cytokeratins is 
variable and dependent upon epithelial cell subtype and the stage of 
differentiation (reviewed in Fuchs et al 1987). However, these expression 
patterns can be altered in wound healing, influenced by extracellular factors 
and affected by cell culture (reviewed in Guin et al 1987). Antibodies raised 
against a- smooth muscle actin (expressed in smooth muscle cells) and 
vimentin (expressed in cells of mesenchymal origin) were used to establish 
the contribution of non -epithelial cells to the primary cultures of murine 
tracheal epithelia. 
The anti-human pan cytokeratin antibody (raised against cytokeratins 
1, 4, 5, 6, 8,10,13,18 and 19) detected all the cells of the tracheal epithelia and 
submucosal gland epithelia in sections of mouse trachea (Figure 7.6a). This 
antibody was used to demonstrate the epithelial nature of the confluent 
primary cultures, with all the culture cells apparently detected, at all time 
points (Figure 7.6b and c). Some variation in the intensity of staining was 
observed in different cells within the same cultures. Small patches of 
intensely stained cells, on a focal plane above the majority of the cells, were 
observed with greater frequency in the older cultures. 
Subtypes of epithelial cells were demonstrated in mouse tracheal 
sections using antibodies raised against the murine homologues of human 
cytokeratins 18 (Figure 7.6g, h and i) and 14 (Figure 7.7a, b and c). 
Cytokeratin 18 was detected in the ciliated and non -ciliated columnar 
cells in the tracheal epithelia and acinar epithelial cells in the submucosal 
glands in sections of mouse trachea (Figure 7.6g). The anti -cytokeratin 18 
antibody detected 91% (± 4) of the cells in primary cultures at day 4. 
Estimation of the proportion of cytokeratin 18 positive cells in primary 
cultures at later time points was complicated by the increased cell density 
and high proportion of positive staining cells. However, no gross alteration 
was observed. A range of intensities of positive signal was observed in 
278 
different cell within the same culture at all time points (Figure 7.6h and i). 
These cells were observed to have a largely confluent "cobblestone" 
appearance similar to the staining apparent with the anti-pan cytokeratin 
antibody, although "gaps ", representing unstained cells, were observed. 
No significant alteration was seen in the staining pattern of 
cytokeratin 18 positive cells during the poorly differentiated stage, or at the 
time of cellular differentiation to produce ciliated cells. This was in contrast 
to the tracheal xenograft model of rat airway epithelium. This model system 
involves re- population of a denuded rat tracheal graft with isolated rat 
epithelial cells (Shimizu et al 1992) and closely parallels rat tracheal cell 
primary culture on coated support membranes. In xenografts, the PDC cells 
initially maintain their original cytokeratin 18 and 14 expression patterns 
when other markers of differentiated cell type are lost. However, at day 3, 
regardless of their original profile, all PDC cells express cytokeratin 14, but 
not cytokeratin 18 (Liu et al 1994). The expression of cytokeratin 18 is not 
restored until the second week, coincident with the first evidence of ciliary 
and secretory differentiation of columnar cells (Shimizu et al 1992). The 
mouse tracheal cells in our culture system did not show such dramatic 
dedifferentiation in the process of establishing a model epithelium. The 
reason for this difference is unclear. 
Cytokeratin 14 was detected in the myoepithelial cells and cuboidal 
epithelial cells of the proximal duct of the submucosal glands, and in less 
than 5% of basal cells in the tracheal epithelium, with an irregular 
distribution pattern, in murine tracheal sections (Figure 7.7a). In primary 
cultures the anti -cytokeratin 14 antibody detected 24% ( ±8) of cells at day 4. 
The proportion of cytokeratin 14 positive cells remained constant, with 23% 
( ±8), 23% ( ±10) and 23% ( ±7) estimated at day 8, 14 and 28 respectively. 
These cells were observed to have a fairly scattered distribution with less 
contact between positive staining cells than the cytokeratin 18 positive cells 
(Figure 7.7b and c). They were observed to have an irregular shape with fine 
cytoplasmic protrusions and to lie in a focal plane below the majority of the 
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epithelial cells. It is possible that these represent the flat, underlying, "basal - 
like" cells observed by TEM. Although basal cells only constitute 5 -10% of 
the native murine tracheal epithelium (Pack et al 1980), an enrichment of 
basal cells may have occurred if only a small proportion of ciliated cells were 
able to attach to the support membrane, as observed in the rat culture model 
(Chang et al 1995). 
The origin of these cytokeratin 14 positive cells remains unclear. The 
great majority of the cells detected by the anti -cytokeratin 14 antibody in 
mouse tracheal sections were, in fact, of submucosal gland origin, both 
myoepithelial and ductal cells. However, immunohistochemical analysis of 
tracheal "husks" remaining after the dissociation of cells for culture, 
demonstrated disruption, but minimal dissociation, of submucosal gland 
cells as a result of this procedure. Thus, it is unlikely that a large proportion 
of the cultured cells originate from the submucosal glands. Nonetheless, it is 
worth noting that in preliminary studies, removal of the most proximal 
portion of the tracheae (to which the thyroid gland is adherent) before 
epithelial cell dissociation resulted in a failure to differentiate and produce 
ciliated cells in culture, despite the standard number of cells being seeded. 
This suggests that cells from the proximal trachea (the main site of murine 
submucosal glands (Borthwick et al 1999)) are important in the development 
of a fully differentiated primary culture of murine tracheal epithelium. 
Furthermore, recent studies have demonstrated that the ciliated duct of 
murine submucosal glands may be a specific niche for airway stem cells 
(Borthwick et al 1998). 
The studies using these anti -cytokeratin antibodies demonstrate the 
existence of distinct subgroups of epithelial cells within the primary cultures. 
However, the alteration of cytokeratin expression patterns in epithelial cells 
under culture conditions necessitates caution in making direct comparison 
between the expression profiles of specific cell subtypes in native tracheal 
epithelium and those in the primary cultures of murine tracheal epithelia on 
the basis of these results. In addition, it is clear from the estimates of cells 
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staining positive for cytokeratin 14 and cytokeratin 18 that either some cells 
exhibit dual staining or cytokeratin 18 negative cells were obscured for the 
purposes of morphometric analysis, perhaps underlying positive staining 
cells. Thus the main conclusion must be that these primary cultures of 
murine tracheal epithelium are indeed primarily epithelial in nature and that 
different subtypes of epithelial cells exist. These subtypes may represent 
columnar and basal cell groups. 
The anti-human a- smooth muscle actin antibody was shown to detect 
smooth muscle, but not epithelial cells, in mouse tracheal sections (Figure 
7.7d). In day 4 primary cultures of murine tracheal epithelia this antibody 
demonstrated the presence of a variable number (< 1% of cells) of scattered, 
individual, positive staining cells (Figure 7.7e). These cells were observed to 
lie in a focal plane below the majority of cultured cells. These a- smooth 
muscle actin positive cells were observed to proliferate gradually, with larger 
clumps of cells detected by day 28 (Figure 7.7f), suggesting outgrowth from 
the single cells contaminating the original cell preparation. The proportion 
of these contaminating cells was variable and largely dependent upon the 
length of the dissociation step and the vigour with which tracheal 
suspensions were agitated. Primary cultures prepared from dissociated cell 
suspensions with large numbers of contaminating cells progressively 
developed lower Rt and lost ability to maintain an air /liquid interface. This 
suggests that growth of these cells may eventually disrupt and "puncture" 
the confluent epithelial membrane when initial contamination is excessive. 
The anti-human vimentin antibody detected connective tissue cells of 
the lamina propria in mouse tracheal sections, but also a slight punctate 
background staining of the epithelial cells (Figure 7.7g). Immunostaining of 
primary cultures demonstrated the same slight background staining 
throughout, but no evidence of genuine positive signal at any time point 
(Figure 7.7h and i). This indicated that there was no contamination with 
vimentin positive cell types in the primary cultures. 
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These results provide confirmation of the almost exclusively epithelial 
nature of these primary cultures of murine tracheal epithelium. 
No positive staining was observed in negative controls, treated in an 
identical manner to the other samples but omitting the primary antibodies 
(Figure 7.6d, e and f). 
7.6 Gene Expression 
Recent investigations of the pathogenesis of CF lung disease have 
focused on the characteristics of the ASL and its role in mucociliary 
clearance and the innate lung defences, as previously discussed. The 
analysis of ASL in vivo has proven to be extremely difficult technically 
and has produced conflicting results (see Chapter 1, section 1.5.1.3). 
Consequently, key studies addressing the ionic composition and 
antibacterial activity of the ASL have been performed in primary cultures 
of human airway epithelia. To maximise the opportunities presented by 
the availability of mouse models of CF, it has been critical to develop a 
primary culture model for murine airway epithelial cells. However, in 
addition to demonstrating morphological equivalence between this 
model system and native murine trachea, it is critical that the cultured 
epithelial cells should express Cftr and murine ß- defensins. 
Primary cultures of murine tracheal epithelia at day 12 -13 (n >_ 3 
for each condition described) were characterised, using RT -PCR, to 
establish the expression of Cftr, Defb-1 and Def b -2, as described in 
Materials and Methods (Chapter 2, sections 2.10.7 to 2.10.11). Defb -2 
expression is upregulated in response to pro -inflammatory stimuli in vivo 
(Morrison et al 1999), hence these studies were performed using cultures 
both with and without exposure to either E. Coli LPS or P. aeruginosa CF 
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FIGURE 7.8 RT -PCR analysis of murine tracheal primary cultures 
RT -PCR of a) Hprt, Cftr and Defb -1, and b) Hprt and Defb -2, from 
primary cultures of murine tracheal epithelia. Cultures were utilised after 30 
minutes exposure to either LPS or P. aeruginosa, in PBS. Untreated 
cultures were exposed to PBS alone. Amplified products were analysed on a 
2% agarose gel, with a 4)X147Haelll marker, amplified plasmid positive 
controls and negative controls, using either heat -inactivated reverse 
transcriptase ( -RT) or distilled water substituted for RNA during cDNA 
synthesis. Defb -2 PCR products were observed only after hybridisation to a 
Defb -2 internal probe. 
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alone. Parallel amplification of the murine hypoxanthine 
phosphoribosyltransferase gene (Hprt) was performed as a control 
(Figure 7.8). These studies demonstrated that the expression pattern of 
these genes in the cultured cells replicated the in vivo situation (Morrison 
et al 1997, Morrison et al 1999). Cftr and Defb -1 were both constitutively 
expressed (Figure 7.8a) whereas Defb2 was induced by exposure to pro - 
inflammatory stimuli (Figure 7.8b). Defb2 expression was not observed 
without prior stimulation (n = 3), but was repeatedly observed in 
response to LPS exposure (n = 4). As in vivo, the level of expression of 
Defb2 after induction was too low to be observed on a stained agarose gel 
after 34 cycles of PCR. However, it was observed after hybridisation with 
an internal oligonucleotide. 
7.7 Electrophysiological characterisation 
To assess the confluency of primary cultures of murine tracheal 
epithelia, Rt was monitored at days 4, 8, 14 and 28. Table 7.1 shows that the 
maximum value of R, (28.4 kS2 cm-2), was measured on day 4, immediately 
following the establishment of an air / liquid interface. Subsequently, Rt 
values decreased to -12 kS2 cm-2 by day 14, after which they remained stable 
at about this value (Table 7.1). These values of Rt are markedly higher than 
those reported for cultures of airway epithelia from other species including 
human (200 -3000 Q cm-2 (Yamaya et al 1992)) and dog tracheal epithelia (200- 
400 Q cm-2 (Kondo et al 1991)). They also greatly exceed those reported for 
poorly differentiated primary cultures of murine tracheal epithelia (- 400 Q 
cm 2 (Clarke et al 1992b)). Interestingly, primary cultures of murine tracheal 
epithelia that failed to achieve elevated values of Rt were able to maintain an 
air /liquid interface, but did not develop ciliated epithelial cells. 
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In contrast to the primary cultures of murine tracheal epithelia, 
confluent Human Bronchial Epithelial (HBE) cell lines, cultured on identical 
collagen coated membranes, failed to maintain an air -liquid interface and 
demonstrated a mean Rt value of 525 ± 81 S2 cm-2 (n = 6), stable from day 7 
after seeding onwards. 
Time (days) Rt (kS2 cm -2) n 
Day 4 28.4 ± 7.6 40 
Day 8 20.3 ± 4.5 31 
Day 14 11.6 ±3.6 21 
Day28 12.1 ±5.1 16 
TABLE 7.1 Transepithelial resistance (Rt) of primary cultures of 
murine tracheal epithelium 
Values are means ± SD; n, total number of cultures tested. 
To investigate the epithelial ion transport properties of primary 
cultures of murine tracheal epithelia, day 28 primary cultures were mounted 
in modified Ussing chambers and 1 and Rt were recorded. Under baseline 
conditions, Rt was 14.3 ± 1.7 kS2 cm-2 (n = 6) and Isc was 12.9 ± 1.0 pA cm-2 (n = 
6). Figure 7.9 demonstrates that the addition of amiloride (10 RM) to the 
apical solution inhibited ISM (P < 0.001). Subsequent addition of cAMP 
agonists (10 pM forskolin, 100 pM IBMX and 500 pM CPT -cAMP) stimulated 
I (P < 0.001; Figure 7.9). Finally, addition of bumetanide (100 µM) to the 
basolateral solution inhibited Ix (P < 0.001; Figure 7.9). These data are 
consistent with studies of native murine epithelia (Smith et al 1992). The 
results suggest the presence of amiloride- sensitive sodium channels and 
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FIGURE 7.9 Ussing chamber analysis of primary cultures of murine 
tracheal epithelia 
'Sc measurements in primary cultures of murine tracheal epithelia, a) 
representative recording of /sc. Amiloride (10 pM), cAMP agonists (10 µM 
forskolin, 100 µM IBMX and 500 p.M CPT -cAMP) and bumetanide (100 µM) 
were added as indicated at time points 1, 2 and 3 respectively. b) magnitude 
of changes in 'Sc (t /sc) stimulated by amiloride, cAMP agonists and 
bumetanide. A /sc was calculated as current measured at the peak of the 
response (- 2 minutes after the addition of amiloride or cAMP agonists and 
-7 minutes after the addition of bumetanide) minus current immediately 
before agonist addition. Values are mean ± SD (n = 6). Asterisks indicate a 
significant change in Ise in response to treatment (p < 0.001). 
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necessary to confirm these conclusions, in particular to exclude the 
possibility that the response to forskolin was mediated by Cae +- dependent Cl- 
channels. 
Thus, primary cultures established from the tracheae of mouse models 
of CF, lacking functional CFTR, would be expected to demonstrate the 
consequences of this channel dysfunction and any resultant abnormalities in 
the ionic composition and antibacterial activity of the ASL. This will enable 
complementary in vitro studies to be performed using cultured tracheae from 
mouse models of CF to investigate the role of ASL and its antibacterial 
components in the development of CF lung disease. 
7.8 Discussion 
This chapter describes the establishment and characterisation of a 
novel primary culture model of differentiated murine tracheal epithelium. 
This technique facilitates the formation of confluent, polarised epithelial 
cultures with a high transepithelial resistance, minimal contamination with 
non -epithelial cell types, differentiation to produce ciliated cells and small 
numbers of goblet cells, expression of Cftr and mouse ß- defensin genes and 
an electrophysiological profile consistent with the presence of amiloride- 
sensitive sodium channels and cAMP -stimulated CI- R chloride channels. 
Thus, this model demonstrates important features of native murine tracheal 
epithelia, particularly with respect to the study of mouse models of CF. 
Further characterisation is required to rigorously demonstrate the 
equivalence of this model and native murine tracheal epithelium. Such 
studies include a) an extension of TEM investigations to provide quantitation 
and analysis at later time points, b) further studies of the secretory cell 
population observed and the factors regulating their presence and quantity, 
c) additional gene expression studies to establish the expression of the 
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recently described murine ß- defensin genes; mBD -3 (Bals et al 1999) and 
mBD -4 (Jia et al 1999), and other components of the innate lung defence 
system, such as lysozyme, and d) further electrophysiological studies to 
confirm the ion channel basis for the observations presented above and 
examine the role of Cat + -dependent Cr channels. In addition, the 
exceptionally high transepithelial resistances displayed by the primary 
cultures of murine tracheal epithelia, in comparison to native murine tracheal 
epithelia, must be considered in any studies of the ASL. 
Despite these reservations, this primary culture system facilitates 
novel approaches for the study of lung disease in mouse models of CF. 
Primary cultures of tracheal epithelium from mouse models of CF should 
now be established and characterised in the manor described above for wild 
type animals. Such cultures can then be compared to those prepared from 
non -CF littermates in a series of studies to evaluate the consequences CN'l'K 
dysfunction in the relative isolation of this model system. These 
investigations should be designed to complement in vivo studies using 
mouse models of CF and studies performed with human airway primary 
cultures. In the former scenario, the absence of many of the "complicating 
factors" present in vivo should facilitate these investigations. However, the 
possible importance of these factors should not be forgotten. Such studies 
should include; a) the analysis of the ionic composition and volume control 
dynamics of murine ASL, b) the antibacterial properties of murine ASL and 
the key components of this response, particularly in 3- defensin knockout 
mice, c) further studies on the internalisation of P. aeruginosa, in a system 
only incorporating epithelial cells, and d) investigation of the adherence of 
CF related pathogens to murine airway epithelial cells, both established and 
regenerating. In the latter case experimental design should a) take advantage 
of the opportunities afforded by inbred strains of mice (see Chapter 1, section 
1.7.4) to study genetic modifiers, b) establish data that confirms or refutes the 
results of human studies and further investigate the key similarities and 
differences between mice and humans. 
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In addition to the study of CF, this model system may be valuable in 
the study of the growth and differentiation dynamics of mouse tracheal 
epithelium, the pathophysiology of other airway diseases for which mouse 
models exist and the evaluation of novel therapies. 
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Chapter 8: Summary and Future Prospects 
The studies described in this thesis characterise an abnormal lung 
phenotype in Cftrt"''Hg" /Cftrt' "'Hg" mice in response to aerosolised Staphylococcus 
aureus and assess the factors contributing to the variability of this phenotype. 
The contributions of bacterial internalisation and the dysfunction of (3- 
defensins to lung disease in mouse models of CF are examined and the 
establishment and characterisation of a primary culture model of 
differentiated murine tracheal epithelium is described. 
Techniques for the delivery of bacteria to the lungs of experimental 
mice were developed, optimised and quantified. Bacterial nebulisation 
chambers were designed and characterised. This technique demonstrated 
moderate dose, reproducible, easily repeatable, minimally invasive delivery, 
throughout the airways and lung parenchyma. The technique was 
subsequently used to characterise the response of mouse models of CF to 
aerosolised bacteria. Tracheal intubation and direct intratracheal instillation 
techniques were optimised and characterised, demonstrating reproducible 
high dose delivery. This technique was subsequently utilised in the 
assessment of bacterial internalisation by epithelial cells. 
Previous studies had demonstrated that Cftrt "'Hg" /Cftrt'g" mice, on a 
mixed outbred MF1 / 129 background strain, were impaired in their ability to 
clear aerosolised S. aureus from their lungs and developed more severe, 
pathogen specific, lung pathology in response to aerosolised CF related lung 
pathogens, than non -CF littermates. Studies were performed to examine the 
sources of variation in this lung phenotype following repeated exposure to 
aerosolised S. aureus. Cftrt"''Hg " /Cftrt "'' mice and Cftrt"'' "g" /Cftrti°" "` mice, 
backcrossed onto a C57B1 /6N background were observed to develop lung 
pathology in response to repeated exposure to aerosolised S. aureus. The 
characteristics of this pathology were similar to that observed in the outbred 
mice. Moreover, as observed in studies using the outbred mice, significantly 
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more severe pathology was observed in mouse models of CF in comparison 
to non -CF littermate controls. The spectrum of disease in response to 
bacterial exposure was narrowed in the C57B1 /6N mice, in comparison to the 
mixed, outbred background strain. However, the predominant effect 
appeared to be an increased severity of disease in the inbred wild type mice, 
suggesting increased predisposition to lung disease in this background 
strain. No difference was observed between the severity of disease observed 
in Cftrtm]Hgu /Cftrt "' "' "` compound heterozygote mice in comparison to 
Cftrt"''"gu/Cftrt"''"g" mice on the same inbred background, despite an expected 
decrease of - 50% in the background level of normal Cftr expression. This 
observation suggests that an abnormal pulmonary phenotype may be 
manifest when the level of functional CFTR falls below a minimum threshold 
level, but will not be exacerbated by further decreases. Although more 
severe lung pathology was evident in mice repeatedly exposed to bacteria 
than control mice, regardless of genotype, variable levels of background lung 
disease were observed. Thus the phenotype variability observed in outbred 
mice was concluded to be related primarily to independently segregating 
genes in the outbred strain and variation in the degree of pre- existing lung 
pathology in the mice. Differences between individual Cftrt"''"gu/Cftrt"°"gu mice 
in the level of residual CFTR function are less likely to have had a significant 
effect. The future use of congenic mice (including C57B1 /6N, BALB /c and 
FVB) born and raised in SPF facilities should enhance the prospects of more 
clearly defined lung phenotypes in Cftrt "''/Cftrt "'' "gu mice. This may be 
particularly true of mice congenic for the Cftrt"''"gu mutation on a BALB /c 
background, a strain demonstrated to be less susceptible to lung infection 
and to have more significant levels of CN" IR activity in the trachea, as 
assessed by electrophysiology. Such phenotypes may be used as 
pathophysiological endpoints for the testing of novel therapies and for the 
isolation of genetic modifiers. Further studies might also include analysis of 
the BALF levels of IL -10, MIP -2 and KC in infected mice, the effect of 
malnourishment on the susceptibility of Cftrt "'"gu /Cftrtr° "gu mice to lung 
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infection, the use of other mouse models of CF, such as the OF508, G551D 
and G480C models and the use of an alginate bead model as a more 
acceptable alternative to the use of agar beads. The future availability of 
gene expression array technologies may also prove illuminating in studying 
the basis for the differences observed in the pulmonary response to bacterial 
exposure between mouse models of CF and non -CF littermates. 
Histopathological assessment of the lungs of mice repeatedly exposed 
to S. aureus revealed a significant difference between the mouse models of CF 
and non -CF controls. This was consistently demonstrated when assessment 
was performed using the total score, but not for the scores assigned to the 
five features from which it was comprised. Thus, the total score assigned for 
severity of pathology was more closely correlated with genotype than any 
individual component part of that score. This suggests an exaggerated 
normal response in these mice, rather than abnormality in any one aspect of 
this response. This would be compatible with a general impairment of the 
antimicrobial properties of the murine tracheal ASL, a mucociliary clearance 
defect or any other mechanism that would have resulted in the prolonged 
presence of bacteria in the lungs of mouse models of CF. To further dissect 
the mechanisms underlying the pathogenesis of the lung pathology 
observed, alternative approaches were adopted, examining specific 
hypotheses for the development of CF lung disease. 
The internalisation of P. aeruginosa by epithelial cells has been 
proposed as a CF 1R- dependent component of the lung defence system. A 
gentamicin exclusion assay was adapted and optimised to assess the 
internalisation of bacteria by adult mouse lung cells. Preliminary studies, in 
adult Cftr`"'' "' " /Cftr`ml "R" mice and non -CF controls, demonstrated 
internalisation of a non -mucoid clinical strain of P. aeruginosa, but did not 
support a role for CF l'K in this process. Further studies are required to 
visualise the cellular compartment responsible for the bacterial 
internalisation observed in vivo, to determine whether these observations 
extend to other mouse models of CF (including mice carrying the G551D and 
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ÁF508 mutations in Cftr) and to determine the effect of different background 
strains. These studies illustrate the potential value of mouse models of CF in 
evaluating the in vivo significance of hypotheses borne from studies 
performed in transformed cell lines. 
The role of the ASL in the pathogenesis of CF lung disease remains the 
subject of considerable controversy. Impairment of the salt- sensitive 
antimicrobial activity of (3- defensins in ASL with a raised concentration of 
NaC1, secondary to CFTR dysfunction, has been proposed to explain the 
development of CF lung disease. The antibacterial profiles of synthetic ß- 
defensins peptides were studied, representing the products of homologous 
human and murine f3- defensin genes. Synthetic hBD -1 and mBD -1 peptides 
displayed broad spectrum, salt- sensitive, antibacterial activity in isolation, in 
vitro. The antibacterial profiles of these two peptides were demonstrated to 
vary significantly with respect to anti- pseudomonal activity, but were 
otherwise very similar. This may contribute to species specific patterns of 
bacterial susceptibility secondary to CFTR dysfunction and the resistance of 
mouse models of CF to lung infection with P. aeruginosa. Raised NaC1 levels 
in the ASL of Cftr' ii11 /Cftr1111 Hg° mice are likely to compromise the antibacterial 
activity of mBD -1 in vivo. This dysfunction may contribute to the abnormal 
pulmonary responses observed in these mice in response to lung infection 
with S. aureus, but have little effect upon the response to P. aeruginosa. Thus, 
it is possible that while the basic mechanisms underlying increased 
susceptibility to lung infection in CF may be conserved between mice and 
humans, this may not extend to the specific profile of bacterial susceptibility. 
Although CftrtmlHgu /Cftrtri1 Hgu mice may not necessarily demonstrate an identical 
bacterial infection profile to humans, the pulmonary response to the classical 
early stage CF- related lung pathogen S. aureus, may provide insights into the 
process of initiation of CF lung disease. 
Further studies are required to build upon these results, including 
further analysis of other members of the (3- defensin gene families and other 
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antimicrobial components of the ASL. In addition, analysis of the ASL in a 
well characterised air -interface primary culture model system and mouse 
models with targeted deletions of specific I3-defensins are required to 
confirm the results of these in vitro studies. Additional studies might include 
complete characterisation of the Defer locus and the development of 
mammalian expression systems in which to analyse biologically synthesised 
and processed I3- defensins. A more complete understanding of the 
antibacterial activity of defensins and of the functional consequences of the 
species- specific variations observed in these molecules may prove to be of 
great value in the design of novel, antibacterial compounds active against 
multiple antibiotic resistant organisms. The use of gene expression arrays, 
based on the fully sequenced genome of P. aeruginosa, may provide 
interesting insights into the mechanism of bacterial killing employed by 
defensins and possible bacterial defence strategies. 
Finally, a novel primary culture model of differentiated murine 
tracheal epithelium was established and characterised. This technique was 
demonstrated to facilitate the formation of confluent, polarised epithelial 
cultures with a high transepithelial resistance. Differentiation to produce 
ciliated cells and small numbers of goblet cells was demonstrated, with 
minimal contamination by non -epithelial cell types. The cultured cells 
were shown to express Cftr and murine ß- defensin genes and to have an 
electrophysiological profile consistent with the presence of amiloride- 
sensitive sodium channels and cAMP -stimulated CFTR chloride channels. 
This model demonstrates important features of native murine tracheal 
epithelia, particularly with respect to the study of mouse models of CF. The 
model system will be of value in the future analysis of a) the ionic 
composition and volume control dynamics of murine ASL, b) the 
antibacterial properties of murine ASL and the key components of this 
response and c) in studies of the internalisation and adherence of CF related 
pathogens to murine airway epithelial cells. Such studies should be 
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performed using selected mouse models of CF and ß- defensin knockout 
mice, on different background strains. 
In conclusion, the studies presented in this thesis demonstrate and 
characterise a phenotype of abnormal pulmonary response to bacteria in 
mice secondary to mutations in Cftr. Important differences between the lung 
disease observed in mouse models of CF to date and human CF lung disease 
were recognised and possible explanations for such differences have been 
studied and discussed. While these species differences may prevent mouse 
models of CF from accurately reproducing all aspects of CF lung disease in 
humans, they may prove as illuminating as the similarities. Rather than 
exclusively pursuing the development of all aspects of classical human CF 
lung disease in mouse models, studies should specifically address the effects 
of Cftr mutation upon the lung pathophysiology of mice. In this manner the 
consequence of Cftr mutation in the mouse lung can be addressed and the 
underlying mechanisms evaluated. By recognising the key similarities and 
differences, mouse models of CF may provide ideal systems for the analysis 
of specific aspects of CF lung disease, such as the initial predisposition to 
infection with S. aureus. In this manner the validity of specific hypotheses 
may be examined in an in vivo model. Extrapolation to human disease 
processes can then be performed, recognising both the similarities and the 
differences between mice and humans. Furthermore, the contrasting 
phenotypes observed in different mouse models of CF, particularly between 
different background strains, are an important strength. Using such 
observations it may be possible to more clearly define the critical factors 
required for the development of CF lung disease in humans. By adopting 
such an approach, mouse models of CF can provide valuable contributions to 
our understanding of this disease process and support efforts towards organ - 
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